ADDRESSING THE TOUGHEST RHEUMATOLOGY CHALLENGES TAKES ALL OF US.

That’s why we collaborate each day with physicians, academics, clinical experts, peers, and others. Together, we can truly make a difference for patients.

As a global biopharmaceutical company, we use our expertise, knowledge, resources, and passion to impact millions around the world.

At AbbVie, our solutions start with science but end with a new way forward. For all of us.

AbbVie focuses on many therapeutic areas, including our commitment to lead the way in rheumatology.

Visit us at booth #5.1 to learn more.

abbvie.com
Table of Contents

Organising Committees ❯ 5
Acknowledgements ❯ 6
Welcome Message ❯ 7
General Information ❯ 8
  – Information about your Participation ❯ 8
  – EULAR Corporate Social Responsibility Statement ❯ 13
  – Networking Opportunities ❯ 13
  – Scientific Information ❯ 13
  – Information on Industry Related Activities ❯ 14
Congress at a Glance:
  – Wednesday, 10 June 2015 ❯ 15
  – Thursday, 11 June 2015 ❯ 16
  – Friday, 12 June 2015 ❯ 18
  – Saturday, 13 June 2015 ❯ 20
Wednesday, 10 June 2015
  – Scientific Programme ❯ 21
Thursday, 11 June 2015
  – Scientific Programme ❯ 33
  – Guided Poster Tours ❯ 61
  – Scientific Poster Session 1 ❯ 68
Friday, 12 June 2015
  – Scientific Programme ❯ 93
  – Guided Poster Tours ❯ 121
  – Scientific Poster Session 2 ❯ 128
Saturday, 13 June 2015
  – Scientific Programme ❯ 155
  – Guided Poster Tours ❯ 175
  – Scientific Poster Session 3 ❯ 183
PReS Programme ❯ 211
Health Professionals in Rheumatology Programme and Posters ❯ 217
PARE Programme and Posters ❯ 229
Satellite Symposia ❯ 237
Company Profiles ❯ 247
EULAR Related Meetings ❯ 262
Congress Venue General Plan ❯ 264
Exhibitors’ List ❯ 266
Exhibition Plan ❯ 267

The acronym “PARE” used in the Programme stands for “People with Arthritis/Rheumatism in Europe”
The acronym “HPR” used in the Programme stands for “Health Professionals in Rheumatology”
The acronym “PReS” used in the Programme stands for “Paediatric Rheumatology European Society”
KEEP IN TOUCH WITH RHEUMATOLOGY

UPDATE YOUR CONTACT DETAILS!

Receive your access codes to the recorded sessions*

Receive your free subscription**

Annals of the Rheumatic Diseases - the EULAR Journal (ARD)**

Go to any Yellow Tower to update your contact information to secure delivery of the EULAR Journal and access to view the recorded presentations

*if purchased
** the patient and exhibitor registration categories do not include the complimentary subscription
YOU’VE ONLY JUST ARRIVED & ALREADY WE’RE THINKING OF YOUR NEXT TRIP

As the official airline network for EULAR 2015 in Rome, we’d like to thank you for choosing the Star Alliance network and hope that all goes really well for you here today.

Whilst you concentrate on the day’s events, we hope you’ll consider us the next time you need to attend a conference.

With over 18,500 flights a day to 1,316 airports across 192 countries, our 27 member airlines will extend a wide choice of flights to any future conference you’re planning to attend. And no matter which of those airlines’ frequent flyer programmes you belong to, you can earn and redeem miles across all of them.

So the next time you want to concentrate all your energies on your conference, we hope you’ll decide to leave the travel arrangements to us.
Organising Committees

EULAR EXECUTIVE COMMITTEE

› President
   Prof. Maurizio Cutolo, Italy
› President-elect
   Prof. Gerd R. Burmester, Germany
› Past President
   Prof. Maxime Dougados, France
› Vice-President representing national PARE organisations
   Marios Kouloumas, Cyprus
› Vice-President representing the Health Professionals in Rheumatology
   Prof. Christina H. Opava, Sweden
› Treasurer
   Prof. Johannes W. J. Bijlsma, Netherlands
› General Secretary
   Prof. Nemanja Damjanov, Serbia
› Editor in Chief of the “Annals of the Rheumatic Diseases - The EULAR Journal”
   Prof. Tore K. Kvien, Norway
› Liaison Officer to EMEUNET
   Dr Caroline Ospelt, Switzerland
› * Liaison Officer to the American College of Rheumatology ACR
   Dr Daniel Aletaha, Austria
› * Liaison Officer, EU Public Affairs
   Mr Neil Betteridge, United Kingdom
› * Liaison Officer to FOREUM Foundation
   Prof. Steffen Gay, Switzerland
› * President UEMS Section of Rheumatology
   Prof. Nada Cikes, Croatia
› * Executive Director
   Mr Heinz Marchesi, Switzerland

EULAR STANDING COMMITTEE CHAIRPERSONS

(ex-officio members of the EULAR Executive Committee)

› Investigative Rheumatology
   Prof. Rik Lories, Belgium
› Clinical Affairs
   Prof. Désirée van der Heijde, Netherlands
› Education and Training
   Prof. Ingrid Lundberg, Sweden
› Epidemiology and Health Services Research
   Prof. Deborah Symmons, United Kingdom
› Musculoskeletal Imaging
   Dr Esperanza Naredo, Spain
› Paediatric Rheumatology
   Prof. Alberto Martini, Italy
› PARE
   Ms Diana Skingle, United Kingdom
› Health Professionals in Rheumatology
   Ms Susan Oliver, United Kingdom

CONGRESS PROGRAMME COMMITTEE

Scientific, Health Professionals, PARE

› The EULAR Executive Committee Members (excluding functions marked with*)
› The EULAR Standing Committee Chairpersons
› Dr Maya Buch, United Kingdom
   Chairperson of the Scientific Programme Committee
› Prof. Dirk Elevaert, Belgium
   Chairperson of the Abstract Selection Committee
› Prof. Ulf Müller-Ladner, Germany
   Past-Chairperson of the Scientific Committee
› Prof. Dominique Baeten, Netherlands
› Dr Stefan Bergman, Sweden
› Prof. Maxime Breban, France
› Prof. Frank Buttgereit, Germany
› Prof. Lesley Crofford, United States
› Ms Annette de Thurah, Denmark
› Dr Maarten de Wit, Netherlands
› Prof. Joâo E. Fonseca, Portugal
› Prof. Elaine Hay, United Kingdom
› Prof. Margreet Kloppenburg, Netherlands
› Prof. Floris Lafeber, Netherlands
› Prof. Willem F. Lems, Netherlands
› Prof. James O’Dell, United States
› Prof. Eliseo Pascual Gomez, Spain
› Prof. Ingemar Petersson, Sweden
› Prof. Gabriela Riemekasten, Germany
› Prof. Carlo Salvarani, Italy
› Prof. Zoltán Szekanecz, Hungary
› Dr Lene Terslev, Denmark
› Prof. Dimitrios Vassilopoulos, Greece
› Prof. Douglas Veale, Ireland
› Prof. Reinhard E. Voll, Germany
› Mr Dieter Wiek, Germany
› Prof. Francesco Zulian, Italy

* These functions are not included in the Congress Programme Committee
Acknowledgements

The EULAR 2015 Organising Committee wishes to express its gratitude to all satellite symposia organisers and exhibitors as well as to the following sponsors:

AbbVie
Passport Programme

Bayer
Passport Programme

MSD
Pocket Programme

Biogen
Passport Programme

Pfizer
Passport Programme

Novartis
Mobile App
Passport Programme

Amgen
USB sticks

AstraZeneca
Mobile charging stations

Sanofi
Cyber café

Future Congresses

Annual European Congress of Rheumatology
eular

Eular 2016
London
United Kingdom
8-11 June 2016

Eular 2017
Madrid
Spain
14-17 June 2017
Welcome Message

AVE!

The doors of Rome are opened wide to welcome the 16th EULAR Annual European Congress of Rheumatology. As in 2010, the "Eternal City", with a history of more than two thousand years, will again host a significant number of participants from almost 120 countries. We are grateful and thank all who are taking part in what EULAR does and offers in order to spark scientific and clinical progress in the broad field of the rheumatic and musculoskeletal diseases. Contributions from both People with Arthritis/Rheumatism in Europe (PARE) and Health Professionals in Rheumatology will add further matters of interest to the scientific contents of the Congress. In addition, this year features a joint congress of EULAR and PReS, the Paediatric Rheumatology European Society – as is the case every 3 years – with an extended programme for paediatric rheumatology.

With an impressive growth in quantity and quality of abstracts and sessions the 2015 EULAR congress is ready to welcoming some 14000 physicians, health professionals, scientific researchers, patients and patient group members, and industry representatives who together form a unique platform in the world to discuss and debate rheumatic and musculoskeletal diseases. A record number of over 4300 abstracts have been submitted, of which 82% were accepted. Over 300 were accepted as oral presentations. The EULAR Scientific Programme will provide 160 sessions and 35 symposia with over 350 speakers. A greater number of poster tours than ever before (more than 40 tours with 10 selected posters on each tour) will offer a much appreciated guided commentary to high-scoring posters. The poster area, accessible throughout the day, will host almost 2000 presentations, which constitute the heart of our congress.

Emerging topics for this year include the rapidly expanding availability of biosimilar drugs and related issues; new treatments for psoriatic arthritis; the management of pain; the emerging role of epigenetics in rheumatic diseases; therapies for orphan diseases; sessions on practical skills and imaging; and What Is New (WIN) and How to Treat (HOT) sessions, the latter providing latest updates on the most important practical questions on rheumatic and musculoskeletal diseases. All the sessions will again be recorded and be available for fully registered participants through the new EULAR website right after the congress.

The congress venue will offer ample spaces for all participants to follow the sessions and symposia and visit the posters, but also for our industry partners to exhibit and network with health care professionals. Pleasant outdoor areas will be available to sit and rest but more importantly to meet and talk with fellow rheumatologists and health professionals from adjacent professions as well as with patients from all over the world.

Last but not least, good news also from the City of Rome, especially for dinner time, since large areas in the city centre have recently been transformed to pedestrian zones, such as around the Coliseum, the Fori Imperiali, the Piazza Navona, the Pantheon, or the Piazza di Spagna. The atmosphere is irresistible.

All of the above highlights have only been possible and realized thanks to the untiring effort and support of all the EULAR members, including the Steering Group, the Scientific and Executive Committees, the whole EULAR Secretariat as well as the MCI staff.

The bottom line is that there are indeed countless attractive reasons to come to Rome to attend the 16th Annual EULAR Congress. Or, as Cicero used to say: res ipsa loquitur (the matter speaks for itself).

Maurizio Cutolo
EULAR President
General Information

CONGRESS VENUE: DATES AND LOCATION

The Annual European Congress of Rheumatology EULAR 2015 will be held at:

Fiera Roma
Via Portuense 1645/1647 - 00148 Rome - Italy
Phone: + 39 06 51 78 260
Website: www.fieraroma.it

The congress opens on Wednesday, 10 June 2015 - 12:00 and closes on Saturday, 13 June 2015 - 15:00.

The EULAR congress Opening Plenary Session, followed by a Networking Platform, is held in the evening of Wednesday, 10 June 2015 at the congress venue itself.

The Fiera Roma is less than 5 kilometres from the Leonardo da Vinci (Fiumicino) airport and close to major highways connecting to the city centre. Public transportation is available from the airport by bus and from the city centre by train. Taxis reach the Fiera Roma from Rome centre in about 30 minutes and cost around EUR 40.

EULAR offers a free shuttle bus service from all official congress hotels to the Fiera Roma (and return) improving the accessibility to the congress venue.

A separate brochure with time schedules is available on the congress website and from the registration desks.

REGISTRATION OPENING HOURS

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>09 June 2015</td>
<td>17:00 - 20:00</td>
</tr>
<tr>
<td>Wednesday</td>
<td>10 June 2015</td>
<td>08:00 - 20:00</td>
</tr>
<tr>
<td>Thursday</td>
<td>11 June 2015</td>
<td>08:00 - 19:30</td>
</tr>
<tr>
<td>Friday</td>
<td>12 June 2015</td>
<td>08:00 - 19:30</td>
</tr>
<tr>
<td>Saturday</td>
<td>13 June 2015</td>
<td>08:00 - 15:00</td>
</tr>
</tbody>
</table>

Scientific Secretariat

EULAR Secretariat
Seestrasse 240
CH-8802 Kilchberg / Zurich
Switzerland
Tel: +41 44 716 3030
Fax: +41 44 716 3039
E-mail: eular@eular.org
Website: www.congress.eular.org

Organising Secretariat

In charge of registration, abstract handling, partnership & investment opportunities, hotel reservations

EULAR 2015
c/o MCI SUISSE SA
Rue de Lyon 75
CH-1211 Geneva 13
Switzerland
Tel: +41 22 33 99 590
Fax: +41 22 33 99 601
E-mail: eular2015@mci-group.com
Website: www.mci-group.com

Local Organising Agency

For social events, excursions, transfers, company events

MCI Rome
41, Via della Ferratella in Laterano
00184 Rome
Italy
Tel: +39 6 70 49 56 93
Fax: +39 6 70 96 292
E-mail: eular2015.soc@mci-group.com
Website: www.mci-group.com/Italy

Information about your participation

Admittance to the EULAR Congress

In respect of Italian and European laws and regulations, as well as due to current health and safety rules and legislation in effect, registration and/or admittance to the EULAR congress shall be limited solely to participants who are 18 years of age or older. Any registration by anyone who is under 18 is unauthorized and in violation of these terms and conditions and will automatically result in the forfeit of their registration. Identification is to be provided to congress staff upon request. Participants below 18 years of age will not be granted access to any part of the congress at any time. This is also valid for children accompanied by their parents and for any other unregistered person. If access to the congress is needed and no registration is available, the person should contact the registration desk. The congress management will take a final decision.
CANCELLATION OF CONGRESS

It is mutually agreed that in the event of total or partial cancellation of the congress due to fire, strike, natural disaster (either threatened or actual), government regulations or causes which would prevent its scheduled opening or continuance, the contractual relationship between EULAR and the participant will be terminated immediately and EULAR shall determine an equitable basis for the eventual refund of a portion of the registration or other fees after due consideration of expenditures and commitments already made. Under no circumstances is EULAR responsible for any participant expenses (such as travel and lodging) or any other incidental or consequential damages.

EULAR CONGRESS MOBILE APP

Since 2003 EULAR has offered a congress programme and guide for mobile devices, at that time pioneering in this upcoming technology. In the last five years, we have also offered a planning tool, the internet based Itinerary Planner. Schedules made in the Planner can be transferred easily to your smartphone or tablet on iOS, Android or WindowsPhone 8 and 8.1.

Apart for general information, the App contains the complete congress programme with all session and lectures, all abstracts in full text and all symposia. Links between these elements allow easy changing content. The location of session and meeting rooms is shown interactively so you know instantly where the next event takes place.

A support desk for mobile devices is located in Hall 5.

DATA SCANNING SYSTEM

Congress badges will contain a barcode acting as an electronic business card and thus enables visitors to leave their contact details for exhibitors quickly and easily.

DRESS CODE

Dress will be informal throughout the congress. EULAR reserves the right to refuse access if it is deemed necessary for the comfort and safety of all delegates.

EXHIBITION ACCESS (RESTRICTED)

Based on “DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 6 NOVEMBER 2011 ON THE COMMUNITY CODE RELATING TO MEDICINAL PRODUCTS FOR HUMAN USE” and on information received from the Italian Medicines Agency in Italy (AIFA), the EULAR Board has decided to restrict the access for congress participants registered as PARE Representative or as Patient to the non-commercial part of the exhibition halls. The access to all other parts of the congress is unrestricted.

We ask the participants involved to follow the specific instructions they will receive together with the congress documents. Hostesses and special signs will help in navigating inside the exhibition halls.

General Information

CERTIFICATE OF ATTENDANCE

A certificate of attendance will be given with the congress bag to each participant.

CHARGING STATIONS FOR SMARTPHONES AND MOBILE DEVICES

Charging stations for smartphones and other mobile devices are available in the registration area and exhibition halls.

CLOAKROOM

A cloakroom service for coats and reasonably sized luggage is available during the opening hours of the congress next to the registration area (Hall 7).
CONTINUING MEDICAL EDUCATION (CME)
CREDITS

EULAR 2015 Rome has been accredited for a maximum of 18 European CME credits. This is an equivalent of 18 hours Continued Medical Education. CME points are recognized by the American Medical Association towards the Physician's Recognition Awards (PRA). To convert CME credits to AMA PRA, contact AMA.

CYBER CAFÉ

Cyber Cafés are located in Halls 5 and 6.

CONGRESS DOCUMENTS AND BADGES

Name badges can be printed at the self-service stations, located at the registration area in Hall 7. Alternatively, congress documents (including name badges) can be collected at the registration desks. Name badges must be worn visibly at all time during the congress and in the exhibition area.

CONGRESS EVALUATION

We would be grateful if you could take a few minutes to support the hostesses that might approach you to get your opinion about the congress and the scientific programme. This will help us to continue improving the congress in future years.

CLIMATE

Rome enjoys a typically Mediterranean climate. Summers (from June to September) are hot and dry with temperatures often above 30°C. High humidity is common at that time.

CREDIT CARDS

Major credit cards are accepted in most hotels, restaurants and shops. If you pay by credit card, you may be asked to show an identity document. Travellers’ cheques (in USD or EUR) can also be cashed in at Italian banks.

CURRENCY

The Italian currency is the Euro (€) and 1 Euro = 100 cents.

ELECTRICITY

Electric appliances in Italy work with 220 volts, AC. 50 Hz electrical sockets comply with European regulations. In most hotels, you will find adaptors for different types of plugs.

FOOD AND BEVERAGE

During official coffee breaks, complimentary coffee and tea is served in the EULAR Village and exhibition/poster areas in Halls 5 and 6. Lunch is provided on Thursday and Friday and is also served in the EULAR Village and exhibition/poster areas in Halls 5 and 6. A self-service restaurant and sandwich bars are available at the congress venue.

HELP POINT FOR SMARTPHONES AND MOBILE DEVICES

A Help Point for phones and other mobile devices as well as recharge options for such devices is available in the EULAR Village, Hall 5. The EULAR Mobile Congress App can also be downloaded there.
ITALY & ROME (FACTS ABOUT)

Italy, officially the Italian Republic (Italian: Repubblica italiana), is a parliamentary republic in Europe. Italy covers an area of 301,338 km² (116,347 sq mi) and has a largely temperate climate; due to its shape, it is often referred to in Italy as "the Boot". With 61 million inhabitants, it is the 5th most populous country in Europe. Italy is a very highly developed country and has the third-largest economy in the Eurozone and the eighth-largest in the world. Italy comprises 20 regions, of which 5 have a special autonomous status.

Rome is a city and special community (named “Roma Capitale”) in Italy. Rome is the capital of Italy and of the region of Lazio. With 2.9 million residents in 1,285 km² (496.1 sq mi), it is also the country's largest and most populated community and fourth-most populous city in the European Union by population within city limits. The Metropolitan City of Rome has a population of 4.3 million residents. The city is located in the central-western portion of the Italian Peninsula, within the region of Lazio (Latium), along the shores of Tiber River. Vatican City is an independent country within the city boundaries of Rome, the only existing example of a country within a city.

Rome's history spans more than two and a half thousand years. Although Roman tradition states the founding of Rome around 753 BC, the site has been inhabited much earlier, being one of the oldest continuously occupied cities in Europe. The city's early population originated from a mix of Latins, Etruscans and Sabines. Eventually, the city successively became the capital of the Roman Kingdom, the Roman Republic and the Roman Empire, and is regarded as one of the birthplaces of Western civilization. It is referred to as “Roma Aeterna” (The Eternal City) and “Caput Mundi” (Capital of the World), two central notions in ancient Roman culture.

After the fall of the Empire, which marked the begin of the Middle Ages, Rome slowly fell under the political control of the Pope, which had settled in the city since the 1st century AD, until in the 8th century it became the capital of the Papal States, which lasted until 1870.

Beginning with the Renaissance, almost all the popes since Nicholas V (1422–55) pursued coherently along four hundred years an architectonic and urbanistic program aimed to make of the city the world’s artistic and cultural centre. Due to that, Rome became first one of the major centres of the Italian Renaissance, and then the birthplace of the Baroque style. Famous artists and architects of the Renaissance and Baroque period made Rome the centre of their activity (Michelangelo, Raphael, Tiziano, Bernini for example), creating masterpieces throughout the city. In 1871 Rome became the capital of the Kingdom of Italy, and in 1946 that of the Italian Republic.

Rome has the status of a global city. In 2011, Rome was the 18th-most-visited city in the world, 3rd most visited in the European Union, and the most popular tourist attraction in Italy. Its historic centre is listed by UNESCO as a World Heritage Site. Monuments and museums such as the Vatican Museums and the Coliseum are among the world’s most visited tourist destinations with both locations receiving millions of tourists a year. Rome hosted the 1960 Summer Olympics and is the seat of United Nations’ Food and Agriculture Organization (FAO).

INSURANCE AND LIABILITY

It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. EULAR and MCI as organisers do not accept any liability or responsibility for personal injuries, or loss of, or damage to private property belonging to the congress participants.

LANGUAGES/OFFICIAL LANGUAGE

Italian is the official language in Italy. The official congress language is English. No simultaneous translation is provided.

PRESS CENTRE

The press and media area is located in Hall 5, first level. Facilities such as computers, telephone, photocopier, and internet access are available for registered press delegates.

SECURITY

Please pay special attention to your personal belongings, especially when walking in the city centre or using the public transportation system, but also inside the congress venue.

Any security problems or concerns within the congress venue should be reported to a member of the EULAR or MCI staff.

Security staff will handle any emergency situation and everyone is required to follow instructions announced via the public information system.

Emergency exits are marked with green exit signs.

SERVICES FOR THE DISABLED

All session rooms at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly in the EULAR Village.
SCIENTIFIC SESSIONS (ACCESS TO)

The meeting rooms for scientific sessions and satellite symposia vary in size. Should the room be full, we invite you to use the overflow facility in Hall 7 or to attend a different session. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a scientific session or satellite symposium. The maximum capacities of the rooms are determined by the local safety and security regulations and have to be respected by law.

SMOKING POLICY

Smoking is not permitted at the congress venue.

TRANSPORTATION

EULAR provides a free shuttle bus service, in the mornings and evenings, between the official congress hotels and the Fiera Roma (and return) ensuring smooth access to the congress venue. In addition, a shuttle service to the main station (Laurentina) is provided throughout the day.

A separate brochure with time schedules is available on the congress website, in the congress bag and from the registration desks.

SHOPPING IN ROME

Shops are generally open from Monday to Saturday, from 9:30 - 12:30 and from 15:30 - 19.30, although shopping centres and department stores often stay open all day, from 10:00 - 22:00.

Pharmacies have the same opening hours as shops. Some pharmacies are open 24 hours. A calendar listing the nearest open pharmacy can be found on the doors of all local pharmacies and you will get support from your hotel. Rome's busy markets are an integral part of local life. They are held in many districts of the city and are open only in the morning from 7:00 - 14:00.

TAXI

Several taxi companies, licensed by the City Hall, offer a very good service. Be careful to check for the license number on the front door of the car. There are taxi ranks in many locations throughout the centre, but it is nearly impossible to hail one driving down the streets, particularly at night. There is a base fee of EUR 3.50 added to the meter fee.

TELEPHONES

For calls to Italy, use the international code +39. The regional code for Rome is 06. Calls from Italy follow international standard dialling rules.

Please respect your fellow congress participants by switching off your mobile phone in all meeting and poster areas.

TIME

Italy is in the Central European Time (CET) Zone, 1 hour ahead of Greenwich Mean Time (GMT), and observes Daylight Saving Time during summer.

TIPPING

Normally, tips are not compulsory and there are no generally established rules, although it is common practice to leave a tip of around 10% of the bill if you were satisfied with the service. Hotel staff, such as luggage handlers, happily accept a small tip. Generally, no other public service workers expect tips.
EULAR Corporate Social Responsibility Statement

EULAR is aware of the environmental, economic and social impact of holding a large congress, and is working closely with its partners to ensure that environmentally, economically and socially friendly policies are in place. For the Rome congress EULAR has made the following sustainability arrangements:

HEALTHY FOOD

All buffets for lunches and coffee breaks offer healthy options; meaning that there is always a choice of fresh fruits and vegetables. A smaller selection of dietary offerings is also available. Local products have been prioritized.

PRINTING

EULAR is committed to ensuring that printing is kept to a minimum to reduce the amount of waste paper. No abstract book will be printed this year. All abstracts will be available online and on a USB stick available to all delegates. This will save the printing of about 20’000’000 pages.

LOCAL SUPPLIERS

EULAR wishes to have a positive local impact. When sourcing materials and supplies, EULAR gives priority to local partners to avoid associated impacts of transportation and to positively impact the local economy.

SERVICES FOR THE DISABLED

EULAR wishes to make the congress experience comfortable for all attendees. All rooms and areas at the congress venue are fully accessible to participants with disabilities. Quiet areas are available throughout the congress venue, mainly in the EULAR Village.

Networking Opportunities

OPENING PLENARY SESSION AND NETWORKING PLATFORM

Wednesday, 10 June 2015 - 18:45-22:00
The Networking Platform will be held after the Opening Plenary Session at the Fiera Roma.
All participants are cordially invited to these events.

EULAR CONGRESS DINNER

Friday, 12 June 2015 - 20:30-24:00
Price: EUR 95 per person (not included in the registration fee)
The EULAR 2015 Congress Dinner will take place at Villa Miani at the top of Monte Mario, offering a breathtaking view over the Vatican and Rome.

The Congress Dinner is a great opportunity to dine and meet with friends and colleagues from around the world in a relaxed atmosphere, enjoying the unmatched charm and fascination of Rome. Those who have shared this evening with us in previous years would not want to miss it.

Come and join us as well!

Scientific Information

CERTIFICATE OF ATTENDANCE

A certificate of attendance will be given with the congress bag to each participant.

CONTINUING MEDICAL EDUCATION (CME) CREDITS

EULAR 2015 Rome has been accredited for a maximum of 18 European CME credits. This is an equivalent of 18 hours Continued Medical Education. CME points are recognized by the American Medical Association towards the Physician's Recognition Awards (PRA). To convert CME credits to AMA PRA, contact AMA.

POSTERS

The scientific posters and health professionals in rheumatology posters are displayed in the poster areas in Halls 5 and 6 from Thursday to Saturday. They are changed on a daily basis. PARE posters are displayed permanently close to the EULAR PARE booth, located in the EULAR Village in Hall 5.

Official Poster viewing will take place at the following hours:
Thursday  11 June 2015  12:00 - 13:45
Friday  12 June 2015  12:00 - 13:45
Saturday  13 June 2015 10:15 - 12:00

Guided Poster tours on selected topics will take place during the official poster viewing times.

SPEAKERS’ PREVIEW ROOM

A Speakers’ Preview Room is available in room 7A, located on the 1st floor of Hall 7 and is open at the following hours:
Wednesday  10 June 2015   08:00 - 20:00
Thursday  11 June 2015   08:00 - 19:00
Friday  12 June 2015   08:00 - 19:00
Saturday  13 June 2015   08:00 - 14:00

The speaker centre is equipped with computers. All speakers are required to check in their presentation at least 2 hours before their session, or on the day before for the early morning sessions.
Information on Industry Related Activities

EXHIBITION

During the congress, EULAR will present an attractive exhibition to the congress participants.

The abstract poster presentation areas are embedded in the exhibition. Coffee, tea and other refreshments are available within the exhibition during breaks.

The exhibition hours are as follows:

<table>
<thead>
<tr>
<th>Day</th>
<th>Dates</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday</td>
<td>10 June 2015</td>
<td>12:00 - 18:30</td>
</tr>
<tr>
<td>Thursday</td>
<td>11 June 2015</td>
<td>08:00 - 17:30</td>
</tr>
<tr>
<td>Friday</td>
<td>12 June 2015</td>
<td>08:00 - 17:30</td>
</tr>
<tr>
<td>Saturday</td>
<td>13 June 2015</td>
<td>08:15 - 14:00</td>
</tr>
</tbody>
</table>

EXHIBITION ACCESS (RESTRICTED)

Based on “DIRECTIVE 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 6 NOVEMBER 2011 ON THE COMMUNITY CODE RELATING TO MEDICINAL PRODUCTS FOR HUMAN USE” and on information received from the Italian Medicines Agency in Italy (AIFA), the EULAR Board has decided to restrict the access for congress participants registered as PARE Representative or as Patient to the non-commercial part of the exhibition halls. The access to all other parts of the congress is unrestricted.

We ask the participants involved to follow the specific instructions they will receive together with the congress documents. Hostesses and special signs will help in navigating inside the exhibition halls.

ALL DATES AND TIMES

<table>
<thead>
<tr>
<th>DATE</th>
<th>REGISTRATION AREA</th>
<th>SPEAKERS PREVIEW</th>
<th>POSTERS VIEWING</th>
<th>NETWORKING OPPORTUNITIES</th>
<th>EXHIBITION</th>
<th>SATELLITE SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday 09 June 2015</td>
<td>17:00 - 20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wednesday 10 June 2015</td>
<td>08:00 - 20:00</td>
<td>08:00 - 20:00</td>
<td></td>
<td>18:45 - 22:00</td>
<td>12:00 - 18:30</td>
<td>13:00 - 14:30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Opening Plenary Session &amp; Networking Platform</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thursday 11 June 2015</td>
<td>08:00 - 19:30</td>
<td>08:00 - 19:00</td>
<td>12:00 - 13:45</td>
<td></td>
<td>08:00 - 17:30</td>
<td>08:30 - 10:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17:45 - 19:15</td>
</tr>
<tr>
<td>Friday 12 June 2015</td>
<td>08:00 - 19:30</td>
<td>08:00 - 19:00</td>
<td>12:00 - 13:45</td>
<td>20:30 - 24:00</td>
<td>08:00 - 17:30</td>
<td>08:30 - 10:00</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EULAR Congress Dinner</td>
<td></td>
<td>17:45 - 19:15</td>
</tr>
<tr>
<td>Saturday 13 June 2015</td>
<td>08:00 - 15:00</td>
<td>08:00 - 14:00</td>
<td>10:15 - 12:00</td>
<td></td>
<td>08:15 - 14:00</td>
<td></td>
</tr>
</tbody>
</table>

PRIVATE EVENTS POLICY

All requests from companies/organisations to host private events during the congress must have been approved prior to the congress by the EULAR Secretariat.

SATELLITE SYMPOSIA (ACCESS TO)

The meeting rooms for scientific sessions and satellite symposia vary in size. Should the room be full, we invite you to use the overflow facility in Hall 7 or to attend a different session. Neither EULAR nor MCI can be held responsible should a delegate be unable to attend a scientific session or satellite symposium. The maximum capacities of the rooms are determined by the local safety and security regulations and have to be respected by law.

SATELLITE SYMPOSIA (TIMINGS)

A number of Satellite symposia are organised during EULAR 2015:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday</td>
<td>13:00 - 14:30</td>
</tr>
<tr>
<td>Thursday</td>
<td>08:30 - 10:00</td>
</tr>
<tr>
<td>Thursday</td>
<td>17:45 - 19:15</td>
</tr>
<tr>
<td>Friday</td>
<td>08:30 - 10:00</td>
</tr>
<tr>
<td>Friday</td>
<td>17:45 - 19:15</td>
</tr>
</tbody>
</table>

Further information is available in the Satellite booklet, included in your congress bag.

Satellite symposia are governed by EULAR guidelines.

Other symposia are strictly prohibited during the duration of the congress, as outlined in the EULAR Code of Practice.
# Congress at a Glance

## WEDNESDAY, 10 JUNE 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall 9</th>
<th>Hall 8</th>
<th>Hall 3</th>
<th>Room 10 F-G</th>
<th>Hall 2</th>
<th>Hall 1</th>
<th>Room 10 B</th>
<th>Room 10 I</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-13:00</td>
<td>EXHIBITION OPENING COCKTAIL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-16:30</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00-18:30</td>
<td>EULAR 2015 Opening Plenary Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:45-20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00-22:00</td>
<td>NETWORKING PLATFORM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### COFFEE BREAK

**What is New (WIN)**
- WIN session 1: Clinical aspects of RA - The therapeutic landscape in RA

**Clinical Science Session**
- Clinical Science session: What is the impact of imaging on the management of rheumatoid arthritis?

**Clinical Science Session**
- Clinical Science session: Challenges in Clinical Practice - Calcinosis

**How to Treat/Manage (HOT)**
- How to Treat/Manage (HOT) - HOT Session 1: Raynaud’s phenomenon & systemic sclerosis - Sjögren’s syndrome

**Clinical Science Session**
- Clinical Science session: Clinical Science session: Do new anti-osteoarthritis drugs have an additional effect on bone quality?

**Outcome Science Session**
- Outcome Science session: Optimising the use of electronic information and technology in clinic and research

**PReS session**
- PReS session: Autoinflammatory diseases

**Basic and Translational Science session**
- Basic and Translational Science session: Co-stimulation: towards genuine immune modulation

### EULAR 2015 Opening Plenary Session

### NETWORKING PLATFORM

### COFFEE BREAK

**Satellite symposium**: Sanofi and Regeneron Pharmaceuticals

**Satellite symposium**: AstraZeneca

**Satellite symposium**: SHARE

**PARE session**: Pre-conference session

**Basic and Translational Science session**
- Estrogens: critical regulator of the immune response - implication for sex bias in the development of autoimmunity

**The Young Rheumatologist**
- Training of rheumatology across Europe

**HPR session**
- Get on the move with rheumatic and musculoskeletal disease

**EULAR projects in education and training**
- A masterclass in constructing reliable assessment questions

**PARE session**
- Building sustainable relationships between patients and researchers

**Practical skills session**
- Laboratory I

**Practical skills session**
- Improving your graphs and tables for publication and presentation I

**Basic and Translational Science session**
- Food and the immune system

**The Young Rheumatologist**
- Science bites: 10 arthritis abstracts + 10 systemic inflammation abstracts

**HPR session**
- Ethnicity - a blind spot within rheumatology?

**PARE session**
- Measuring success: how to evaluate the impact of your campaign

**Practical skills session**
- Capillaroscopy I

**Practical skills session**
- Crystals I

---

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area in Hall 7
# Congress at a Glance

## THURSDAY, 11 JUNE 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall 9</th>
<th>Hall 8</th>
<th>Hall 3</th>
<th>Room 10 F-G</th>
<th>Hall 2</th>
<th>Hall 1</th>
<th>Room 10 B</th>
<th>Room 10 I</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td>Satellite symposium</td>
<td></td>
<td></td>
<td>Satellite symposium</td>
<td>Satellite symposium</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td>AbbVie</td>
<td></td>
<td></td>
<td>Sanofi and Regeneron Pharmaceuticals</td>
<td>GSK</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>UCB</td>
<td>medac</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td>What is New (WIN)</td>
<td></td>
<td>Abstract session</td>
<td>Abstract session</td>
<td>How to Treat/Manage (HOT)</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td>WIN session 2: Behcet's disease</td>
<td></td>
<td>Developments in the treatment of RA</td>
<td>SpA clinical</td>
<td>HOT session 3: Sarcoidosis</td>
</tr>
<tr>
<td>12:00-13:45</td>
<td><strong>POSTER VIEWING AND LUNCH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:10-13:35</td>
<td><strong>GUIDED POSTER TOURS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00-13:45</td>
<td><strong>POSTER VIEWING AND LUNCH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td></td>
<td></td>
<td></td>
<td>What is New (WIN)</td>
<td></td>
<td>Clinical Science session</td>
<td>Challenges in Clinical Practice session</td>
<td>How to Treat/Manage (HOT)</td>
</tr>
<tr>
<td>15:15</td>
<td></td>
<td></td>
<td></td>
<td>WIN session 3: Systemic sclerosis/myositis</td>
<td></td>
<td>Perspectives on stratified medicine in RA</td>
<td>Glucocorticoid sparing in non-RA rheumatic diseases</td>
<td>HOT session 4: Severe gout</td>
</tr>
<tr>
<td>15:15-15:45</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td></td>
<td></td>
<td>What is New (WIN)</td>
<td></td>
<td>Clinical Science session</td>
<td>Challenges in Clinical Practice session</td>
<td>How to Treat/Manage (HOT)</td>
</tr>
<tr>
<td>17:15</td>
<td></td>
<td></td>
<td></td>
<td>WIN session 4: Osteoporosis/bone diseases</td>
<td></td>
<td>Axial SpA disease modification</td>
<td>Clinically suspect arthralgia</td>
<td>HOT session 5: Added value of imaging in RA Myositis</td>
</tr>
<tr>
<td>19:15</td>
<td></td>
<td></td>
<td></td>
<td>Abbvie</td>
<td></td>
<td>Pfizer</td>
<td>Bristol-Myers Squibb</td>
<td>MSD</td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area in Hall 7
THURSDAY, 11 JUNE 2015

<table>
<thead>
<tr>
<th>Room 10 D-E</th>
<th>Room 10 C</th>
<th>Room 10 A</th>
<th>Room 10 H</th>
<th>SC2 - Room A</th>
<th>Room 8 A</th>
<th>Room 9 A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic and Translational Science session</strong></td>
<td><strong>Satellite symposium</strong></td>
<td><strong>Satellite symposium</strong></td>
<td><strong>Satellite symposium</strong></td>
<td><strong>Satellite symposium</strong></td>
<td><strong>Satellite symposium</strong></td>
<td><strong>Satellite symposium</strong></td>
</tr>
<tr>
<td>Inflammation and fatigue</td>
<td>Celgene</td>
<td>IBSA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**COFFEE BREAK**

- **Abstract session**
  - SLE, Sjögren’s, APS: etiology, pathogenesis, animal models
- **Abstract session**
  - SLE, Sjögren’s and APS: clinical aspects other than treatment
- **HPR Abstract session**
  - Evidence based practice
- **Abstract session**
  - Osteoarthritis clinical aspects
- **PARE session**
  - Championing work
- **Abstract session**
  - Adaptive immunology in rheumatic disease
- **Abstract session**
  - Emerging concepts in genomics and genetics

**POSTER VIEWING AND LUNCH**

**GUIDED POSTER TOURS**

- **Basic and Translational Science session**
  - A painful joint - where is the pain coming from?
- **The Young Rheumatologist**
  - International experience
- **HPR session**
  - Cardiovascular risk assessment - getting to grips with the challenges
- **EULAR projects in Health Professionals**
  - Health Professionals' mentoring and networking
- **PARE session**
  - Lost in the system - how to use innovative care to bring health services back to the patient
- **Practical skills session**
  - Ultrasound basic I
- **Practical skills session**
  - Crystals II

**COFFEE BREAK**

- **Basic and Translational Science session**
  - Imaging & structure of the immune system
- **The Young Rheumatologist**
  - Being a researcher in the rheumatology world
- **HPR session**
  - Innovations in healthcare - can you Google it?
- **EULAR projects in Investigative Rheumatology**
  - Who cares? Primary care focus
- **Joint Primary care/ PARE session**
  - Ultrasound advanced I
- **Practical skills session**
  - ABC of biopsies: when to perform and how to interpret I
- **Satellite symposium**
  - AstraZeneca
- **Satellite symposium**
  - RAISE supported by Janssen
- **Satellite symposium**
  - Biologische Heilmittel Heel

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area in Hall 7
# Congress at a Glance

**FRIDAY, 12 JUNE 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall 9</th>
<th>Hall 8</th>
<th>Hall 3</th>
<th>Room 10 F-G</th>
<th>Hall 2</th>
<th>Hall 1</th>
<th>Room 10 B</th>
<th>Room 10 I</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 10:00</td>
<td></td>
<td></td>
<td></td>
<td>Satellite symposium: Abbvie</td>
<td>Satellite symposium: Pfizer</td>
<td>Satellite symposium: PEARLS supported by Janssen</td>
<td>Satellite symposium: Novartis Pharmaceuticals</td>
<td>Satellite symposium: Lilly</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>COFFEE BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td>What is New (WIN)</td>
<td>Abstract session: Comorbidities in RA</td>
<td>Abstract session: SpA and PsA treatment</td>
<td>How to Treat/Manage (HOT): HDT session 6: JIA and other paediatric rheumatic diseases Inherited collagen disorders</td>
<td>Abstract session: RA prognosis, predictors, outcome</td>
<td>Abstract session: SLE and Sjögren’s new treatment options</td>
<td>PReS Abstract session: Basic aspects in paediatric rheumatology</td>
<td>Abstract session: SpA and PsA basic and translational research</td>
</tr>
<tr>
<td>12:00 - 13:45</td>
<td>POSTER VIEWING AND LUNCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:45 - 15:45</td>
<td>GUIDED POSTER TOURS**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45 - 17:15</td>
<td>POSTER VIEWING AND LUNCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:45 - 19:15</td>
<td>Satellite symposium: UCB</td>
<td>Satellite symposium: Menarini</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area in Hall 7
FRIDAY, 12 JUNE 2015

<table>
<thead>
<tr>
<th>Room 10 D-E</th>
<th>Room 10 C</th>
<th>Room 10 A</th>
<th>Room 10 H</th>
<th>SC2 - Room A</th>
<th>Room 8 A</th>
<th>Room 9 A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic and Translational Science session</td>
<td>Satellite symposium</td>
<td>Satellite symposium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complement as a driver and target in inflammatory disease</td>
<td>GSK</td>
<td>Bioiberica</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**COFFEE BREAK**

<table>
<thead>
<tr>
<th>Abstract session</th>
<th>Abstract session</th>
<th>HPR Abstract session</th>
<th>Abstract session</th>
<th>PARE Abstract session</th>
<th>Abstract session</th>
<th>Abstract session</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSC pathogenesis, etiology and animal models</td>
<td>New insights into imaging</td>
<td>Getting to grips with evidence</td>
<td>Vasculitis</td>
<td>PARE</td>
<td>Cartilage - bone - synovium</td>
<td>Cytokines and inflammatory mediators</td>
</tr>
</tbody>
</table>

**POSTER VIEWING AND LUNCH**

**GUIDED POSTER TOURS**

<table>
<thead>
<tr>
<th>Basic and Translational Science session</th>
<th>The Young Rheumatologist</th>
<th>HPR session</th>
<th>EULAR projects in musculoskeletal imaging</th>
<th>PARE session</th>
<th>Practical skills session*</th>
<th>Practical skills session*</th>
</tr>
</thead>
<tbody>
<tr>
<td>New pathogenic aspects in vasculitis</td>
<td>Evidence based medicine. To design and understand clinical trials and meta-analysis</td>
<td>Social and work participation - research into practice</td>
<td></td>
<td></td>
<td>Capillaroscopy II</td>
<td>Improving your graphs and tables for publication and presentation II</td>
</tr>
</tbody>
</table>

**COFFEE BREAK**

<table>
<thead>
<tr>
<th>Basic and Translational Science session</th>
<th>The Young Rheumatologist</th>
<th>HPR session</th>
<th>EULAR projects in epidemiology and health services</th>
<th>PARE session</th>
<th>Practical skills session*</th>
<th>Practical skills session*</th>
</tr>
</thead>
<tbody>
<tr>
<td>EULAR/EFIS session: Autoimmunity and inflammation in anti-checkpoint antibody therapies of cancer?</td>
<td>The art of writing</td>
<td>Fit to fight rheumatic and musculoskeletal diseases - how much exercise is beneficial and safe?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area in Hall 7
### Congress at a Glance

#### SATURDAY, 13 JUNE 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 10 I</th>
<th>Room 10 D-E</th>
<th>Room 10 C</th>
<th>Room 10 A</th>
<th>SC2 - Room A</th>
<th>Room 8 A</th>
<th>Room 9 A</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>Basic and Translational Science session</td>
<td>Basic and Translational Science session</td>
<td>The Young Rheumatologist</td>
<td>HPR session</td>
<td>Joint Clinical/ HPR/PARE session</td>
<td>Practical skills session*</td>
<td>Practical skills session*</td>
</tr>
<tr>
<td>10:00</td>
<td>Autoimmune B cells in human disease</td>
<td>Bone phenotypes of osteoarthritis; towards personalised treatment</td>
<td>Strategic decisions in a career</td>
<td>Unlocking the mystery of health economics</td>
<td>Family business</td>
<td>Ultrasound basic II</td>
<td>MRI II</td>
</tr>
</tbody>
</table>

10:00-12:00: POSTER VIEWING AND COFFEE BREAK

10:10-11:50: GUIDED POSTER TOURS**

10:00-12:00: POSTER VIEWING AND LIGHT LUNCH

<table>
<thead>
<tr>
<th>Time</th>
<th>Room 10 I</th>
<th>Room 10 D-E</th>
<th>Room 10 C</th>
<th>Room 10 A</th>
<th>SC2 - Room A</th>
<th>Room 8 A</th>
<th>Room 9 A</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00-13:30</td>
<td>Basic and Translational Science session</td>
<td>Basic and Translational Science session</td>
<td>The Young Rheumatologist</td>
<td>HPR session</td>
<td>Joint Clinical/ HPR/PARE session</td>
<td>Practical skills session*</td>
<td>Practical skills session*</td>
</tr>
<tr>
<td>13:45-14:45</td>
<td>Basic and Translational Science session</td>
<td>Bone phenotypes of osteoarthritis; towards personalised treatment</td>
<td>Strategic decisions in a career</td>
<td>Unlocking the mystery of health economics</td>
<td>Family business</td>
<td>Ultrasound advanced II</td>
<td>ABC of biopsies: when to perform and how to interpret II</td>
</tr>
</tbody>
</table>

** In order to participate in a guided poster tour, please register at the poster tours & workshops desk, located in the registration area in Hall 7

** In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
13:30 - 14:30  Room 10 A

Health Professionals session

Health Professionals Welcome session

Learning objectives:
• To gain an insight into the HPR programme during the congress and the perspective of the incoming President of EULAR and chair elect of HPR Standing Committee
• To be informed about the HPR newsletter and value of access to the HPR stand whilst attending the congress
• To network with other attendees

Chairperson(s):
Susan Oliver (United Kingdom)
Devid Biscontini (Italy)

Kate Betteridge (United Kingdom)  13:35
Abstract N° SP0001
Getting around: congress, newsletter, resources and important facts for attendees

Gerd R. Burmester (Germany)  13:53
The vision for the EULAR Congress 2015 and the role of HPs in the future

Anthony Redmond (United Kingdom)  14:11
Abstract N° SP0002
EULAR Congress 2015: vision from the Chair Elect for HPR and the insights into the programme; key points

13:30 - 14:30  SC2 - Room A

PARE session

Pre-Conference session

Learning objectives:
The session will give an overview about the congress venue and relevant venues for PARE delegates and will introduce the PARE and joint sessions

Chairperson(s):
Dieter Wiek (Germany)

Faculty  13:35
Information about the Congress center and the PARE programme

12:00 - 13:00  Halls 5&6

Exhibition opening cocktail

14:30 - 15:00  Halls 5&6

Coffee break
What is New (WIN)

WIN session 1

Ronald van Vollenhoven (Sweden)  
Abstract N° SP0003
Clinical aspects of RA - diagnosis, assessment  
15:05

João E. Fonseca (Portugal)  
Abstract N° SP0004
The therapeutic landscape in RA - bDMARDs, biosimilars and beyond  
15:20

Clinical Science session

Psoriatic arthritis - a clinical perspective

Learning objectives:
• Is it possible to diagnose psoriatic arthritis in patients with psoriasis and what are the clinical features that will help to detect arthritis early in psoriasis patients?
• Which comorbidities are associated with psoriatic arthritis and how do they impact on the morbidity and mortality of PsA patients?
• Are PsA and SpA different diseases or do they represent distinct presentations of the same disease?

Chairperson(s):
Peggy Jacques (Belgium)
Kurt de Vlam (Belgium)

Muhammad Haroon (Ireland)  
Can we detect psoriatic arthritis early in psoriasis?  
15:05

Helena Marzo-Ortega (United Kingdom)  
Comorbidity in psoriatic arthritis - beyond the skin and joints  
15:25

Douglas Veale (Ireland)  
Psoriatic arthritis or spondyloarthritis - different or one and the same disease?  
15:45

W. Tillett (United Kingdom)
G. Shaddick, A. Jobling, M. Thomas, E. Korendowych, N. McHugh on behalf of the LOPAS II working group
Abstract N° OP0001
Work disability after initiation of anti-TNF and DMARD treatment in psoriatic arthritis; investigator led, UK, multicentre observational cohort study (LOPAS II)  
16:05

J. Rockberg (Sweden)  
M. Mittal, A. Joshi, Y. Bao, J. Anderson, R. Linder, J. Stålhammar, U. Lindqvist
Abstract N° OP0002
Characteristics, referral and treatment patterns of patients diagnosed with psoriatic arthritis - a retrospective cohort study based in Sweden  
16:15

Challenges in Clinical Practice session

Difficult vasculitis

Learning objectives:
• To review advances in the use of biological therapy for the treatment of AAV
• To identify the distinct subtypes of adult primary CNS vasculitis, the outcome predictors and the optimal management

Chairperson(s):
Raashid Luqmani (United Kingdom)
Carlomaurizio Montecucco (Italy)

Rodrigo Cartin Ceba (United States)  
Case 1 presentation: A difficult to treat case with relapsing granulomatosis with polyangiitis  
15:05

Ulrich Specks (United States)  
Case 1 discussion: Biological therapy in ANCA associated vasculitis: new perspectives  
15:15

Nicolo Pipitone (Italy)  
Case 2 presentation: Amyloid beta-related CNS angiitis presenting with cognitive dysfunction  
15:45

Carlo Salvareani (Italy)  
Case 2 discussion: The spectrum of primary CNS angiitis: diagnosis and treatment  
15:55

How to Treat / Manage (HOT)

HOT session 1

Gabriela Riemekasten (Germany)  
Raynaud’s phenomenon and systemic sclerosis  
15:05

Raynaud’s phenomenon and systemic sclerosis

Xavier Mariette (France)  
Sjögren’s syndrome  
15:45

Clinical Science session

Do new anti-osteoporotic drugs have an additional effect on bone quality?

Learning objectives:
• To get insight in new developments on the measurements of bone quality in daily practice
• To learn about modern treatment of osteoporosis (first 5 years), including new drugs with exciting workings mechanisms
• To be informed about the most often asked question in the field of osteoporosis: what to do after 5 years of treatment?
Chairperson(s):
Gerolamo Bianchi (Italy)
Stephanie Finzel (Germany)

Claus-C. Glüer (Germany) 15:05
How to measure bone quality in osteoporotic patients

Socrates Papapoulos (Netherlands) 15:25
Modern treatment of osteoporosis, the first 5 years of treatment

Kenneth Saag (United States) 15:45
What to do after 5 years of treatment of osteoporosis?

M. Muratore (Italy) 16:05
S. Casciaro, P. Pisani, M. Peccarisi, A. Greco, M. D. Renna, L. Quarta, O. E. Casilli, F. Calcagnile, F. Conversano
Fracture risk prediction: comparative evaluation of ultrasound-based fragility score and DXA-measured BMD against FRAX

L. G. Machado (Brazil) 16:15
D. Domiciano, C. Figueiredo, J. Lopes, V. Caparbo, L. Takayama, R. Oliveira, R. M. R. Pereira
Visceral fat measured by dual-energy X-ray absorptiometry is associated with increased risk of non-spine fractures in nonobese elderly women: a population-based prospective cohort analysis from the São Paulo Ageing & Health (SPAH) study

15:00 - 16:30  Hall 1
Outcome Science session
Optimising the use of electronic information and technology in clinic and research

Learning objectives:
• To get an overview of electronic support in clinical decision making
• To learn how to use electronic medical records in research
• To get the patient perspective on web-based resources in the consultation

Chairperson(s):
Ingemar Petersson (Sweden)
Elaine Hay (United Kingdom)

Staffan Lindblad (Sweden) 15:05
Electronic information as a support tool for clinical decision making

Juan-Angel Jover (Spain) 15:25
The electronic medical record as a research resource

Beryl Svanberg (Sweden) 15:45
Internet resources facilitating the consultation

Y. El Miedany (Egypt) 16:05
M. El Gaafary, S. Youssef, D. Palmer
Electronic patient reported outcome measures (e-PROMS) for early arthritis in standard clinical practice: a pilot study

M. Regardt (Sweden) 16:15
S. Pettersson, S. Svantesson, T. Tarre, K. Wretbring, S. Ernestam
Can an e-health service enhance communication in early arthritis?

15:00 - 16:30  Room 10 B
PReS session
Autoinflammatory diseases

Learning objectives:
• To understand the last advances in the exciting field of autoinflammatory diseases
• To understand how to diagnose and manage these disorders

Chairperson(s):
Michael Hofer (Switzerland)
Carine Wouters (Belgium)

Orsetta Zuffardi (Italy) 15:05
Rare-disease genetics in the era of next-generation sequencing

Seza Ozen (Turkey) 15:25
New autoinflammatory diseases

Marco Gattorno (Italy) 15:45
Impact on NGS in daily practice in autoinflammatory diseases

S. Volpi (Switzerland) 16:05
E. Santori, P. Picco, G. Rice, R. Caorsi, A. Martini, Y. Crow, M. Gattorno, F. Candotti
Blood interferon signature as a screening for type I interferonopathies in children with early-onset SLE and vasculopathy

E. Pisaneschi (Italy) 16:15
F. R. Lepri, D. Minervino, V. Messia, M. Pardeo, F. De Benedetti, A. Insalaco
Single center experience in next generation sequencing for genetic diagnosis of autoinflammatory disorders (AIDS)
15:00 - 16:30  Room 10 I

**Basic and Translational Science session**

**Co-stimulation: towards genuine immune modulation**

**Learning objectives:**
- To understand the overall role of co-stimulation in the initiation and perpetuation of an adaptive (auto)immune response
- To realize that different types of co-stimulation have very specific effects in the immune response
- To recognize the potential of co-stimulation blockade for treatment and eventually prevention of autoimmune diseases

**Chairperson(s):**
John D. Isaacs (United Kingdom)
Kristine Germar (Netherlands)
Bernard Vanhove (France)
Rene van Lier (Netherlands)
Michael Croft (United States)
P. Blanco (France)
L. C. M. Arruda (Brazil)
M. C. Oliveira, D. A. Moraes, D. T. Covas, K. C. R. Malmegrim

15:05
Bernard Vanhove (France)
Abstract N° SP0016
Revisiting anti-CD28 therapy

15:25
Rene van Lier (Netherlands)
Abstract N° SP0017
Modulation of CD70-CD27 interactions

15:45
Michael Croft (United States)
Abstract N° SP0018
OX40 stimulation and blockade in cancer and autoimmunity

16:05
P. Blanco (France)
Abstract N° OP0009
OX40 ligand contributes to human lupus pathogenesis by promoting T follicular helper response

16:15
L. C. M. Arruda (Brazil)
M. C. Oliveira, D. A. Moraes, D. T. Covas, K. C. R. Malmegrim
Abstract N° OP0010
Autologous hematopoietic stem cell transplantation increases T cell PD-1 expression and regulatory mechanisms in systemic sclerosis patients

15:00 - 16:30  Room 10 D-E

**Basic and Translational Science session**

**Estrogens: critical regulator of the immune response; implication for sex bias in the development of autoimmunity**

**Learning objectives:**
- To learn:
  - The different effects of estrogens and androgens on the immune response
  - The effects of estrogens on development of autoimmunity and their influence on the immune response in pregnancy

**Chairperson(s):**
Maurizio Cutolo (Italy)
Monika Østensen (Norway)
Rainer H. Straub (Germany)
Divaker Choubey (United States)
Gil Mor (United States)

15:05
Maurizio Cutolo (Italy)
Estrogens versus androgens effects on the immune response

15:30
Divaker Choubey (United States)
Abstract N° SP0019
Estrogens effects on B cells and implications for sex bias in development of autoimmunity

15:55
Gil Mor (United States)
Estrogens and the immune system response in pregnancy

15:00 - 16:30  Room 10 C

**The Young Rheumatologist**

**Training of rheumatology across Europe**

**Learning objectives:**
- To define the perspective of EULAR in training young rheumatologists across Europe
- To clarify the role of UEMS in unifying rheumatology training in Europe

**Chairperson(s):**
Sofia Ramiro (Netherlands)
Francisca Sivera (Spain)
Johannes W. J. Bijlsma (Netherlands)
Nada Cikes (Croatia)

15:05
Sofia Ramiro (Netherlands)
The perspective of EULAR

15:30
Nada Cikes (Croatia)
The perspective of UEMS rheumatology section and board

15:55
Vasilia Iorgoveanu (Romania)
Involvement of salivary glands in primary Sjögren's syndrome. Elastographic assessment and correlations with ultrasonographic findings

16:05
E. Sivera (Spain)
Abstract N° OP0011
Rheumatology training experience - European survey among rheumatology trainees & newly qualified specialists

16:15
J. M. Senabre Gallego (Spain)
J. Rosas, G. Santos-Soler, E. Salas-Heredia, X. Barber, A. Pons, C. Cano, M. L. Lorente on behalf of AIRE-MB
Abstract N° OP0012
Use of musculoskeletal ultrasound among young rheumatologists in Europe
Health Professionals session
Get on the move with rheumatic and musculoskeletal disease

Learning objectives:
• Present existing evidence about physical activity, physical inactivity and sedentary time in patients with inflammatory arthritis
• Investigate the level of activity and presence of symptoms
• Describe challenges in long-term physical activity promotion

Chairperson(s):
Thijs Swinnen (Belgium)
Carine Savel (France)

Katrine Loeppenthin (Denmark) 15:05
Abstract N° SP0021
Physical activity behavior, fatigue, sleep and pain in patients with rheumatoid arthritis

Bente Appel Esbensen (Denmark) 15:23
Abstract N° SP0022
Reduction of sedentary behavior in patients with rheumatoid arthritis - experiences from an intervention study

Louise Larkin (Ireland) 15:41
Abstract N° SP0023
How to measure physical activity in people with rheumatoid arthritis - focus on objective measurements

Birgitta Nordgren (Sweden) 15:59
Abstract N° SP0024
Challenges in supporting behaviour change in a two-year real-life physical activity program

N. Konijn (Netherlands) 16:17
Abstract N° OP0013
Effective treatment rapidly improves both disease activity and physical activity in early rheumatoid arthritis

PARE session
Building sustainable relationships between patients and researchers

Learning objectives:
• To gain insights into the facilitators and barriers of sustainable involvement of patients in rheumatology research and the benefits of the network model
• To learn more about the limitations and opportunities of patient involvement in clinical research, in particular in clinical trials

Chairperson(s):
Maarten de Wit (Netherlands)
Ingvild Kjeken (Norway)

Lena Andersen (Denmark) 15:05
Abstract N° SP0025
Participatory research - my role as a collaborative partner in scientific initiatives

Ilse De Keyser (Belgium) 15:41
Abstract N° SP0027
A happy ending after all - patient initiated research in rheumatic diseases in Sweden

A. Higginbottom (United Kingdom) 16:17
C. Jinks, J. Bird, C. Rhodes, S. Blackburn, K. Dziedzic
Abstract N° OP0014-PARE
From design to implementation - patient and public involvement in an NIHR research programme in osteoarthritis in primary care
15:00 - 16:30  Room 8 A

Practical skills session*

Laboratory I

Learning objectives:
• When is using a laboratory analysis useful in rheumatic diseases
• What needs to be observed when ordering a lab analysis in the discussed diagnose cases
• Multiple choice system will be used in this course

Chairperson(s):
Gerd R. Burmester (Germany)
Thomas Dörner (Germany)

Thomas Dörner (Germany) 15:05
APS

Pierre Miossec (France) 15:30
Vasculitis, systemic autoimmunity

Eugen Feist (Germany) 15:55
Inflammatory joint diseases

15:00 - 16:30  Room 9 A

Practical skills session*

Improving your graphs and tables for publication and presentation I

Learning objectives:
• How to develop graphs for publications and presentations
• Which type of graph is best used to highlight a particular result

Chairperson(s):
Maarten Boers (Netherlands)

Maarten Boers (Netherlands) 15:05
Abstract N° SP0029
Improving your graphs and tables for publication and presentation

16:30 - 17:00  Halls 5&6
Coffee break

17:00 - 18:30  Hall 8

Clinical Science session

What is the impact of imaging on the management of rheumatoid arthritis?

Learning objectives:
• To deepen the understanding of the implementation process of imaging in clinical practice
• To review latest advances in the role of imaging in early arthritis management
• To have insights into imaging-guided managing biologic therapies

Chairperson(s):
Daniela Fodor (Romania)
Andrea Delle Sedie (Italy)

Maria-Antonietta d’Agostino (France) 17:05
Abstract N° SP0030
Is imaging sufficiently standardised to implement in clinical practice?

Paul Emery (United Kingdom) 17:25
Abstract N° SP0031
Imaging in early arthritis management - diagnosis and monitoring

Georg Schett (Germany) 17:45
Imaging to guide biologic therapy tapering/withdrawal

I. Sahbudin (United Kingdom) 18:05
L. Pickup, Z. Cader, A. Abishek, C. D. Buckley, G. Allen, P. Nightingale, P. de Pablo, K. Raza, A. Filer
Abstract N° OP0015
Ultrasound-defined tenosynovitis is a strong predictor of early rheumatoid arthritis

M. Andersen (Denmark) 18:15
Abstract N° OP0016
The effects of biologics on imaging pathology reflects changes in ex-vivo mediator release from rheumatoid arthritis synovial explants: a cohort study

17:00 - 18:30  Hall 3

Challenges in Clinical Practice session

Calcinosis

Chairperson(s):
László Czirják (Hungary)
Marco Matucci-Cerinic (Italy)

Susanne Schinke (Germany) 17:05
Abstract N° SP0032
Case 1 presentation: Calcinosis in SSc: mystery with different faces and therapeutic approaches

Gabriela Riemekasten (Germany) 17:15
Case 1 discussion: The different faces of calcinosis: the time is important for therapy selection

Begonya Alcacer-Pitarch (United Kingdom) 17:45
Case 2 presentation: Skin ulceration and crystal-induced inflammation

Francesco Del Galdo (United Kingdom) 17:55
Case 2 discussion: Balancing management of skin ulceration and crystal-induced inflammation

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
17:00 - 18:30  Room 10 F-G

How to Treat / Manage (HOT)

HOT session 2

Michael Nurmohamed (Netherlands)  17:05
Abstract N° SP0033
EULAR recommendation update on cardiovascular disease in RA

Maxime Dougados (France)  17:30
Abstract N° SP0034
EULAR recommendations on the management of comorbidities in rheumatic diseases

Laure Gossec (France)  17:55
Abstract N° SP0035
EULAR recommendation update on the management of PsA

17:00 - 18:30  Hall 2

Clinical Science session

Pregnancy in rheumatic diseases

Learning objectives:
To learn about new advances and data about inflammatory rheumatic diseases during pregnancy

Chairperson(s):
Radboud Dolhain (Netherlands)
Joao Dias (Portugal)

Eliza Chakravarty (United States)  17:05
Contraception in rheumatic diseases

Bonnie Bermas (United States)  17:25
Abstract N° SP0036
SLE and Sjögren’s: maternal and fetal risks; treatment strategies

Monika Østensen (Norway)  17:45
Abstract N° SP0037
Treatment in RA and SpA during pregnancy: present and future

A. Strangfeld (Germany)  18:05
D. Pattloch, M. Spilka, B. Manger,
B. Krummel-Lorenz, A. Gräßler, J. Listing, A. Zink
Abstract N° OP0017
Pregnancies in patients with rheumatoid arthritis: treatment decisions, course of the disease, and pregnancy outcomes

M. E. Clowse (United States)  18:15
F. Förger, J. Cush, D. Wolf, A. Golembesky,
L. Shaughnessy, D. De Cuypier, U. Mahadevan
Abstract N° OP0018
Pregnancy outcomes with trimesters of maternal exposure to Certolizumab pegol: prospective and retrospective reports from safety surveillance

17:00 - 18:30  Hall 1

Outcome Science session

Searching for evidence to support clinical practice - using non-steroidals as an example

Learning objectives:
• To understand why evidence to support clinical practice may differ according to the data source
• To understand the strengths and weakness of clinical trials, observational studies, primary care databases and clinical guidelines as sources of evidence for NSAID effectiveness

Chairperson(s):
Francis Guillemin (France)
George Kitas (United Kingdom)

Désirée van der Heijde (Netherlands)  17:05
Does continuous use of non-steroidals prevent the development of radiographic spinal progression in SpA - clinical trials vs. observational studies?

Lennart Jacobsson (Sweden)  17:25
Are non-steroidals harmful from a CV perspective in patients with inflammatory arthritis - what do controlled trials and observational data tell us?

Danielle van der Windt (Netherlands)  17:45
Abstract N° SP0038
Do non-steroidals have a role in the management of non-inflammatory pain - clinical trials vs. guidelines

C. Pontes (Spain)  18:05
R. Morros, J. R. Marsal, F. de Abajo, J. R. Castillo,
J. Rios, X. Carné, P. du Souich
Abstract N° OP0019
Osteoarthritis, drug use and risk of cardiac ischaemic events: a case-control study

J. Widdifield (Canada)  18:15
C. Moura, Y. Wang, M. Abrahawodiumicz,
M.-E. Beauchamp, M. Paterson, A. Huang, G. Boire,
P. Fortin, L. Bessette, C. Bombardier, J. Hanly,
D. Feldman, S. Bernatsky
Abstract N° OP0020
The influence of drug exposures on joint surgeries in rheumatoid arthritis patients: cross-provincial comparisons

17:00 - 18:30  Room 10 B

PReS session

From children to adults

Learning objectives:
• To understand how to manage transition from paediatric to adult care
• To know the fate of childhood rheumatic diseases in adult age
Basic and Translational Science session

Food and the immune system

Learning objectives:
The session of food and immune system will highlight new insights on the relationship between dietary components (lipids, antigens, sodium) and the immune function in health and disease

Chairperson(s):
Berent J. Prakken (Netherlands)
Elena Neumann (Germany)

Hilde Cherouitre (United States) 17:05
Dietary antigens and immune system

Eric Kalkhoven (Netherlands) 17:35
Lipsid and NKT cells in fat

Jens M. Titze (United States) 17:55
Sodium sensing and imaging

B. Sehnert (Germany) 18:15
Low salt diet ameliorates collagen-induced arthritis

Basic and Translational Science session

Computers in rheumatology - friends or foes?

Learning objectives:
• This session will focus on cutting edge technology using the latest information technology in medicine and rheumatology
• The participants will learn about the latest developments in artificial intelligence and how to utilise large electronic data banks for research
• In addition, the role of computers in diagnosis, decision making and laboratory analysis will be addressed

Chairperson(s):
Gerd R. Burmester (Germany)
Tom Huizinga (Netherlands)

Guido Germano (United States) 17:05
Abstract N° SP0042
Artificial intelligence in medicine - are we there yet?

Joshua Denny (United States) 17:25
Electronic record keeping - use of big data

Bert Kappen (Netherlands) 17:45
Abstract N° SP0043
Learning and reasoning in health informatics

Eugen Feist (Germany) 18:05
Abstract N° SP0044
Automated laboratory analysis - men against machines

17:00 - 18:30 Room 10 D-E

The Young Rheumatologist

Science bites: 10 arthritis abstracts & 10 systemic inflammation abstracts

Learning objectives:
How to present your results in 3 minutes

Chairperson(s):
Timothy R. Radstake (Netherlands)
Anna Moltó (Spain)
E. Generaal (Netherlands)

E. Volkmann (United States) 17:09
Cyclophosphamide versus mycophenolate for systemic sclerosis-related interstitial lung disease

S. Bosello (Italy) 17:13
NT-proBNP and Troponin T in systemic sclerosis: prognostic biomarkers of cardiac involvement

17:00 - 18:30 Room 10 C
M. Mortada (Egypt) 17:17
M. M. Ashour, S. F. Abbas, H. A. Ammar, N. Ezzeldin, N. A. Salama
Abstract N° FRI0546
Multiple versus single ultrasound guided suprascapular nerve block in treatment of frozen shoulder in diabetic patients

S. P. Chinchilla (Spain) 17:21
I. Urionagüena, F. Perez-Ruiz
Abstract N° FRIO309
Serum magnesium levels in patients in relation to diuretic treatment

J. F. Ferreira (United Kingdom) 17:25
M. Y. Md Yusof, S. Das, E. M. Vital, P. Emery
Abstract N° FRI0155
Rituximab associated late onset neutropaenia: safety of retreatment Rituximab therapy in 900 patients

M. Ferrari (United Kingdom) 17:29
S. C. Onuoha, D. Sblattero, C. Pitzas
Abstract N° FRI0103
Synovial specific prodrug for the next generation of anti-TNF therapy in rheumatoid arthritis

J. Zhao (China) 17:33
M. Li, Q. Wang, Y. Liu, C. Huang, Z. Tian, Y. Zhao, X. Zeng
Abstract N° FRIO383
Long-term outcomes and predictors of mortality in systemic lupus erythematosus-associated pulmonary arterial hypertension: a single center cohort study

E. Silvagni (Italy) 17:37
A. Bortoluzzi, M. Padovan, F. Furini, M. Borrelli, M. Govoni
Abstract N° FRI0384
Usefulness of brain MRI in early lupus: how the morphological imaging changes at onset of the disease and after follow-up

N. Groot (Netherlands) 17:41
D. Shaikhani, A. Kardolus, R. Dolhain, M. Bijl, K. de Leeuw, R. Fritsch, I. Bultink, S. Kamphuis on behalf of CHILL-NL study group
Abstract N° SAT0446
The CHILL-NL study: very long term outcome of childhood-onset SLE: disease activity, disease damage and quality of life

E. Orlova (Russian Federation) 17:45
D. Karateev, L. Denisov, A. Kochetkov, E. Nasonov
Abstract N° THU0591
Comparative efficacy of two exercises programs in patients with early rheumatoid arthritis: 6-month randomized controlled trial

A. Ariani (Italy) 17:49
Abstract N° FRI0443
Can quantitative chest CT predict interstitial lung disease worsening in systemic sclerosis? Results from a multicentre prospective cohort study
### Health Professionals session

#### Ethnicity - a blind spot within rheumatology?

**Learning objectives:**
- Awareness of existing barriers to health care in ethnic minority patients
- Awareness of the different cultural health beliefs about disease and treatments
- Knowledge on reasons for variations in priority treatment outcomes for different cultural groups
- Knowledge on interventions to overcome health literacy barriers in minority patients

**Chairperson(s):**
Marios Kouloumas (Cyprus)
Rinie Geenen (Netherlands)
Heidi A. Zangi (Norway)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker (Country)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:05</td>
<td>Kanta Kumar (Kenya)</td>
<td>Barriers to health care in ethnic minority patients with rheumatic and musculoskeletal diseases</td>
</tr>
<tr>
<td>17:23</td>
<td>Homaira Sofia Khan (United Kingdom)</td>
<td>The minority patient’s journey - delay in seeking medical help, beliefs about medicines and consequences for adherence to treatment</td>
</tr>
<tr>
<td>17:59</td>
<td>Ade Adebajo (United Kingdom)</td>
<td>Overcoming barriers to health literacy in ethnic populations using a multi-lingual interactive mind-map</td>
</tr>
<tr>
<td>18:17</td>
<td>Y. Prior (United Kingdom)</td>
<td>Abstract N° OP0024-HPR Participation in valued life activities in people with rheumatoid arthritis: a comparison between the UK and Sweden</td>
</tr>
</tbody>
</table>

### PARE session

#### Measuring success - how to evaluate the impact of your campaign

**Learning objectives:**
- How to measure the impact of projects and campaigns
- How campaigns lead to policy changes

**Chairperson(s):**
Kirsten Lerstroem (United Kingdom)
Elsa Mateus (Portugal)
Jürgen Clausen (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker (Country)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:05</td>
<td>Jacob Andreas Holch (Denmark)</td>
<td>Successfully measuring impact in practice - changing national policy in Denmark</td>
</tr>
<tr>
<td>17:45</td>
<td>M. Ekroth (Finland)</td>
<td>Redefining success in campaigning: from activities to collective impact</td>
</tr>
<tr>
<td>18:05</td>
<td>J. Hirvonen, R. Katko, L. Salminen, M. Kukkurainen, L. Pirila, H. Mäkinen on behalf of the Finnish Rheumatism Association, the Finnish Rheumatology Nurses, the Finnish Society for Rheumatology, Abbvie, Astra Zeneca, Pfizer, BMS and MSD</td>
<td>Campaign against the shortage of rheumatology professionals</td>
</tr>
<tr>
<td>18:15</td>
<td>K. Koutsogianni, J. Papadakis, M. Skoulataki, M. Chatziioannou, T. Kalantzii</td>
<td>Campaign for early and accurate diagnosis and early intervention in RMDs</td>
</tr>
</tbody>
</table>
17:00 - 18:30  Room 8 A

**Practical skills session**

**Capillaroscopy I**

**Learning objectives:**
Learn how to do a capillaroscopy scan and how to interpret the results

**Chairperson(s):**
Ariane L. Herrick (United Kingdom)
Vanessa Smith (Belgium)

Ariane L. Herrick (United Kingdom) 17:05
Abstract N° SP0052
Incidence, significance and clinical approach to the Raynaud’s phenomenon

Vanessa Smith (Belgium) 17:20
Abstract N° SP0053
How to differentiate normal from abnormal capillaroscopic patterns and their diagnostic role in rheumatic diseases

Maurizio Cutolo (Italy) 17:35
Abstract N° SP0054
The predictive and prognostic power of the capillaroscopic analysis

Alberto Sulli (Italy) 17:50
Abstract N° SP0055
Capillaroscopic versus laser Doppler analysis of the microcirculation

Walter Hermann (Germany) 18:00
How to select the most appropriate capillaroscopic device: pros and cons

**Faculty** 18:10
Practical session with patients and case discussion

17:00 - 18:30  Room 9 A

**Practical skills session**

**Crystals I**

**Learning objectives:**
Learn how to use a microscope to detect and interpret crystals in synovial fluid

**Chairperson(s):**
Eliseo Pascual (Spain)
Anne Kathrin Tausche (Germany)

Tutors(s):
Eleonora Norkuviene (Lithuania)
Francisca Sivera (Spain)
José Pimentao (Portugal)

18:45 - 20:00  Hall 9

**EULAR 2015 Opening Plenary Session**

20:00 - 22:00  EULAR Garden

 Networking platform

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
A show this big deserves big news. AbbVie is planning the launch of Phase 3 clinical trials for an investigational oral selective JAK-1 inhibitor. Learn more about how you can get involved in this and other ongoing RA and OA research. And join us in our pursuit to help patients lead healthier lives.

Visit Booth 6.7
08:00 - 19:30  Hall 7

Registration

08:30 - 10:00  Room 10 I

**Basic and Translational Science session**

**Beyond GWA: functional genomics**

**Learning objectives:**
Learn about new approaches to connect genetics, epigenetics and transcriptome analysis

**Chairperson(s):**
Anthony G. Wilson (Ireland)
Christian G. Ammitzboll (Denmark)

**Gilles Chiocchia (France)** 08:35
Abstract N° SP0056
Functional genomics in SpA

**Stephen Eyre (United Kingdom)** 08:55
Abstract N° SP0057
From gene to pathway

**Soumya Raychaudhuri (United States)** 09:15
Abstract N° SP0058
Epigenetics and functional genomics

**A. Walsh (United States)** 09:35
J. W. Whitaker, C. C. Huang, Y. Cherkas, S. Lamberth, C. Brodmerkel, M. Curran, R. Dobrin
Abstract N° OP0027
Identification of molecular disease drivers using eQTLs derived from a cohort of rheumatoid arthritis patients

**C. Duarte (United Kingdom)** 09:45
T. Vyse, L. Boteva, M. Fernando
Abstract N° OP0028
Independent and interactive effects of interferon (IFN)-alpha and the lupus risk haplotype HLA-DRB1*03:01 on gene expression in ex-vivo B cells

08:30 - 10:00  Room 10 D-E

**Basic and Translational Science session**

**Inflammation and fatigue**

**Learning objectives:**
- Understand the mechanisms by which inflammation is associated with fatigue
- Learn how inflammation affects the brain and the body to cause fatigue
- Know the bidirectional influences of inflammation on sleep

**Chairperson(s):**
Piercarlo Sarzi-Puttini (Italy)
Li Alemo Munters (United States)

**Roald Omdal (Norway)** 08:35
Abstract N° SP0059
CNS effects of inflammation: the brain and fatigue
11 June 2015

**Hakan Westerblad (Sweden)**
Abstract N° SP0060
Peripheral effects of inflammation: skeletal muscle and fatigue

**Leslie J. Crofford (United States)**
Abstract N° SP0061
Inflammation and sleep: bidirectional effects

**10:00 - 10:30**
Halls 5&6
Coffee break

**10:30 - 12:00**
Hall 9

**What is New (WIN)**

**WIN session 2**

**Hasan Yazici (Turkey)**
Abstract N° SP0061
Behcet’s disease

**Fabrizio de Benedetti (Italy)**
Abstract N° SP0062
Paediatric rheumatology

**10:30 - 12:00**
Hall 8

**Abstract session**

**Developments in the treatment of RA**

**Chairperson(s):**
Rene Westhoven (Belgium)
Peggy Jacques (Belgium)

**M. C. Genovese (United States)**
Abstract N° OP0029
Baricitinib, an oral janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors: results of the phase 3 RA-BEACON study

**T. Kuijper (Netherlands)**
Abstract N° OP0030
Tapering DMARDs in the treach trial - flare rates, sustained remission and radiological progression

**J. Smolen (Austria)**
Abstract N° OP0031
A phase 2 study evaluating the efficacy and safety of subcutaneously administered Ústekinumab and Guselkumab in patients with active rheumatoid arthritis despite treatment with Methotrexate

**V. Ruiz-Esquide (Spain)**
Abstract N° OP0032
Relationship between clinical remission and serum levels of Tocilizumab in the treatment of rheumatoid arthritis

**G. R. Burmester (Germany)**
Abstract N° OP0033
Efficacy and safety of Mavrilimumab, a fully human GM-CSFR-ALPHA monoclonal antibody in patients with rheumatoid arthritis: primary results from the EARTH EXPLORER 1 study

**J.-E. Gottenberg (France)**
Abstract N° OP0034
Efficacy and safety of Mavrilimumab, a fully human GM-CSFR-ALPHA monoclonal antibody in patients with rheumatoid arthritis: primary results from the EARTH EXPLORER 1 study

**M. Bredemeier (Brazil)**
Abstract N° OP0036
Comparison of low- and high-dose Rituximab for the treatment of rheumatoid arthritis: an updated systematic review and meta-analysis

**M. Dougados (France)**
Abstract N° LB0001
Baricitinib, an oral janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to cDMARD therapy: results of the phase 3 RA-build study

Abstract N° OP0032
Relationship between clinical remission and serum levels of Tocilizumab in the treatment of rheumatoid arthritis

**J. W. J. Bijnens (Netherlands)**
Abstract N° OP0033
Rapid and sustained remission in early rheumatoid arthritis (RA) treated to target with Tocilizumab, Methotrexate, or their combination: the U-Act-Early strategy study

Abstract N° OP0035
Tolerance of Rituximab, Abatacept and Tocilizumab in common practice: analysis of the 3 registries of the French society of rheumatology (AIR, ORA and REGATE)

**M. van der Heijde, Y.-C. Chen, M. Greenwald, E. Drescher, J. Liu, S. Beattie, I. de la Torre, T. Rooney, D. Schlichting, S. de Bono, P. Emery**
Abstract N° LB0001
Baricitinib, an oral janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to cDMARD therapy: results of the phase 3 RA-build study
10:30 - 12:00  Hall 3

Abstract session

SpA clinical

Chairperson(s):
Raj Sengupta (United Kingdom)
Floris A. van Gaalen (Netherlands)

P. Bakker (Netherlands) 10:30
A. Moltó, A. Etcheto, R. van den Berg, F. van Gaalen, F. van den Bosch, R. Landewé, M. Dougados, D. van der Heijde
Abstract N° OP0037
The performance of different classification criteria sets for spondyloarthritis in the ASAS-COMOSPA study

X. Baraliakos (Germany) 10:40
Abstract N° OP0038
Patients with fibromyalgia (FM) do not fulfill classification criteria for axial spondyloarthritis (axSpA) but patients with axSpA may fulfill classification criteria for FM

A. Deminger (Sweden) 10:50
Abstract N° OP0039
A five year prospective study of bone mineral density in ankylosing spondylitis

F. Maas (Netherlands) 11:00
S. Arends, E. van der Veer, F. Wink, M. Efde, H. Bootsma, R. N. Chaudhry, E. Brouwer, A. Spoorenberg
Abstract N° OP0040
Comparison of radiographic damage of the zygapophyseal joints and the vertebral bodies of the cervical spine in patients with ankylosing spondylitis before and after 4 years of TNF-alpha blocking therapy

P. Machado (Netherlands) 11:10
X. Baraliakos, D. van der Heijde, J. Braun, R. Landewé
Abstract N° OP0041
MRI inflammation and fat deposition both contribute to syndesmophyte formation at the same site: a multi-level analysis in patients with ankylosing spondylitis

V. Navarro-Compán (Netherlands) 11:20
S. Ramiro, R. Landewé, M. Dougados, C. Miceli, D. van der Heijde
Abstract N° OP0042
Sacroiliac inflammation on MRI is related to disease activity only in male patients with axial spondyloarthritis: a longitudinal analysis in the DESIR cohort

W. P. Maksymowych (Canada) 11:30
S. Pedersen, S. Wichuk, P. Chiochwanwisawkit, Z. Zhao, R. G. Lambert, B. Connor-Spady, D. Spady
Abstract N° OP0043
Predictors of sustained remission on anti-TNF in an observational cohort of patients with ankylosing spondylitis: the role of MRI parameters of inflammation and structural damage

10:30 - 12:00  Room 10 F-G

How to Treat / Manage (HOT)

HOT session 3

Joachim Müller-Quernheim (Germany) 10:35
Abstract N° SP0062
Sarcoidosis

Xavier Puéchal (France) 11:15
Abstract N° SP0063
Relapsing polychondritis

10:30 - 12:00  Hall 2

Abstract session

Epidemiology and health services research

Chairperson(s):
Loreto Carmona (Spain)
Johan Karlsson (Sweden)

J. Lindhardsen (Denmark) 10:35
M. Faurschou, G. H. Gislason, L. Dreyer
Abstract N° OP0046
Cause-specific mortality in rheumatoid arthritis - a nationwide cohort study

J. C. Sergeant (United Kingdom) 10:45
S. M. M. Verstappen, C. Morgan, R. N. Luben, A. Bhaniani, S. Anuj, A. MacGregor, N. Wareham, D. P. M. Symmons, K.-T. Khaw, I. N. Bruce on behalf of RA-MAP consortium
Abstract N° OP0047
Metabolic and lifestyle predictors of inflammatory polyarthritis in the EPIC-2-NOAR study

I. Markusse (Netherlands) 10:55
L. Dirven, H. Han, K. Ronday, I. Speyer, P. Kerstens, W. Lems, T. Huizinga, C. Allaart
Abstract N° OP0048
Survival in early rheumatoid arthritis patients after 10 years of targeted treatment
A. van Zanten (Netherlands) 11:05
Abstract N° OP0049
Presence of ACPA in a large (>40,000) population based cohort from the Netherlands

M. C. Soh (United Kingdom) 11:15
C. Nelson-Piercy, L. McCowan, M. Westgren, D. Pasupathy
Abstract N° OP0050
Presence of ACPA in a large (>40,000) population based cohort from the Netherlands

J. A. Kopec (Canada) 11:25
Abstract N° OP0051
Relationship between physical activity and hip pain in persons with and without femoroacetabular impingement: a population-based case-control study

D. Kim (Republic of Korea) 11:45
Abstract N° OP0053
Factors associated with early loss to follow-up in a multicenter longitudinal rheumatoid arthritis cohort

Abstract session
SSc clinical and treatment
Chairperson(s):
Frank van den Hoogen (Netherlands)
Serena Guiducci (Italy)

D. Khanna (United States) 10:35
Abstract N° OP0054
Safety and efficacy of subcutaneous Tocilizumab in adults with systemic sclerosis: week 48 data from the faSscinate trial

M. G. Lazzaroni (Italy) 10:45
E. Colombo, I. Cavazzana, O. Distler, R. Hesselstrand, V. Smith, P. Caramaschi, E. Hachulla, A. Balbir-Gurman, K. Romanowska-Próchnicka, V. Ricciere, Y. Allanore, P. Airo’ on behalf of EUSTAR co-authors
Abstract N° OP0055
Anti-RNA polymerase III antibodies in patients with systemic sclerosis: a EUSTAR multicenter collaborative study

C. P. Denton (United Kingdom) 10:55
Abstract N° OP0056
Macitentan in patients with digital ulcers associated with systemic sclerosis: results from the DUAL-1 and DUAL-2 randomised controlled trials

C. Parraga Prieto (United Kingdom) 11:05
J. Galloway, F. Ibrahim, R. Campbell, H. Chinoy, P. Gordon
Abstract N° OP0057
Idiopathic inflammatory myopathy is associated with an increased risk of cardiovascular events in the first five years after diagnosis

E. Hachulla (France) 11:15
Abstract N° OP0058
Efficacy of Sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study

O. Kowal-Bielecka (Poland) 11:25
J. Giovannelli, G. Riemekasten, P. Airò, S. Vettori, F. Cozzi, O. Distler, Y. Allanore, C. P. Denton, D. Launay, E. Hachulla on behalf of EUSTAR co-authors
Abstract N° OP0059
Phenotypes determined by cluster analysis and their survival in the prospective EUSTAR cohort of patients with systemic sclerosis

C. Frantz (France) 11:35
J. Avouac, O. Distler, F. Amrouche, D. Godard, A. T. Kennedy, J. Varga, M. Matucci, Y. Allanore
Abstract N° OP0060
Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey

O. Kowal-Bielecka (Poland) 11:45
Abstract N° OP0061
Update of EULAR recommendations for the treatment of systemic sclerosis
PReS Abstract session
Clinical aspects of paediatric rheumatology

Chairperson(s):
Isabelle Koné-Paut (France)
Jordi Anton (Spain)

J. Swart (Netherlands)
10:35
A. Pistorio, F. Bovis, E. Alekseeva, M. Hofer, S. Nielsen,
J. Anton, A. Consolaro, V. Panaviene, V. Stanevicha,
M. Trachana, C. Ailioaie, P. Quartier, F. De Benedetti,
E. Tsitsami, B. Flato, P. Dolezalova, T. Constantin,
T. Herlin, S. Kamphuis, S. Sawhney, D. Maritsi,
V. Vargova, L. Villa, C. Pallotti, A. Ravelli, A. Martini,
N. Wulfraat, N. Ruperto

Abstract N° OP0062
The addition of one or more biologics to Methotrexate in children with juvenile idiopathic arthritis increases the incidence of infections and serious adverse events.
The 5882 PHARMACHILD cohort

L. S. H. Lim (Canada)
10:45
E. Pullenayegum, L. Lim, D. D. Gladman,
B. M. Feldman, E. D. Silverman

Abstract N° OP0063
From childhood to adulthood: longitudinal trajectory of damage in patients with childhood-onset systemic lupus erythematosus (CSLE)

G. Horneff (Germany)
10:55
H. I. Huppertz, P. Haas, K. Tenbrock, K. Minden
on behalf of BIKER Registry Collaborative Group

Abstract N° OP0064
Drug survival and reasons for discontinuation of biological therapy in 1679 polyarticular juvenile idiopathic arthritis patients

N. Ruperto (Italy)
11:05
H. Brunner, C. Wallace, M. Toth, I. Foeldvari,
J. Bohnsack, D. Milojevic, E. Rabinovich, P. Vavrincova,
D. Kingsbury, K. Marzan, P. Quartier, K. Minden,
E. Chalom, G. Horneff, R.-M. Kuester, J. Dare,
M. Bereswill, H. Kupper, J. Kalabic, A. Martini,
D. Lovell on behalf of PRINTO and PRCSG

Abstract N° OP0065
Long-term safety and effectiveness of Adalimumab in children with moderately to severely active polyarticular or polyarticular-course juvenile idiopathic arthritis

M. E. Zannin (Italy)
11:15
D. Ferrari, V. Gerloni, I. Pontikaki, C. Bracaglia,
R. Cimaz, G. Simonini, F. Falcini, F. Corona, S. Viola,
L. Breda, F. La Torre, F. Vittadello, G. Martini, F. Zulian

Abstract N° OP0066
Safety of anti-TNFα agents for the treatment of juvenile idiopathic arthritis-related uveitis: data from the ORCHIDEA registry

G. Alayli (Turkey)
11:25
O. Kuru, Y. Durmaz, S. Canbaz, A. Bilgici,
D. Durmus, Y. Zahiroglu, I. Ilhanli

Abstract N° OP0067
Chronic widespread pain in childhood and adolescence

P. Hissink Muller (Netherlands)
11:35
D. M. Brinkman, D. Schonenberg,
Y. Koopman-Keemink, J. M. van den Berg, P. Bekkering,
M. van Rossum, L. W. van Suijlekom-Smit, C. F. Allaart,
R. ten Cate

Abstract N° OP0068
Three treatment strategies in recent onset DMARD naïve juvenile idiopathic arthritis: initial results of the Best for Kids-study

F. Speth (Germany)
11:45
C. Hinze, S. Loeb, J.-P. Haas

Abstract N° OP0069
Varicella vaccination in patients with paediatric rheumatic diseases receiving immunosuppression: proposal of a pre-vaccination check list to ensure safety
T. Nemeth (Hungary) 11:15
O. Vilinovszki, K. Szilveszter, A. Mocsai
Abstract Nº OP0074
The effect of cell-specific Syk-deletion on experimental autoimmune arthritis

F. Hosoi (Japan) 11:25
S. Iguchi, Y. Yoshihara, R. Kaneko, Y. Nakachi, D. Akasaka, K. Yonekura, Y. Iwasawa, E. Sasaki, T. Utsugi
Abstract Nº OP0075
TAS5315, a novel Bruton's tyrosine kinase (BTK) inhibitor, demonstrates potent efficacy in mouse collagen-induced arthritis model

M. Biniecka (Ireland) 11:35
M. Canavan, V. Ng, T. Smith, T. McGarry, D. Veale, U. Fearon
Abstract Nº OP0076
Dysregulated bioenergetics within the inflamed joint

R. D. Little (Australia) 11:45
Abstract Nº OP0077
Muscle alterations in an experimental model of chronic arthritis

Abstract session
SLE, Sjögren’s, APS: etiology, pathogenesis, animal models

Chairperson(s):
Patrizia Rovere-Querini (Italy)
Christophe Richez (France)
J. Wither (Canada) 10:35
Abstract Nº OP0078
Presence of an interferon signature in anti-nuclear antibody positive individuals prior to the onset of systemic autoimmune rheumatic disease

R. Hoffman (United States) 10:45
Abstract Nº OP0079
Pharmacodynamic changes in gene expression observed in two phase 3 trials of BAFF blockade with Tabalumab in SLE

G. Nocturne (France) 10:55
Abstract Nº OP0080
CXCL13 and CCL11 serum levels are associated with lymphoma occurrence and disease activity in primary Sjögren’s syndrome. Data from the French prospective cohort assess

C. Lessard (United States) 11:05
Abstract Nº OP0081
Identification of a Sjögren's syndrome-associated variant that influences OAS1 isoform switching and protein expression

J. Cortés-Hernández (Spain) 11:15
C. Solé-Marcé, B. Ferrer, M. Gimenez, J. Ordi-Ros
Abstract Nº OP0082
Microarray and miRNA analysis of cutaneous lupus: differential expression in discoid lupus versus subacute lupus

M. Aringer (Germany) 11:25
M. Skwarek, B. Heschel, J. Fantina
Abstract Nº OP0083
Explaining low C-reactive protein (CRP) levels in systemic lupus erythematosus (SLE): reduced membrane-bound, increased soluble interleukin-6 (IL-6) receptors

M. G. Raimondo (United Kingdom) 11:35
C. Pericleous, A. Radziszewska, M. O. Borghi, P. L. Meroni, I. Giles, A. Rahman, Y. Ioannou
Abstract Nº OP0084
Oxidation of β2-glycoprotein I is strongly associated with the presence of anti-domain I antibodies in patients with antiphospholipid syndrome

A. G. Vakrakou (Greece) 11:45
S. Boiu, A. Papadopoulou, E. Kanavakis, M. N. Manoussakis
Abstract Nº OP0085
The patients with primary Sjögren's syndrome display inflammasome activation in the peripheral blood and the salivary glands that correlates with deficient degradation of DNA

Abstract session
SLE, Sjögren's and APS: clinical aspects other than treatment

Chairperson(s):
Jonathan Kay (United States)
Georges Bertsias (Greece)
L. Andreoli (Italy) 10:35
Abstract Nº OP0086
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy, and menopause in patients with systemic lupus erythematosus and/or the antiphospholipid syndrome
E. Theander (Sweden) 10:45
C. Turesson, T. Mandl, P. Olsson
Abstract N° OP00087
Smokers have reduced risk of primary Sjögren's syndrome (PSS), and smoke cessation may trigger development of the disease

P. Brito Zeron (Spain) 10:55
Abstract N° OP0088
Categorization of baseline systemic activity at diagnosis using the ESSDAI disease activity states (DAS) in primary Sjögren's syndrome: association with poor outcomes

K. Lévesque (France) 11:15
Abstract N° OP0090
Determinants of survival of fetuses with autoimmune congenital heart block and factors associated with neonatal and late-onset dilated cardiomypathy: 214 cases from the French registry of neonatal lupus

R. F. Van Vollenhoven (Sweden) 11:35
Abstract N° OP0092
Remission in SLE: consensus findings from a large international panel on definitions of remission in SLE (DORIS)

K. Hickman (United Kingdom) 11:45
I. Magder, M. Petri
Abstract N° OP0093
The natural history of thrombotic events in systemic lupus erythematosus and associated risk factors

**HPR Abstract session**

**Evidence based practice**

Chairperson(s):
Christina H. Opava (Sweden)
Yvonne van Eijk-Hustings (Netherlands)

I. Larsson (Sweden) 10:30
S. Bergman, A. Bremander
Abstract N° OP0094-HPR
Person-centred care (PCC) may improve health care consumer skills more than regular care - a RCT in patients with CIA undergoing biological therapy

B. A. Esbensen (Denmark) 10:40
K. V. Jensen, C. B. Jacobsen
Abstract N° OP0095-HPR
Men living with rheumatoid arthritis - a qualitative study

I. Cordeiro (Portugal) 10:50
D. Barbosa (Portugal) 10:50
C. Bode, E. Taal, M. van de Laar
Abstract N° OP0096-HPR
Medication adherence in rheumatoid arthritis and psoriatic arthritis patients

R. Arends (Netherlands) 11:00
E. M. H. Selten (Netherlands) 11:10
Abstract N° OP0098-HPR
Structure and importance of patients’ reasons for treatment choices in hip and knee osteoarthritis: a concept mapping study

H. Alexanderson (Sweden) 11:20
Á. Björklund, C. Ottosson, M. Dastmalchi, I. E. Lundberg
Abstract N° OP0099-HPR
Fatigue in adult idiopathic inflammatory myopathies
Abstract session

Osteoarthritis clinical aspects

Chairperson(s):
Roberta Ramonda (Italy)
Martin Englund (Sweden)

C. Wang (United States) 10:35
M. Iversen, T. McAlindon, W. F. Harvey, J. Wong,
R. Fielding, J. Driban, L. L. Price, C. Schmid
Abstract N° OP0103
Comparative effectiveness of Tai Chi versus physical
therapy in treating knee osteoarthritis: a randomized,
single-blind trial

J.-T. van der Woude (Netherlands) 10:45
R. J. van Heerwaarden, S. Spruijt, K. Wiegart,
P. M. van Roermund, D. B. Saris, S. C. Mastbergen,
E. P. Lafeber
Abstract N° OP0104
Knee joint distraction compared with high tibial
osteotomy: a randomized controlled trial

E. L. Healey (United Kingdom) 10:55
N. Foster, E. Nicholls, M. Holden, J. Kigozi, S. Jowett,
S. Tooth, E. M. Hay on behalf of the BEEP trial team
Abstract N° OP0105
Improving the effectiveness of exercise therapy for older
adults with knee osteoarthritis: a pragmatic randomised
controlled trial (the BEEP trial)

J. J. Edwards (United Kingdom) 11:05
K. P. Jordan, M. Porcheret, E. L. Healey, C. Jinks,
J. Bedson, K. Clarkson, E. M. Hay, K. S. Dziedzic
Abstract N° OP0106
Effect of a model consultation on quality of care of
osteoarthritis: a primary care cluster randomised trial

S. Talbi (Morocco) 11:15
H. Azzouzi, N. Aradoini, F. F. Lazrak, S. keita,
M. Errasfa, F. E. Abourazzak, T. Harzy
Abstract N° OP0107
Does metabolic syndrome or its individual components
affect pain and function in knee osteoarthritis women?

L. Alekseeva (Russian Federation) 11:25
N. Kashevarova, E. Zaitseva, O. Pushkova,
A. Smirnov, N. Demin, E. Nasonov
Abstract N° OP0108
Risk factors for progression of knee joint osteoarthrosis
(5-year prospective study)

A. Neuprez (Belgium) 11:45
O. Bruyère, N. Dardenne, S. Distechè, E. Maheu,
N. Burlet, J.-Y. Reginster
Abstract N° OP0110
Assessment and determinants of aesthetic
discomfort in hand osteoarthritis: the Liège hand
osteoarthritis cohort (LIHOC)

Learning objectives:
- To provide best practices in promoting interventions
to support people with RMDs to find a job or to stay at
work
- To present the role of patients, patient organisations,
health professionals and employers to find opportunities
to overcome barriers

Chairperson(s):
Souzi Makri (Cyprus)
Jolanta Grygielska (Poland)

Robbert Janssen (Netherlands) 10:35
Abstract N° SP0064
EU awarded best practice: professional peer
support in staying at work

Debbie Cohen (United Kingdom) 10:55
Abstract N° SP0065
What really works: Engaging health care
professionals in supporting patients into work

Suzanne Verstappen (United Kingdom) 11:15
Abstract N° SP0066
Challenges to make work productivity a meaningful
outcome for clinical trials and for
health care interventions
A. Bosworth (United Kingdom) 11:35
C. Jacklin, L. Wetherly
Abstract N° OP0111-PARE
National rheumatoid arthritis society - rheumatoid arthritis and chronic fatigue

F. Moscogiuri (United Kingdom) 11:45
Abstract N° OP0112-PARE
Improving patient outcomes through clinical networks

10:30 - 12:00  Room 8 A

Abstract session

Adaptive immunology in rheumatic disease

Chairperson(s):
Geraldine Falgarone (France)
John D. Isaacs (United Kingdom)

H. M. McGettrick (United Kingdom) 10:35
Abstract N° OP0113
Homeostatic regulation of T cell trafficking by a B cell derived peptide is lost in early rheumatoid arthritis

M. Daïen (France) 10:45
C. Hua, R. Audo, M. Hahne, B. Combe, J. Morel
Abstract N° OP0114
A proliferative inducing ligand (APRIL) promotes IL-10 production by human B cells

M. Akiyama (Japan) 10:55
Abstract N° OP0115
Increased T follicular helper subset 2 related to increased IgG4 and plasmablasts through IL-4 in IgG4-related disease

A. Pianta (United States) 11:05
E. E. Drouin, Q. Wang, S. Arvilkar, C. E. Costello, A. C. Steere
Abstract N° OP0116
Identification of N-Acetylglucosamine-6-Sulfatase and Filamin a as novel targets of autoimmune T and B cell responses in rheumatoid arthritis

J. Decourcey (United Kingdom) 11:15
A. Nerviani, S. Melgar, S. Bulfone-Paus, C. E. Loscher, M. Bombardieri, C. Pitzalis
Abstract N° OP0117
Snare regulation of TH17 cells and ectopic lymphoid structure (ELS) formation in rheumatoid arthritis

J. Leipe (Germany) 11:25
F. Pirronello, S. Hermann, M. Schiemann, H. Schulze-Koops, A. Skapenko
Abstract N° OP0118
Altered T cell plasticity favors TH17 cells in rheumatoid arthritis

P. Schafer (United States) 11:35
Y. Ye, L. Wu, J. Kosek, Z. Yang, L. Liu, M. Thomas, M. Palmisano, R. Chopra
Abstract N° OP0119
The CRL4 cereblon E3 ubiquitin ligase modulator CC-220 induces degradation of the transcription factors Aiolos and Ikaros: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus

K. Meguro (Japan) 11:45
Abstract N° OP0120
Roles of B cell leukemia/lymphoma 3 in the development of T follicular helper cells and the pathogenesis of rheumatoid arthritis

10:30 - 12:00  Room 9 A

Abstract session

Emerging concepts in genomics and genetics

Chairperson(s):
Anne Barton (United Kingdom)
Annette van der Helm (Netherlands)

A. Hinks (United Kingdom) 10:35
Abstract N° OP0121
Analysis of the MHC region in a large cohort of juvenile idiopathic arthritis cases identifies independent effects at HLA-DRB1 for the most common subtypes of JIA

H. Moncrieffe (United States) 10:45
Abstract N° OP0122
Fine mapping of the CHR 22Q13.1 juvenile idiopathic arthritis risk locus

H. W. van Steenbergen (Netherlands) 10:55
J. A. van Nies, T. W. Huizinga, A. Cantagrel, E. Berenbaum, A. H. van der Helm-van Mil
Abstract N° OP0123
II2RA is associated with persistence of rheumatoid arthritis
D. van der Woude (Netherlands) 11:05
J. van Heemst, A. H. Hensvold, X. Jiang,
H. Van Steenbergen, K. Lundberg, L. Klareiskog,
T. W. Huizinga, A. H. van der Helm-van Mil,
A. I. Catrina, R. E. Toes
Abstract N° OP0124
The protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA

A. Ferreiro-Iglesias (Spain) 11:15
A. Montes, E. Pérez-Pampín, P. Carreira, B. Joven,
R. Caliz, M. A. Ferrer, M. J. Moreno-Ramos, E. Raya,
C. Magro, Y. Vasilopoulos, T. Sarafidou, A. Balsa,
D. Pascual-Salcedo, A. Fernández-Nebro, M. C. Ordóñez,
J. J. Alegre-Sancho, A. Márquez, F. Navarro, V. Moreira,
F. J. Blanco, J. Narvaez, J. D. Cañete, J. Martin,
J. J. Gómez-Reino, A. Gonzalez
Abstract N° OP0125
Replication of GWAS of response to TNF inhibitors in patients with rheumatoid arthritis

J. Tornero (Spain) 11:25
A. Fernández-Nebro, F. Blanco, A. Ortiz, J. D. Cañete,
J. Maymó, M. Alperi-López, B. Fernández-Gutierrez,
A. Olívé, H. Corominas, A. Erra, M. I. Acosta Colman,
Abstract N° OP0126
A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis

L. Bossini-Castillo (Spain) 11:35
E. Lopez-Isac, S. Guerra, S. Assassi, C. P. Simeon,
P. E. Carreira, N. Ortego-Centeno, L. Beretta, C. Lunardi,
G. Riemekasten, T. Witte, N. Hunzelmann, A. Kreuter,
J. H. Distler, A. E. Yoskuyl, J. de Vries-Bouwstra,
A. Herrick, J. Worthington, C. Denton, C. Fonseca,
T. Radstake, M. D. Mayes, J. Martin
Abstract N° OP0127
Association of TYK2 with systemic sclerosis, a new locus in the IL-12 pathway

A. Budu-Aggrey (United Kingdom) 11:45
S. Lohr, J. Bowes, S. Uebe, I. N. Bruce, M. Feletar,
H. Marzo-Ortega, P. Hellilw, A. W. Ryan, D. Kane,
E. Korendowycz, G.-M. Alenius, E. Giardina, J. Packham,
R. McManus, O. FitzGerald, N. McHugh, M. A. Brown,
E. Behrens, H. Burkhardt, U. Hufmeier, P. Ho, A. Reis,
A. Barton
Abstract N° OP0128
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus

Guided Poster tours 12:10 - 13:35
Poster tour
T1: Genetics, epigenetics and microRNA
Chairperson(s): Caroline Ospelt (Switzerland)
Diane van der Woude (Netherlands)
J. Nossent (Australia)
S. S. Johnsen, G. Bakland
Abstract N° THU0001
ERAP-1 haplotype influences clinical phenotype but not cytokine expression in ankylosing spondylitis

J. Sainz (Spain)
L. Canet, R. Cáliz, C. B. Lupañez, H. Canhão,
I. Filipescu, A. Escudero, J. Segura-Catena,
M. J. Soto-Pino, M. Á. Ferrer, E. Pérez-Pampín,
A. González-Utrilla, M. Á. López-Navot, E. Collantes,
J. E. Fonseca
Abstract N° THU0002
Estrogen-related polymorphisms and risk of rheumatoid arthritis: a multicenter study

Y. B. Joo (Republic of Korea)
S.-Y. Bang, Y. Park, K. Kim, J. Choi, H.-S. Lee, S.-C. Bae
Abstract N° THU0003
Searching for the genetic variants associated with bone erosion of rheumatoid arthritis using high-density genotype data for immune loci in a Korean population

S. Yoshida (Japan)
K. Ikari, T. Furuya, A. Taniguchi, H. Yamanaka,
S. Momohara
Abstract N° THU0004
The C677T polymorphism in the MTHFR gene contributes to an increased risk of hip fracture in Japanese patients with rheumatoid arthritis

A. K. Chauhan (United States)
Abstract N° THU0005
Immune complexes and complement mediate epigenetic changes and trigger TLR signaling in CD4+ T cells

R. A. Pollock (Canada)
D. D. O’Rielly, A. Dohey, D. Codner, V. Chandran,
D. Gladman, P. Rahman
Abstract N° THU0006
Validation of differential methylation in maternally versus paternally transmitted psoriatic disease
S. Alivernini (Italy)
B. Tolusso, M. Kurowska-Stolarska, S. Canestri, R. Benvenuto, A. Mangoni, A. L. Fedele, L. Petricca, E. Gremese, I. B. McInnes, G. Ferraccioli
Abstract N° THU0007
MicroRNA-155/PU.1 axis as an epigenetic regulator of B cell activation in rheumatoid arthritis

A. Skapenko (Germany)
S. Lukas, S. Haupt, V. Söntgerath, J. Leipe, H. Schulze-Koops
Abstract N° THU0008
Hypermethylation of treg-specific demethylated regions in the Ikaros transcription factor family members, Helios and Eos, in rheumatoid arthritis tregs

---

12:10 - 13:35 Hall 6

Poster tour

T2: Innate immune mechanism in rheumatic diseases

Chairperson(s):
Angelo Manfredi (Italy)
Nils Venhoff (Germany)
E. Garcia-Melchor (Spain)
M. Guma, J. Yagüe, M. Juan, J. Harper
Abstract N° THU0023
Soluble uric acid exerts a suppressive effect on the response of macrophages to monosodium urate crystals

F. Rivellese (United Kingdom)
Abstract N° THU0024
Human mast cells stimulated with IL-33 and immune complexes down-regulate monocyte activation in rheumatoid arthritis

Q. Wang (Netherlands)
M. M. van Timmeren, A. H. Petersen, J. Yuan, H. Moorlag, R. Li, A. H. Boots, P. Heeringa
Abstract N° THU0025
Effect of ageing on anti-MPO antibody mediated glomerulonephritis in mice

E. J. W. Geven (Netherlands)
A. Sloetjes, I. DiCeglie, W. de Munter, S. van Dalen, G. Ascone, P. L. E. M. van Lent
Abstract N° THU0026
A systemic shift towards a pro-inflammatory monocyte subpopulation in bone marrow upon locally induced experimental osteoarthritis

T. McGarry (Ireland)
Abstract N° THU0027
The effect of novel compound MCC950 on the NLRP3 inflammasome in the RA joint

---

12:10 - 13:35 Hall 6

Poster tour

T3: RA - pathogenesis and biology

Chairperson(s):
Zoltán Szekanecz (Hungary)
Agnes Horvath (Hungary)
L. Sun (China)
Y. Sun, W. Kong, W. Chen, G. Yao, X. Feng
Abstract N° THU0037
Comparable therapeutic potential of umbilical cord mesenchymal stem cells in collagen induced arthritis with anti-tumor necrosis factor or anti-CD20

H.-R. Kim (Republic of Korea)
S.-H. LEE, S.-H. LEE, H.-Y. KIM on behalf of department of rheumatology, Konkuk University School of medicine
Abstract N° THU0038
Vascular endothelial growth factor (VEGF) induces osteoclastogenesis in rheumatoid arthritis

S. Ahmed (United States)
N. Akhtar
Abstract N° THU0039
Regulation of ASK-1 expression by microRNA-17 and its correlation with rheumatoid arthritis pathogenesis
In rheumatoid arthritis, smoking is not associated with anti-citrullinated protein antibodies (ACPA) per se, but with the concurrent presence of rheumatoid factor, ACPA and anti-carbamylated protein antibodies.

H. U. Scherer (Netherlands)
A. Kempers, R. Nejadnik, Y. Rombouts, W. Jiskoot, T. W. Huizinga, R. E. Toes

Abstract N° THU0041
Anti-citrullinated protein antibody binding profile to human FC gamma receptors.

D. Shealy (United States)
D. Gardner, E. Lacy, S. Wu

Abstract N° THU0042
Preclinical characterization of Sirukumab, a human monoclonal antibody that targets human interleukin-6 signaling.

M. Kato (Japan)

Abstract N° THU0043
AAA-ATPASE P97 regulates apoptotic and autophagy-associated cell death in arthritis.

A. Llop-Guevara (Spain)
C. Cendón, I. di Ceglie, M. Porras, P. L. van Lent, T. Kamradt, L. Gómez-Casajús, J. Román

Abstract N° THU0044
Simultaneous inhibition of JAK and SYK kinases ameliorates chronic, severe and destructive arthritis in mice.

Y.-W. Park (Republic of Korea)

Abstract N° THU0045
Dysregulated osteoclastogenesis is related to natural killer T cell dysfunction in rheumatoid arthritis.

R. Toes (Netherlands)

Abstract N° THU0046
Abatacept decreases disease activity in the absence of CD4+ T cells in the collagen induced arthritis model.

12:10 - 13:35 Hall 6
Poster tour
T4: RA - predictors of complications and outcomes I

Chairperson(s):
Leslie J. Crofford (United States)
Elena Nikipherou (United Kingdom)
L. Lu (United States)
S. R. Schoenfeld, S. Rai, Y. Zhang, H. K. Choi
Abstract N° THU0086
The survival impact of statins in rheumatoid arthritis: a general population-based cohort study

H. Ince-Askan (Netherlands)
J. M. Hazes, R. J. Dolhain
Abstract N° THU0087
Is the disease course during first pregnancy predictive for the next pregnancy?

Poster tour

T5: RA - prognosis

Chairperson(s):
Deborah Symmons (United Kingdom)
Anja Strangfeld (Germany)

D. De Cock (Belgium)
L. Corluy, R. Joos, C. Langenaken, V. Taelman,
F. Raeman, I. Ravillinge, K. Vandeyvere, J. Lenaerts,
E. Geens, P. Geusens, J. Vanhoof, A. Durnez, J. Remans,
B. Vander Cruyssen, E. Van Essche, A. Sileghem,
G. De Brabanter, J. Joly, S. Meyfroidt, K. van der Elst,
R. Westhovens, P. Verschueren on behalf of the CareRA study group
Abstract N° THU0117
Low-risk patients also benefit from remission induction treatment in early rheumatoid arthritis: week 52 results from the CareRA trial

L. M. M. Steunebrink (Netherlands)
H. E. V onkeman, P. M. ten Klooster, H. H. Kuper,
A. E. van der Bijl, P. L. van Riel, M. A. van de Laar
Abstract N° THU0118
General applicability of a new treat-to-target treatment strategy in Dutch patients with early rheumatoid arthritis: results from the DREAM remission induction cohort II

L. Kuusalo (Finland)
K. Puolakka, H. Kautiainen, M. Leirisalo-Repo,
V. Rantalaiho on behalf of NEO-RACo Study Group
Abstract N° THU0119
Impact of neglecting intra-articular glucocorticoid-injections in remission targeted treatment of early rheumatoid arthritis: results from the DREAM remission induction cohort II

F. Salaffi (Italy)
M. Carotti, A. Ciapetti, M. Di Carlo, M. Gutierrez
Abstract N° THU0122
A tailored telemonitoring tight control strategy for patients with early rheumatoid arthritis. Is more effective than usual care treatment in daily clinical practice?

M. de Hair (Netherlands)
M. Jurgens, F. Lafeber, J. Jacobs, J. van Laar on behalf of the Society for Rheumatology Research Utrecht
Abstract N° THU0123
Is a high contribution of tender joint count and VAS general health to the DAS28 associated with poor clinical response to treatment in early DMARD-naïve RA patients?

P. Mehta (United Kingdom)
K. Davey, R. Williamson, R. Rao, P.-P. Tak
Abstract N° THU0124
Meta-analysis of randomised controlled trials of biologics in DMARD-naive and DMARD-inadequate responder subjects with rheumatoid arthritis: efficacy and safety

N. Konijn (Netherlands)
L. van Tuyl, D. Den Uijl, M. Ter Wee, P. Kerstens,
A. Voskuyl, D. van Schaardenburg, W. Lems,
M. Nurmmohamed
Abstract N° THU0125
Prednisolone causes dose related unfavourable effects on body composition in early rheumatoid arthritis patients during the first year of treatment

T. S. Jørgensen (Denmark)
S. Tarp, D. E. Furst, A. Dossing, P. Taylor, H. Bliddal,
R. Christensen
Abstract N° THU0126
Added-value of combining Methotrexate with a biological agent compared to biological monotherapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials

12:10 - 13:35 Hall 6

Poster tour

T6: RA - small molecules 1

Chairperson(s):
João E. Fonseca (Portugal)
Juan J. Gomez-Reino Carnota (Spain)

A. Manzo (Italy)
S. Bugatti, F. Benaglio, G. Sakellariou, B. Vitolo,
M. Scarabelli, R. Caporali, C. Montecucco
Abstract N° THU0120
Prognostic significance of residual autoimmune/inflammatory activity for disease relapse upon DMARD suspension in patients with early rheumatoid arthritis in sustained remission after DAS-driven therapy

H. Gul (United Kingdom)
M. J. Isorna Porto, F. Ponchel, E. Hensor, R. Wakefield,
P. Emery
Abstract N° THU0121
Do the immunological and ultrasound characteristics reflect the clinical remission phenotype in patients with rheumatoid arthritis?

N. Konijn (Netherlands)
L. van Tuyl, D. Den Uijl, M. Ter Wee, P. Kerstens,
A. Voskuyl, D. van Schaardenburg, W. Lems,
M. Nurmmohamed
Abstract N° THU0125
Prednisolone causes dose related unfavourable effects on body composition in early rheumatoid arthritis patients during the first year of treatment

A. Marren (United States)
Y. Chen, D. Frazier, J. Geier
Abstract N° THU0173
Pregnancy outcomes in the Tofacitinib RA safety database through April 2014

J. Curtis (United States)
E. B. Lee, G. Martin, X. Mariette, K. Terry, Y. Chen,
J. Geier, J. Andrews, M. Kaur, H. Fan, C. Nduaka
Abstract N° THU0174
Analysis of non-melanoma skin cancer across the Tofacitinib rheumatoid arthritis clinical programme
Effects of Baricitinib on multibiomarker disease activity scores and their components in a phase 2B study in moderate-to-severe rheumatoid arthritis patients

Abstract N° THU0175
Effects of Baricitinib on multibiomarker disease activity scores and their components in a phase 2B study in moderate-to-severe rheumatoid arthritis patients

A. A. Othman (United States)

M.-E. Mohamed, H. Camp, P. Jiang, R. Padley, A. Asatryan
Abstract N° THU0176
Pharmacokinetics, safety and tolerability of the selective JAK1 inhibitor, ABT-494, in healthy volunteers and subjects with rheumatoid arthritis

R. Mueller (Switzerland)
Abstract N° THU0177
The influence of initial glucocorticoid therapy on the progression of early RA. Results from the Swiss prospective observational registry

R. F. van Vollenhoven (Sweden)
Abstract N° THU0178
Relationship between NK cell count and important safety events in rheumatoid arthritis patients treated with Tofacitinib

J. Wollenhaupt (Germany)
Abstract N° THU0179
Tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension up to 6 years

R. Fleischmann (United States)
V. Strand, B. Wilkinson, K. Kwok, E. Bananis
Abstract N° THU0180
Relationship between different clinical measurements and patient-reported outcomes: results from a phase 3 study of Tofacitinib or Methotrexate in Methotrexate-naïve patients with rheumatoid arthritis

I. Gaydukova (Russian Federation)
A. P. Rebrov, A. I. Akulova
Abstract N° THU0237
Effectiveness of different schemes of Etoricoxib administration in reduction of active sacroiliitis in patients with axial spondyloarthritis - results of a 12-week, prospective, open-label study

J. Sieper (Germany)
Abstract N° THU0238
A randomized, double-blind, placebo-controlled, 16-week study of subcutaneous Golimumab in patients with active nonradiographic axial spondyloarthritis

S. Arends (Netherlands)
E. Brouwer, F. Wink, R. Bos, F. Maas, H. Bootsma, E. van der Veer, A. Spoorenberg
Abstract N° THU0239
Drug survival and clinical efficacy of 7 years Etanercept treatment in patients with ankylosing spondylitis: results from the GLAS cohort

E. van den Bosch (Belgium)
Abstract N° THU0240
Early clinical response is a better predictor of long-term remission than baseline disease characteristics following Adalimumab treatment in peripheral spondyloarthritis

B. Glintborg (Denmark)
Abstract N° THU0241
Association between tobacco smoking and response to tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: results from the Danish nationwide DANBIO registry

L. Fang (China)
Z. Liao, Z. Lin, O. Jin, Y. Pan, J. Gu
Abstract N° THU0242
Safety of Adalimumab therapy in HBsAg carriers with ankylosing spondylitis: a prospective study

A. Marsman (Netherlands)
Abstract N° THU0243
A concentration-effect curve of Adalimumab in ankylosing spondylitis patients; does it exist or not?

C. Holroyd (United Kingdom)
W. Fong, B. Davidson, R. Armstrong, N. Harvey, E. Dennison, C. Cooper, C. J. Edwards
Abstract N° THU0244
Effectiveness of dose reduction of TNF inhibitors in maintaining low disease activity in severe ankylosing
SCIENTIFIC PROGRAMME / THURSDAY 11 JUNE 2015 / 47

12:10 - 13:35 Hall 5

Poster tour

T8: Lupus nephritis - pathogenesis and animal models

Chairperson(s):
Reinhard E. Voll (Germany)
Nina Chevalier (Germany)

E. Smith (United Kingdom)

Abstract N° THU0373
Demonstration of an ‘excellent’ biomarker panel for identifying active lupus nephritis in children

V. M. Liarski (United States)
D. Yanez, N. van Panhuys, R. Germain, L. Lan, M. Giger, M. Clark

Abstract N° THU0374
Use and validation of cell distance mapping (CDM) in studying the pathogenesis of tubulointerstitial inflammation in human lupus nephritis

V. Kytaridis (United States)

Abstract N° THU0375
Inhibition of STAT3 alleviates nephritis in lupus prone mice

S. Truglia (Italy)
C. Alessandri, F. Ciccia, A. Rizzo, T. Colasanti, F. Miranda, F. R. Spinelli, F. Ceccarelli, G. Triolo, G. Valesini, E. Conti

Abstract N° THU0376
Potential role of interleukin 32 in lupus nephritis pathogenesis

J. Cortés-Hernández (Spain)
C. Solé-Marcé, M. Vidal, M. L. Felip, J. Ordi-Ros

Abstract N° THU0377
MIR-29C in urinary exosomes as predictor of early renal fibrosis in lupus nephritis

N. A. Young (United States)
S. Agarwal, S. Aqel, J. Hampton, K. Jones, L.-C. Wu, N. Powell, J. Sheridan, M. Bruss, W. Jarjour

Abstract N° THU0378
Moderate exercise is beneficial and social stress is detrimental to disease progression in an animal model of lupus nephritis: extra-medicinal influences in autoimmune disease

K. Nishikawa (Japan)

Abstract N° THU0379
Dichotomy in FC gamma receptor IIB deficiency and autoimmune-prone slam haplotype reveals the role of slam haplotype in monocytosis and the significant effect of FC gamma receptor IIB deficiency in Yaa-related lupus nephritis

L. Sun (China)

Abstract N° THU0380
Increased expression of bruton tyrosine kinase in patients with lupus nephritis and its clinic significance

12:10 - 13:35 Hall 5

Poster tour

T9: Treatment of SLE and Sjögren's - clinical aspects

Chairperson(s):
Willem F. Lems (Netherlands)
Lucía Silva-Fernández (Spain)

A. Ruffatti (Italy)

Abstract N° THU0386
Aphaeretic procedures and intravenous immunoglobulins in addition to conventional therapy to treat pregnant women with high-risk antiphospholipid antibody syndrome. A prospective cohort study

M. Petri (United States)
R. S. Martin, C. Hislop, M. A. Scheinberg, R. A. Furie

Abstract N° THU0387
Effects of Blisibimod, an inhibitor of B cell activating factor, on patient reported outcomes and disease activity in patients with systemic lupus erythematosus

M. Cesaroni (United States)
J. Jordan, J. Schreiter, M. Chevrier, W.-H. Shao, B. Hilliard, P. Cohen, R. Caricchio, J. Benson

Abstract N° THU0388
Combining RNA-SEQ and machine learning to classify an SLE-specific gene signature and in vitro responses to IFN-I pathway inhibition

D. A. Martin (United States)

Abstract N° THU0389
A multiple dose study of AMG 811 (anti-IFN-gamma) in subjects with systemic lupus erythematosus and active nephritis

M. Y. Md Yusof (United Kingdom)
D. Shaw, Y. El-Sherbiny, S. Dass, A. C. Rawstron, E. M. Vital, P. Emery

Abstract N° THU0390
Management of primary and secondary non-response to B cell depletion therapy in systemic lupus erythematosus: 10-year experience at a single centre
M. Pugès (France)
P. Biscay, T. Barnetche, M.-E. Truchetet, C. Richez, E. Lazaro, P. Duffau
Abstract N° THU0391
Efficacy and tolerability of influenza and pneumococcal vaccines in patients with systemic lupus erythematosus: a systematic literature review and meta-analysis

S. De Vita (Italy)
L. Quartuccio, R. Seror, S. Salvin, P. Ravaud, M. Fabris, G. Nocturne, S. Gandolfo, M. Isola, X. Mariette
Abstract N° THU0392
Efficacy and safety of Belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study

A. Alunno (Italy)
F. Carubbi, O. Bistoni, S. Caterbi, E. Bartoloni, P. Di Benedetto, P. Cipriani, R. Giacomelli, R. Gerli
Abstract N° THU0393
IL-17 producing pathogenic T lymphocytes co-express CD20 and are depleted by Rituximab in primary Sjögren’s syndrome: a novel target for an old weapon

L. Quartuccio (Italy)
S. Salvin, L. Corazza, S. Gandolfo, C. Pistis, M. Fabris, S. De Vita
Abstract N° THU0394
Low numbers of blood and salivary natural killer cells are associated with a better response to Belimumab in primary Sjögren’s syndrome: results of the BELISS study

R. Seror (France)
Abstract N° THU0395
Worsening of systemic activity and increases of B cell biomarkers in Sjögren’s syndrome after suspension of Belimumab treatment: long-term follow-up after the end of the BELISS study

K. Papp (Canada)
Abstract N° THU0413
Apremilast, an oral phosphodiesterase 4 inhibitor: improvements in nail and scalp psoriasis and psoriasis area and severity index in patients with moderate to severe plaque psoriasis (ESTEEM 1 and 2)

D. van der Heijde (Netherlands)
Abstract N° THU0414
Secukinumab inhibits radiographic progression in patients with psoriatic arthritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (FUTURE 1)

H.-M. Lorenz (Germany)
F. Behrens, R. Lippe, J. Jobst, P.-A. Löschmann, L. Meier
Abstract N° THU0415
Etanercept as monotherapy or in combination with conventional disease-modifying anti-rheumatic drugs in psoriatic arthritis: results from a large, prospective, multicenter, observational study

C. Edwards (United Kingdom)
F. Blanco, J. Crowle, C. Hu, K. Shah, C. Birbara
Abstract N° THU0416
Disease activity and safety during long-term (104-week) treatment with Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (PALACE 3)

O. FitzGerald (Ireland)
R. Fleischmann, B. Hoepken, L. Peterson, D. Gladman
Abstract N° THU0417
Improvements in extra-articular manifestations of psoriatic arthritis over 96 weeks of Certolizumab pegol treatment

A. Gottlieb (United States)
I. B. McInnes, P. Mease, P. Rahman, S. Kandala, M. Patekar, S. Mpofu
Abstract N° THU0418
Secukinumab significantly reduces psoriasis burden in patients with psoriatic arthritis: results from the phase 3 FUTURE 2 study
12:10 - 13:35  Hall 5

Poster tour

T11: Osteoarthritis

Chairperson(s):
Margreet Kloppenburg (Netherlands)
Ruth Wittoek (Belgium)
S. Lapshina (Russian Federation)
L. Myasoutova

Abstract N° THU0437
Understanding between physician and patient with osteoarthritis as a key factor in increasing the effectiveness of therapy
P. Frallonardo (Italy)

Abstract N° THU0438
Role of calcium crystals in inflammation. Synovial fluid analysis by scanning electron microscopy in patients with knee osteoarthritis. Clinical and laboratory investigations in different phases of the disease
G. Hirsch (United Kingdom)
T. O’Neill, G. Kitas, A. Sinha, R. Klocke

Abstract N° THU0439
Accurate intra-articular placement does not result in superior pain reduction following clinically guided corticosteroid injection in knee osteoarthritis; findings of an observational cohort
N. O. Kuchuk (Netherlands)
K. Wiegant, J.-T. A. van der Woude, P. M. van Roermund, E. Eckstein, S. C. Mastbergen, F. P. Lafeber

Abstract N° THU0440
Clinical benefit and cartilaginous tissue repair after knee joint distraction: 5 years follow-up
C. Lozada (United States)

Abstract N° THU0441
Risk-benefit of co-administered Traumeel® (TR14) and Zeel® (ZE14) intra-articular (IA) injections in patients with moderate-to-severe pain associated with OA of the knee (OAK)
J.-T. van der Woude (Netherlands)

Abstract N° THU0442
Knee joint distraction compared with total knee prosthesis: a randomized controlled trial (preliminary results)
J. Martel-Pelletier (Canada)

Abstract N° THU0443
The levels of the adipokines leptin, adipins and adiponectin predict knee osteoarthritis progression as assessed by MRI and total knee replacement occurrence in symptomatic patients
E. Kontny (Poland)
A. Zielinska, K. Ksiezopolska-Orłowska, P. Głusko, W. Maśliński

Abstract N° THU0444
Secretory activity of abdominal subcutaneous adipose tissue in rheumatoid arthritis and osteoarthritis patients - similarities, differences and association with clinical data
I. Starodubtseva (Russian Federation)
L. Vasilieva, A. Nikitin, N. Barsukova

Abstract N° THU0445
The change of laboratory markers in serum under the influence of inhibitor of interleukin-1 in the therapy of secondary osteoarthritis in patients with rheumatoid arthritis
A. Lurati (Italy)
A. Laria, K. A. Re, M. Marrazza, D. Mazzocchi, M. Scarpellini

Abstract N° THU0446
Different distribution and activation degree of TH17 CD4+ cells in peripheral blood in patients with osteoarthritis, rheumatoid arthritis and healthy donors: preliminary results of the MAGENTA CLICAOS (clinical cell analysis in osteoarthritis) study

12:10 - 13:35  Hall 5

Poster tour

T12: Education in rheumatology

Chairperson(s):
Ingrid Lundberg (Sweden)
Estibaliz Loza (Spain)
M. Curran (United States)
R. Singh

Abstract N° THU0573
Development of a paediatric rheumatology education resource-sharing website: if you build it, will they come?
D. G. Fernández-Avila (Colombia)
L. Sastre, S. Mora

Abstract N° THU0574
Development of a series of simulators and design a course based on a clinical simulation, for teaching diagnostic approach to patients with joint pain and suspected rheumatic disease
L. Gossec (France)
P. Chauvin, C. Hudry, F. Mathoret-Philibert, M. Poussière, T. de Chalus, F. Russo-Marie, J. M. Joubert, A. Saraux, F. Berenbaum

Abstract N° THU0575
The most frequent fears and beliefs of 226 patients with rheumatoid arthritis or spondyloarthritis, using a novel questionnaire
P. Santos-Moreno (Colombia)
Abstract N° THU0576
Reduction in adverse events to biological therapy in patients with rheumatoid arthritis after the implementation of one educational strategy for patients and physicians and a scheme of infection risk prevention

M. Zaman (United Kingdom)
on behalf of All Wales Rheumatology Group [AWRG]
Abstract N° THU0577
Welsh national audit of 2013 EULAR recommendations on the management of medium-high dose steroid use in rheumatic diseases

A. D. Woolf (United Kingdom)
J. Erwin, J. A. Howarth, K. J. Edwards
Abstract N° THU0578
Promoting musculoskeletal health in the workplace - the training needs of line managers

C. Beauvais (France)
M. Rodère, B. Peirera, M. Soubrier, L. Gossec
Abstract N° THU0579
What knowledge is essential for patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA)? Results of a multicentric survey among health professionals and patients with DELPHI methodology. An initiative of the French rheumatology society therapeutic education section

D. Stevens (United Kingdom)
D. Collins, E. Price, L. Williamson
Abstract N° THU0580
A two-minute sitting exercise programme to encourage sedentary patients to exercise

G. W. Cannon (United States)
A. M. Barker, J. P. Beck, J. Berdan, M. J. Battistone
Abstract N° THU0581
Three years of experience of the center of excellence in patient-centered education in musculoskeletal care demonstrates successful teaching of the knowledge and skills required for trainees to deliver excellent musculoskeletal care

A. Omar (Canada)
I. Sari, R. Inman, N. Haroon
Abstract N° THU0582
Readability of online ankylosing spondylitis patient education material

S. Pettersson (Sweden)
S. Möller, J. Gustafsson, E. Sveungsson, I. Gunnarsson, E. Welin Henriksson
Abstract N° THU0603-HPR
Patients’ versus physicians’ assessment of disease activity in systemic lupus erythematosus

C. A. Flurey (United Kingdom)
S. Hewlett, K. Rodham, A. White, R. Noddings, J. Kirwan
Abstract N° THU0604-HPR
“Men don’t cry”: the experiences and coping styles of men with RA: a Q-methodology study

T. Swinnen (Belgium)
M. Milosevic, T. Scheers, J. Lefevre, S. van Huffel, W. Dankert, R. Westhovens, K. de Vlam
Abstract N° THU0605-HPR
Patterns of physical activity matter: bout analysis reveals differences between patients with axial spondyloarthritis and healthy controls

S. McKenna (Ireland)
N. Kennedy
Abstract N° THU0606-HPR
The effects of physical activity interventions on body functions & structures, activity and participation outcomes, in people who have rheumatoid arthritis: a systematic review

C. Brumini (Brazil)
J. Natour, L. Y. Miura, A. Jones
Abstract N° THU0607-HPR
Effectiveness of bracing in elderly with knee osteoarthritis: a randomized controlled trial

L. M. Edelaar (Netherlands)
J. H. van Dieën, M. van der Esch, L. D. Roorda, J. Dekker, W. F. Lems, M. van der Leeden
Abstract N° THU0608-HPR
Nonlinearity and relevant thresholds in the relationship between muscle strength and activity limitations in patients with knee osteoarthritis: results of the AMS-OA cohort

B. Hamnes (Norway)
J. Primdahl, Y. van Eijk-Hustings
Abstract N° THU0609-HPR
Readability of patient information and consent documents in rheumatologic studies compared to participants educational level

B.-M. Gilljam (Sweden)
J. Nygren, S. Arvidsson, P. Svedberg on behalf of Health innovations for children’s mental health
Abstract N° THU0610-HPR
Involving children with juvenile idiopathic arthritis in health-related research - why and how?

12:10 - 13:35 Hall 5

HPR Poster tour

T13: Getting to grips with the evidence

Chairperson(s):
Annette de Thurah (Denmark)
Reuben Escorpizo (Switzerland)
12:10 - 13:35  Hall 5

PARE Poster tour
T14: PARE 1

Chairperson(s):
Dieter Wiek (Germany)
Elsa Mateus (Portugal)

C. B. Jacklin (United Kingdom)
A. Bosworth, S. Collins
Abstract N° PARE0001
Development of a training module for health professionals called "rheum2talk"

K. Blidberg (Sweden)
A. Carlsson
Abstract N° PARE0002
Swedish national guidelines for musculoskeletal diseases

J.-N. Dachicourt (France)
D. Poivret, C. Bonnet, G. Chales, F. Alliot-Launois, L. Carton, L. Grange on behalf of Association Francaise de lutte anti-rhumatismale
Abstract N° PARE0003
Mobile apps "the bone thief ", first electronic application on osteoporosis

I. A. Bulgakova (Russian Federation)
Abstract N° PARE0004
Important TUV A children school at the world arthritis day

I. Cederlund (Sweden)
Abstract N° PARE0005
Patient education - a joint venture. National health care working together with the Swedish rheumatism association

J. Loza (Spain)
I. Carmona, P. Zarco, M. T. Flórez
Abstract N° PARE0006
Facilitators and barriers of patients with SpA to physical exercise

K. Fligelstone (United Kingdom)
Abstract N° PARE0007
Systemic sclerosis medical student lecture - the benefits of patient participation

K. Gilbert (United Kingdom)
Abstract N° PARE0008
Using online self-publishing to publish and market a book for patient education (polymyalgia rheumatica and giant cell arteritis: a survival guide): a description and analysis of the process and an evaluation of the result

A. Claassen (Netherlands)
Abstract N° PARE0009
Factors influencing the use of a self-management care booklet for patients with rheumatoid arthritis

S. Sestini (Italy)
L. Millucci, D. Braconi, G. Bernardini, A. Santucci
Abstract N° PARE0010
Alkaptonuria: an old disorder with a late diagnosis

C. A. Rhodes (United Kingdom)
H. Hayes
Abstract N° PARE0011
An insight into membership of involve from the patient and organisational perspective

13:45 - 15:15  Hall 9

What is New (WIN)
WIN session 3

Marco Matucci-Cerinic (Italy) 13:50
Systemic sclerosis/myositis

Wan-Fai Ng (United Kingdom) 14:30
Sjögren’s syndrome

13:45 - 15:15  Hall 8

Clinical Science session
Perspectives on stratified medicine in RA

Learning objectives:
• To learn about current approaches that can be used to stratify treatments in people with RA
• To understand the nature of synovial pathobiological subtypes and how these may be associated with distinct molecular profiles; and whether such subtyping might be predictive of biologic drug response
• To gain insights from the oncology clinical trial landscape and explore how future trials in RA might evolve to enable the delivery of stratified medicine

Chairperson(s):
Costantino Pitzalis (United Kingdom)
Rogier M. Thurlings (Netherlands)

Bernard Combe (France) 13:50
Abstract N° SP0068
What current strategies do we employ for stratifying treatments in RA?

Michael Townsend (United States) 14:10
Abstract N° SP0069
Synovial phenotypes in RA and prediction of response - ready for application?

Mahesh Parmar (United Kingdom) 14:30
Modelling future trials to achieve stratified medicine - lessons from an oncology perspective

B. Lauwerys (Belgium) 14:50
A. De Groof, E. Humby, J. Ducreux, S. Kelly, A. Nzeusseu Toukap, C. Pitzalis, P. Durez
Abstract N° OP0129
Higher expression of TNF alpha-induced genes in the synovium of early RA patients correlates with disease activity, and predicts absence of response to first line therapy
B. V. Cuppen (Netherlands) 15:00
Abstract N° OP0130
A proteomics approach to predict the TNF-alpha inhibitor response in RA: the added clinical value of a protein score

13:45 - 15:15 Hall 3

Challenges in Clinical Practice session
Glucocorticoid sparing in non-RA rheumatic diseases

Learning objectives:
To inform about the most beneficial use of glucocorticoids in giant cell arteritis, polymyalgia rheumatica and SLE, and to understand current glucocorticoid-sparing strategies in these diseases

Chairperson(s):
Eric Matteson (United States)
Christian Dejaco (Austria)

Christian Dejaco (Austria) 13:50
Abstract N° SP0070
Case 1 presentation: GCA and PMR: steroids or bust?

Bhaskar Dasgupta (United Kingdom) 14:00
Abstract N° SP0071
Case 1 discussion: GC sparing in PMR and GCA - fact or myth

Gamal Chehab (Germany) 14:30
Case 2 presentation: “More or less”

Matthias Schneider (Germany) 14:40
Abstract N° SP0072
Case 2 discussion: How and why should we spare GC drugs in successful SLE strategy

13:45 - 15:15 Room 10 F-G

How to Treat / Manage (HOT)
HOT session 4

Janitzia Vazquez Mellado (Mexico) 13:50
Abstract N° SP0073
How to treat severe gout

Rene Rizzoli (Switzerland) 14:30
Metabolic bone disease

13:45 - 15:15 Hall 2

Clinical Science session
Use and abuse of opioids in non-malignant pain

Learning objectives:
• To understand the size of the problem of opioid misuse
• An update on current evidence base for opioid use
• To learn techniques for managing withdrawal from opioids - how to manage patient expectations

Chairperson(s):
Jurgen Damen (Netherlands)
Philip Conaghan (United Kingdom)

Roger Knaggs (United Kingdom) 13:50
Abstract N° SP0074
The global burden of use and abuse of opioids in non-malignant pain

Christoph Baerwald (Germany) 14:15
Current evidence for risk/benefit of opioids in chronic non-malignant pain

Julie Ashworth (United Kingdom) 14:40
Abstract N° SP0075
Clinical approaches to opioid use in chronic pain

S. Salman (Iraq) 15:05
B. Sherif, A. Al-Zohyri
Abstract N° OP0131
Effects of some non steroidal anti-inflammatory drugs on ovulation in women with mild musculoskeletal pain

13:45 - 15:15 Hall 1

Outcome Science session
Functioning measures of function: PROM's and CROM's in the light of the WHO ICF

Chairperson(s):
Ingemar Petersson (Sweden)
Nina Brodin (Sweden)

Gerold Stucki (Switzerland) 13:50
Abstract N° SP0076
International classification of functioning, ICF, in RMDs - an overview/update

Rikke H. Moe (Norway) 14:10
Abstract N° SP0077
ICF related patient reported outcome measures, PROMs, in RMDs - what is useful in the clinical situation

Kjerstin Stigmar (Sweden) 14:30
Abstract N° SP0078
Clinician reported outcome measures, CROMs, in RMDs

D. Kuettel (Denmark) 14:50
J. Primdahl, L. M. Ørnbjerg, H. C. Horn, R. Christensen, K. Hørslev- Petersen
Abstract N° OP0132
The impact of patient- reported flares on radiographic progression in rheumatoid arthritis patients with low-disease activity: a prospective cohort study based on the AMBRA trial

W. Wei (United States) 15:00
C. Chen, E. Sullivan, S. Blackburn, J. R. Curtis
Abstract N° OP0133
Differences in physician-reported and DAS28-based assessment of disease remission among patients with rheumatoid arthritis (RA) in clinical practices
13:45 - 15:15  Room 10 B

**PReS session**

### Dermatomyositis 1

**Learning objectives:**
- To have a comprehensive view on the pathogenesis of chronic myositis
- To have understand the role of autoantibodies and imaging in diagnosis and management of juvenile dermatomyositis

**Chairperson(s):**
Lucy Wedderburn (United Kingdom)
Angelo Ravelli (Italy)
Kanneboyina Nagaraju (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presenter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:50</td>
<td>Neil McHugh</td>
<td>Pathogenesis</td>
</tr>
<tr>
<td>14:10</td>
<td>Clara Malattia</td>
<td>Autoantibodies</td>
</tr>
<tr>
<td>14:30</td>
<td>G. M. Moneta</td>
<td>Imaging</td>
</tr>
<tr>
<td>14:50</td>
<td>G. Laverny</td>
<td>Increased muscle interferon-γ expression levels in juvenile dermatomyositis</td>
</tr>
</tbody>
</table>

**Abstract N° SP0079**

Pathogenesis by Neil McHugh (United Kingdom)

**Abstract N° SP0080**

Autoantibodies by Clara Malattia (Italy)

**Abstract N° SP0081**

Imaging by G. M. Moneta (Italy)

---

13:45 - 15:15  Room 10 I

**Basic and Translational Science session**

### New players in lupus

**Learning objectives:**
- To learn about new insights into pathogenesis and treatment strategies of SLE

**Chairperson(s):**
Joachim R. Kalden (Germany)
Angela Tincani (Italy)
Mariana Kaplan (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presenter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:50</td>
<td>Martin Herrmann</td>
<td>The role of NETs in the pathogenesis of SLE</td>
</tr>
<tr>
<td>14:10</td>
<td>Anushka Soni</td>
<td>Fuctional MRI from acute to chronic pain and placebo effects in joint diseases</td>
</tr>
<tr>
<td>14:30</td>
<td>F. Pan</td>
<td>Pain at multiple sites outside the knee predicts knee cartilage volume loss: a prospective study in older adults</td>
</tr>
</tbody>
</table>

**Abstract N° SP0082**

The role of NETs in the pathogenesis of SLE by Martin Herrmann (Germany)

**Abstract N° SP0084**

Central and peripheral pain in joint diseases by Anne-Marie Malfait (United States)

**Abstract N° SP0085**

Peripheral pain measurements in small animal models of OA by Anushka Soni (United Kingdom)

**Abstract N° SP0088**

Central and peripheral pain in joint diseases by Niels Eijkelkamp (Netherlands)

---

13:45 - 15:15  Room 10 D-E

**Basic and Translational Science session**

### A painful joint - where is the pain coming from?

**Learning objectives:**
- The primary clinical outcome of OA is pain, but the actual process leading to pain are still obscure
- In this session we learn about pain pathways in osteoarthritis
- We learn how changes in the joint, spinal cord, and brain interact, with knowledge from animal models towards human clinical functional MRI presented

**Chairperson(s):**
Simon Mastbergen (Netherlands)
Rinie Geenen (Netherlands)
Niels Eijkelkamp (Netherlands)

<table>
<thead>
<tr>
<th>Time</th>
<th>Presenter</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:50</td>
<td>C. Ding</td>
<td>Pain at multiple sites outside the knee predicts knee cartilage volume loss: a prospective study in older adults</td>
</tr>
<tr>
<td>14:10</td>
<td>F. Pan</td>
<td>Peripheral pain measurements in small animal models of OA</td>
</tr>
<tr>
<td>14:30</td>
<td>Anushka Soni</td>
<td>Fuctional MRI from acute to chronic pain and placebo effects in joint diseases</td>
</tr>
<tr>
<td>14:50</td>
<td>Niels Eijkelkamp</td>
<td>Central and peripheral pain in joint diseases</td>
</tr>
</tbody>
</table>

**Abstract N° SP0084**

Central and peripheral pain in joint diseases by Anne-Marie Malfait (United States)

**Abstract N° SP0085**

Fuctional MRI from acute to chronic pain and placebo effects in joint diseases by Anushka Soni (United Kingdom)

**Abstract N° SP0088**

Central and peripheral pain in joint diseases by Niels Eijkelkamp (Netherlands)
J. Monfort (Spain) 15:00
J. Pujol
Abstract N° OP0139
Central sensitization assessed by fMRI in knee osteoarthritis patients

13:45 - 15:15  Room 10 C
The Young Rheumatologist
International experience

Learning objectives:
To learn how you find a unit to visit, how you can find funding, and what you can expect to gain from an international visit

Chairperson(s):
Victoria Navarro-Compán (Spain)
Snezna Sodin Semrl (Slovenia)
Helga Radner (Austria) 13:50
Abstract N° SP0086
Experience in the US
Karin Lundberg (Sweden) 14:10
Abstract N° SP0087
Long term benefits from international exchange
Raquel Marques (Portugal) 14:30
Abstract N° SP0088
Juvenile dermatomyositis cohort biomarker study and repository (UK & Ireland)
Marton Nikolett (Hungary) 14:40
Abstract N° SP0089
Studying the role of immune complexes and extracellular vesicles on osteoclastogenesis
Ramona A. Valea (Romania) 14:50
Abstract N° SP0090
Ultrasound findings in patients with asymptomatic hyperuricemia

Faculty 15:00
General discussion

13:45 - 15:15  Room 10 A
Health Professionals session
Cardiovascular risk assessment - getting to grips with the challenges

Learning objectives:
• To have an understanding of state of the art and future perspectives of CVR assessment in people with RA
• To get an overview of how nurse-led assessment and management of patients’ CVR is performed in Europe
• To explore common issues in the assessment and management of CVR between RA and diabetes
• To be able to assess RA patients’ risk and calculate a risk score for CV death based on the European SCORE model (mSCORE)
• To explore the challenges/barriers to implementation and registration of systematic screening of CVR in people with RA
• To gain an insight into how to deliver this approach using a patient centred approach

Chairperson(s):
Laure Gossec (France)
Ricardo Ferreira (Portugal)

George Kitas (United Kingdom) 13:50
Abstract N° SP0091
Accuracy of cardiovascular risk algorithms in rheumatoid arthritis and its management: next steps to a targeted approach

Jette Primdahl (Denmark) 14:10
Abstract N° SP0092
How do nurses assess and manage the patient’s cardiovascular risk? Results from European studies

Danielle Moens (Netherlands) 14:30
Abstract N° SP0093
Common issues between diabetes and rheumatoid arthritis regarding cardiovascular risk assessment and management

T. Harrison (Canada) 14:50
Abstract N° OP0141-HPR
Modifiable lifestyle factors negatively impact treating to target and haq scores in early rheumatoid arthritis patients

F. Sivera (Spain) 15:00
N. Martinez Alberola, M. Andres, C. Fernández-Carballido, R. Martín-Domenech, M. P. Martínez-Vidal, A. San Martin-Alvarez
Abstract N° OP0140-HPR
The role of a nurse-clinic in the assessment and prevention of cardio-vascular risk

13:45 - 15:15  Room 10 H
EULAR Projects in Health Professionals
Health Professionals' mentoring and networking

Chairperson(s):
Christina H. Opava (Sweden)
Jo Adams (United Kingdom)

Faculty 13:50
Interactive session on future options for HPR mentoring and networking activities

13:45 - 15:15  SC2 - Room A
PARE session
Lost in the system - how to use innovative care to bring health services back to the patient

Learning objectives:
• Introduction to the chronic care model
• How a multi-disciplinary team improves patient outcomes
• How national organisations can support patients in their journey through the healthcare system
Chairperson(s):
Ailsa Bosworth (United Kingdom)
Jean-Noël Dachicourt (France)

Rafael Bengoa (Spain) 13:50
Abstract N° SP0094
Introduction to the chronic care model

Thea Vliet Vlieland (Netherlands) 14:10
Abstract N° SP0095
Multi disciplinary team

Ursula Faubel (Germany) 14:30
Abstract N° SP0096
Deutsche Rheuma-Liga supporting people to find their way through the health system

S. Blackburn (United Kingdom) 14:50
K. Stevenson, S. Somerville, H. Duffy, R. Hughes, K. Dziedzic
Abstract N° OP0142-PARE
Improving the routine care of patients with back pain: the role of public involvement in taking successful research into clinical practice

G. Korevaar (Netherlands) 15:00
Abstract N° OP0143-PARE
Patient advocacy: patient choice in Dutch healthcare

13:45 - 15:15 Room 9 A
Practical skills session
Ultrasound basic I

Learning objectives:
Use and interpretation of US techniques to support diagnosis of the bespoken disease manifestations

Chairperson(s):
Sandrine Jousse-Joulin (France)
Wolfgang A. Schmidt (Germany)
Emilio Filippucci (Italy) 13:50
Basic skills for diagnosing crystal deposits in gout + demo
Frédérique Gandjbakhch (France) 14:10
Basic skills for diagnosing enthesisitis in SpA + demo
George W. Bruyn (Netherlands) 14:30
Basic skills for diagnosing tenosynovitis in RA + demo
Ingrid Möller (Spain) 14:50
Basic skills for diagnosing lateral hip pain + demo

13:45 - 15:15 Room 9 A
Practical skills session
Crystals II

Learning objectives:
Learn how to use a microscope to detect and interpret crystals in synovial fluid

Chairperson(s):
Anne Kathrin Tausche (Germany)
Eliseo Pascual (Spain)

Tutor(s):
Eleonora Norkuniene (Lithuania)
Francisca Sivera (Spain)
Francesca Oliviero (Italy)

15:15 - 15:45 Halls 5&6
Coffee break

15:45 - 17:15 Hall 9
What is New (WIN)
WIN session 4

Frank Buttgerieit (Germany) 15:50
Abstract N° SP0097
Osteoporosis/bone diseases

Philip Conaghan (United Kingdom) 16:30
Abstract N° SP0098
Osteoarthritis

15:45 - 17:15 Hall 8
Clinical Science session
Axial SpA: disease modification

Learning objectives:
• To understand what is considered disease modification in axial SpA
• To understand which drugs are ably to modify the disease course in axial SpA

Chairperson(s):
Xenophon Baraliakos (Germany)
Laure Gossec (France)
Robert B. M. Landewé (Netherlands) 15:50
What is disease modification in axial SpA?

Joachim Sieper (Germany) 16:10
Abstract N° SP0099
Which drugs modify the course of axial SpA?

Irene van der Horst-Bruinsma (Netherlands) 16:30
Abstract N° SP0100
What is the effect of gender, age and disease duration on treatment efficacy?

W. P. Maksymowych (Canada) 16:50
Y. Zheng, S. Wichuk, P. Chiowchanwisawakit, R. G. Lambert
Abstract N° OP0144
The effect of TNF inhibition on radiographic progression in ankylosing spondylitis: an observational cohort study of 384 patients

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
J. Sieper (Germany) 17:00
Abstract N° OP0145
Continuous versus on demand treatment of ankylosing spondylitis with Diclofenac over 2 years does not prevent radiographic progression of the spine - results from a randomized prospective multi-center trial (ENRADAS)

15:45 - 17:15  Hall 3

Challenges in Clinical Practice session
Clinically suspect arthralgia

Learning objectives:
- To understand the size and challenges of the problem in primary care
- To understand the “tipping points” which trigger onward referral and investigation
- To learn about innovative approaches in secondary care

Chairperson(s):
Christian D. Mallen (United Kingdom)
Ade Adebajo (United Kingdom)

Samantha Hider (United Kingdom) 15:50
Abstract N° SP0101
Case 1 presentation: What symptoms do GPs see and what do they do?

Dirkjan van Schaardenburg (Netherlands) 16:00
Abstract N° SP0102
Case 2 discussion: What symptoms do GPs see and what do they do?

Annette van der Helm (Netherlands) 16:30
Abstract N° SP0103
Case 2 presentation: Innovative approaches to managing clinically suspect arthralgia

Karim Raza (United Kingdom) 16:40
Abstract N° SP0104
Case 2 discussion: Innovative approaches to managing clinically suspect arthralgia

How to Treat / Manage (HOT)

HOT session 5

Charles Peterfy (United States) 15:50
Abstract N° SP0105
Added value of imaging in RA

Marianne de Visser (Netherlands) 16:30
Abstract N° SP0106
Myositis

Clinical Science session
Regenerative rheumatology

Learning objectives:
What is the evidence available for the use of stem cells and growth factors

Chairperson(s):
Francisco J. Blanco (Spain)
Jaime C. Branco (Portugal)

Nuno M. Neves (Portugal) 15:50
Abstract N° SP0107
How to produce scaffolds, stem cells and growth factors

Christian Jorgensen (France) 16:10
Abstract N° SP0108
Local repair and immunomodulation with stem cells and growth factors

Andreas Zeiher (Germany) 16:30
Lessons from cardiology: promising or disappointing?

S. van Dalen (Netherlands) 16:50
R. Schelbergen, A. Sloetjes, N. Cremers, M. ter Huurne, E. Wagener, W. van den Berg, P. van Lent
Abstract N° OP0146
Locally administered adipose derived mesenchymal stem cells augment their anti-inflammatory efficacy through IL-1β mediated influx of neutrophils into knee joints with experimental osteoarthritis

S. C. Mastbergen (Netherlands) 17:00
A. Miranda, K. Coeleveld, B. P. Meij, P. M. van Roermund, M. Tryfonidou, F. P. Lafeber
Abstract N° OP0147
Intrinsic cartilage repair by joint distraction is triggered by a regenerative transcriptional response

Outcome Science session
Work productivity as an outcome measure

Learning objectives:
- To understand the impact of RMDs on employment in Europe
- To learn about prognostic factors for work and employment in RMDs
- To understand the current issues of using work productivity as an outcome measure in clinical settings

Chairperson(s):
Bruno Fautrel (France)
Suzanne Verstappen (United Kingdom)
Stephen Bevan (United Kingdom) 15:50
Abstract N° SP0109
The impact of RMDs on employment in Europe
15:45 - 17:15  Room 10 B

**PReS session**

**Dermatomyositis II**

**Learning objectives:**
- To understand the differences between childhood and adult dermatomyositis
- To know the last advances in treatment

**Chairperson(s):**
Pavla Dolezalova (Czech Republic)
Nico Wulfraat (Netherlands)

Brian Feldman (Canada)  15:50
Abstract N° SP0111
Calcinosi, lipodystrophy and other paediatric features

Nicola Ruperto (Italy)  16:10
Abstract N° SP0112
Treatment

Angelo Ravelli (Italy)  16:30
Course and outcome

A. Consolaro (Italy)  16:50
Abstract N° OP0150
Development and preliminary validation of a new composite disease activity measure for juvenile dermatomyositis

K. S. Berntsen (Norway)  17:00
Abstract N° OP0151
The 6-minute walk test assessed in juvenile dermatomyositis after long term follow-up; the impact of muscle, lung, and heart dysfunction
The Young Rheumatologist
Being a researcher in the rheumatology world

Learning objectives:
To help young Ph.D.'s and Ph.D. students to find their way in the clinical world

Chairperson(s):
Marjolein de Hair (Netherlands)
Kerstin Klein (Switzerland)
Ursula Fearon (Ireland)

Ursula Fearon (Ireland) 15:50
How to bring your results from the bench to bedside

Dagmar Scheel-Toellner (United Kingdom) 16:15
Lost in translation - how to understand what clinicians talk about

Rene Toes (Netherlands) 16:40
Career opportunities in a clinical environment

C. Perez-Sanchez (Spain) 17:05
Abstract N° OP0156
In vitro treatment with anti-cardiolipin and anti-DSDNA antibodies modifies the expression of microRNAs related to cardiovascular disease in patients with antiphospholipid syndrome and systemic lupus erythematosus

EULAR projects in Investigative Rheumatology

Chairperson(s):
Rik Lories (Belgium)
Xavier Mariette (France)

Peter van der Kraan (Netherlands) 15:50
Osteoarthritis study group:
OA from the patient to the bench

Vanessa Smith (Belgium) 16:10
Microcirculation in rheumatic diseases study group:
reflections after the first year

Johan Rönnelid (Sweden) 16:30
Laboratory investigation in rheumatology study group:
the added value of collaboration with the international Federation of Clinical Chemistry

Ingrid Zegers (Belgium) 16:50
The working group for harmonisation of autoantibody tests (WG-HAT): current status of development of new reference standards for autoantibodies
15:45 - 17:15  SC2 - Room A

Joint Primare care/PARE session
Who cares? Primary care focus

Learning objectives:
• How to improve the dialogue between patients, primary and secondary care
• How to optimise the care provided by primary care

Chairperson(s):
Stefan Bergman (Sweden)
Codruţa Zabalan (Romania)
Jurgen Damen (Netherlands)
Zoe Paskins (United Kingdom)
Stala Kioupi (Cyprus)
Connie Ziegler (Denmark)
L. Ball (United Kingdom)
J. Kirk, T. Miranda, E. Edwards, B. Colaco

15:45 - 17:15  Room 9 A

Practical skills session*
ABC of biopsies: when to perform and how to interpret I

Learning objectives:
Learn when to perform and how to interpret biopsies

Chairperson(s):
Pedro Machado (Portugal)
Karen Salomon-Escoto (United States)
Costantino Pitzalis (United Kingdom)

Hilde Berner Hammer (Norway) 16:50
Abstract N° SP0124
How to enhance synovitis detection: impact of joint position and scanning technique + demo

15:45 - 17:15  Room 8 A

Practical skills session*
Ultrasound advanced I

Learning objectives:
• When and how to best apply contrast in US
• How to use US in evaluation and diagnosis of the bespoken disease manifestations

Chairperson(s):
Annamaria Iagnocco (Italy)
Marcin Szkudlarek (Denmark)
Louise Diederichsen (Denmark)

17:45 - 19:15
Satellite symposia

• Roche
• AbbVie
• Pfizer
• Bristol-Myers Squibb
• MSD
• Amgen
• AstraZeneca
• RAISE supported by Janssen
• Biologische Heilmittel Heel

Satellite symposia

• Roche
Hall 8
• AbbVie
Hall 3
• Pfizer
Room 10 F-G
• Bristol-Myers Squibb
Hall 2
• MSD
Hall 1
• Amgen
Room 10 I
• AstraZeneca
Room 10 D-E
• RAISE supported by Janssen
Room 10 C
• Biologische Heilmittel Heel
Room 10 H

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
KEEP IN TOUCH WITH RHEUMATOLOGY

UPDATE YOUR CONTACT DETAILS!

Receive your access codes to the recorded sessions*

Receive your free subscription**

Annals of the Rheumatic Diseases - the EULAR Journal (ARD)**

Go to any Yellow Tower to update your contact information to secure delivery of the EULAR Journal and access to view the recorded presentations

*if purchased
** the patient and exhibitor registration categories do not include the complimentary subscription
Guided Poster Tours

Thursday 11 June 2015

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 7, on a "first-come-first-served" basis on the day of the poster tour.

**Poster tour T1: Genetics, epigenetics and microRNA**

**Chairperson(s):** Caroline Ospelt (Switzerland), Diane van der Woude (Netherlands)

**THU0001**
ERAP-1 HAPLOTYPE INFLUENCES CLINICAL PHENOTYPE BUT NOT CYTOKINE EXPRESSION IN ANKYLOSING SPONDYLITIS / J. Nossent* - S. S. Johnsen - G. Bakland

**THU0002**

**THU0003**
SEARCHING FOR THE GENETIC VARIANTS ASSOCIATED WITH BONE EROSION OF RHEUMATOID ARTHRITIS USING HIGH-DENSITY GENOTYPE DATA FOR IMMUNE LOCI IN A KOREAN POPULATION / Y. B. Joo* - S.-Y. Bang - Y. Park - K. Kim - J. Choi - H. S. Lee - S. C. Bae

**THU0004**

**THU0005**
IMMUNE COMPLEXES AND COMPLEMENT MEDICATE EPIDEMIOGENIC CHANGES AND TRIGGER TLR SIGNALING IN CD4+ T CELLS / A. K. Chauhan*

**THU0006**

**THU0007**

**THU0008**
HYPERMETHYLATION OF TREG-SPECIFIC DEMETHYLATED REGIONS IN THE IKAROS TRANSCRIPTION FACTOR FAMILY MEMBERS, HELIOS AND EOS, IN RHEUMATOID ARTHRITIS TREGS / A. Skapenko* - S. Lukas - S. Haupt - V. Sontrager - J. Leipe - H. Schulze-Koops

**Poster tour T2: Innate immune mechanism in rheumatic diseases**

**Chairperson(s):** Angelo Manfredi (Italy), Nils Venhoff (Germany)

**THU0023**
SOLUBLE URIC ACID EXERTS A SUPPRESSIVE EFFECT ON THE RESPONSE OF MACROPHAGES TO MONOSODIUM URATE CRYSTALS / E. Garcia-Melchor* - M. Guma - J. Yagüe - M. Juan - J. Harper

**THU0024**

**THU0025**

**THU0026**

**THU0027**

**THU0028**
CIGARETTE SMOKE TRIGGERED CIRCULATING AND INFILTRATING NEUTROPHIL EXTRACELLULAR TRAPS BY AUTOFLAGY DEPENDENT WAY IN RA PATIENTS / L. Wang* - L. Qian - X. Li

* Presenting author


THU0032  SELECTIVE, AUTOANTIBODY-IMMUNE COMPLEX MEDIATED PROPORTIONAL AND FUNCTIONAL CHANGES OF SPECIFIC NK-CELL SUBSETS IN EARLY SEROPOSITIVE BUT NOT SERONEGATIVE RHEUMATOID ARTHRITIS / P. Chalan - E. Brouwer* - J. Bijzet - B.-J. Kroesen - M. Boots

**Poster tour T3: RA - pathogenesis and biology**  
**Hall 6**

THU0037  COMPARATIVE THERAPEUTIC POTENTIAL OF UMBILICAL CORD MESENCHYMAL STEM CELLS IN COLLAGEN INDUCED ARTHRITIS WITH ANTI-TUMOR NECROSIS FACTOR OR ANTI-CDDO / Y. Sun - W. Kong - W. Chen - G. Yao - X. Feng - L. Sun


THU0039  REGULATION OF ASK-1 EXPRESSION BY MICRORNA-17 AND ITS CORRELATION WITH RHEUMATOID ARTHRITIS PATHOGENESIS / N. Akhtar - S. Ahmed*


THU0042  PRECLINICAL CHARACTERIZATION OF SIRUKUMAB, A HUMAN MONOCLONAL ANTIBODY THAT TARGETS HUMAN INTERLEUKIN-6 SIGNALING / D. Gardner - E. Lacy - S. Wu - D. Shealy*


**Poster tour T4: RA - predictors of complications and outcomes**  
**Hall 6**


THU0079  POLYPHARMACY, ALTHOUGH NOT COMBINATION DMARD THERAPY, IN RHEUMATOID ARTHRITIS IS ASSOCIATED WITH INCREASED HOSPITALISATION RISK / M. Filkova* - F. Ibrahim - S. Norton - D. Scott - T. Mant - A. Cope - M. Molbakia - J. Galloway


THU0082  COMPARISON OF M-DAS AND DAS28, TWO COMPOSITE SCORES FOR PREDICTION OF STRUCTURAL DAMAGES IN EARLY ARTHRITIS: DATA FROM THE ESPOIR COHORT / M. Couderc* - B. Pereira - M. Stuiver - M. D. Koning - L. V. D. Stadt - D. V. Schraardenburg


THU0084  DAMAGES IN EARLY ARTHRITIS: DATA FROM THE ESPOIR COHORT / M. Couderc - B. Pereira - M. V. Devauchelle-Pensec - X. Mariette - M. Soubrier


* Presenting author

THU0087  Is the Disease Course During First Pregnancy Predictive For the Next Pregnancy? / H. Ince-Askan* - J. M. Hayes - R. J. Dolhain

Poster tour T5: RA - prognosis


THU0119  Impact of Neglecting intra-articular glucocorticoid-injections in Remission Targeted Treatment of Early Rheumatoid Arthritis / L. Kuusalo* - K. Puolakka - H. Kauttiainen - M. Leirisalo-Repo - V. Rantalaaho on behalf of Neo-RaCo Study Group

THU0120  Prognostic Significance of Residual Autoimmune/Inflammatory Activity for Disease Relapse upon DMARD Suspension in Patients with Early Rheumatoid Arthritis in Sustained Remission After DAS-driven Therapy / A. Manzo* - S. Bugatti - F. Benaglio - G. Sakellariou - B. Vitolo - M. Scarabelli - R. Caporali - C. Montecucco


THU0123  Is a High Contribution of Tender Joint Count and VAS General Health to the DAS28 Associated with Poor Clinical Response to Treatment in Early DMARD-naïve RA Patients? / M. de Hair* - M. Jurgens - F. Labeber - J. Jacobs - J. van Laar on behalf of the Society for Rheumatology Research Utrecht


Poster tour T6: RA - small molecules

THU0173  Pregnancy Outcomes in the Tofacitinib RA Safety Database Through April 2014 / A. Marren* - Y. Chen - D. Frazier - J. Geier


THU0180  Relationship Between Different Clinical Measurements and Patient-reported Outcomes: Results from a Phase 3 Study of Tofacitinib or Methotrexate in Methotrexate-naïve Patients with Rheumatoid Arthritis / R. Fleischmann* - V. Strand - B. Wilkinson - K. Kwock - E. Bananis

* Presenting author
Poster tour T7: Spondyloarthritis treatment

Chairperson(s): Dominique Baeten (Netherlands), Francesco Ciccia (Italy)

THU0236

THU0237
EFFECTIVENESS OF DIFFERENT SCHEMES OF ETORICOXIB ADMINISTRATION IN REDUCTION OF ACTIVE SACRIFILIUMS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS - RESULTS OF A 12-WEEK, PROSPECTIVE, OPEN-LABEL STUDY / I. Gaydukovuka* - A. P. Rebrov - A. I. Akulova

THU0238

THU0239

THU0240

THU0241

THU0242
SAFETY OF ADALUMAB THERAPY IN HBSAG CARRIERS WITH ANKYLOSING SPONDYLITIS: A PROSPECTIVE STUDY / L. Fang* - Z. Liao - Z. Lin - O. Jin - Y. Pan - J. Gu

THU0243

THU0244
EFFECTIVENESS OF DOSE REDUCTION OF TNF INHIBITORS IN MAINTAINING LOW DISEASE ACTIVITY IN SEVERE ANKYLOSING SPONDYLITIS / W. Fong - C. Holroyd* - B. Davidson - R. Armstrong - N. Harvey - E. Dennison - C. Cooper - C. J. Edwards

Poster tour T8: Lupus nephritis - pathogenesis and animal models

Chairperson(s): Reinhart E. Voll (Germany), Nina Chevalier (Germany)

THU0373

THU0374
USE AND VALIDATION OF CELL DISTANCE MAPPING (CDM) IN STUDYING THE PATHOGENESIS OF TUBULOINTERSTITIAL INFLAMMATION IN HUMAN LUPUS NEPHTRIS / V. M. Liarski* - D. Yaney - N. van Panhuys - R. Germain - D. Lan - M. Giger - M. Clark

THU0375
INHIBITION OF STAT3 ALLEVIATES NEPHRITIS IN LUPUS PRONE MICE / V. Kyttaris*

THU0376

THU0377

THU0378
INHIBITION OF STAT3 ALLEVIATES NEPHRITIS IN LUPUS PRONE MICE / V. Kyttaris*

THU0379

THU0380
INCREASED EXPRESSION OF BRUTON TYROSINE KINASE IN PATIENTS WITH LUPUS NEPHRITIS AND ITS CLINIC SIGNIFICANCE / W. Kong - W. Deng - X. Feng - G. Yao - W. Chen - X. Tang - Y. Sun - S. Huang - Z. Zhang - B. Shi - L. Sun*

Poster tour T9: Treatment of SLE and Sjögren’s - clinical aspects

Chairperson(s): Willem F. Lems (Netherlands), Lucia Silva-Fernández (Spain)

THU0386

THU0387
EFFECTS OF BLISIBIMOD, AN INHIBITOR OF B CELL ACTIVATING FACTOR, ON PATIENT REPORTED OUTCOMES AND DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOUS / M. Petri* - R. S. Martin - C. Hislop - M. A. Scheinberg - R. A. Furie

* Presenting author
THU0388  COMBINING RNA-SEQ AND MACHINE LEARNING TO CLASSIFY AN SLE-SPECIFIC GENE SIGNATURE AND IN VITRO RESPONSES TO IFN-1 PATHWAY INHIBITION / M. Cesaroni* - J. Jordan - J. Schreter - M. Chevrier - W. H. Shao - B. Hilliard - P. Cohen - R. Caricchio - J. Benson


THU0393  IL-17 PRODUCING PATHOGENIC T LYMPHOCYTES CO-EXPRESS CD20 AND ARE DEPLETED BY RITUXIMAB IN PRIMARY SJÖGREN’S SYNDROME: A NOVEL TARGET FOR AN OLD WEAPON / A. Alunno* - F. Carubbi - O. Bistoni - S. Caterbi - E. Bartoloni - P. Di Benedetto - P. Cipriani - R. Giacomelli - R. Gerli


THU0395  UNDERSTANDING BETWEEN PHYSICIAN AND PATIENT WITH OSTEOARTHRITIS AS A KEY FACTOR IN INCREASING THE EFFECTIVENESS OF THERAPY / S. Lapshina* - M. Myasoutova


* Presenting author


THU0445  THE CHANGE OF LABORATORY MARKERS IN SYMPTOM OF INHIBITOR OF INTERLEUKIN-1 IN THE THERAPY OF SECONDARY OSTEOARTHRITIS IN PATIENTS WITH RHEUMATOID ARTHRITIS / I. Starodubtsaeva* - L. Vasilieva - A. Nikitin - N. Barsukova

THU0446  DIFFERENT DISTRIBUTION AND ACTIVATION DEGREE OF TH17 CD4+ CELLS IN PERIPHERAL BLOOD IN PATIENTS WITH OSTEOARTHRITIS, RHEUMATOID ARTHRITIS AND HEALTHY DONORS: PRELIMINARY RESULTS OF THE MAGENTA CLICAO (CLINICAL CELL ANALYSIS IN OSTEOARTHRITIS) STUDY / A. Lurati* - A. Laria - K. A. Re - M. Marrazza - D. Mazzochi

**Poster tour T12: Education in rheumatology**

*Chairperson(s): Ingrid Lundberg (Sweden), Estibaliz Loza (Spain)*

THU0573  DEVELOPMENT OF A PAEDIATRIC RHEUMATOLOGY EDUCATION RESOURCE-SHARING WEBSITE: IF YOU BUILD IT, WILL THEY COME? / M. Curran* - R. Singh

THU0574  DEVELOPMENT OF A SERIES OF SIMULATORS AND DESIGN A COURSE BASED ON A CLINICAL SIMULATION, FOR TEACHING DIAGNOSTIC APPROACH TO PATIENTS WITH JOINT PAIN AND SUSPECTED RHEUMATIC DISEASE / D. G. Fernández-Avila* - L. Sastre - S. Mora


THU0577  WELSH NATIONAL AUDIT OF 2013 EULAR RECOMMENDATIONS ON THE MANAGEMENT OF MEDIUM-HIGH DOSE STEROID USE IN RHEUMATIC DISEASES / M. Zaman* on behalf of All Wales Rheumatology Group [AWRG]


THU0579  WHAT KNOWLEDGE IS ESSENTIAL FOR PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND SPONDYLOARTHRITIS (SPA)? RESULTS OF A MULTICENTRIC SURVEY AMONG HEALTH PROFESSIONALS AND PATIENTS WITH DELPHI METHODOLOGY. AN INITIATIVE OF THE FRENCH RHEUMATOLOGY SOCIETY THERAPEUTIC EDUCATION SECTION / C. Beauvais* - M. Rodère - B. Peirera - M. Soubrier - L. Gossec

THU0580  A TWO- MINUTE SITTING EXERCISE PROGRAMME TO ENCOURAGE SEDENTARY PATIENTS TO EXERCISE / D. Stevens* - D. Collins - E. Price - L. Williamson


**HPR Poster tour T13: Getting to grips with the evidence**

*Chairperson(s): Annette de Thurah (Denmark), Reuben Escorpizo (Switzerland)*

THU0603-HPR  PATIENTS’ VERSUS PHYSICIAN’S ASSESSMENT OF DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS / S. Pettersson* - S. Möller - J. Gustafsson - E. Svengsson - I. Gunnarsson - E. Welin Henriksson


THU0606-HPR  THE EFFECTS OF PHYSICAL ACTIVITY INTERVENTIONS ON BODY FUNCTIONS & STRUCTURES, ACTIVITY AND PARTICIPATION OUTCOMES, IN PEOPLE WHO HAVE RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW / S. McKenna* - N. Kennedy


THU0609-HPR  READABILITY OF PATIENT INFORMATION AND CONSENT DOCUMENTS IN RHEUMATOLOGIC STUDIES COMPARED TO PARTICIPANTS EDUCATIONAL LEVEL / B. Hamnes* - J. Primdahl - Y. van Eijk-Hustings


PARE Poster tour T14: PARE 1  

Chairperson(s): Dieter Wiek (Germany), Elsa Mateus (Portugal)

PARE0001  DEVELOPMENT OF A TRAINING MODULE FOR HEALTH PROFESSIONALS CALLED "RHEUM2TALK" / C. B. Jacklin* - A. Bosworth - S. Collins

PARE0002  SWEDISH NATIONAL GUIDELINES FOR MUSCULOSKELETAL DISEASES / K. Blidberg* - A. Carlsson


PARE0004  IMPORTANT TUVA CHILDREN SCHOOL AT THE WORLD ARTHRITIS DAY / I. A. Bulgakova*

PARE0005  PATIENT EDUCATION - A JOINT VENTURE NATIONAL HEALTH CARE WORKING TOGETHER WITH THE SWEDISH RHEUMATISM ASSOCIATION / I. Cederlund*

PARE0006  FACILITATORS AND BARRIERS OF PATIENTS WITH SPA TO PHYSICAL EXERCISE / J. Loza* - L. Carmona - P. Zarco - M. T. Flórez

PARE0007  SYSTEMIC SCLEROSIS MEDICAL STUDENT LECTURE - THE BENEFITS OF PATIENT PARTICIPATION / K. Fligelstone*

PARE0008  USING ONLINE SELF-PUBLISHING TO PUBLISH AND MARKET A BOOK FOR PATIENT EDUCATION (POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: A SURVIVAL GUIDE): A DESCRIPTION AND ANALYSIS OF THE PROCESS AND AN EVALUATION OF THE RESULT / K. Gilbert*


PARE0010  ALKAPTONURIA: AN OLD DISORDER WITH A LATE DIAGNOSIS / S. Sestini* - L. Millucci - D. Braconi - G. Bernardini - A. Santucci

PARE0011  AN INSIGHT INTO MEMBERSHIP OF INVOLVE FROM THE PATIENT AND ORGANISATIONAL PERSPECTIVE / C. A. Rhodes* - H. Hayes

* Presenting author
Scientific Poster Session 1

Thursday, 11 June 2015 12:00 - 13:45

Genomics, genetics and epigenetics of rheumatic diseases

Hall 6

THU0001 ERAP-1 HAPLOTYPE INFLUENCES CLINICAL PHENOTYPE BUT NOT CYTOKINE EXPRESSION IN ANKYLOSING SPONDYLITIS / J. Nossent* - S. S. Johnsen - G. Bakland


THU0003 SEARCHING FOR THE GENETIC ASSOCIATION WITH BONE EROSION OF RHEUMATOID ARTHRITIS USING HIGH-DENSITY GENOTYPIC DATA FOR IMMUNE LOCUS IN A KOREAN POPULATION / Y. B. Joo* - S.-Y. Bang - Y. Park - H.-S. Lee - S.-C. Bae


THU0005 IMMUNE COMPLEXES AND COMPLEMENT MEDIATE EPIDEMIOLOGIC CHANGES AND TRIGGER TLR SIGNALING IN CD4+ T CELLS / A. K. Chauhan*


THU0008 HYPERMETHYLATION OF TREG-SPECIFIC DEMETHYLATED REGIONS IN THE IKAROS TRANSCRIPTION FACTOR FAMILY MEMBERS, HELIOS AND EOS, IN RHEUMATOID ARTHRITIS TREGS / A. Skapenko* - S. Lukas - S. Haupt - V. Sonntag - J. Leipe - H. Schulze-Koops


THU0013 VALIDATION OF THE ASSOCIATION OF A FUNCTIONAL MICROSATELLITE IN MACROPHAGE MIGRATION FACTOR WITH HIP OA / L. Vidal* - M. Calaza - A. Gonzalez


* Presenting author


* Presenting author

Innate immunity in rheumatic diseases

Hall 6

THU0023 SOLUBLE URIC ACID EXERTS A SUPPRESSIVE EFFECT ON THE RESPONSE OF MACROPHAGES TO MONOSODIUM URATE CRYSTALS / E. García-Melchor* - M. Guma - J. Yague - M. Juan - J. Harper


THU0029 IDENTIFICATION OF CEREBRAL INFARCTION-SPECIFIC ANTIBODY MARKERS FROM AUTOANTIBODIES BY AUTOPHAGY DEPENDENT WAY IN RA PATIENTS / L. Wang* - L. Qian - X. Li


THU0032 SELECTIVE, AUTOANTIBODY-IMMUNE COMPLEX MEDIATED PROPORTIONAL AND FUNCTIONAL CHANGES OF SPECIFIC NK-CELL SUBSETS IN EARLY SEROPositive BUT NOT SERONEgATIVE RHEUMATOID ARTHRITIS / P. Chalan - E. Brouwer* - J. Bijzet - B.-J. Kroesen - M. Boots

THU0033 A FUNCTIONAL INHIBITORY ROLE FOR THE GAS6/MERTK AXIS IN MODULATING SYNOVIAL INFLAMMATION IN RHEUMATOID ARTHRITIS / A. Nerviani* - F. Humby - S. Kelly - M. Bombardieri - C. Pitzalis

THU0034 INHIBITION OF IFN ALPHA SIGNALLING REDUCES HMGB1 TRANSLLOCATION AND NEUTROPHIL EXTRACELLULAR TRAP FORMATION IN JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (ISLE) / A. Midgley* - M. W. Beresford


THU0036 PROTEOME ANALYSES OF HDL PARTICLES ALLOWS TO IDENTIFY BIOMARKERS OF DISEASE ACTIVITY IN SLE PATIENTS: GELSOlin, INDIAN HEDGEhOG PROTEIN AND S100A8 / S. Parra* - N. Canela - M. de las Heras - N. Amigó - P. Sahun - X. Correig - A. Castro
Rheumatoid arthritis - etiology, pathogenesis and animal models

THU0037  COMPARABLE THERAPEUTIC POTENTIAL OF UMBILICAL CORD MESENCHYMAL STEM CELLS IN COLLAGEN INDUCED ARTHRITIS WITH ANTI-TUMOR NECROSIS FACTOR OR ANTI-CD20 / Y. Sun - W. Kong - W. Chen - G. Yao - X. Feng - L. Sun*


THU0039  REGULATION OF ASK-1 EXPRESSION BY MICRORNA-17 AND ITS CORRELATION WITH RHEUMATOID ARTHRITIS PATHOGENESIS / N. Akhtar - S. Ahmed*


THU0042  PRECLINICAL CHARACTERIZATION OF SIRUKUMAB, A HUMAN MONOCLONAL ANTI-BODY THAT TARGETS HUMAN INTERLEUKIN-6 SIGNALING / D. Gardner - E. Lacy - S. Wu - D. Shealy*


THU0051  PPAR-GAMMA AGONIST INHIBITS MIGRATION AND INVASION BY DOWN REGULATING TNF ALPHA-INDUCED CYR61 EXPRESSION IN RHEUMATOID ARTHRITIS-FIBROBLAST LIKE SYNOVIOCYTES / E.-J. Kwon* - M. Cho - E. J. park - J. Kim


THU0053  FC GAMMA RECEPTORS ENHANCE BONE EROSION IN EXPERIMENTAL ARTHRITIS BY STIMULATING SYNOVIAL INFLAMMATION AND ACTIVATION OF OSTEOCLASTS / I. di Ceglie - M. Porras - P. L. van Lent - T. Kamradt - L. Gómez-Casajús - J. Román


THU0055  IL-21 SIGNALING IN B CELLS IS CRITICAL FOR THE DEVELOPMENT OF COLLAGEN INDUCED ARTHRITIS IN MICE / K. Sakuraba* - K. Fujimura - S. Kamura - Y. Esaki - H. Miyahara - Y. Yoshikai - H. Yamada

THU0056  EXPRESSION OF P53-INTERACTING RNA IN RHEUMATOID ARTHRITIS / L. Plestilova* - A. Ciurea - C. Kolling - M. Hameetman - T. Huizinga - J. Stoop - R. Toes*


THU0058  SYNOVITIS IN RHEUMATOID ARTHRITIS DISPLAY PART OF HISTOLOGICAL CHARACTERISTICS OF IGG4-RELATED DISEASE / L.-F. Chen - Y.-Q. Mo - J.-D. Ma - D.-H. Zheng - L. Dai*

THU0059  CITRULLINATED FIBRINOGEN PROMOTES BONE MARROW MESENCHYMAL STEM CELLS TO ASSUME A PRO-INFLAMMATORY PHENOTYPE / Y. Sun - W. Deng - W. Chen - G. Yao - X. Feng - L. Sun*


THU0061  THE EFFECT OF ANTI-IL-6 RECEPTOR ANTIBODY ON CARTILAGE DESTRUCTION IN A MOUSE MODEL OF COLLAGEN-INDUCED ARTHRITIS / M. Suzuki* - Y. Bi - H. Yoshida - K. Tanaka - M. Hashizume - Y. Matsumoto

* Presenting author

CELLULAR RA-BINDING PROTEIN (CRABP)-II SUPPRESSION SENSITIZES RHEUMATOID FIBROBLAST-LIKE SYNOVIOCYTES TO FAS-INDUCED APOPTOSIS / N. Mosquera* - J. J. Gomez-Reino - C. Conde


THU0070 DUAL TARGETING OF KAEMPFEROL ON THE KINASE ACTIVITIES OF FGFR3 AND RSK2 SUPPRESSES RHEUMATOID ARTHRITIS IN VITRO AND IN VIVO / S.-J. Moon* - J.-H. Jeong - Y.-Y. Cho - J.-K. Min


THU0074 TRANSCRIPTION FACTOR SOXS IS AN ESSENTIAL REGULATOR OF RANKL EXPRESSION IN SYNOVIAL FIBROBLAST CONTRIBUTING TO BONE EROSION IN EXPERIMENTAL ARTHRITIS MODEL / W. Tan* - Y. Shi - L. Xu - E. Wang - M. Zhang


THU0076 MICRORNA-124 INHIBITS PROGRESSION OF ADJUVANT-INDUCED ARTHRITIS IN RATS / Y. Nakamachi* - K. Ohnuma - K. Uto - Y. Noguchi - J. Saegusa - S. Kawano


THU0079 POLYPHARMACY, ALTHOUGH NOT COMBINATION DMARD THERAPY, IN RHEUMATOID ARTHRITIS IS ASSOCIATED WITH INCREASED HOSPITALISATION RISK / M. Filkova* - F. Ibrahim - M. Norton - D. Scott - T. Mant - A. Cope - M. Molokhia - J. Galloway

THU0080 PREDICTORS AND CONSEQUENCES OF ACHIEVING PERSISTENT REMISSION, INTERMITTENT REMISSION OR NEVER-ACHIEVING REMISSION IN PATIENTS WITH RECENT ONSET INFLAMMATORY POLYARTHRITIS: RESULTS FROM THE NORFOLK ARTHRITIS REGISTER (NOAR) / M. J. Cook* - J. Diffin - C. A. Scirè - M. Lunt - G. Caselli - L. Rovati


THU0082 COMPARISON OF M-DAS AND DAS28, TWO COMPOSITE SCORES FOR PREDICTION OF STRUCTURAL DAMAGES IN EARLY ARTHRITIS: DATA FROM THE ESPOIR COHORT / M. Cordier* - B. Pereira - V. Devauchelle-Pensec - X. Mariette - M. Soubrer


* Presenting author
THU0086

THU0087

THU0088
SERUM SURVIVIN PREDICTS TREATMENT RESPONSE IN ACTIVE RHEUMATOID ARTHRITIS / A. Levitsky* - M. Erlandsson - R. F. van Vollenhoven - M. I. Bokarewa

THU0089
BIOMARKERS OF EROSIIVE DISEASE IN A COHORT OF EARLY-RHEUMATOID ARTHRITIS PATIENTS TREATED ACCORDING TO THE TREAT TO TARGET STRATEGY / A. L. Fedele* - E. Gremsen - S. Allervinini - L. Petricca - B. Tolusso - S. Canestri - G. Ferraccioli

THU0090

THU0091
A COMPARISON OF EQ5D INDEX FROM THE UK, US, AND JAPAN PREFERENCE WEIGHTS MODEL, AND MAPPING ALGORITHM FROM CLINICAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM SIMPONI ARIA STUDY / C. Han* - C. O. Bingham - R. Westhovens - M. E. Weinblatt - L. Kim - D. Baker - S. Peterson - E. Hisa on behalf of GO-FURTHER Investigators

THU0092

THU0093

THU0094
IMPACT OF BIOLOGIC DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATION FROM THE CORRONA REGISTRY / D. A. Pappas* - G. W. Reed - Y. Bao - S. Grant - V. Garg

THU0095
DIFFERENCE IN PHYSICAL FUNCTION BETWEEN REMISSION AND LOW DISEASE ACTIVITY IN EARLY RHEUMATOID ARTHRITIS / E. Galuppi* - I. Farina - F. Bergossi - C. De Giorgio - G. Ciancio - M. Govoni

THU0096

THU0097
IMPACT OF PATIENT SUPPORT PROGRAM USE ON CLINICAL OUTCOMES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS / E. van den Bosch* - S. Wassenberg - A. Ostor - N. Vartohipi - V. Garg - J. Kalabic

THU0098
SERUM PROGRAMULIN AUTOANTIBODIES IN RHEUMATOID ARTHRITIS ASSOCIATED WITH HIGHER DISEASE ACTIVITY / G. Assmam* - S. Zinke - M. Gerling - M. Ong - N. Fadde - K. D. Preus - L. Thurner - M. Pfleundschuh

THU0099
PATIENT GLOBAL DISEASE ACTIVITY IS HIGHLY ASSOCIATED WITH PAIN AND PATIENT REPORTED OUTCOMES, BUT NOT WITH ULTRASOUND FINDINGS DURING ONE YEAR TREATMENT OF PATIENTS WITH ESTABLISHED RA STARTING BIOLOGIC MEDICATION / H. B. Hammer* - T. Uhlig

THU0100

THU0101

THU0102
DIFFERENCES IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED DAS REMISSION OR SDAI REMISSION BUT NOT BOOLEAN REMISSION / J. Smolen* - D. Aletaha - X. Wei - J. D. Ma - L. J. Yang - Y. Q. Mo - D. H. Zheng - L. Dai*

THU0103
DIFFERENCES IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED DAS REMISSION OR SDAI REMISSION BUT NOT BOOLEAN REMISSION / J. Smolen* - D. Aletaha - X. Wei - J. D. Ma - L. J. Yang - Y. Q. Mo - D. H. Zheng - L. Dai*

THU0104
PHYSICAL FUNCTION IN RELATION TO GENDER IN PATIENTS WITH RHEUMATOID ARTHRITIS - A 15 YEAR FOLLOW UP STUDY FROM THE BARFOOT COHORT / K. Eberhardt - K. Forslind - B. Svensson* - A. Bremander - B. Chou - J. Zhu - V. K. Ranganath

THU0105
COMBINATION OF BASELINE SCORE HAPLOTYPE OF SERUM METALLOPROTEINASE 3 FOR PREDICTING RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS ACHIEVED THERAPEUTIC TARGET / X. Wei* - J. D. Ma - L. J. Yang - T. Wang - Y. Q. Mo - D. H. Zheng - L. Dai*

THU0106

THU0107

THU0108
NO CLEAR ASSOCIATION BETWEEN THE PRESENCE OF SUBCLINICAL SYNOVITIS AND PATIENT REPORTED OUTCOMES IN RA PATIENTS IN REMISSION / M. van der Ven* - M. Kuiper - A. Gerards - I. Tchetverikov - A. Weel - J. van Zeben - M. Hazes - J. Luime

THU0109
AGREEMENTS BETWEEN PATIENT GLOBAL ASSESSMENT, PAIN AND FATIGUE AS SCORED ON 0-100 VISUAL ANALOGUE SCALES BY PATIENTS WITH RHEUMATOID ARTHRITIS / S. M. Koop - P. M. Ten Klooster* - H. E. Vankoman - L. M. Steunebrink - M. A. Van De Laar

THU0110
WORK PRODUCTIVITY IN RHEUMATOID ARTHRITIS: ANALYSIS FROM MULTICENTER TURKISH STUDY / O. N. Pamuk* - C. Han* - C. O. Bingham - R. Westhovens - M. E. Weinblatt - L. Kim - D. Baker - S. Peterson - E. Hisa on behalf of GO-FURTHER Investigators

THU0111

THU0112

* Presenting author


THU0219 IMPACT OF NEGLECTING INTRA-ARTICULAR GLUCOCORTICOID-INJECTIONS IN REMISSION TARGETED TREATMENT OF EARLY RHEUMATOID ARTHRITIS / L. Kuusalo* - P. Kalakka - H. Kautiainen - M. Leirisalo-Repo - V. Rantala on behalf of NEO-RACo Study Group

THU0120 PROGNOSTIC SIGNIFICANCE OF RESIDUAL AUTOIMMUNE/INFLAMMATORY ACTIVITY FOR DISEASE RELAPSE UPON DMARD SUSPENSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS IN SUSTAINED REMISSION AFTER DMARD-DRIVEN THERAPY / A. Manzo* - S. Bugatti - F. Benaglio - G. Sakellarious - B. Vitolo - M. Scarabelli - R. Caporali - C. Montecucco


THU0122 A TAILORED TELEMONITORING TIGHT CONTROL STRATEGY FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. IS MORE EFFECTIVE THAN USUAL CARE TREATMENT IN DAILY CLINICAL PRACTICE? / F. Salaffi* - M. Carotti - A. Ciapetti - M. Di Carlo - M. Gutierrez

THU0123 IS A HIGH CONTRIBUTION OF TENDER JOINT COUNT AND VAS GENERAL HEALTH TO THE DAS28 ASSOCIATED WITH POOR CLINICAL RESPONSE TO TREATMENT IN EARLY DMARD-NAÏVE RA PATIENTS? / M. de Hair* - M. Jurgens - F. Lafeber - J. Jacobs - J. van Laar on behalf of the Society for Rheumatology Research Utrecht


** Rheumatoid arthritis - comorbidity and clinical aspects

Hall 6


THU0129 UROGENITAL AA AMYLOIDOSIS IN RHEUMATOID ARTHRITIS - A POSTMORTEM CLINICOPATHOLOGIC STUDY OF 234 AUTOPSY PATIENTS / Á. Apáthy* - M. Bény


THU0131 RHEUMATOID ARTHRITIS AND PREGNANCY IN ROMANIAN FEMALES / A. Boca* - I. Ancuta - M. Micu - R. Popescu - C. Tataru - C. Comsa - M. Bojinca - C. Mihai - C. Ancuta - V. Stoica

* Presenting author
THU0132 FOR USE OF ANTI-RHEUMATIC DRUGS BEFORE AND DURING PREGNANCY AND LACTATION: PROGRESS OF A EULAR TASK FORCE / A. C. Skorpen* - M. Østensen on behalf of EULAR task force


THU0135 COMPARISON OF CARDIOVASCULAR DISEASE EVENT RATES AMONG PATIENTS WITH RHEUMATOID ARTHRITIS ACROSS 10 COUNTRIES - IMPLICATIONS FOR CV RISK ASSESSMENT / Atacca-RA Consortium*


THU0137 DENOSUMAB, WITH AND WITHOUT BIOLOGIC THERAPY AND THE RISK OF INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS / B. Haraoui* - D. Choquette - A. Adjo'o Zo'o - L. Coupal

THU0138 LEFT VENTRICULAR DEFORMATION BY SPECKLE TRACKING ECCOHRADIOGRAPHY AT 2-YEAR FOLLOW-UP IN TREATMENT NAIVE RHEUMATOID ARTHRITIS PATIENTS / B. B. Løgstrup* - D. Masic - T. B. Laurberg - A. H. Nielsen - L. D. Kristensen - T. Ellingsen


THU0140 BASELINE PAIN LEVEL SIGNIFICANTLY PREDICTS FATIGUE IN RA PATIENTS WITH LOW DISEASE ACTIVITY AFTER SIX MONTHS DMARD TREATMENT / C. L. Olsen* - E. Lie - H. A. Zangi

THU0141 UTILIZATION OF MULTIPLE DISEASE ACTIVITY MEASURES IN RHEUMATOID ARTHRITIS PATIENTS DETECTED A UNIQUE SURTYPE OF RHEUMATOID ARTHRITIS / C. Wiesenhuber*

THU0142 PREDICTION OF NON-ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS / D. Choquette* - L. Coupal - V. Nadon

THU0143 HETEROGENEITY OF JOINT DEFORMITY IN RHEUMATOID ARTHRITIS REVEALED BY CLUSTER ANALYSIS / E. T. Koh* - L. Z. Liu - J. W. L. Tan - W. Q. See - K. P. Leong on behalf of TSSH Rheumatoid Arthritis Study Group

THU0144 UNDERSTANDING FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): THE ROLE OF RA DISEASE ACTIVITY FLARES / E. Mlyasoevova* - C. S. Crowson - J. M. Davis - E. L. Matteson - S. E. Gabriel


THU0148 STRUCTURE OF CO-MORBID DISEASES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SARATOV REGION OF RUSSIA / L. Afanaciev* - N. Nikitina - A. Rebrow


THU0150 USE OF METHOTREXATE IN PATIENTS WITH RECENT ONSET RHEUMATOID ARTHRITIS ALTER SERUM CHOLESTEROL AND TRIGLYCERIDE LEVELS / J. Calvo Gutiérrez* - R. Ortega Castro - R. Jimenez Gasco - J. Font


THU0154 ASSOCIATIONS OF OSTEOPOROTIC FRACTURE GENES IN PATIENTS WITH RHEUMATOID ARTHRITIS / S. Rantapää-Dahlqvist - K. Wiberg* - L. Ärlestig - U. Pettersson

THU0155 FIBROMYALGIA MIMICS HIGH DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS / L. Coupal - V. Font Ugalde - M. C. Castro Villegas - A. Escudero Contreras - E. Collantes Estevez

THU0156 IMPACT OF VERIFICATION BIAS ON THE EVALUATION OF DIAGNOSTIC ACCURACY OF LUNG ULTRASOUND IN RHEUMATOID ARTHRITIS-RELATED RELATED INTERSTITIAL LUNG DISEASE / M. Antivalle* - M. Chevallard - M. Battelino - M. C. Ditto - V. Varisco - F. Rigamonti - A. Batticciotto - F. Atzeni - P. Sarzi-Puttini


* Presenting author
**Rheumatoid arthritis - non biologic treatment and small molecules**

**THU0158**

**THU0159**
Sequence of Amyloid A Deposition in the Heart - A Postmortem Clinicopathologic Study of 161 Rheumatoid Arthritis Patients / M. Bély* - Á. Apáthy

**THU0160**

**THU0161**

**THU0162**
The Correlation Between Carotid Ultrasound, Coronary Artery Calcification Score and Lipid Profile in Patients with RA / O. Garnish* - V. Levcenko - A. Romanovskiy

**THU0163**

**THU0164**
Comparison of the Effect of Denosumab and Aprendonate on Bone Density and Microarchitectute at the Distal Radius in Rheumatoid Arthritis Females with Low Bone Mass: A Randomized Controlled Trial / P. Wong* - T. Y. Zhu - L. Qin - E. K. Li - L.-S. Tam

**THU0165**

**THU0166**

**THU0167**
Neo-Epitopes of Connective Tissue Turnover Are Biomarkers of Disease Activity and Modulated in Response to Tofacitinib or Tocilizumab in Rheumatoid Arthritis / S. Hirata*

**THU0168**

**THU0169**
Does Prednisone Really Affect Tuberculin Skin Test Reaction in Patients with Rheumatoid Arthritis? / O. Reitblat - T. Lerman - O. Cohen - T. Reitblat*

**THU0170**
Is Rheumatoid Arthritis Cervical Spine Involvement Decreasing over Time? Results from a Systematic Review / T. Zhang* - J. E. Pope

**THU0171**
Breastfeeding is Associated with a Reduced Risk of Rheumatoid Arthritis Among Korean Women / Y.-J. Ha* - Y. J. Lee - S. W. Chung - E. H. Kang - Y. W. Song

**THU0172**

---

* Presenting author
THU0182


THU0183

PREDICTABILITY TO ACHIEVE LOW ACTIVITY AND/OR REMISSION WITH LEFLUNOMIDE USE IN PATIENTS WITH RHEUMATOID ARTHRITIS / E.-O. Fabricio* - C. Sifuentes - M. Mariana - C. A. Arce-Salinas

THU0184

PATIENTS CENTERED BARRIERS TO TREAT TO TARGET(T2T) IMPLEMENTATION / I. Laurindo* - D. Torigoe - M. Bertolo - L. Rezende - C. Brenol - J. Vasconcelos - I. Pereira - M. Freitas - R. Ranza - L. Romairo - L. Mota

THU0185


THU0186

SAFETY OF TOFACITINIB COMPARED TO BIOLOGICAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO METHOTREXATE: OVERVIEW OF SYSTEMATIC REVIEW / J. M. Reyes Sanchez* - A. E. Rodriguez - V. Prieto

THU0187

SERUM 14-3-3ETA IS A MODIFIABLE, MECHANISTIC BIOMARKER THAT PREDICTS TOCILIZUMAB RESPONSE / K. Hanami* - S. Hirata - A. Marotta - Y. Tanaka

THU0188


THU0189

PLACEBO EFFECT IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS / N. Abdullah*

THU0190


THU0191


Spondyloarthritis - treatment

THU0192

EFFECT OF SULFASALAZINE ON DECREASE OF UVEITIS FLARES IN PATIENTS WITH ANKYLOSING SPONDYLITIS / A. Godzenko* - A. Bochkova - O. Rumiantseva - I. Rasumova - V. Badokin - S. Erdes

THU0193


THU0194

SERUM BIOMARKERS ASSOCIATED WITH DISEASE ACTIVITY AND RESPONSE TO USTEKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN THE TOPAS STUDY / B. Dasgupta* - S. Telesco - J. Sieper - D. Poddubny

THU0195


THU0196


THU0197

SURVIVAL ON DRUG IN PATIENTS WITH SPONDYLOARTHRITIS RECEIVING CERTOLIZUMAB PEGOL. RESULTS FROM THE NATIONWIDE SWEDISH RHEUMATOLOGY QUALITY REGISTER / C. Dackhammar* - H. Forsblad-d’Elia - C. Stach - B. Hoepken - O. Davies - T. Nurminen - J. Braun

THU0198


THU0199

FUNCTIONAL STATUS REMAINS STABLE DESPITE CONTINUOUS RADIOGRAPHIC SPINAL PROGRESSION OVER TEN YEARS IN PATIENTS WITH ANKYLOSING SPONDYLITIS RECEIVING ANTI-TNF THERAPY / D. Poddubny

THU0200


THU0201


THU0202


THU0203

NSAIDS ADMINISTRATION IN PATIENTS WITH AXIAL SPA IN CLINICAL REMISSION WITH BIOLOGICS / D. K. Patrikos*

THU0204

CORRELATION BETWEEN SERUM LEVEL OF INFliximab OR ADAlimumab AND CLINICAL RESPONSE IN SPONDYLOARTHRITIS SEEMS TOO STRONG TO GIVE THE OPPORTUNITY OF AN INTEREST ON DOSAGE FOR THERAPEUTIC ADAPTATION / T. Grange - E. Solau-Gervais*

THU0205

CARDIOVASCULAR EVALUATION USING NON-INVASIVE IMAGING METHODS IN PATIENTS WITH ANKYLOSING SPONDYLITIS BEFORE AND AFTER 12 MONTHS OF TREATMENT WITH ANTI-TNF DRUGS / F. Atzeni* - L. Gianturco - S. Bongiovanni - D. Colombo - R. Talotta - P. Sarzi-Puttini - M. Turiel

* Presenting author


THU0214  EFFECT OF TNF INHIBITORS ON RADIOGRAPHIC PROGRESSION OF SACROILIAC JOINTS IN AXIAL SPONDYLOARTHRITIDES TUNISIAN PATIENTS / I. Mahmoud - K. Maatallah* - O. Saidane - L. Metoui - W. Hamdi - R. Tekaya - L. Abdelmoula


THU0216  ADHERENCE TO ANTI-TNF THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS - RESULTS FROM DAILY CLINICAL PRACTICE IN SLOVAKIA / M. Zhay* - M. Salkova - M. Oetterova - J. Rovensky - I. Rybar

THU0217  PARADOXICAL PSORIATIC EFFECTS OF ANTI-TNF THERAPY IN PATIENTS WITH ANKYLOSING SPONDYLITIS / M. Zhay* - M. Salkova - M. Oetterova - J. Rovensky - I. Rybar

THU0218  BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS ASSOCIATED WITH RESPONSE TO GOLIMUMAB IN PATIENTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS / M. Dougados* - G. Bergman - W. P. Maksymowych - S. Curtis - S. Huyck - A. Tontcheva - J. Sieper


THU0222  BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS ASSOCIATED WITH RESPONSE TO GOLIMUMAB IN PATIENTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS / M. Dougados* - G. Bergman - W. P. Maksymowych - S. Curtis - S. Huyck - A. Tontcheva - J. Sieper


THU0227  POSTOPERATIVE INFECTION RATES AFTER SURGERY WITH PROSTHESIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED BY TNF-ALPHA BLOCKADE COMPARED TO CONVENTIONAL NSAIDS / S.-J. Hong* - S.-H. Lee - H.-R. Kim - H.-I. Yang


* Presenting author
Infection-related rheumatic diseases

THU0230


THU0231

DISCONTINUATION OF ANTI-TNF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. A SYSTEMATIC LITERATURE REVIEW / V. Navarro-Compañ* - C. Plascencia - E. de Miguel - A. Balsa - E. Martin-Mola - J. D. Cañete

THU0232


THU0233


THU0234


THU0235


THU0236


THU0237

EFFECTIVENESS OF DIFFERENT SCHEMES OF ETORICOXIB ADMINISTRATION IN REDUCTION OF ACTIVE SACROILAC JOINT INFLAMMATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS - RESULTS OF A 12-WEEK, PROSPECTIVE, OPEN-LABEL STUDY / I. Gaydukova* - A. P. Rebrov - A. I. Akulova

THU0238


THU0239

ASSOCIATION BETWEEN TOBACCO SMOKING AND RESPONSE TO TUMOR NECROSIS FACTOR ALPHA INHIBITOR TREATMENT IN ANKYLOSING SPONDYLITIS: RESULTS FROM THE DANISH NATIONWIDE DANBIO REGISTRY / B. Glintborg* - P. A. Rocchetta - E. F. van der Veer - A. Spoorenberg

THU0240

SAFETY OF ADALimumAB THERAPY IN HBsAg CARRIERS WITH ANKYLOSING SPONDYLITIS: A PROSPECTIVE STUDY / L. Fang* - Z. Liao - Z. Lin - O. Jin - Y. Pan - J. Gu

THU0241


THU0242


THU0243

AN INVESTIGATION INTO THE CLINICAL USE OF GOLIMUMAB THERAPY AND DISCONTINUATION OF ANTI-TNF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. A SYSTEMATIC REVIEW / T. Rusman* - S. ten Wolde - S. M. Euser - T. van der Ploeg - O. van Hall - I. E. van der Horst-Bruinsma

THU0245


THU0246


THU0247

ASSOCIATION BETWEEN TOBACCO SMOKING AND RESPONSE TO TUMOR NECROSIS FACTOR ALPHA INHIBITOR TREATMENT IN ANKYLOSING SPONDYLITIS: RESULTS FROM THE DANISH NATIONWIDE DANBIO REGISTRY / B. Glintborg* - P. A. Rocchetta - E. F. van der Veer - A. Spoorenberg

THU0248


THU0249

MRI CHANGES ASSOCIATED WITH NEUROLOGICAL COMPLICATIONS IN ACUTE PYOGENIC VERTEBRAL SACROILIITIS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS - RESULTS OF A 24 MONTH FOLLOW UP STUDY / I. Gaydukova* - A. P. Rebrov - A. I. Akulova

THU0250


THU0251

ASSOCIATION BETWEEN TOBACCO SMOKING AND RESPONSE TO TUMOR NECROSIS FACTOR ALPHA INHIBITOR TREATMENT IN ANKYLOSING SPONDYLITIS: RESULTS FROM THE DANISH NATIONWIDE DANBIO REGISTRY / B. Glintborg* - P. A. Rocchetta - E. F. van der Veer - A. Spoorenberg

THU0252

AN INVESTIGATION INTO THE CLINICAL USE OF GOLIMUMAB THERAPY AND DISCONTINUATION OF ANTI-TNF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. A SYSTEMATIC REVIEW / T. Rusman* - S. ten Wolde - S. M. Euser - T. van der Ploeg - O. van Hall - I. E. van der Horst-Bruinsma

THU0253

AN INVESTIGATION INTO THE CLINICAL USE OF GOLIMUMAB THERAPY AND DISCONTINUATION OF ANTI-TNF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. A SYSTEMATIC REVIEW / T. Rusman* - S. ten Wolde - S. M. Euser - T. van der Ploeg - O. van Hall - I. E. van der Horst-Bruinsma

THU0254


THU0255

THU0253  GOUT AND HIV; INFLAMMASEONE ACTIVATION VERSUS ANTIRETROVIAL DRUG SIDE EFFECTS / M. Hughes* - A. Kinderlehrer


THU0255  CHIKUNGUNYA FEVER IN PATIENTS UNDER BIOLOGICS DOES NOT SEEM TO BE HARMFUL / L. Brunier - K. Polomat - C. Deligny - V. Dehlinger - M. Blettery - S. Arfi - G. Jean-Baptiste - M. Blettery - M. Debandt*


THU0260  PYOMYSOTIS: RETROSPECTIVE REVIEW OF 41 CASES TREATED AT A SPANISH UNIVERSITY HOSPITAL / V. García Coca* - C. Medina Quiñones - W. A. Sifuentes Giraldo - M. J. Garcia Villanueva - J. L. Morell Hita - A. González García - F. Dronda Núñez


Vasculitis

THU0263  THE CHANGING FACE OF RHEUMATOID ARTHRITIS AND SYSTEMIC VASCUITIS - A POSTMORTEM CLINICOPATHOLOGIC STUDY OF 237 RHEUMATOID ARTHRITIS PATIENTS / A. Apathy* - M. Bély

THU0264  AUDIT OF MANAGEMENT OF GIANT CELL ARTERITIS AS PER BSR/BPHR/RCP GUIDELINES / A. A. Memon* - C. Jayaillike - M. A. Alvi

THU0265  OUTCOMES OF AND PREDICTIVE FACTORS IN JAPANESE PATIENTS WITH MPO-ANCA-ASSOCIATED VASCUITIS: LONG-TERM DATA FROM A SINGLE RHEUMATOLOGY CENTER / A. Suzuki* - T. Okai - G. Lyckina


THU0270  IMMUNOSUPPRESSIVE THERAPY IN COMBINATION WITH STEROIDS IN THE TREATMENT OF GIANT CELL ARTERITIS / A. Carbonella* - G. Berardi - F. Parisi - A. Zoli - E. Gremese - F. Ferraccioli


THU0272  FACTORS ASSOCIATED WITH ABSENTEEISM, PRESENTEEISM AND ACTIVITY IMPAIRMENT IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) / C. Baldini* - S. L’abbate - C. Congestri - F. Ferri - M. Aringer*


THU0275  PERIPHERAL NEUROLOGICAL INVOLVEMENT IN PRIMARY SYSTEMIC VASCUITIS / C. E. Pena* - M. Pera - J. Marcos - A. Salas - A. Testi - M. A. García

THU0276  TOCILIZUMAB IN UVEITIS ASSOCIATED WITH BEHCET’S DISEASE. MULTICENTER STUDY OF 7 PATIENTS / G. Sambuceti - M. A. Cimmino

THU0277  DIAGNOSTIC PERFORMANCE AND DISEASE ACTIVITY ASSESSMENT BY FDG-PET IN LARGE-VEssel VASCUITIS: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS / M. Soussan - P. Nicolas - C. Schramm - S. Katshian - O. Fain - A. Mezinian*


THU0279  THE CHANGING FACE OF RHEUMATOID ARTHRITIS AND SYSTEMIC VASCUITIS - A POSTMORTEM CLINICOPATHOLOGIC STUDY OF 237 RHEUMATOID ARTHRITIS PATIENTS / A. Apathy* - M. Bély


* Presenting author
Fibromyalgia and pain in rheumatic diseases

THU0281
EVALUATING S100A12 AS A SERUM BIOMARKER FOR INFLAMMATORY DISEASE ACTIVITY IN PAEDIATRIC PRIMARY CHRONIC VASCULITIDES USING A NOVEL MONOCLONAL SANDWICH ELISA / G. Armaroli* - K. Brown - D. Cabral - S. Benseler - D. Föll - C. Kessel on behalf of PedVas study group

THU0282

THU0283

THU0284
WORK DISABILITY OVER TIME IN BEHÇET’S SYNDROME PATIENTS / G. Hatemi* - K. Tasclar - Y. Ozguler - S. Ugurlu - V. Hamuryudan

THU0285
THE ASSOCIATION OF GIANT CELL ARTERITIS AND ITS HISTOPATHOLOGY WITH ALL-Cause AND CARDIOVASCULAR MORTALITY / G. Tomasson* - J. Björnsson - Y. Zhang - V. Gudnason - P. A. Merkel

THU0286

THU0287
CLINICAL AND ECONOMIC BURDEN OF PATIENTS WITH MICROSCOPIC POLYANGIITIS (MPA) IN THE UNITED STATES / K. Raimundo* - A. Farr - G. Kim - G. Duna

THU0288

THU0289

THU0290

THU0291

THU0292
RISK FACTORS ASSOCIATED WITH CRANIAL ISCHEMIC COMPLICATIONS IN PATIENTS WITH BIOPSY-PROVEN GIANT CELL ARTERITIS / O. M. Olivas* - M. Martin - M. Galindo - I. Mateo - P. E. Carreira

THU0293
SAFETY AND EFFICACY OF SHORT-TERM TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH REFRACTORY TAKAYASU ARTERITIS / P. Novikov* - S. Smittenko - A. Elonakov - G. Kolibueva - S. Moiseev

THU0294

THU0295

THU0296

THU0297
SEROLOGY WITH CRANIAL ISCHEMIC COMPLICATIONS IN PATIENTS WITH BIOPSY-PROVEN GIANT CELL ARTERITIS / O. M. Olivas* - M. Martin - M. Galindo - I. Mateo - P. E. Carreira

THU0298

THU0299

THU0300

THU0301

THU0302
PROPOSED DISEASE ACTIVITY CATEGORY THRESHOLDS FOR BEHÇET’S SYNDROME ACTIVITY SCALE (BSAS) SCORES FOR A POTENTIAL “TREAT TO TARGET” APPROACH TO BEHÇET’S SYNDROME / Y. Yazici* - H. Bernstein - C. Swearingen
THU0307 VITAMIN D STATUS AND THE EFFICACY OF HIGH-DOSE INTRAMUSCULAR CHOLECALCIFEROL ON MUSCULOSKELETAL PAIN AND MORNING FATIGUE IN PATIENTS WITH CHRONIC RHEUMATIC DISEASES / B. Y. Choi* - S. H. Chang - Y. W. Song

THU0308 USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN CHINESE PATIENTS WITH RHEUMATIC DISEASES: PREVALENCE AND ASSOCIATED DEMOGRAPHIC, CLINICAL AND SOCIAL FACTORS / C. C. Mok* - C. Y. Pak - C. S. Wong - C. H. To - S. M. Tse - L. Y. Ho

THU0310 QUANTITATIVE ASSESSMENT OF FATIGUE IN ROUTINE CARE USING A DIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE (MDHAQ) / E. Nikiphorou* - I. Castrejon - R. Jain - A. Huang - J. A. Block - T. Pincus


THU0313 IMPACT OF WHOLE-BODY CRYOTHERAPY ON GENE EXPRESSION OF PERIPHERAL BLOOD CELLS IN PATIENTS WITH FIBROMYALGIA / S. Drynda - O. Mika - J. Kekow*

THU0314 RHEUMATOID ARTHRITIS PATIENTS WITH FIBROMYALGIA: CLINICAL FEATURES HAVE SIGNIFICANTLY LESS SYNOVITIS AS DEFINED BY POWER DOPPLER ULTRASOUND / A. Mian - K. Chaabo* - J. Wajed - B. Kirkham - T. Garrood


THU0317 FIBROMYALGIA IN PATIENTS WITH EUTHYROID HASHIMOTO'S THYROIDITIS / M. Bilge* - M. Adas - M. N. Yannaz - A. Helvaci

THU0318 THE RELIABILITY AND VALIDITY OF THE TURKISH VERSION OF FIBROMYALGIA SURVEY DIAGNOSTIC CRITERIA AND SYMPTOM SEVERITY SCALE / M. N. Yannaz* - S. Atar - M. Biçer

THU0319 PAIN AND FUNCTIONAL IMPAIRMENT IN CHILDREN WITH CHRONIC REGIONAL PAIN SYNDROME COMARED TO GENERALIZED CHRONIC PAIN AT PRESENTATION AND 12 MONTH FOLLOW-UP / N. Jäger* - B. Hugle - E. Wollesen - E. Schnöbel-Müller - M. Offenbächer - J.-P. Haas

THU0320 CARDIOVASCULAR RESPONSE TO SUBMAXIMAL EXERCISE STRESS TEST IN FIBROMYALGIA WOMEN / O. Dzekan* - M. Stanislavchuk


THU0322 TNX-102 SL FOR TREATMENT OF FIBROMYALGIA: APPROACHES TO PAIN MEASUREMENT / R. M. Gendreau* - D. Clauw - J. Gendreau - B. Daugherty - S. Lederman

THU0323 THE BENEFITS OF 6 WEEK HOME TRAINING PROGRAM IN FEMALES WITH FIBROMYALGIA / R. Marcu - A. M. Bumbea - T. Avramescu

THU0324 MINDFULNESS CHARACTERISTICS IN 4986 PEOPLE WITH FIBROMYALGIA / S. Mist* - K. D. Jones


THU0328 SECONDARY FIBROMYALGIA IN PATIENTS WITH OTHER RHEUMATIC DIAGNOSES: CLUES FOR RECOGNITION ON A DIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE (MDHAQ) AND PHYSICIAN RHEUMETRIC CHECKLIST / T. Pincus* - E. Nikiphorou - A. Huang - I. Castrejon

Epidemiology, health services and outcome research

THU0329 RISK OF CANCER IS NOT INCREASED IN PATIENTS WITH CUTANEOUS LUPUS ERYTHEMATOSUS: A POPULATION-BASED STUDY / A. Singh* - C. Crowson - M. Davis - H. Maradit-Kremers - E. Matteson - V. Chowdhary

THU0330 VACCINATION STATUS IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH SUBCUTANEOUS BIOLOGIC DRUGS AND A QUALITY OF CARE IMPROVEMENT PROJECT / A. Begazo* - P. Vela


THU0333 RECOMMENDATIONS FOR SCREENING OF FREQUENT COMORBIDITIES ARE SPARSE AND INCOMPLETE IN CHRONIC INFAMMATORY RHEUMATIC DISEASES: A SYSTEMATIC LITERATURE REVIEW FOR A EULAR PROJECT / A. Baillet* - L. Gossec - L. Carmona - M. de Wit - Y. Van Eijk-Hustings - M. Dougados

* Presenting author

THU0335 PREVALENCE OF ARTHRITIS INCREASES WITH OBESITY AND LOW SOCIOECONOMIC STATUS: EXTRAPOLATED DATA FROM A 10-YEAR UNITED STATES NATIONAL SURVEY / B. Mehta* - K. Michaud - Q. Shi - P. Ethhimiou


THU0338 GOOGLING ANKYLOSING SPONDYLITIS: INTERNET SEARCH ACTIVITY FROM FRENCH POPULATION / C. Pratti* - X. Guillot - D. Wendling


THU0340 PREVALENCE OF JOINT INVOLVEMENT AND FREQUENCY OF JOINT EXAMS FOR PATIENTS WITH PLQUE PSORIASIS WITHOUT CONFIRMED PSORIATIC ARTHRITIS: AN ANALYSIS ACROSS FIVE EUROPEAN COUNTRIES / T. Makkinova - R. Wood - D. H. Tag - J. Piercy - S. Lobosco - B. S. Stolshek - D. J. Harrison

THU0341 COST EFFECTIVENESS ANALYSIS OF ABATACEPT COMPARED WITH ADALIMMUMAB ON BACKGROUND METHOTREXATE IN BIOLOGIC-NAIVE RA ADULT PATIENTS BY CYCLICAL CITRULLINATED PEPTIDE-POSITIVE SUBGROUPS / E. Alemao* - M. Schiff - S. Johal - M. Al - M. Ruten-van Molken

THU0342 ESTABLISHING CLINICAL MEANING AND SEVERITY CUT-POINTS OF PATIENT REPORTED OUTCOME MEASURES SCORES IN JUVENILE IDIOPATHIC ARTHRITIS / E. Morgan* - B. Huang - K. Barnett - A. Carle - C. Mara - J. Farrell - K. Cook


THU0344 PATIENT PREFERENCES FOR THE ATTRIBUTES OF BIOLOGICAL AGENTS IN RHEUMATIC DISEASES IN SPAIN / I. Ibero* - E. Raya - J. M. Nolla - E. Martin-Mola - M. Rodríguez - G. Nocera - B. Aragon

THU0345 SCREENING FOR REVERSIBLE HYDROXYCHLOROQUINE-RELATED OCULAR TOXICITY USING AN AMSLER GRID / S. Banerjee - J. Ritchie* - L. Williamson - D. Stevens

THU0346 UTILIZATION AND OUTCOMES AFTER TOTAL ANKLE ARTHROPLASTY: TIME TRENDS STUDY USING U.S. NATIONWIDE SAMPLE / J. A. Singh* - R. Ramachandran

THU0347 ESTIMATING THE COST OF ILLNESS OF GIANT CELL ARTERITIS / J. B. Babigumira - M. Li - D. M. Boudreau - J. H. Best* - L. P. Garrison

THU0348 THE INFLUENCE OF DRUG EXPOSURES AND COMORBIDITY ON SURVIVAL IN PATIENTS WITH RHEUMATOID ARTHRITIS / J. Widdifield* - M. Abrahamowicz - M. Paterson - C. Bombardier - G. Tomlinson - A. Huang - B. Kuriya - S. Bernatsky


THU0351 CURRENT SMOKING IS A RISK FACTOR FOR GIANT CELL ARTERITIS IN PATIENTS WITH POLYMYALGIA RHEUMATICA / K. Albrecht* - D. Huscher - M. Aringer - S. Bischoff - G. Hoese - W. Ochs - K. Thiele - A. Zink on behalf of the German Collaborative Arthritis Centres


THU0356 SENSITIVITY TO CHANGE OF DIFFERENT DEFINITIONS OF SACROILIAC RADIOLOGICAL STRUCTURAL FRAGILITY FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS COMPARED TO OSTEOPOROSIS AND FRAGILITY FRACTURES IN SYSTEMIC LUPUS ERYTHEMATOSUS: SOMETHING NEW TO BE EXPLORED? / L. Carli* - C. Tani - S. Vagnani - V. Spera - M. Mazzantini - O. Di Munno - M. Mosca


* Presenting author


THU0370  TREATMENT PERSISTENCE AMONG PATIENTS WITH RHEUMATOID DISEASE (RD) NEWLY TREATED WITH SUBCUTANEOUS TNF-ALPHA BLOCKERS / A. Svedborn - J. Dalen - R. Lyu - Q. Ding - S. Sajan - V. Sazonov - C. M. Black - S. Kachroo*

THU0371  COMPLIANCE WITH ALLOPURINOL AMONG HYPERTENSIVE PATIENTS WITH GOUT DIAGNOSIS AND THE RELATIONSHIP TO ONSET OF END-STAGE RENAL DISEASE / S. Perreau* - J. Nuevo - S. Baumgartner - R. Morlock


SLE, Sjögren’s and APS - etiology, pathogenesis and animal models

Hall 5


THU0375  INHIBITION OF STAT3 ALLEVIATES NEPHRITIS IN LUPUS PRONE MICE / V. Kyttaris*


THU0378  MODERATE EXERCISE IS BENEFICIAL AND SOCIAL STRESS IS DETRIMENTAL TO DISEASE PROGRESSION IN AN ANIMAL MODEL OF LUPUS NEPHRITIS / J. Cortés-Hernández* - M. Vidal - M. L. Felp - J. Ordí-Ros


THU0380  INCREASED BODY MASS INDEX AND BIOLOGIC SURVIVAL IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES / O. Elkayam* - M. Lidar - T. Reitblat - A. Balbir-Gurman - R. Almog


* Presenting author


Hall 5


SLE, Sjögren's and APS - treatment

THU0391  Efficacy and Tolerability of Influenza and Pneumococcal Vaccines in Patients with Systemic Lupus Erythematosus: An Observational Study / M. Y. Md Yusof* - D. Shaw - C. Hislop - M. A. Scheinberg - R. A. Furie


THU0394  Worsening of Systemic Activity and Increases of B Cell Biomarkers in Sjögren's Syndrome after Suspension of Belimumab Treatment: Long-Term Follow-Up after the End of the Beliss Study / L. Quartuccio* - S. Salvin - L. Corazza - S. Gandolfo - C. Pistis - M. Fabris - S. De Vita


THU0399  Effectiveness and Safety of Low-Dose Cyclosporine A in Patients with Primary Sjögren's Syndrome (PSS) with Articular Involvement - Results of a Pilot Study / C. Richez - G. Nocturne - S. Truglia - F. Miranda - C. Alessandri - F. Conti - G. Valesini

THU0400  Response to Eculizumab in the Antiphospholipid Antibody Syndrome / E. Zazpanis* - R. Furie - D. Horowitz

THU0401  Impact of Belimumab Treatment on Quality of Life, Evaluated by LupusQol Questionnaire, in Patients Affected by Systemic Lupus Erythematosus / F. Morello* - F. Ceccarelli - F. R. Spinelli - L. Massaro - C. Perricone - S. Truglia - E. Miranda - C. Alessandri - F. Conti - G. Valesini


THU0403  A Randomised, Open-Label Study to Evaluate the Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously byPrefilled Syringe or Autoinjector / H. Struemper* - A. Ruffatti - M. A. Scheinberg - R. A. Furie


* Presenting author
Psoriatic arthritis

THU0405

THU0406

THU0407
INTEGRATED SAFETY OF USTEKINUMAB IN PSORIATIC ARTHRITIS: 2 YEAR FOLLOW-UP FROM THE PSORIATIC ARTHRITIS INTERNATIONAL RHEUMATOLOGY (PRINT) STUDY / M. Patekar - S. Mpofu

THU0408
SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-IR PATIENTS WITH PSORIATIC ARTHRITIS: DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 1) / D. van der Heijde - R. Landewe - D. van der Heijde - M. Dougados - P. Emery - M. de Wit - M. Cutolo - P. A. Lohmann - L. Meier

THU0409
INTRODUCTION TO THE UPDATE OF THE EUULAR RECOMMENDATIONS FOR THE MANAGEMENT OF PSA / S. Ramiro* - J. S. Smolen - C. Cooper - C. I. Edwards

THU0410

THU0411
OSTEOPOROSIS: WHAT IS THE BURDEN OF DISEASE IN PSORIATIC ARTHRITIS? / G. Haugeberg* - B. H. Grandaunet - C. Cooper - C. J. Edwards

THU0412

THU0413
AJPMAILST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR: IMPROVEMENTS IN NAIL AND SCALP PSORIASIS AND PSORIASIS AREA AND SEVERITY INDEX IN PATIENTS WITH MODERATE TO SEVERE PLAQEU PSORIASIS (ESTEEM 1 AND 2) / K. Papp* - J. Crowley - C. Paul - M. Gooderham - K. Reich - C. Hu - R. Day - C. Griffiths

THU0414

THU0415

THU0416
DISEASE ACTIVITY AND SAFETY DURING LONG-TERM (104-WEEK) TREATMENT WITH AJPMAILST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE III, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 3) / C. Edwards* - F. Blanco - J. Crowley - C. Hu - K. Shah - C. Bibara

THU0417
IMPROVEMENTS IN EXTRA-ARTICULAR MANIFESTATIONS OF PSORIATIC ARTHRITIS OVER 96 WEEKS OF CERTOLIZUMAB PEGOL TREATMENT / O. FitzGerald* - R. Fleischmann - B. Hoepken - L. Peterson - D. Gladman

THU0418
SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-IR PATIENTS WITH PSORIATIC ARTHRITIS: DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 1) / D. van der Heijde* - R. Landewe - D. van der Heijde - M. Dougados - P. Emery - M. de Wit - M. Cutolo - S. Oliver - L. Gossec

THU0419

THU0420

THU0421
SECUKINUMAB IS EFFECTIVE IN REDUCING DACTYLITIS AND ENTHESITIS USING MULTIPLE MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS: DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING A SUBCUTANEOUS SECUKINUMAB INHIBITS RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS: DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 2) / B. Kirkham* - I. B. McInnes - P. Mease - J. Kremer - S. Kandala - M. Patekar - S. Mpofu

THU0422

THU0423
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR: IMPROVEMENTS IN NAIL AND SCALP PSORIASIS AND PSORIASIS AREA AND SEVERITY INDEX IN PATIENTS WITH MODERATE TO SEVERE PL AQEU PSORIASIS (ESTEEM 1 AND 2) / K. Papp* - J. Crowley - C. Paul - M. Gooderham - K. Reich - C. Hu - R. Day - C. Griffiths

THU0424

THU0425

THU0426
ULTRASOUND IDENTIFIES ADDITIONAL EROSIONAL DISEASE IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS: RESULTS FROM THE TICOPA STUDY / L. C. Coates* - J. E. Freeston - J. Nam - P. G. Conaghan - P. S. Helliswell

* Presenting author
Osteoarthritis

THU0425 SUSTAINED IMPROVEMENTS IN SKIN OUTCOMES FOLLOWING CERTOLIZUMAB PEGOL TREATMENT OF PSORIATIC ARTHRITIS PATIENTS WITH PRIOR ANTI-TNF EXPOSURE OR SEVERE SKIN INVOLVEMENT AT BASELINE / M. Khraishi* - B. Hoenken - J. D. Davies - T. Arledge - L. Peterson - P. J. Mease

THU0426 VALIDATION OF THE TORONTO PSORIATIC ARTHRITIS SCREEN II (TOPAS II) QUESTIONNAIRE IN A TURKISH POPULATION / M. T. Duruöz* - C. Sanal Top


THU0434 BONE DENSITY AND METABOLISM WITH DISEASE CONDITION IN PSORIATIC ARTHRITIS AFTER TREATMENT WITH ADALIMUMAB FOR 52 WEEKS / S. Jais* - M. Higashiyama - T. Tomita - M. Matsu - H. Tsuboi - J. Hashimoto

THU0435 TREATMENT PERSISTENCE WITH SUBCUTANEOUS BIOLOGIC THERAPIES IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA) / R. Iyu - Q. Ding - M. Govoni - C. Maksin - J. Korn - T. Fan - A. Ogbonnaya - C. M. Black - S. Kachroo*

THU0436 REAL-WORLD COMPARATIVE EFFECTIVENESS OF ADALIMUMAB AND TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: RESULTS OF AN ADMINISTRATIVE CLAIMS ANALYSIS / V. Garg* - J. Griffith - O. A. Hayes - Y. Bao

THU0451  SENSITIVITY TO CHANGE OF SF-36 HEALTH SURVEY AND PATIENT GENERATED INDEX IN PEOPLE WITH CHRONIC KNEE PAIN COMMENCED ON ORAL ANALGESIA: ANALYSIS OF DATA FROM A CLINICAL TRIAL / A. Papou* - S. Hussain - D. McWilliams - W. Zhang - M. Doherty


THU0456  INFRAPATELLAR FAT PAD VOLUME AND SIGNAL INTENSITY ALTERATION WERE ASSOCIATED WITH KNEE OSTEOARTHRITIC CHANGES IN PATIENTS WITH KNEE SYMPTOMATIC OSTEOARTHRITIS / J. Cai - K. Wang - J. Xu - S. Zheng - X. Yang - C. Ding*

THU0457  LONG TERM BARRIERS AND FACILITATORS TO EXERCISE AND PHYSICAL ACTIVITY IN OLDER ADULTS WITH KNEE PAIN: THE BEEP LONGITUDINAL QUALITATIVE STUDY / C. Jinks* - A. Moore - M. A. Holden - N. E. Foster

THU0458  BODY MASS INDEX AND BODY FAT CONTENT CORRELATE SIMILARLY WITH SYNOVIAL LEPTIN IN KNEE OSTEOARTHRITIS / C. Orellana* - J. Calvet - N. Navarro - M. Garcia Manrique - E. Casado - J. Gratacos - M. Larrosa

THU0459  CLINICAL FEATURES OF DISFUNCTIONAL PAIN IN KNEE OSTEOARTHRITIS / E. Turovskaya - L. I. Alekseeva* - E. G. Filatova


THU0461  ILLNESS PERCEPTIONS PREDICT RESPONSE TO INTRA-ARTICULAR STEROID INJECTIONS IN KNEE OSTEOARTHRITIS / G. Hirsch* - G. Kitas - T. O'Neill - J. Duda - R. Klocke


THU0463  POLYMERIC NANO/ Particles WITH THERMALLY RESPONSIVE DUAL RELEASE PROFILES FOR COMBINED THERAPY OF OSTEOARTHRITIS / M. L. Kang - J. Y. Ko - J. E. Kim - G. I. Im*.

THU0464  ADHESIVE BARRIER/DIRECTIONAL CONTROLLED RELEASE FOR CARTILAGE REPAIR BY ENDGENOUS PROGENITOR CELL RECRUITMENT / G. I. Im* - J. M. Lee - E. A. Kim


THU0469  POTENTIAL BIOMARKERS OF DIABETES-ASSOCIATED OSTEOARTHRITIS: AN EXPLORATORY STUDY / I. Shirinsky* - O. Sazonova - N. Kalinovskaya - V. Shirinsky

THU0470  EFFECTS OF DIABETES ON KNEE PAIN AND FUNCTION IN PERSONS AT RISK OF OSTEOARTHRITIS HAVING NO OR MILD SYMPTOMS: DATA FROM THE OSTEOARTHRITIS INITIATIVE / I. Shirinsky* - V. Shirinsky


THU0473  EFFECTS OF DIABETES ON KNEE PAIN AND FUNCTION IN PERSONS AT RISK OF OSTEOARTHRITIS HAVING NO OR MILD SYMPTOMS: DATA FROM THE OSTEOARTHRITIS INITIATIVE / I. Shirinsky* - V. Shirinsky

THU0474  A PHASE 1 CLINICAL TRIAL OF ATB-346, A GASTROINTESTINAL-SAFE NONSTEROIDAL ANTI-INFLAMMATORY DRUG / J. L. Wallace*

THU0475  FACTORS ASSOCIATED WITH CARE SEEKING IN A POPULATION-BASED COHORT WITH KNEE PAIN / J. Cibere*

THU0476  PATHOGENIC RELATIONSHIP BETWEEN OSTEOARTHRITIS, OVERWEIGHT AND INFLAMMATION / A. Pelyakova* - B. Zavadovska - L. Seewordova - Y. Akhverdyan - I. Zborovskaya

THU0477  SERUM LEVELS OF RESISTIN AND INTERLEUKIN-17 ARE ASSOCIATED WITH INCREASED CARTILAGE DEFECTS AND BONE MARROW LESIONS IN PATIENTS WITH KNEE SYMPTOMATIC OSTEOARTHRITIS / K. Wang* - J. Xu - J. Cai - Z. Shuang - X. Yang - C. Ding*

* Presenting author
THU0478 longitundinal associations between painful knee osteoarthritis and difficulties in physical functioning among community-dwelling women: A 9 years follow-up study in Japan / A. Kira* - T. Nishimura - Y. Abe - K. Aoyagi

THU0479 the sex ratios of knee and hip osteoarthritis are different in Korea: data from the Korean national health and nutrition examination survey 2013 / K. W. Moon*

THU0480 screening for the presence of sacroiliitis is recommended for young patients undergoing hip arthroplasty / L. Waters* - S. Blankeley - J. Fountain - N. J. Goodson


THU0482 defining an international standard set of outcomes measures for patients with hip or knee osteoarthritis (oa): consensus of the international consortium of health outcome measurement (ichom) hip and knee oa working group / L. March* - P. Conaghan - O. Rolfsen - S. Wissig - C. Stowell - P. Franklin on behalf of ICHOM Hip and Knee OA Working Group

THU0483 relation of synovitis, effusions, bone marrow lesions and cartilage damage to pain sensitisation in people with knee osteoarthritis presenting for total knee replacement: an observational study / A. Kuttapitiya - A. Harrison - L. Assi - D. Christidis - V. Ejindu - C. Heron - F. Howe - C. Hing - P. Mitchell - S. Bridle - N. Sofa*

THU0484 more pain, stiffness and ultrasound detected changes in patients with erosive than non-erosive hand osteoarthritis / O. Slegova* - O. Ruzickova - K. Pavelka - L. Senolt


THU0487 prolonged symptom elevation but not progression following incident radiographic knee osteoarthritis: data from the osteoarthritis initiative / R. Case* - K. P. Jordan - G. Peat

THU0488 a 6 month trial evaluating efficacy of one intra-articular injection of 2% sodium hyaluronate versus hylan g-f 20 in the treatment of painful tibiofemoral osteoarthritis / R. L. Dreiser* - R. Avouac - T. Bardin on behalf of the French study group

THU0489 morphometric study of australian hips: an etiological study to explain the low prevalence of hip osteoarthritis in australia / S. Sliman* - K. Testas - I. Bencharif - M. Boukredra - R. Chilibeub


THU0493 the natural history and clinical significance of knee effusion-synovitis change - a 2.7-year older adults cohort study / X. Wang* - X. Jin - W. Han - Z. Zhu - L. Blizard - F. Cicuttini - G. Jones - C. Ding


THU0495 oxidized low density lipoproteins and efficacy of osteoarthritis therapy with avacado and soya unsaponifiables / Y. Akverdyran* - B. Zavodosky - J. Polyakova - L. Seewerdova - A. Zborovsky


**Presenting author**

THU0503 ANTI-C1Q ANTIBODY AS MARKER OF RENAL INVOLVEMENT IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS / C. Picardi* - N. Fabien - B. Ranchin - P. Cochat - A. Belot

THU0504 CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS FOLLOWING TREATMENT WITH ADALUMAB / D. Kingsbury* - P. Quartier - G. Horneff - K. Minden - M. Toth - N. Varothai - A. Cardoso - J. Kalabic

THU0505 THE IMMUNE RESPONSE TO HEPATITIS A VACCINE IN CHILDREN WITH AUTOINFLAMMATORY DISORDERS / D. Maritsi* - G. Vartzelis - Z. Metaxa - O. Vougouka - N. Spyridis - S. Diamantopoulos


THU0509 FIRST MONTH REPORT OF IRANIAN Periodic Fever and Autoinflammatory Registry (IPFAIR) / F. Mehregan* - V. Ziaee - M. H. Moradinejad - Y. Aghighi - S. R. Raseekarimi

THU0510 RENAL OUTCOMES IN A JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS COHORT - EXPERIENCE OF A TERTIARY CENTER / M. Rodrigues - F. Aguilar* - A. Caldas Afonso - J. Brito


THU0512 A SERIOUS GAME DESIGNED FOR CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / J.-D. Cohen - D. Bentayou - M.-A. Bernard Brunel - S. Trope*


THU0514 EFFECT OF LONG-TERM TREATMENT WITH ANAKINRA (KINERET®) ON BONE MINERAL DENSITY IN PATIENTS WITH SEVERE CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES / K. Timdahl* - B. Goldbach-Mansky - M. Leinonen - H. Olivecrona

THU0515 COMORBIDITY IN CHILDREN AND ADOLESCENCES WITH JUVENILE IDIOPATHIC ARTHRITIS / L. F. Bogmat* - N. S. Shevchenko - M. V. Demjanenko


THU0517 THE IMMUNE RESPONSE TO HEPATITIS A VACCINE IN CHILDREN WITH AUTOINFLAMMATORY DISORDERS / C. Biancardi* - I. Borzani - A. Ravelli - F. Corona - G. Filacamo

THU0518 ANTIC1Q ANTIBODY AS MARKER OF RENAL INVOLVEMENT IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS / C. Picardi* - N. Fabien - B. Ranchin - P. Cochat - A. Belot

THU0519 THE IMMUNE RESPONSE TO HEPATITIS A VACCINE IN CHILDREN WITH AUTOINFLAMMATORY DISORDERS / C. Biancardi* - I. Borzani - A. Ravelli - F. Corona - G. Filacamo

THU0520 DISCONTINUATION OF ANTI-TNF IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS IN CLINICAL REMISSION / M. Camacho-Lovillo* - E. Gil-González - M. A. Gantes Pedraza - M. A. López-Salcedo


THU0522 THE METHOTREXATE TREATMENT CAN PREVENT UVEITIS ONSET IN JUVENILE IDIOPATHIC ARTHRITIS: THE EXPERIENCE IN A COHORT WITH INCREASED PROPORTION OF METHOTREXATE / M. M. Kostik* - E. V. Gaidar


THU0524 CERTOLIZUMAB PEGOL IS EFFECTIVE IN CHILDREN WITH JIA NOT SUFFICIENTLY RESPONSIVE TO OTHER TNF ALPHA ANTAGONISTS / N. Tzaribachev* - C. Guettel - C. Tzaribachev - B. Koos


THU0526 ANALYSIS OF BONE MINERAL DENSITY IN CHILDREN AGED 0 TO 12Y IN GUANGZHOU CITY / P. Zhang* - Y. Mou - J. Gu

THU0527 KAWASAKI DISEASE - AN EXPERIENCE FROM EASTERN INDIA / P. P. Giri* - P. Pal

* Presenting author
<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU0530</td>
<td>MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: SINGLE CENTER EXPERIENCE</td>
<td>S. Rodionovskaya - I. Nikishina - I. Alakaeva - M. Kaleda</td>
</tr>
<tr>
<td>THU0533</td>
<td>DYNAMICS OF GROWTH IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS TREATED WITH ABACAPSE</td>
<td>V. Seraya - E. Zholobova</td>
</tr>
<tr>
<td>THU0534</td>
<td>JOINT HYPERMOBILITY IN Oligoarticular Juvenile Idiopathic Arthritis</td>
<td>F. Cecchin - F. Sperotto - M. Balzarini - F. Vittadello - G. Martini - F. Zulian</td>
</tr>
<tr>
<td>THU0536</td>
<td>EFFICACY AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: RESULT FROM LONG-TERM, INTERVENTIONAL, OPEN LABEL EXTENSION STUDY IN PATIENTS FROM POLAND AND RUSSIA WHO COMPLETED THE MULTINATIONAL TRIAL</td>
<td>E. Smolewska - Z. Zub - G. Dębowska</td>
</tr>
<tr>
<td>THU0537</td>
<td>SELECTED FACTORS OF COMPLEMENT LECTIN PATHWAY FACTORS IN POLISH CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS</td>
<td>K. Kaczmarska - A. Pawlak - M. Pawlak - J. Czajka</td>
</tr>
</tbody>
</table>

**Other orphan diseases**

<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>THU0541</td>
<td>AMYLOIDOSIS IN ALKAPTONURIA IN A COHORT OF ITALIAN PATIENTS</td>
<td>A. T. Baldaccini - M. Piacentini - M. Piacentini - S. Piacentini - G. Bernardini - G. Piacentini - G. Piacentini</td>
</tr>
<tr>
<td>THU0547</td>
<td>EVALUATION OF VENOUS DISEASE SPECIFIC QUALITY OF LIFE IN PATIENTS WITH VASCULAR BEHÇET’S DISEASE</td>
<td>A. Martini - I. Ceccherini - M. Gattorno</td>
</tr>
<tr>
<td>THU0549</td>
<td>JOINT HYPERMOBILITY IN Oligoarticular Juvenile Idiopathic Arthritis</td>
<td>F. Cecchin - F. Sperotto - M. Balzarini - F. Vittadello - G. Martini - F. Zulian</td>
</tr>
<tr>
<td>THU0551</td>
<td>MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: SINGLE CENTER EXPERIENCE</td>
<td>S. Rodionovskaya - I. Nikishina - I. Alakaeva - M. Kaleda</td>
</tr>
</tbody>
</table>

* Presenting author


THU0557 HEMOPHAGOSITIC LYMPHOMATOSIS SYNDROME (HLH) IN ADULTS. DISEASES TRIGGERS, COURSE, TREATMENT AND PRONOSTIC FACTORS. DIFFERENCES BETWEEN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) AND OTHER CAUSES OF SECUNDARY HEMOPHAGOSITIC LYMPHOMATOSIS SYNDROME. REPORT OF THIRTY-TWO CASES / L. Y. Komsalova* - L. M. Lopez

THU0558 PROGRESSION RISK FACTORS IN PATIENTS WITH UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE: A COHORT STUDY / M. Garcia Gonzalez* - L. Exposito - H. Sánchez - S. Bustabad - I. Ferraz-Amaro - B. Rodríguez-Lozano

THU0559 BEHÇET’S DISEASE COMPLICATED WITH CEREBRAL VENOUS SINUS THROMBOSIS: A REPORT OF NINE CASES / L. Akyol - K. Adam - M. Özgen - M. Sayarlıoglu*

THU0560 Atherosclerosis in Behçet Disease: A Systematic Review & Metaanalysis / M. Merashli* - I. Chiis Ster - P. RJ Ames

THU0561 Salivary IL-1 Alpha and IL-1 Beta Levels Associated with Oral mucosal disease activity in Behçet’s Disease / N. Alpay-Kantüz - B. Toz - F. Berktaş - M. Güzel - S. Egun - M. Koray - N. Polat - B. Eser - A. Gül*

THU0562 A Comparison between ankylosing spondilitis patients and familial Mediterranean fever with ankylosing spondilitis patients / A. Yazici - O. Ozdemir Isik* - D. Temiz Karadag - O. Ozkul - C. Albayrak Tasar - A. Cefe


THU0566 Certain Autoimmune Diseases Are Associated with Distinctive Karyotypes and Outcome in Patients with Myelodysplastic Syndrome / S. J. Lee* - S. H. Joo - E. B. Lee - Y. W. Song - S.-S. Yoon - J. K. Park


THU0568 Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-Center Experience / S. Uğurlu* - B. Ergezen - H. Ozdogan

THU0569 Bone Imaging Findings in Genetic and Acquired Lipodystrophic Syndromes: A Retrospective Study of 24 Cases / S. Teboul Core* - C. Rey Jouv in - A. Miquel - C. Vatier - J. Capeau - F. Berenbaum - J.-D. Laredo - C. Vigouroux - J. Sellam

THU0570 The Distribution of Mefv Gene Mutations in Turkish Familial Mediterranean Fever Patients, A Multicenter Study / T. Kasifoglu* on behalf of Turkish FMF Study Group

THU0571 Association of Microscopic Colitis with Autoimmune Diseases in a Series of 97 Cases / W. A. Sifuentes Giraldo* - M. Llop Vilaltella - C. Bouruncle Alaluna - C. González-García - E. Loza Santamaría - J. L. Morell Hita - A. López San Román


THU0573 Development of a Paediatric Rheumatology Education Resource-Sharing Website: If You Build It, Will They Come? / M. Curran* - R. Singh

THU0574 Development of a Series of Simulators and Design a Course Based on a Clinical Simulation, for Teaching Diagnostic Approach to Patients with Joint Pain and Suspected Rheumatoid Disease / D. G. Fernández-Avila* - L. Sastre - S. Mora


THU0577 Welsh National Audit of 2013 Eular Recommendations on the Management of Medium-High Dose Steroid Use in Rheumatic Diseases / M. Zamari* on behalf of All Wales Rheumatology Group [AWRG]


* Presenting author

Education
THU0579 WHAT KNOWLEDGE IS ESSENTIAL FOR PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND SPONDYLOARTHRITIS (SPA)? RESULTS OF A MULTICENTRIC SURVEY AMONG HEALTH PROFESSIONALS AND PATIENTS WITH DELPHI METHODOLOGY. AN INITIATIVE OF THE FRENCH RHEUMATOLOGY SOCIETY THERAPEUTIC EDUCATION SECTION / C. Beauvais* - M. Rodère - B. Peirera - L. Soubrier - L. Gossec

THU0580 A TWO-MINUTE SITTING EXERCISE PROGRAMME TO ENCOURAGE SEDENTARY PATIENTS TO EXERCISE / D. Stevens* - D. Collins - E. Price - L. Williamson


THU0582 READABILITY OF ONLINE ANKYLOSING SPONDYLITIS PATIENT EDUCATION MATERIAL / A. Omar* - I. Sari - R. Inman - N. Haroon


THU0584 DEVELOPMENT OF A RELATIVE AVERAGE MONTHLY COST COMPARISON (WAC) TABLE OF SELECTED NSAIDS/DMARDS/BIOLOGIC MEDICATIONS FOR EDUCATION OF CALIFORNIA MEDICAID POPULATION HEALTHCARE PROVIDERS / A. L. Wong* - P. Chan - I. Thompson on behalf of the California Department of Health Care Services Medical Drug Utilization Review (DUR) Board

THU0585 A SURVEY COMPARING THE VIEWS OF DOCTORS AND PATIENTS ON THE IMPORTANT ASPECTS OF BIOLOGIC THERAPY / B. Boyce* - O. Savovic-Abel - R. Haigh


THU0587 EVALUATION OF PATIENTS' AWARENESS REGARDING GLUCOCORTICOIDS SIDE EFFECTS AND PREVENTION STRATEGIES / C. Piausanu* - V. Iorgoveanu - A. Neagu - R. Ionescu

THU0588 MANAGEMENT OF THE ACUTE SWOLLEN JOINT - AN AUDIT OF MEDICAL INPATIENTS / N. Narayan* - R. Klocke

THU0589 COLLABORATIVE DEVELOPMENT OF PAEDIATRIC MUSCULOSKELETAL MATTERS (PMM) - AN ONLINE EVIDENCE BASED INFORMATION RESOURCE FOR PAEDIATRIC MUSCULOSKELETAL MEDICINE / N. Smith* - S. Jandial - T. Rapley - H. Foster

THU0590 MANAGEMENT OF INFLAMMATORY BACK PAIN - HOW GOOD ARE OUR GENERAL INTERNAL MEDICINE TRAINEES? / P. Das* - A. Moorthy

---

**Rehabilitation**

**Hall 5**


THU0592 EFFICACY OF REHABILITATION WITH TAI JI QUAN ON DISABILITY, QUALITY OF LIFE, PAIN, PSYCHOLOGICAL DISTRESS, SLEEP IN AN ITALIAN COHORT OF PATIENTS WITH FIBROMYALGIA SYNDROME / A. Del Rosso* - G. Paololetti - M. Cala - S. Maddali Bongi

THU0593 EFFICACY OF 6-MONTH COMPLEX REHABILITATION PROGRAM IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS RECEIVING ADA LIMUMAB / E. Orlova* - D. Karateev - L. Denisov - A. Kochetkov - E. Nasonov


THU0595 PHYSICAL ACTIVITY AND RHEUMATOID ARTHRITIS, A SYSTEMATIC REVIEW / F. Verhoeven* - N. Tordi - C. Prati - C. Demougeot - E Mougin - D. Wendling

THU0596 IS GROUP-BASED EXERCISE BETTER THAN HOME-BASED EXERCISE IN PATIENTS WITH ANKYLOSING SPONDYLITIS STABILIZED WITH TUMOR NECROSIS FACTOR-ALPHA INHIBITOR THERAPY? A RANDOMIZED CONTROLLER STUDY / J. Sollini* - T. Nava - A. Parlatoni - V. Moretti - P. Scendoni


THU0600 VALUE OF MESOTHERAPY FOR TREATMENT OF CHRONIC LOW BACK PAIN: A RANDOMIZED TRIAL / S. H. Senara* - W. Y. Abdel Wahed

THU0601 BROAD MULTIDISCIPLINARY INPATIENT REHABILITATION FOR INFLAMMATORY RHEUMATIC DISEASE DOES NOT CONTRIBUTE TO IMPROVED HEALTH OUTCOMES / T. Uhlig* - O. Bjørneboe - F. Krell - Ø. Palm - I. C. Olsen - M. Grotle


* Presenting author
Scientific Programme

08:00 - 19:30  Hall 7
Registration

08:30 - 10:00  Room 10 I

Basic and Translational Science session
Transition from chronic inflammation to cancer: the basic story

Chairperson(s):
Steffen Gay (Switzerland)
Guido Valesini (Italy)
Maurizio Cutolo (Italy) 08:35
Abstract N° SP0127
Transition from chronic inflammation to cancer: immune endocrine synergies
Caroline Ospelt (Switzerland) 09:00
Abstract N° SP0128
Common epigenetic biomarkers in chronic inflammation and cancer
Chris Buckley (United Kingdom) 09:25
Stromal cells in the persistence of chronic inflammation and cancer transition

17:45 - 19:15

Satellite symposia
- AbbVie
- Pfizer
- PEARLS supported by Janssen
- Novartis Pharmaceuticals
- Lilly
- GSK
- Bioiberica

08:30 - 10:00  Room 10 D-E

Basic and Translational Science session
Complement as a driver and target in inflammatory disease

Learning objectives:
To understand the role of complement in the pathogenesis of rheumatic diseases and complement as a potential therapeutic target

Chairperson(s):
Thomas Kamradt (Germany)
Angelo Manfredi (Italy)
Jörg Köhl (Germany) 08:35
Abstract N° SP0129
The complement system in inflammatory diseases
Ming-Hui Zhao (China) 09:00
Abstract N° SP0130
C5A and its receptor in ANCA-associated vasculitis
Antonio Risitano (Italy) 09:25
C3 as a therapeutic target in PNH and beyond
E. Assirelli (Italy) 09:50
P. Dolzani, L. Pulsatelli, O. Addimanda, R. Meliconi
Abstract N° OP0159
Complement factors in osteoarthritis articular compartments
The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study

10:00 - 10:30  Halls 5&6
Coffee break
**10:30 - 12:00**  
**Hall 9**

**What is New (WIN)**

**WIN session 5**

**Leslie J. Crofford (United States)**  
Abstract No SP0131  
Fibromyalgia  
10:35

**Dimitrios Vassilopoulos (Greece)**  
Abstract No SP0132  
Infection and rheumatic diseases  
11:15

---

**10:30 - 12:00**  
**Hall 8**

**Abstract session**

**Comorbidities in RA**

**Chairperson(s):**  
Vivian Bykerk (United States)  
Annette van der Helm (Netherlands)

**L. R. Harrold (United States)**  
Abstract No OP0160  
The impact of rheumatoid arthritis on patient reported outcomes and quality of life prior to biologic initiation  
10:35

**A. Richter (Germany)**  
A. Strangfeld, M. Schneider, T. Klopsch, A. Kapelle, J. Kaufmann, A. Zink, J. Listing  
Abstract No OP0161  
Discontinuation of biologic DMARDs increases the risk of sepsis and mortality after serious infection  
10:45

**J. Askling (Sweden)**  
M. Holmqvist, L. Ljungh  
Abstract No OP0162  
Acute Coronary syndrome in rheumatoid arthritis: are patients diagnosed today also at increased risk?  
10:55

**B. Erhayem (United Kingdom)**  
Abstract No OP0163  
Treatment-naïve, early rheumatoid arthritis patients demonstrate vascular and myocardial abnormalities on cardiac MRI  
11:05

**W. P. Nieuwenhuis (Netherlands)**  
M. Reijnierse, A. H. M. van der Helm-van Mil  
Abstract No OP0164  
Can information obtained by extremity MRI at disease presentation be used to identify rheumatoid arthritis among undifferentiated arthritis patients?  
11:15

**J. Brouwer (Netherlands)**  
R. Fleurbaij, J. M. Hazes, J. S. Laven, R. J. Dolhain  
Abstract No OP0165  
Subfertility in female rheumatoid arthritis patients is often unexplained or caused by anovulation  
11:25

---

**10:30 - 12:00**  
**Hall 3**

**Abstract session**

**SpA and PsA treatment**

**Chairperson(s):**  
Maxime Dougados (France)  
Janneke de Winter (Netherlands)

**J. Sieper (Germany)**  
Abstract No OP0168  
Secukinumab significantly improves signs and symptoms of active ankylosing spondylitis: 52-week data from measure 2, a randomized, double-blind, placebo-controlled phase 3 trial with subcutaneous loading and maintenance dosing  
10:35

**D. Gladman (Canada)**  
Abstract No OP0169  
Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase 3, randomized, controlled trials  
10:45

**G. Varkas (Belgium)**  
H. Cypers, I. Van Praet, L. Jans, P. Carron, D. Elewaut, F. van den Bosch  
Abstract No OP0170  
Treatment of axial spondyloarthritis with an optimal dosage of NSAIDs: a 6-week follow up study focusing on magnetic resonance imaging of the sacroiliac joints  
10:55

**J. Braun (Germany)**  
Abstract No OP0171  
Achievement of remission of inflammation in the spine and sacroiliac joints measured by magnetic resonance imaging (MRI) in patients with axial spondyloarthritis, and associations between MRI and clinical remission, over 96 weeks of treatment with Certolizumab pegol  
11:05

---

**A. Finckh (Switzerland)**  
Abstract No OP0166  
Antibodies against periodontal pathogens are not associated with joint swelling or autoimmunity associated with RA in a cohort of healthy individuals at increased risk of rheumatoid arthritis.  
11:35

**M. Tilanus (Netherlands)**  
P. Barrera Rico, C. J. van Daal, J. Fransen  
Abstract No OP0167  
Protection by hepatitis B vaccination of rheumatoid arthritis patients using biologicals  
11:45
Abstract N° OP0172
D. Poddubnyy (Germany) 11:15
J. Sieper
No differences in the rate of new fatty lesions following resolution of inflammation on MRI between Infliximab added to Naproxen and Naproxen alone in early axial spondyloarthritis: results from the part I of the INFAST study

Abstract N° OP0173
R. G. Dragoi (Romania) 11:25
E. C. Amaricali, M. Dragoi, H. Popoviciu, C. Avram
Inspiratory muscle training as a method for improving aerobic capacity and pulmonary function in patients with ankylosing spondylitis: a randomized controlled study

Abstract N° OP0174
A. Kavanaugh (United States) 11:35
Efficacy and safety of Ustekinumab in psoriatic arthritis patients with spondylitis and peripheral joint involvement: results from a phase 3, multicenter, double-blind, placebo-controlled study

Abstract N° OP0175
P. Mease (United States) 11:45
M. C. Genovese, M. W. Greenwald, C. T. Ritchlin, A. Beaulieu, A. Deadhar, R. Newmark, J. Feng, N. Erondu, A. Nirula
Two-year clinical response to Brodalumab, an anti-IL-17 receptor antibody, in patients with psoriatic arthritis

Abstract N° OP0176
S. Ajeganova (Sweden) 10:45
I. Hafström, B. Svensson
Failure to achieve early remission augments risk of mortality in rheumatoid arthritis

Abstract N° OP0177
S. M. Goodman (United States) 10:55
Body mass index is an independent risk factor for not achieving sustained remission in early rheumatoid arthritis: results from the CATCH observational study

Abstract N° OP0178
E. Nikiphorou (United Kingdom) 11:05
L. Carpenter, S. Norton, P. Kiely, J. Dixey, A. Young
Different levels of moderate disease in rheumatoid arthritis (RA) are associated with varying risk for joint destruction and failure. Time to update DAS cut-offs for biologic DMARD use?

Abstract N° OP0179
P. Verschuereen (Belgium) 11:15
F. B. G. Lamers-Karnebeek (Netherlands) 11:25
T. Jansen, P. Van Riel, J. Luime, J. Jacobs
Ultrasonography as predictor for flare in rheumatoid arthritis patients with low disease activity: nine month results from POET-US-study

Abstract N° OP0171
A. Finckh (Switzerland) 11:35
A. Neto, A. Lubbeke, B. Moeller, A. Ciurea, P. Zufferey, C. Gabay on behalf of physicians of the SCQM
The impact of statin use on structural bone damage in rheumatoid arthritis

Abstract N° OP0172
L. R. Harrold (United States) 11:45
G. W. Reed, D. H. Solomon, J. R. Curtis, M. Liu, J. D. Greenberg, J. M. Kremer
The comparative effectiveness of Tocilizumab as compared to Abatacept in those with prior exposure to anti-TNF agents
Abstract session

SLE and Sjögren's: new treatment options

Chairperson(s):
Marta Mosca (Italy)
Gerda M. Steup-Beekman (Netherlands)

D. Isenberg (United Kingdom) 10:35
Abstract N° OP0184
Efficacy and safety of Tabalumab in patients with systemic lupus erythematosus (SLE): results from 2 phase 3, 52-week, multicenter, randomized, placebo-controlled trials

J. Smolen (Austria) 10:45
Abstract N° OP0185
Significant clinical improvement and reduction of severe flares following administration of an IL-6 monoclonal antibody in systemic lupus erythematosus (SLE) subjects with high disease activity

I. N. Bruce (United Kingdom) 10:55
M. Urowitz, R. van Vollenhoven, C. Aranow, J. Fettiplace, M. Oldham, E. Menius, B. Wilson, C. Aranow, D. Roth, D. Gordon
Abstract N° OP0186
5-year organ damage accrual and safety in patients with SLE treated with Belimumab plus standard of care

L. J. Durcan (United States) 11:05
W. A. Clarke, L. Magder, M. Petri
Abstract N° OP0187
Hydroxychloroquine blood levels in SLE: clarifying dosing controversies and improving adherence.

S. Sciascia (United Kingdom) 11:15
B. J. Hunt, E. Talavera, G. Lliso, D. Roccioletto, M. Khamashita, M. J. Cuadrado
Abstract N° OP0188
Impact of hydroxychloroquine treatment on pregnancy outcome in patients with antiphospholipid antibodies

D. Cornec (France) 11:25
Abstract N° OP0189
High grade salivary gland involvement, assessed by histology or ultrasonography, is associated with a poor response to Rituximab in primary Sjögren's syndrome patients

G. M. Verstappen (Netherlands) 11:35
P. M. Meiners, O. B. Cornelis, R. W. Hendriks, A. Vissink, F. G. Kroese, H. Bootsma
Abstract N° OP0190
Abatacept treatment targets TFH-cells in patients with primary Sjögren's syndrome

O. Amengual (Japan) 11:45
D. Fujita, E. Otta, L. Carmona, O. Kenji, M. Sugira-Ogasawara, A. Murashima, T. Atsumi
Abstract N° OP0191
Prophylaxis for the prevention of obstetric complications in asymptomatic women with antiphospholipid antibodies

PReS Abstract session

Basic aspects in paediatric rheumatology

Chairperson(s):
Johannes Roth (Germany)
Ivan Foeldvari (Germany)

D. Popp (Germany) 10:35
B. Petersen, F. Rühle, J. Roth
Abstract N° OP0192
S100 proteins in dendritic cells regulate inflammatory processes

S. K. Fassl (Germany) 10:45
Abstract N° OP0193
Pyrin and PSTPIP1, mutated in FMF, PAPA-, and PAMI syndrome, are involved in the hypersecretion of alarmins MRp8/14

C. Kessel (Germany) 10:55
S. Fühner, S. Brockmeyer, H. Wittkowski, D. Föll
Abstract N° OP0194
Hexameric S100A12 is required for pro-inflammatory TLR4-signalling

A. Omenetti (Italy) 11:05
Abstract N° OP0195
Enhanced NLRP3-dependent interleukin-1B secretion correlates with disease activity in pyogenic sterile arthritis pyoderma gangrenosum and severe acne (PAPA) syndrome

N. Ter Haar (Netherlands) 11:15
T. Tak, B. Vastert, S. de Roock
Abstract N° OP0196
The role of neutrophils in the inflammatory cascade of systemic onset juvenile idiopathic arthritis

L. E. Ling (United States) 11:25
Abstract N° OP0197
High-resolution, integrated molecular profiling reveals persistent inflammation in Kawasaki disease patients with coronary artery aneurysms
J. Ong (United Kingdom) 11:35
A. Midgley, M. Beresford

Abstract N° OP0198
Expression of low density granulocytes and histone citrullination in juvenile-onset systemic lupus erythematosus and juvenile idiopathic arthritis

L. Lamot (Croatia) 11:45
M. Vidović, M. Perica, L. Tambić Bukovac, K. Gotovac, F. Borovečki, M. Harjaček

Abstract N° OP0199
TRP channels overexpression contributes to inflammasome activation in clavicular cortical hyperostosis?

10:30 - 12:00 Room 10 I
Abstract session
SpA and PsA basic and translational research

Chairperson(s):
Dominique Baeten (Netherlands)
Marina Frleta (United Kingdom)

D. D. O’Rielly (Canada) 10:30

Abstract N° OP0200
Global DNA methylation patterns differ between responders and non-responders in psoriatic arthritis patients treated with tumor necrosis factor-α inhibitors

P. C. Robinson (Australia) 10:40
P. Leo, J. J. Pointon, J. Harris, K. Cremin, L. A. Bradbury, S. Stebbings, A. Harrison, E. Duncan, P. Wordsworth, M. A. Brown

Abstract N° OP0201
Exomewide association study of ankylosing spondylitis identifies additional coding region genetic associations with as and strengthens evidence of shared genetic background with inflammatory bowel disease

M. N. van Tok (Netherlands) 10:50
L. M. van Duivenvoorde, I. Kramer, P. Ingold, J. D. Taurog, F. Kolbinger, D. L. Baeten

Abstract N° OP0202
Anti-IL-17A treatment blocks inflammation and new bone formation in experimental spondyloarthritis in HLA-B27 transgenic rats

F. Costantino (France) 11:00

Abstract N° OP0203
A family-based genome-wide association study reveals an association of spondyloarthropathies with MAPK14

N. Haroon (Canada) 11:10
G. Guggino, Z. Zhang, K. Yee, H. Abdullah, R. Alessandro, S. Raimondo, G. Triolo, F. Ciccia

Abstract N° OP0204
Autophagy and unfolded protein response: a fine balance that can influence the pathogenesis of ankylosing spondylitis and inflammatory bowel disease

F. Ciccia (Italy) 11:20
M. M. Luchetti, G. Guggino, M. Rossini, S. Raimondo, A. Gabrielli, R. Alessandro, A. Rizzo, G. Triolo

Abstract N° OP0205
Gut dysbiosis in patients with HLA-B27+ ankylosing spondylitis is associated with ileitis, down-regulation of tight junction proteins, increased serum levels of LPS and monocytes anergy

D. D. O’Rielly (Canada) 11:30

Abstract N° OP0206
Interactions between smoking and methylation status is highly predictive of radiographic progression in ankylosing spondylitis

S.-R. Kwon (Republic of Korea) 11:40
W. park, M.-J. Son, M.-J. Lim, K.-H. Jung

Abstract N° OP0207
The relationship among the inflammation, osteoblast activity, and adipogenesis in patients with ankylosing spondylitis

W. S. Tan (United Kingdom) 11:50

Abstract N° OP0208
Synovial immunopathology defines clinical responsiveness to DMARD therapy in early psoriatic arthritis: a pre- and post-treatment mechanistic study using a minimally invasive ultrasound-guided synovial biopsy procedure

10:30 - 12:00 Room 10 D-E
Abstract session
SSc pathogenesis, etiology and animal models

Chairperson(s):
Otylia Kowal-Bielecka (Poland)
Rucsandra Dobrota (Switzerland)

M. Kapoor (Canada) 10:35

Abstract N° OP0209
Soluble Ephrin-B2 ectodomain contributes to the pathogenesis of systemic sclerosis

M. Manetti (Italy) 10:45
I. Rosa, M. Fazi, S. Guiducci, L. Ibbà-Manneschi, M. Matucci-Cerinic

Abstract N° OP0210
Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice
J. Huang (Germany) 10:55

Abstract N° OP0211
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis

P. Sandner (Germany) 11:05
E. Haasbach, C. Beyer, J. Distler

Abstract N° OP0212
The effects of SGC stimulators on wound healing in the tight skin (TSK-1) mouse skin fibrosis model

E. Volkmann (United States) 11:15

Abstract N° OP0213
Systemic sclerosis is associated with a unique colonic microbial consortium

Q. Peng (China) 11:25
X. Shu, X. Lu, G. Wang

Abstract N° OP0214
Long non-coding RNA expression profile in dermatomyositis: a microarray related study

J. Sepulveda Delgado (Mexico) 11:35
O. Vera-Lastra, M. D. P. Cruz Dominguez, L. Montiel Cervantes, J. Vela, L. J. Jara

Abstract N° OP0215
Endothelial progenitor cells recruitment and NT-PROBNP release is related severity and progression of asymptomatic diastolic dysfunction in patients with systemic sclerosis

L. Haobo (China) 11:45
Z. Guangfeng, Z. Xiao

Abstract N° OP0216
Resveratrol ameliorates pulmonary fibrosis and inhibits human lung fibroblasts activation via modulating SIRT1 and GLI1 signaling

10:30 - 12:00 Room 10 C

Abstract session
New insights into imaging

Chairperson(s):
Carlos M. Gonzalez (Spain)
Giorgio Tamborrini (Switzerland)

O. Amengual (Japan) 10:35

Abstract N° OP0223
Significance of IgG phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results from the initial and validation international multi-centre studies

E. Bellis (Italy) 10:45

Abstract N° OP0217
Ultrasound-detected synovitis and tenosynovitis independently associate with flare in patients with rheumatoid arthritis in clinical remission

H. W. van Steenbergen, M. Reijnierse, A. H. van der Helm-van Mil

Abstract N° OP0218
Prevalence of MRI-detected inflammation in symptom-free persons from the general population and the generation of age-dependent RAMRIS-based reference values

T. Okano (Japan) 11:05

Abstract N° OP0219
Additional intensive treatment for rheumatoid arthritis patients with positive power Doppler signals even after achieving clinical remission might reduce the radiological joint damage - SCRUM study

D. Werner (Germany) 11:15
D. Simon, J. Rech, J. Haschka, T. Buder, W. Neuhuber, G. Schett, A. J. Hueber, A. Kleyer

Abstract N° OP0220
Intraarticular micro channels of MCP joints increase during development of rheumatoid arthritis

F. Ingegnoli (Italy) 11:25
P. Boracchi, R. Guaitierotti, V. Smith, M. Cuto, I. Foeldvari on behalf of EUSTAR co-authors

Abstract N° OP0221
Nailfold capillaroscopy patterns in adulthood are similar in patients with juvenile and adult-onset systemic sclerosis: a EUSTAR case-control study

S. Bruijnen (Netherlands) 11:35

Abstract N° OP0222
Non-invasive PET imaging of B cells in RA patients initiating Rituximab treatment

P. Parmanne (Finland) 11:45

Abstract N° LB0002
Novel injection needle with real-time detection of synovial fluid - exploratory clinical study
HPR Abstract session
Getting to grips with evidence

Chairperson(s):
Anthony Redmond (United Kingdom)
Andrea Domjan (Hungary)

L. Kwakkenbos (Canada) 10:35
O. Minton, P. Stone, S. Alexander, M. Baron, M. Hudson, B. Thombs
Abstract N° OP0224-HPR
Identifying clinically significant fatigue in rheumatic diseases: a case-definition approach

R. Geenen (Netherlands) 10:45
C. L. Overman, F. P. Lafeber, J. M. van Laar, A. C. Marijnissen on behalf of investigators of the Society for Rheumatology Research Utrecht (SRU)
Abstract N° OP0225-HPR
The association between fatigue and disease activity in patients with rheumatoid arthritis: a latent growth curve model analysis of between-subject differences and within-subject changes

R. Arends (Netherlands) 10:55
C. Bode, E. Taal, M. van de Laar
Abstract N° OP0226-HPR
An in-depth process-evaluation of a goal management intervention given by rheumatology nurses

R. Tanaka (Japan) 11:05
J. Ozawa, N. Kito, H. Moriyama
Abstract N° OP0227-HPR
Does exercise therapy improve health-related quality of life in people with knee osteoarthritis? A systematic review

K. Hackett (United Kingdom) 11:15
K. Deane, T. Rapley, V. Deary, N. Kolehmainen, S. Bowman, E. Price, J. Newton, W.-F. Ng
Abstract N° OP0228-HPR
Identifying targets for a non-pharmacological therapy intervention package to improve participation in primary Sjögren’s syndrome patients: a group concept mapping study

M. Klokkerud (Norway) 11:25
Abstract N° OP0229-HPR
Developing a national core set of outcome measures for rehabilitation in rheumatic and musculoskeletal diseases

I. Thyberg (Sweden) 11:35
P. Arvidsson, M. Thyberg, M. Björk, Ö. Dahlström
Abstract N° OP0230-HPR
Increased health related quality of life in early RA today compared to patients diagnosed during the 1990’s. The Swedish TIRA project

N. Cuperus (Netherlands) 11:45
Abstract N° OP0231-HPR
How do we perceive activity pacing in rheumatology care? An international DELPHI survey

Vasculitis

Chairperson(s):
Haner Diroskeneli (Turkey)
Marco A. Cimmino (Italy)

G. Restuccia (Italy) 10:35
Abstract N° OP0232
Outcomes following renal transplantation (RTX) in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV): an analysis of 46 patients

E. Brouwer (Netherlands) 11:15
S. Arends, M. Stellingwerf, A. Rutgers, N. van der Geest, A. Glaudemans, R. Slart
Abstract N° OP0233
Different scoring methods of FDG PET/CT in giant cell arteritis: need for standardization

Abstract N° OP0234
Neuroimaging in differentiating cerebral amyloid angiopathy with and without inflammation

E. Beltrán (Spain) 11:45
G. Hunder, R. Brown, T. Christianson, C. Giannini, J. Morris
Abstract N° OP0235
Long term biologic therapy in refractory uveitis due to Behçet’s disease. Multicenter study of 165 patients

C. Salvarani (Italy) 11:05
E. Brouwer (Netherlands) 11:15
S. Arends, M. Stellingwerf, K.-J. Lensen, A. Rutgers, N. van der Geest, A. Glaudemans, R. Slart
Abstract N° OP0236
Neuroimaging in differentiating cerebral amyloid angiopathy with and without inflammation

10:30 - 12:00 Room 10 H
Abstract session
Vasculitis

10:30 - 12:00 Room 10 A
HPR Abstract session
Getting to grips with evidence

10:30 - 12:00 Room 10 H
Abstract session
Vasculitis
10:30 - 12:00 SC2 - Room A

Abstract session
PARE

Chairperson(s):
Ursula Faubel (Germany)
Boriana Boteva (Bulgaria)

A. Carlsson (Sweden) 10:35
E. Sundin, K. Bildberg
Abstract N° OP0240-PARE
Empowerment and support for a healthier life style

H. Thorseng (Denmark) 10:45
Abstract N° OP0241-PARE
How to live a better life with osteoarthritis - a socially imbalanced disease

K. Lerstrom (United Kingdom) 10:55
B. Rubio
Abstract N° OP0242-PARE
Capabilities of European lupus groups: members of lupus Europe

10:30 - 12:00 Room 8 A

Abstract session
Cartilage - bone - synovium

Chairperson(s):
Willem F. Lems (Netherlands)
Anne-Marie Malfait (United States)
P. D. Miller (United States) 10:35
Abstract N° OP0248
Responder analysis of the effects of Abaloparatide (parathyroid hormone related peptide) and Teriparatide on bone mineral density in postmenopausal women with osteoporosis: results of the ACTIVE trial

M. van den Bosch (Netherlands) 10:45
A. Blom, R. Schelbergen, T. Vogl, J. Roth, W. van den Berg, P. van der Kraan, P. van Lent
Abstract N° OP0249
The alarmins S100A8/A9 induce canonical WNT signaling in naïve mouse knee joints and experimental OA
R. Gago-Fuentes (Spain) 10:55
J. F. Bechberger, F. J. Blanco, C. Naus, M. D. Mayán
Abstract N° OP0250
The regulatory role of the C-terminal domain of connexin 43 in articular cartilage

M. R. McClung (United States) 11:05
Abstract N° OP0251
Effects of 2 years of treatment with Romosozumab followed by 1 year of Denosumab or placebo in postmenopausal women with low bone mineral density

S. Kihara (Japan) 11:15
Abstract N° OP0252
P21 deficiency was susceptible to osteoarthritis with inflammation

M. Forien (France) 11:25
N. Hafsia, F. Poirier, D. Delacour, P. Reboul, M. Cohen-Solal, F. Lioté, H. K. Ea
Abstract N° OP0253
Galectin 3 deficiency altered chondrocyte primary cilia formation and exacerbated cartilage destruction

B. Seriolo (Italy) 11:35
A. Casabella, S. Paolino, G. Botticella, M. Meroni, C. Seriolo, L. Molfetta
Abstract N° OP0254
Association between Dickkopf-1 levels, 25-hydroxyvitamin D status and bone mineral density in postmenopausal patients with systemic sclerosis

W. Bouaziz (France) 11:45
Abstract N° OP0255
MMP13 is transcriptionally repressed by the HIF1α/β-catenin interaction in chondrocytes and osteoarthritis in mice

10:30 - 12:00 Room 9A

Abstract session

Cytokines and inflammatory mediators

Chairperson(s):
Steffen Gay (Switzerland)
Cindy Strehl (Germany)

M. A. Nielsen (Denmark) 10:35
Abstract N° OP0256
ADAM17 and Galectin-9 are critical regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis

F. Sun (Switzerland) 10:45
R. E. Gay, B. A. Michel, S. Ye, S. Gay, M. Neidhart, E. Karouzakis
Abstract N° OP0257
Characterization of a DNA demethylation pathway during inflammation in macrophages

C. Iwahashi (Japan) 10:55
M. Fujimoto, Y. Takahashi, T. Ohkawara, S. Serada, T. Naka
Abstract N° OP0258
Experimental autoimmune uveitis in mice lacking TNF receptors

K. Klein (Switzerland) 11:05
R. E. Gay, C. Kolling, M. Kato, B. A. Michel, S. Gay, C. Ospelt
Abstract N° OP0259
The bromodomain protein BRD1 regulates the matrix degrading and inflammatory properties of rheumatoid arthritis synovial fibroblasts

R. Hasseli (Germany) 11:15
Abstract N° OP0260
Adipokines alter the interaction of rheumatoid arthritis synovial fibroblasts with endothelial cells

L. Campillo-Gimenez (France) 11:25
Abstract N° OP0261
Four different types of calcium pyrophosphate crystals differentially induced IL-1β production by THP-1 cells

S. Mastbergen (Netherlands) 11:35
L. van Vulpen, K. Coeleveld, R. Schutgens, G. Roosendaal, F. Lafeber
Abstract N° OP0262
In vitro evidence of interleukin-1beta, not tumor necrosis factor-alpha, as crucial factor for cartilage damage in haemophilic arthropathy

H.-H. Kim (Republic of Korea) 11:45
J. Lee
Abstract N° OP0263
CCL19 and CCL21 chemokines enhance osteoclast migration and resorption activity

12:00 - 13:45 Halls 5&6
Poster viewing & lunch
Guided Poster tours 12:10 - 13:35

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshops desk, located in the registration area, Hall 7, on a “first-come-first-served” basis on the day of the poster tour.

Poster tour 12:10 - 13:35 Hall 6

F1: RA - predictors of complications and outcomes 2

Chairperson(s):
Leslie J. Crofford (United States)
Cecilia Chung (United States)
M. R. Gigante (Italy)
E. Gremese, B. Tolusso, A. L. Fedele, S. Canestri, B. Aquilanti, C. Di Mario, L. Petricca, S. Alivernini, G. Ferraccioli

Abstract N° FRI0021
Weight loss in obese rheumatoid arthritis patients improves disease activity without modifying RA treatment

B. Möller (Switzerland)
S. Florentinus, F. Ganz, Y. Li, H. Kupper, A. Finckh

Abstract N° FRI0022
Anemia is an independent predictor of radiographic damage progression in anti-TNF-treated rheumatoid arthritis patients from two large phase III trials

M. C. van Maaren (Netherlands)

Abstract N° FRI0023
Anti-CCP: no risk factor for 10-year cardiovascular morbidity in a large cohort of rheumatoid arthritis patients

A. Alunno (Italy)
V. Caneparo, O. Bistoni, S. Caterbi, R. Terenzi, E. Bartoloni, M. Gariglio, S. Landolfo, R. Gerli

Abstract N° FRI0024
Interferon gamma-inducible protein 16 (IFI16) in rheumatoid arthritis: a novel biomarker for pulmonary involvement?

M. Bokarewa (Sweden)

Abstract N° FRI0025
Predicting rheumatoid arthritis by measuring survivin in unselected samples - epidemiological study within two university cities of Sweden

V. Pascual Ramos (Mexico)

Abstract N° FRI0026
Disease activity predicts ABCB1 and ABCG2 drug-efflux transporters function in rheumatoid arthritis (RA) patients

Y. Nakashima (Japan)

Abstract N° FRI0027
MRI-proven bone marrow oedema at baseline is the strongest predictor toward the development of rapid radiographic progression at 1 year in patients with early-stage rheumatoid arthritis: results from Nagasaki university early arthritis cohort

P. Sewerin (Germany)

Abstract N° FRI0028
Gazing into the crystal ball? Prospective MRI score to predict negative EULAR-response in patients with rheumatoid arthritis (RA) before therapy-escalation to a biological therapy

L. Dai (China)

Abstract N° FRI0029
Rheumatoid arthritis MRI scoring (RAMRIS) correlates with synovial stroma activation or fiber deposit in RA patients

Poster tour 12:10 - 13:35 Hall 6

F2: RA - comorbidities 1

Chairperson(s):
Johannes W. J. Bijlsma (Netherlands)
Stefan Bruijnen (Netherlands)
H. Wadström (Sweden)
T. Frisell, J. Askling

Abstract N° FRI0061
Cervical dysplasia and cervical cancer in women with rheumatoid arthritis

M. Tada (Japan)
K. Inui, Y. Sugioaka, K. Mamoto, T. Okano, T. Koike, H. Nakamura

Abstract N° FRI0062
Influence of biologic agents on bone mineral density and bone mineral markers in patients with rheumatoid arthritis: data from the AIRTIGHT study

J. Nagasawa (Japan)

Abstract N° FRI0063
Non-neutralizing autoantibody against GM-CSF in connective tissue diseases and its association with pulmonary involvements

E. Arkema (Sweden)
J. Askling

Abstract N° FRI0064
How has the risk of serious infection in patients with rheumatoid arthritis treated with non-biologic disease modifying drugs changed over time?
C. Charles-Schoeman (United States)
G. B. Gugiu, H. Ge, A. Shahbazian, Y. Y. Lee, X. Wang,
D. E. Furst, V. K. Ranganath, M. Maldonado, S. T. Reddy
Abstract N° FR10065
Proteomic profiling following immunoaffinity capture of
high-density lipoprotein (HDL) identifies changes in
multiple HDL-associated proteins following treatment
with Abatacept or Adalimumab in the AMPE study of
patients with rheumatoid arthritis

L. B. Nordberg (Norway)
S. Lillegraven, E. Lie, A.-B. Aga, I. C. Olsen, T. Uhlig,
D. van der Heijde, T. K. Kvien, E. A. Haavardsholm on
behalf of the ARCTIC study group
Abstract N° FR10066
The clinical and ultrasonographic presentation of
seronegative RA is more severe compared to seropositive
RA in an inception cohort of DMARD-naïve patients
classified according to the 2010 ACR/EULAR criteria

M. Akiyama (Japan)
Y. Kaneko, H. Kondo, K. Yamaoka, T. Takeuchi
Abstract N° FR10067
Lack of response is associated with acute exacerbation of
interstitial lung disease during Tocilizumab treatment in
patients with rheumatoid arthritis

M. E. Sandberg (Sweden)
S. Saevardsdottir, R. Altawil, L. Klareskog, L. Alfredsson,
J. Lampa on behalf of the EIRA working group
Abstract N° FR10068
Remaining pain despite inflammation control in
rheumatoid arthritis - long-term strongly increased risk
for widespread pain and fatigue

D. Manka (United States)
R. Feaver, S. Collado, S. Hoang, E. Berzin, A. Armstrong,
D. Gardner, H. Liu, A. Mackey, D. Shealy, B. Blackman
Abstract N° FR10069
Neutralization of IL6 by Sirukumab (SIR) inhibits
inflammation and cellular stress in a human vascular
surrogate system of atherosclerosis

12:10 - 13:35 Hall 6

Poster tour

F3: RA - safety and efficacy for treatment
after TNF inhibitor

Chairperson(s):
Lene Terslev (Denmark)
Uffe Møller Døhn (Denmark)

M. Kihara (Japan)
L. Kearsley-Fleet, R. Davies, K. D. Watson, M. Lunt,
D. P. Symmons, K. L. Hyrich on behalf of British Society
for Rheumatology Biologics Register for Rheumatoid
Arthritis
Abstract N° FR10145
Choice and effectiveness of Tocilizumab among patients
with rheumatoid arthritis: an observational study from
the British society for rheumatology biologics register for
rheumatoid arthritis

J. Alvaro-Gracia (Spain)
J. P. Vinicki, M. Arredondo, E. Ramírez-Herráiz, A. Ortiz,
S. Castañeda Sanz, A. Morell, R. García-Vicuña
Abstract N° FR10146
Effectiveness of retreatment after relapse of rheumatoid
arthritis patients under down-titrated biological therapy

M. G. Avila (Spain)
A. Alonso, M. López Lasanta, A. Pluma, E. Quesada,
S. Marsal
Abstract N° FR10147
Long-term follow-up study of biological therapy
discontinuation in rheumatoid arthritis

K. Krüger (Germany)
S. Mueller, U. Maywald, A. Fuchs, J.-P. Flacke,
I. Haug-Rost, H. Heinisch, T. Wilke
Abstract N° FR10148
Non-adherence and non-persistence in the therapy of
rheumatoid arthritis with Methotrexate: an analysis of
German claims data based on 9,592 RA patients

V. Grosso (Italy)
R. Gorla, P. Sarzi-Puttini, F. Atzeni, R. Pellerito,
E. Fusaro, G. Paolazzi, P. A. Rochetta, E. G. Favalli,
A. Marcheson, R. Caporali
Abstract N° FR10149
Fifteen years of biological treatment for rheumatoid
arthritis: data from the Italian LORHEN registry

J. Pablos (Spain)
E. Navarro, F. Blanco, J. Roman-Ivorra, A. Alonso,
E. Martín-Mola, M. Cantalejo
Abstract N° FR10150
Maintenance of response in patients with rheumatoid
arthritis (RA) after switching to TCZ administered alone
compared to the combination of TCZ and MTX

T. A. Simon (United States)
C. Poncet, M. Hochberg, M. Boers on behalf of
Abatacept Epidemiology and Safety Panel
Abstract N° FR10151
Incidence rates of skin cancers during exposure to
intravenous and subcutaneous Abatacept in patients with
rheumatoid arthritis: results from pooled clinical trial data

V. P. Bykerk (United States)
G. R. Burmester, B. G. Combe, D. E. Furst,
T. W. J. Huizinga, D. A. Wong, P. Emery
Abstract N° FR10152
On drug and drug-free remission by baseline disease
duration in the AVERT trial: Abatacept versus
Methotrexate comparison in patients with early
rheumatoid arthritis

G. R. Burmester (Germany)
M. Bao, W. Reiss, T. Wallace, S. Lacey, A. Kivitz
Abstract N° FR10153
Immunogenicity, safety and efficacy of subcutaneous
Tocilizumab in patients who missed doses
J. E. Gottenberg (France)
Abstract N° FRI0154
Incidence of cancers in patients with rheumatoid arthritis and a history of cancer treated with Rituximab or Abatacept

W. Fong (United Kingdom)
E. Reeves, W. Tim, T. Elliot, E. James, C. J. Edwards
Abstract N° FRI0195
ERAP1 allotypes and disease severity in ankylosing spondylitis

D. Solmaz (Turkey)
A. Tekinalp, O. Avci, B. Turgut
Abstract N° FRI0196
CCR2 expression was increased in patients with ankylosing spondylitis independent from disease activity

C. Prati (France)
F. Cailotto, K. Heritage, D. Wendling, R. Lories
Abstract N° FRI0197
Role of arginase in a cellular and murine model of endochondral ossification

Poster tour
F4: Understanding spondyloarthritis
Chairperson(s):
Rik Lories (Belgium)
Heleen Cypers (Belgium)
Y. Jimenez-Gomez (Spain)
Abstract N° FRI0190
Role of leukocyte subsets in the inflammation, oxidative stress and bone turnover in ankylosing spondylitis patients

P. Triggianese (Italy)
P. Conigliaro, M. S. Chimenti, E. Ballanti, R. Perricone, L. Biancone, F. Pallone, G. Montealeone, I. Montealeone
Abstract N° FRI0191
IL17 producing non-T cells in patients with enteropathic spondyloarthropathy: the association with disease activity

R. Campanilho-Marques (Portugal)
Abstract N° FRI0192
Effect of TNF blocking therapy on osteoclasts from ankylosing spondylitis patients

U. Syrbe (Germany)
J. Bleil, R. Maier, A. Hempfing, J. Sieper, H. Appel
Abstract N° FRI0193
Osteoblasts promote new bone formation at sites of cartilage and bone erosions while fat marrow is found within the subchondral bone marrow in ankylosing spondylitis

L. T. Hermansen (Denmark)
Abstract N° FRI0194
Is there an association between spondyloarthritis and antibodies towards Borrelia, Ehrlichia and Chlamydia species?

Poster tour
F5: Vasculitis
Chairperson(s):
Carlo Salvarani (Italy)
Luca Quartuccio (Italy)
A. Lo Gullo (Italy)
M. J. Koster, C. Crowson, A. Makol, S. Ytterberg, E. Matteson, K. Warrington
Abstract N° FRI0244
Venous thromboembolic events and cerebrovascular accident in patients with giant cell arteritis: a population based retrospective cohort study

B. Erer (Turkey)
E. Aydın, B. Toz, M. Erelel, A. Göçmez, N. Alpay Kanitez, A. Gül, İnanç, L. Ocak, S. Kamali
Abstract N° FRI0245
Lung damage in ANCA associated vasculitis assessed by vasculitis damage index: recurrent pulmonary infections have a significant contribution

N. Palmou (Spain)
Abstract N° FRI0246
Relapses and predictive factors in Henoch-Schönlein purpura. Study of 417 patients

K. Murakami (Japan)
Y. Komagata, C. Mori, K. Fukuoka, M. Karube, S. Kaname, Y. Arimura
Abstract N° FRI0247
The release of nets from MPO-AAV neutrophils was increased by anti-MPO antibody and correlated with disease activity

J. H. Stone (United States)
K. Tuckwell, N. Collinson, M. Klearman, S. Dimonaco on behalf of the GIACTA Investigators
Abstract N° FRI0248
Baseline data on patients in GIACTA (Tocilizumab in giant cell arteritis)
A. Hočevar (Slovenia)
Ž. Rotar, A. Ambrožič, M. Plešivčnik Novljan, B. Lestan,
S. Praprotnik, M. Tomšič
Abstract N° FRI01249
IgAV score - a feasible predictor of IgA vasculitis severity

E. Tombetti (United Kingdom)
R. Khamis, D. Gopalan, A. Kiprianos, B. Ariff, J. C. Mason
Abstract N° FRI01250
Coronary CT-angiography reveals the extent of coronary artery disease in Takayasu arteritis

M. J. Koster (United States)
C. Labarca, C. Crowson, A. Makol, S. Ytterberg,
E. Matteson, K. Warrington
Abstract N° FRI01251
Glucocorticoid use and associated adverse events based on initial daily oral prednisone dose in biopsy-proven giant cell arteritis

M. Gilio (Italy)
G. Tramontano, S. D’Angelo, P. Leccese, A. Padula,
R. Scarpa, I. Olivieri
Abstract N° FRI01252
Behcet’s disease and pregnancy: what is the relationship?

E. Toussirot (France)
A. Martin, M. Soubrier, S. Redeker, A. Regent on behalf of Le CRI
Abstract N° FRI01253
Clinical efficacy of Tocilizumab in polymyositis rheumatica: an open-label study

S. D’Angelo (Italy)
P. Leccese, A. Padula, A. Nigro, M. Gilio, A. Carriero,
C. Palazzi, I. Olivieri
Abstract N° FRI01254
Predictive factors for the response to Infliximab therapy in patients with Behcet’s disease

Y. Yazici (United States)
H. Bernstein, C. Swearingen
Abstract N° FRI01280
Patients treated for Behcet’s syndrome in the US have higher disease activity scores at presentation if they fulfill diagnostic criteria and if they are females

J. Fechtenbaum (France)
K. Briot, A. Etheto, S. Kolta, A. Feydy, C. Roux
Abstract N° FRI01284
Influence of vertebral fractures severity and pelvic parameters on global spinal balance in osteoporotic patients

M. Bukhari (United Kingdom)
N. Goodson, M. Boers
Abstract N° FRI01285
The effect of steroids on fracture, adjusting for bone mineral density

O. Ruzickova (Czech Republic)
O. Sleglova
Abstract N° FRI01286
Cardiovascular risk and bone loss in patients with erosive and non-erosive hand osteoarthritis

Y. Hirano (Japan)
S. Hirabara, M. Isono, Y. Oishi, T. Kojima, N. Ishiguro
Abstract N° FRI01287
Daily teriparatide treatment for two years on osteoporosis in patients with rheumatoid arthritis - impact of concomitant drugs (Prednisolone and biologics) on effects of Teriparatide

R. I. Marcu (Romania)
S. Patru, A. C. Bighea, R. Traistaru, R. S. Popescu
Abstract N° FRI01288
Role of physical exercise program in patients with osteoporosis

C. Roux (France)
S. Papapoulos, H. G. Bone, P. Dakin, E. Czerwiński,
D. Frey, D. Kendler, E. M. Lewiecki, J. Malouf,
D. Mellström, J. Y. Reginster, H. Resch, N. S. Daizadeh,
A. Wang, M. Gavin, R. B. Wagnman, M. L. Brandi
Abstract N° FRI01289
Denosumab treatment in postmenopausal women with osteoporosis for up to 9 years: results through year 6 of the FREEDOM extension

F. Y. G. Kutsal (Turkey)
A. M. ATA
Abstract N° FRI01290
Comorbidities in osteoporotic patients: a retrospective study

K. Briot (France)
M. Maravic, C. Roux
Abstract N° FRI01291
Decrease in anti-osteoporotic drugs prescriptions: is there an immediate consequence on hip fracture incidence?

V. Skakić (Serbia)
I. Tasić, M. Rašić Popović, S. Stojanović, B. Stamenković,
S. Kostić, D. P. Dejan Popović, G. Lazarević,
D. Bogdanović, V. Stefanović
Abstract N° FRI01292
Osteoporosis - a risk factor for cardiovascular diseases (a follow-up study)
12:10 - 13:35  Hall 6

Poster tour

F7: Epidemiology and health services research

Chairperson(s):
Ingemar Pettersson (Sweden)
Axel Finckh (Switzerland)
S. Federici (Italy)
J. Frenkel, S. Ozen, M. Finetti, F. Garibotto, H. Lachmann, A. Martini, N. Ruperto, M.Gattorno on behalf of Eurofever Registry

Abstract N° FRI0335
The Eurofever project: towards the longitudinal stage

M. Tatangelo (Canada)
G. Tomlinson, B. Kuriya, C. Bombardier

Abstract N° FRI0336
Disease activity patterns in rheumatoid arthritis in the first 3-years of follow-up in usual care: Markov modeling shows rapid improvement in DAS28 states in the 1st year followed by stable states in the last 2 years. Results from the Ontario best practices research initiative (OBRI)

C. Borghi (Italy)
J. Nuevo, J. Medina, F. Tubach

Abstract N° FRI0337
Association between serum uric acid levels and cardiovascular risk. A post hoc analysis of the European cardiovascular risk patients: disease prevention and management in usual daily practice (EURIKA) study

A. Pasma (Netherlands)
E. den Boer, A. van ’t Spijker, R. Timman, B. van den Bemt, J. J. Busschbach, J. M. Hazes

Abstract N° FRI0338
Non-adherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients

S. D. Mathias (United States)
P. Berry, J. deVries, A. Askanase, K. Pascoe, H. Colwell, D. Chang

Abstract N° FRI0339
Development of a novel patient reported outcome (PRO) measure: the systemic lupus erythematosus (SLE) steroid questionnaire (SSQ)

N. Accortt (United States)
W. J. Carman, C. Enger, J. Iles, M. S. Anthony

Abstract N° FRI0340
Birth outcomes among infants of women with chronic inflammatory arthritis or psoriasis treated and not treated with Etanercept (enbrel) during pregnancy

A. H. Anis (Canada)
W. Zhang, N. Bansback, H. Sun, R. Pedersen, S. Kotak

Abstract N° FRI0341
Influence of tapering Etanercept on work productivity outcomes in patients with early rheumatoid arthritis tapered: 117 week results from the PRIZE study

A. Finney (United Kingdom)
K. Dziedzic, M. Lewis, S. Ryan, E. Healey

Abstract N° FRI0342
Measuring pain intensity in older adults with ‘multisite’ peripheral joint pain using a composite score

J. Nuevo (Spain)

Abstract N° FRI0343
Evaluation of the impact of current treatment on serum urate profile, gout flares and tophi in patients with gout in France, Germany, United Kingdom and the United States

R. Morlock (United States)
N. M. Flores, K. Annunziata, J. Chapnick, J. Nuevo

Abstract N° FRI0344
Economic burden of controlled gout, uncontrolled gout, and gout exacerbated by common comorbidities: results from the 2012-2013 national health and wellness survey

S. Manders (Netherlands)
M. van de Laar, S. Rongen-van Dartel, R. Bos, H. Visser, H. Brus, T. Jansen, H. Vonkeman, F. van Riel, W. Kievit

Abstract N° FRI0345
Tapering MTX in patients with RA using TNFi treatment is possible

M. Gencturk (Turkey)
O. Eren, M. Yuksel

Abstract N° FRI0346
Evaluation study for self management of patients with ankylosing spondylitis (AS) through a personal health system

12:10 - 13:35  Hall 5

Poster tour

F8: Lupus and APS - etiology, pathogenesis and new treatment approaches

Chairperson(s):
Reinhard E. Voll (Germany)
Cristina Pamfil (Romania)
F. Miranda (Italy)
C. Barbati, C. Alessandri, F. R. Spinelli, F. Ceccarelli, S. Truglia, E. Marocchi, F. Conti

Abstract N° FRI0373
Characterization of the microparticles in the plasma and urine of patients affected by SLE: clinical and laboratory relationships

D. M. Pegtel (Netherlands)

Abstract N° FRI0374
Economic burden of controlled gout, uncontrolled gout, and gout exacerbated by common comorbidities: results from the 2012-2013 national health and wellness survey

D. M. Pegtel (Netherlands)

Abstract N° FRI0374
Inflammatory exosomes implicate a role for Epstein-Barr virus infection in the pathophysiology of systemic lupus erythematosus
Y. El-Sherbiny (United Kingdom)  
A. A. Mohamed, Y. M. Yusof, E. Vital, P. Emery  
Abstract N° FRI0375  
Flow-based cell-specific interferon signature as a biomarker in systemic lupus erythematosus

S. Kawano (Japan)  
Abstract N° FRI0376  
Mechanism of phenotype conversion from rheumatoid arthritis to lupus in FcγRIIB-deficient C57BL/6 Ya mice

M.-P. Tsang-A-Sjoe (Netherlands)  
Abstract N° FRI0377  
Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and disease-related manifestations

E. M. Mccarthy (Ireland)  
G. Kearns, C. Jefferies  
Abstract N° FRI0378  
The role of monocyte subsets in systemic lupus erythematosus pathogenesis

S.-J. Moon (Republic of Korea)  
J.-K. Min  
Abstract N° FRI0379  
Metformin suppresses systemic autoimmunity in roqinas/san mice through inhibition of B cell differentiation into plasma cells via AMPK/MTOR/STAT3 pathway regulation

Y. Y. Kim (Republic of Korea)  
Abstract N° FRI0380  
HM71224, a selective Bruton's tyrosine kinase inhibitor, ameliorates murine lupus development

W. White (United States)  
D. Drubin, X. Guo, L. Yang, R. Zeng, Y. Wu, M. Roberts, R. Lescarbeau, A. van Hooser, M. Macoritto, M. Petri  
Abstract N° FRI0381  
Interferon dysregulation in an academic SLE cohort is associated with distinct signaling differences in blood neutrophils vs. peripheral blood mononuclear cells

K. Palumbo-Zerr (Germany)  
Abstract N° FRI0433  
Nuclear receptor NR4A1 as a checkpoint of physiological wound healing and fibrosis

B. Maurer (Switzerland)  
Abstract N° FRI0434  
TIE2 as a novel key factor of microangiopathy in systemic sclerosis

M. Tomcik (Germany)  
Abstract N° FRI0435  
Interleukin-35 is overexpressed in systemic sclerosis and its serum levels are elevated in early disease

T. Higuchi (Japan)  
Y. Kawaguchi, I. Masuda, K. Takagi, A. Tochimoto, H. Yamanaka, K. Okada  
Abstract N° FRI0436  
CCPA reverses the fibrotic phenotype of dermal fibroblasts in systemic sclerosis

P. Di Benedetto (Italy)  
P. Ruscitti, V. Liakouli, F. Carubbi, O. Berardicurti, I. Fantano, A. F. Campese, E. Alesse, I. Serepani, R. Giacomelli, P. Cipriani  
Abstract N° FRI0437  
Decreased expression of angiopoietin 1 on perivascular mesenchymal stem cells from SSc patients induces an antiangiogenetic effect, when co-cultured with endothelial cells

J. Avouac (France)  
M. Ponsoye, C. Frantz, N. Ruzehaji, M. Elhai, B. Ruiz, A. Cauvet, Y. Allanore  
Abstract N° FRI0438  
Treatment with Abatacept prevents experimental dermal fibrosis and induces regression of established fibrosis in a preclinical model of systemic sclerosis

V. Haunerding (Switzerland)  
E. Pachera, R. Dobrota, P. Błyszczuk, O. Distler, G. Kania  
Abstract N° FRI0439  
The role of the myeloid inflammatory bone marrow compartment in onset and progression of myocardial fibrosis in systemic sclerosis

P. Christopoulos (Greece)  
V.-K. Bournia, S. Panopoulos, A. Vaiopoulos, M. Koutsilieris, P. Sfikakis  
Abstract N° FRI0440  
Increased messenger RNA levels of the mesenchymal cadherin-11 in the peripheral blood correlate with diffuse skin involvement in systemic sclerosis

12:10 - 13:35 Hall 5

Poster tour

F9: SSc pathogenesis and etiology

Chairperson(s):  
Gabriela Riemekasten (Germany)  
Britta Maurer (Switzerland)
S. Alivernini (Italy)
S. L. Bosello, M. Kurowska-Stolarska, S. Canestri, L. Bui, M. M. Fabrizi, B. Tolusso, I. B. McInnes, G. Ferraccioli
Abstract N° FRI0441
MicroRNA-34A unbalance is associated to IL-6/IL-6R pathway in CD14 cells and skin compartment of systemic sclerosis patients

J. Guzman (Canada)
T. Loughlin, A. Henrey, R. Berard, N. Shiff, R. Jurencak, S. Benseler, L. Tucker on behalf of ReACCh-Out Investigators
Abstract N° FRI0499
Using patient-relevant variables to describe the disease course in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort

D. Ekdawy (United Kingdom)
E. Smith, L. Oni, A. Midgley, R. Corkhill, C. Jones, S. Marks, P. Newland, C. Pilkington, K. Tullus, M. Beresford
Abstract N° FRI0500
Exploring the relationship of urinary vascular cell adhesion molecule-1 with lupus nephritis disease activity over time

M. Glerup (Denmark)
T. Herlin, M. Twilt
Abstract N° FRI0501
Antinuclear antibody-positive patients - are they a separate entity?

N. Ruperto (Italy)
Abstract N° FRI0502
Long-term safety of Adalimumab treatment in paediatric patients with polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis

A. N. Colebatch-Bourn (United Kingdom)
Abstract N° FRI0503
EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice

PReS Poster tour
F10: Clinical aspects of paediatric rheumatic diseases 1

Chairperson(s):
Alberto Martini (Italy)
Sebastian Vastert (Netherlands)
T. Kullenberg (Sweden)
B. Hallén, H. Olivecrona, M. Leinonen
Abstract N° FRI0494
Steroid-sparing effect of Anakinra (Kineret®) in the treatment of patients with severe cryopyrin-associated periodic syndromes

J. Peitz (Germany)
I. Becker, G. Horneff
Abstract N° FRI0495
What might be the factors for staying in remission in JIA? Data from the German BIKER registry

N. Ruperto (Italy)
Abstract N° FRI0496
Efficacy and safety of Canakinumab in children with systemic juvenile idiopathic arthritis with and without fever

E. G. Favalli (Italy)
I. Pontikaki, A. Becciolini, M. Biggioggero, N. Ughi, A. Marcheson, V. Gerloni, P. I. Meroni
Abstract N° FRI0497
Drug retention and pattern of discontinuation of the first-line anti-TNF drug in a large cohort of patients with adult or juvenile-onset inflammatory arthritides

K. Minden (Germany)
J. Klotzsche, M. Niewerth, A. Zink, E. Seipelt, J.-P. Haas, G. Ganser, G. Horneff
Abstract N° FRI0498
How tolerable is Methotrexate in the long-term use in juvenile idiopathic arthritis (JIA)?
E. Casado (Spain)
Abstract N° FRI0537
Ultrasound-guided percutaneous aspiration or fragmentation in patients with shoulder calcified tendinitis: short- and long-term results

F. Bailly (France)
V. Foltz, S. Rozenberg, L. Gossec, B. Fautrel on behalf of Spine Group of the French Society of Rheumatology
Abstract N° FRI0538
Development and validation of a questionnaire for the identification of different behavioral strategies in patients with chronic low back pain

A. M. B. Abdul Rani (Malaysia)
M. Moayedfar, D. Kumar
Abstract N° FRI0539
An integrated manufacturing method of customized medical knee implants using automated 3D model reconstruction and prototyping procedure

L. Brunier (Martinique)
K. Polomat, V. Dehlinger, P. Numeric, S. Olindo, C. Deligny, A. Signate, S. Arfi, M. Debandt, G. Jean-Baptiste, P. Cabre
Abstract N° FRI0540
Evaluation of medical treatment for lumbar canal stenosis at 3 months in the prospective TELEMAR cohort and predictors of failure of medical treatment

R. V. Bubnov (Ukraine)
Abstract N° FRI0541
Trigger points dry needling under ultrasound guidance for low back pain therapy. Comparative study

E. Ceceli (Turkey)
S. Guermuk, M. Okumus, S. Kocagozlu, H. Goksu, A. Karagoz
Abstract N° FRI0542
Comparison of two methods of neuropathic pain assessment in carpal tunnel syndrome and their correlation with hand functions

M. Karadeniz (Turkey)
T. Dandinoglu
Abstract N° FRI0543
Does electrophysiologically severe patients have also higher neuropathic complaints in carpal tunnel syndrome?

G. Jones (Australia)
L. I. Laslett, H. Menz, F. Cicuttini
Abstract N° FRI0544
Non-structural factors associated with current and new foot pain: data from the Tasmanian older adult cohort study

E. A. Clarke (United Kingdom)
S. Bawa
Abstract N° FRI0545
Safer sleeping with soap? Quinine, cramps and weighing up anecdotal evidence

12:10 - 13:35  Hall 5

Poster tour
F12: New insights in diagnostic and prognostic markers in rheumatic diseases

Chairperson(s):
Esperanza Naredo (Spain)
Denis Poddubnyy (Germany)
D. Simon (Germany)
Abstract N° FRI0560
Comparison of bone microstructure of psoriatic arthritis and psoriasis patients - an HR-PQCT study of anabolic and catabolic bone changes

R. Yoshimi (Japan)
Abstract N° FRI0561
The availability of on-demand ultrasonography assessment in the most affected joint for management of RA patients in daily practice

M. van der Ven (Netherlands)
M. Karreman, A. Weel, I. Tchetverikov, M. Vis, T. Nijsten, M. Hazes, J. Luime
Abstract N° FRI0562
Ultrasound enthesitis in primary care psoriasis patients with musculoskeletal complaints

L. Meneghel (Italy)
Abstract N° FRI0563
Detection of IgG anti-domain I beta2 glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome

J. Maymò (Spain)
Abstract N° FRI0564
RA and remission: acceptable inflammatory activity in magnetic resonance imaging associated with absence of progression of erosions at one year

K. Conrad (Germany)
U. Höpner, N. Röber, M. Aringer, S. Rudolph, A. Gräßler, K. Lüthke, L. Unger, M. Mahler
Abstract N° FRI0565
The presence of anti-DFS70 antibodies suggests absence of connective tissue diseases in patients with anti-nuclear antibodies (ANA)
H. B. Hammer (Norway)
L. Terslev, T. K. Kvien
Abstract N° FRI0566
Ultrasound demonstrates tenosynovitis to be frequent in RA patients as well as being responsive to biologic treatment

H.-D. Zucht (Germany)
Abstract N° FRI0567
Identification of novel systemic sclerosis autoantigen candidates and development of an autoantibody assay panel enabling their subsequent validation

P. Collado (Spain)
Abstract N° FRI0568
Toward standardized musculoskeletal ultrasound (MSUS) in paediatric rheumatology: age related MSUS normal findings

12:10 - 13:35  Hall 5
HPR Poster tour
F13: Multidisciplinary teams

Chairperson(s):
Susan Oliver (United Kingdom)
Yvonne van Eijk-Hustings (Netherlands)

F. M. Lourenzi (Brazil)
Abstract N° FRI0611-HPR
Global progressive resistance training improved functional capacity in patients with rheumatoid arthritis

K. Rome (New Zealand)
T. Morpeth, M. Frecklington
Abstract N° FRI0612-HPR
Fear of falling and foot pain, impairment and disability in people with rheumatoid arthritis: an exploratory study

B. D. Thombs (Canada)
A. Levis, G. Kelley
Abstract N° FRI0613-HPR
Assessing reporting bias in trials of exercise interventions for pain management in rheumatic diseases: an application of the test for excess significance

Y. Prior (United Kingdom)
A. Hammond, S. Tyson, A. Tennant
Abstract N° FRI0614-HPR
Development and psychometric testing of the British English measure of activity performance of the hand (MAP-Hand) questionnaire in rheumatoid arthritis

E. Chew (Singapore)
K. Griva, P. Cheung
Abstract N° FRI0615-HPR
Evaluation of coping styles in established rheumatoid arthritis patients in an Asian cohort

E. Tarakci (Turkey)
S. N. Arman, K. Barut, O. Kasapcopur
Abstract N° FRI0616-HPR
Fatigue, quality of sleep and pain in children with juvenile idiopathic arthritis

N. Smith (United Kingdom)
H. Foster, R. Wyllie, C. English, B. Davies, T. Rapley
Abstract N° FRI0617-HPR
What are the educational needs of nurses involved in the care of children and young people with rheumatic disease?

V. L. Ruffing (United States)
A.-M. Orbai, C. O. Bingham
Abstract N° FRI0618-HPR
Measuring the effectiveness of patient education for patients receiving injectable biologic medications

12:10 - 13:35  Hall 5
PARE Poster tour
F14: PARE 2

Chairperson(s):
Diana Skingle (United Kingdom)
Jean-Noël Dachicourt (France)

J. Ortutay (Hungary)
E. Rozán
Abstract N° PARE0012
Building patient led organisations - an example of Hungary

R. Taylor (United Kingdom)
S. Blackburn, A. Higginbottom, C. Rhodes, K. Dziedzic
Abstract N° PARE0013
Demystifying research jargon: a volunteer led glossary

U. G. Viora (Italy)
R. Giannelli, S. Severoni, G. Voltan on behalf of ANMAR Italia
Abstract N° PARE0014
PDTA in rheumatic inflammatory and autoimmune diseases

K. Blidberg (Sweden)
A. Carlsson
Abstract N° PARE0015
How the Swedish rheumatism association work to increase research on osteoarthritis

M. Siber (Switzerland)
E. S. Rösch
Abstract N° PARE0016
Multichannel sensitisation campaign with prominent ambassadors

J. Loza (Spain)
L. Carmona, P. Zarco, M. T. Flórez
Abstract N° PARE0017
Recommendations for rheumatologists on physical exercise in spondyloarthritis (EJES 3-D study)
S. Moufarrej (United Arab Emirates)
R. Basheer, K. Thornely
Abstract N° PARE0018
The dilemmas of disclosure of side effects of rheumatic biological drugs

S. de Souza (United Kingdom)
H. Lempp
Abstract N° PARE0019
Patient perspectives on footwear in rheumatoid arthritis - a patient-led qualitative study

A. Carlsson (Sweden)
C. Fjellström
Abstract N° PARE0020
To influence by meeting those in power - a week of political activities

S. De Jong (Netherlands)
G. Korevaar, Y. Kat
Abstract N° PARE0021
National arthritis activity guide (reumabeweegwijzer) directs patients to physical activities in their own neighborhood

13:45 - 15:15 Hall 9
What is New (WIN)
WIN session 6
Rik Lories (Belgium)
Abstract N° SP0135
Psoriatic arthritis
Xenophon Baraliakos (Germany)
Abstract N° SP0136
Axial and peripheral spondyloarthritis

13:45 - 15:15 Hall 8
Clinical Science session
Therapeutic insights from early clinical studies in SLE
Chairperson(s):
Falk Hiepe (Germany)
Ronald van Vollenhoven (Sweden)
Jens Humrich (Germany)
Abstract N° SP0137
Low-dose IL-2 therapy in refractory SLE: early insights from a phase I/IIA clinical trial
Mary K. Crow (United States)
Type I interferon in lupus: a promising target?
Josephina Cortes-Hernandez (Spain)
Abstract N° SP0138
TNF-alpha-targeted therapy in lupus - a possibility for skin/other manifestations

13:45 - 15:15 Room 10 F-G
How to Treat / Manage (HOT)
HOT session 7
Gerd R. Burmester (Germany)
Abstract N° SP0139
Undifferentiated inflammatory and early rheumatoid arthritis
Rene Westhovens (Belgium)
Abstract N° SP0140
Modern management principles of RA

13:45 - 15:15 Hall 3
Challenges in Clinical Practice session
Autoinflammatory disease
Learning objectives:
The attendant
- Knows the different clinical presentations of auto-inflammatory diseases
- Knows the differential diagnosis of auto-inflammatory diseases
- Knows how to diagnose auto-inflammatory diseases and is familiar with novel diagnostic approaches
- Has insight into the etiology and pathogenesis of auto-inflammatory diseases
Chairperson(s):
Nurten Duru (Netherlands)
Angela Tincani (Italy)
Paul Klarenbeek (Netherlands)
Abstract N° SP0139
Case 1 presentation: A patient with tumor-forming autoimmune disease
Nick de Vries (Netherlands)
Abstract N° SP0140
Case 1 discussion: Lumping syndromes using splitting antibodies
Hennie G. Raterman (Netherlands)
Abstract N° SP0141
Case 2 presentation: A patient with chronic inflammation
Alexandre E. Voskuyl (Netherlands)
Abstract N° SP0142
Case 2 discussion: Differential diagnosis of adult Still’s disease
**Clinical Science session**

Are we ready for RCTs in scleroderma? Importance of disease stratification and application of predictive markers

**Chairperson(s):**
Oliver Distler (Switzerland)
Christopher Denton (United Kingdom)

Christopher Denton (United Kingdom) 13:50
What are we aiming to treat in SSc trials - does one size fit all?

Yannick Allanore (France) 14:10
Predictors and outcome measures of vasculopathy

Francesco Del Galdo (United Kingdom) 14:30
Predictors and outcome measures of fibrosis

Y. Allanore (France) 14:50
What are we aiming to treat in SSc trials - does one size fit all?

A. Jagerschmidt, M. Jasson, O. Distler, C. Denton, D. Khanna
Abstract N° OP0266
Lysophosphatic acid receptor 1 antagonist SAR100842 as a potential treatment for patients with systemic sclerosis: results from a phase 2A study

J. G. Coghlan (United Kingdom) 15:00
Abstract N° OP0268
Anti-citrullinated protein antibody (ACPA) status in the general population and as a predictor of future inflammatory polyarthritis: the EPIC-2-NOAR study

L. Ljung (Sweden) 15:00
S. Rantapää Dahlqvist
Abstract N° OP0269
Obesity and the risk for development of rheumatoid arthritis - results from a population-based nested case-control study

**Outcome Science session**

Predicting the development of RA

**Learning objectives:**
- To understand current knowledge of environmental and lifestyle risk factors for RA
- To understand how risk factors can be combined to assign a risk of developing RA to an individual
- To understand the pathway between asymptomatic RA related autoimmunity and the development of clinical symptomatic RA

**Chairperson(s):**
Leslie J. Crofford (United States)
Paola de Pablo (United Kingdom)

Jamie Sergeant (United Kingdom) 13:50
Abstract N° SP0144
Genetic scores to predict the development of RA

Karen Costenbader (United States) 14:10
Environmental and lifestyle predictors for the development of RA

Dirkjan van Schaardenburg (Netherlands) 14:30
Predicting RA development in asymptomatic patients with RA related autoimmunity

S. M. Verstappen (United Kingdom) 14:50
J. C. Sergeant, R. N. Luben, A. Bhaniani, S. Anuj, A. MacGregor, N. Wareham, D. P. Symmons, K. T. Khaw, I. N. Bruce on behalf of RA-MAP consortium
Abstract N° OP0268
Anti-citrullinated protein antibody (ACPA) status in the general population and as a predictor of future inflammatory polyarthritis: the EPIC-2-NOAR study

L. Ljung (Sweden) 15:00
S. Rantapää Dahlqvist
Abstract N° OP0269
Obesity and the risk for development of rheumatoid arthritis - results from a population-based nested case-control study

**PReS session**

Other myopathies

**Learning objectives:**
- To know the various forms of inflammatory myopathies
- To understand those diseases that can mimic inflammatory myopathies

**Chairperson(s):**
Rolando Cimaz (Italy)
Seza Ozen (Turkey)

Carlo Minetti (Italy) 14:10
Primary myopathies mimicking inflammatory myositis

Andy Mammen (United States) 14:30
Abstract N° SP0146
Drugs causing muscle disease

G. C. Varnier (Italy) 14:50
Abstract N° OP0270
Further validation of the hybrid MMT/CMAS (HMC), a new measure of muscle disease activity in juvenile dermatomyositis

A. Notarnicola (Sweden) 15:00
Abstract N° OP0271
Analysis of the autoantibody repertoire in idiopathic inflammatory myopathies using antigen bead array
Basic and Translational Science session
New insights in osteo-immunology

Learning objectives:
• To get insight in effects of systemic inflammation on bone cells
• To learn about recent developments on the role of ACPA on bone quality in early RA, and about prevention of fractures in patients with RA (=practical part of the session)

Chairperson(s):
Kenneth Saag (United States)
Jos Hoes (Netherlands)
Hiroshi Takayanagi (Japan)

13:50
Abstract N° SP0147
Effects of systemic inflammation on osteoblasts, osteoclasts, and osteocytes
Stephanie Finzel (Germany)

14:08
ACPA and changes in cortical and trabecular bone in early RA
José Antonio P. da Silva (Portugal)

14:26
The interaction between anti-rheumatic drugs/treatment and bone
Paula Hoff (Germany)

14:44
Immunology of the fracture hematoma
Á. Horváth (Hungary)

15:02

Abstract N° OP0272
Effects of anti-TNF therapy on markers of bone homeostasis in rheumatoid arthritis and ankylosing spondylitis

Basic and Translational Science session
New pathogenic aspects in vasculitis

Learning objectives:
• Describe the interplay between inflammatory cells and endothelial cells as cause of vascular damage in ANCA-associated vasculitis
• Review advances in immune mechanisms in medium and large vessel vasculitis and assess how to incorporate them to provide a more tailored therapeutic approach
• Recognize the recent genomewide association studies and their implications to the pathogenesis of vasculitis

Chairperson(s):
Kenneth Warrington (United States)
Francesco Ciccia (Italy)
Cees G.M. Kallenberg (Netherlands)

13:50
Abstract N° SP0149
Endothelial damage in vasculitis
Cornelia Weyand (United States)

14:10
Immune mechanisms in medium and large-vessel vasculitis
Javier Martin (Spain)

14:30
Abstract N° SP0150
Genetics of vasculitis: lessons learned from genome-wide association studies
C. Miyabe (United States)

14:50
K. Strel, Y. Miyabe, J. H. Stone, A. D. Luster, S. Unizony

Abstract N° OP0273
Tocilizumab enhances regulatory T cell activation and proliferation in giant cell arteritis
L. Quartuccio (Italy)

15:00

Abstract N° OP0274
Cryoglobulinemic vasculitis and primary Sjögren’s syndrome are independent risk factors for lymphoma in a large worldwide population of patients with positive serum cryoglobulins

The Young Rheumatologist
Evidence based medicine. To design and understand clinical trials and meta-analysis

Learning objectives:
To provide an overview on the design and interpretation of observational studies, clinical trials and meta-analysis

Chairperson(s):
Alessia Alunno (Italy)
Katerina Chatzidionysiou (Sweden)
Lucía Silva-Fernández (Spain)

13:50
Abstract N° SP0151
Observational studies
Juan A. Avina-Zubieta (Canada)

14:10
Meta-analysis presentation, interpretation and relevance
Manuela LeBars (France)

14:30
Abstract N° SP0152
The phases of clinical trials and their relevance for drug approval
Health Professionals session
Social and work participation - research into practice

Learning objectives:
• To describe the different restrictions in social participation in adults with musculoskeletal conditions and their impact on health and well-being
• To discuss different ways to assess social and work participation in clinical practice
• To learn and spark ideas through a workshop, through discussion and formation of collaboration across different disciplines and countries, for different ways to manage social and work participation in adults with musculoskeletal conditions
• To develop strategies and intervention plans for people with arthritis, to improve social and work participation

Chairperson(s):
Hana Smucrová (Czech Republic)
Begonya Alcacer-Pitarch (United Kingdom)
Ross Wilkie (United Kingdom)

Mathilda Bjork (Sweden) 14:08
Abstract N° SP0154
“Social participation is important to me”; the experience of adults with rheumatoid arthritis

Jenny Hubertsson (Sweden) 14:26
Abstract N° SP0155
Arthritis and work: an inventory of European studies

Hendrik J. Bieleman (Netherlands) 14:44
Abstract N° SP0156
Work disability management in musculoskeletal disorders

B. Hamnes (Norway) 15:02
A. Ronningen, Å. Skarbo
Abstract N° OP0277-HPR
“I am so much more than my work”: A qualitative study of experiences after participating in return to work programs for people with rheumatic diseases
### Practical skills session*  
**Capillaroscopy II**

**Learning objectives:**
Learn how to do a capillaroscopy scan and how to interpret the results

**Chairperson(s):**
Ariane L. Herrick (United Kingdom)  
Vanessa Smith (Belgium)

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ariane L. Herrick (United Kingdom)</td>
<td>Incidence, significance and clinical approach to the Raynaud's phenomenon</td>
<td>13:50</td>
</tr>
<tr>
<td>Vanessa Smith (Belgium)</td>
<td>How to differentiate normal from abnormal capillaroscopic patterns and their diagnostic role in rheumatic diseases</td>
<td>14:05</td>
</tr>
<tr>
<td>Maurizio Cutolo (Italy)</td>
<td>The predictive and prognostic power of the capillaroscopic analysis</td>
<td>14:20</td>
</tr>
<tr>
<td>Alberto Sulli (Italy)</td>
<td>Capillaroscopic versus laser Doppler analysis of the microcirculation</td>
<td>14:35</td>
</tr>
<tr>
<td>Walter Hermann (Germany)</td>
<td>How to select the most appropriate capillaroscopic device: pros and cons</td>
<td>14:45</td>
</tr>
<tr>
<td>Faculty</td>
<td>Practical session with patients and case discussion</td>
<td>14:55</td>
</tr>
</tbody>
</table>

### Practical skills session*  
**Improving your graphs and tables for publication and presentation II**

**Learning objectives:**
- How to develop graphs for publications and presentations
- Which type of graph is best used to highlight a particular result

**Chairperson(s):**
Maarten Boers (Netherlands)

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Title</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maarten Boers (Netherlands)</td>
<td>Improving your graphs and tables for publication and presentation</td>
<td>13:50</td>
</tr>
</tbody>
</table>

### What is New (WIN)  
**WIN session 7**

- **Kimme Hyrich (United Kingdom)**  
  Abstract N° SP0164  
  Comorbidity of RA and other rheumatic diseases  
  15:50

- **Zoltán Szekanecz (Hungary)**  
  Abstract N° SP0165  
  Cardiovascular risk in IMIDs  
  16:30

### Clinical Science session  
**Combination therapy with biologics in rheumatic diseases - what does the future hold?**

**Learning objectives:**
- Therapeutic interventions in rheumatology have advanced tremendously with the introduction of the antibodies targeting pivotal mediators in the inflammatory process
- What is coming beyond this first era of biologicals?
- This session will give insight in the combination of biologics with small molecules, the most novel strategies in design of biologic drugs, and will inform you about the position of biosimilars?

**Chairperson(s):**
Maurizio Cutolo (Italy)  
Jacob M. van Laar (Netherlands)

- **Daniel Furst (United States)**  
  Combination therapy with biologics and small molecules; safe or foolish?  
  15:50

- **Ton Logtenberg (Netherlands)**  
  Bispecific antibodies in treatment of rheumatic diseases, is it the future?  
  16:07

- **Erik Hack (Netherlands)**  
  Fusion proteins, combined cytokine therapy, with tissue structure modifying, anti-inflammatory, and analgesic properties in one molecule  
  16:24

- **Mathias Locher (Switzerland)**  
  Bispecific TNF/IL-17 inhibitor for the treatment of inflammatory diseases  
  16:41

- **Richard Vesely (United Kingdom)**  
  EMA and EULAR; can we COMBINE our efforts in a more efficient way; what the future holds?  
  16:58

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
Challenges in Clinical Practice session

Polymyalgia rheumatica versus elderly onset rheumatoid arthritis: a diagnostic challenge

Learning objectives:
- To learn to distinguish polymyalgia rheumatica from elderly onset rheumatoid arthritis on the basis of the clinical symptoms, biomarkers including immune biomarkers and ultrasound/magnetic resonance analysis of joints
- To learn how to made the early differential diagnosis between both conditions

Chairperson(s):
Roberto Caporali (Italy)
Bhaskar Dasgupta (United Kingdom)
Alberto Sulli (Italy)

Abstract N° SP0168
Case 1 presentation: An elder patient with intensive pain in both arms
Marco A. Cimmino (Italy)

Abstract N° SP0169
Case 1 discussion: How to differentiate PMR from elderly onset RA using imaging
Ignacio Villa (Spain)

Abstract N° SP0170
Case 2 presentation: Symmetrical severe shoulder pain in an elder patient
Marcos Lopez-Hoyos (Spain)

Abstract N° SP0171
Treatment in refractory myositis
Li Alemo Munters (United States)

Abstract N° SP0172
Physical exercise as a DMARD in myositis
Jiri Vencovsky (Czech Republic)

Abstract N° SP0173
New ACR/EULAR response criteria for myositis
N. Pipitone (Italy)

Does MRI provide an added value over serum creatine kinase measurement in myositis?
A. G. S. Oldroyd (United Kingdom)

Abstract N° OP0278
The standardised mortality rate in UK adult-onset myositis patients is seven times higher than the UK general population

Outcome Science session

Cost effectiveness of biologics in RA

Learning objectives:
- To get an overview of the current knowledge and available data on cost effectiveness in RA
- To be able to critically discuss different sources for the information
- To understand the inclusion of cost effectiveness data in RA guidelines in different health care systems

Chairperson(s):
Annelies Boonen (Netherlands)
Johan Karlsson (Sweden)
Martin Neovius (Sweden)

What are the current and future challenges for evaluations of cost effectiveness of biologics in RA?
James O’Dell (United States)

A review of the cost effectiveness data from recently presented clinical trials and studies in RA
Bruno Fautrel (France)

Cost effectiveness and guidelines-how to learn across health care systems?
A. Vanier (France)

F. Tubach, T. Alfaiate, X. Mariette, B. Fautrel

Step-down strategy of spacing TNF-blockers injections for established rheumatoid arthritis in remission: a cost-utility analysis based on the STRASS trial
M. Hifinger (Netherlands) 17:00
Abstract N° OP0281
Rheumatologists consider patient preferences and costs when choosing treatments for rheumatoid arthritis (RA) patients. A cross-European discrete choice experiment

15:45 - 17:15 Room 10 B
PReS session
From basic science: JIA pathogenesis
Learning objectives:
• To understand the role of innate immunity in the pathogenesis of juvenile idiopathic arthritis
• To understand the interplay between T regulatory cells and effector cell in the pathogenesis of chronic synovitis
Chairperson(s):
Fabrizio de Benedetti (Italy)
Berent J. Prakken (Netherlands)
Berent J. Prakken (Netherlands) 15:50
Regulatory T cells and the pathogenesis of JIA
Lucy Wedderburn (United Kingdom) 16:10
Abstract N° SP0176
The TH-1/TH-17 balance in JIA
Johannes Roth (Germany) 16:30
Innate immunity and JIA
J. A. Ellis (Australia) 16:50
Abstract N° OP0282
The association of PTPN22 RS2476601 with juvenile idiopathic arthritis is specific to females
G. Schulert (United States) 17:00
N. Fall, N. Shen, S. Thornton, A. Grom
Abstract N° OP0283
MicroRNA 125A-5P has increased expression in active systemic juvenile idiopathic arthritis and is an essential modulator of regulatory macrophage phenotypes in vitro

15:45 - 17:15 Room 10 D-E
Basic and Translational Science session
Scleroderma mechanisms - new perspectives
Learning objectives:
• To understand the potential molecular mechanisms that contribute to the observed heterogeneity of SSc through gene expression studies of systemic sclerosis and identification of disease-specific gene expression signatures
• To learn about recent insights into the pathogenesis of systemic sclerosis, suggesting a link between autoantigen expression of cancer and autoantibody response in the development of systemic sclerosis
Chairperson(s):
Mike O. Becker (Germany)
Jörg Distler (Germany)
Maria Trojanowska (United States) 15:50
Abstract N° SP0177
Linking vasculopathy and fibrosis
Michael Whitfield (United States) 16:10
Abstract N° SP0178
Understanding heterogeneity of SSc - opportunities with gene expression studies
Anthony Rosen (United States) 16:30
Abstract N° SP0179
The SSc-cancer paradigm - new insights
E. Pachera (Switzerland) 16:50
Abstract N° OP0284
Long noncoding RNA MIR503HG is a novel factor in the pathogenesis of systemic sclerosis
C. B. Chighizola (Italy) 17:00
E. Raschi, L. Cesana, M. O. Borghi, P. L. Meroni
Abstract N° OP0285
The pathogenic role of immune complexes containing scleroderma-specific autoantibodies in the inductor phase of the disease

15:45 - 17:15 Room 10 I
Basic and Translational Science session
EULAR/EFIS session: Autoimmunity and inflammation in anti-checkpoint antibody therapies of cancer?
Learning objectives:
• To understand how check point blockers modulate the immune response and their link with autoimmunity
• To learn about the side effects of check point blockers on autoimmunity in cancer patients
• To identify groups of patients more prone to autoimmune manifestations during check point blockade therapy
Chairperson(s):
Catherine Sautes-Fridman (France)
Georg Schett (Germany)
Wolf H. Fridman (France) 15:50
Abstract N° SP0180
The tumour immune micro environment: a target for checkpoint therapies

Michele Maio (Italy) 16:15
Activities and safety of anti-checkpoint in patients with advanced cancer

Salvatore M. Corsello (Italy) 16:40
Abstract N° SP0181
The impact of immune checkpoint inhibitors on autoimmunity, the endocrine side effects of cancer immunotherapy

15:45 - 17:15 Room 10 C

The Young Rheumatologist
The art of writing

Learning objectives:
To improve writing skills and optimising your work

Chairperson(s):
Pedro Machado (Portugal)
Paul Studenic (Austria)

Iain B. McInnes (United Kingdom) 15:50
How to improve a proposal for grant application

Ronald van Vollenhoven (Sweden) 16:10
Abstract N° SP0182
How to write an outstanding original paper

Loreto Carmona (Spain) 16:30
Abstract N° SP0183
To publish or perish: how to review manuscripts and grant proposals

Richard Bucala (United States) 16:50
Abstract N° SP0184
How to choose the best journal for submitting your paper

15:45 - 17:15 Room 10 A

Health Professionals session
Fit to fight rheumatic and musculoskeletal diseases - how much exercise is beneficial and safe?

Learning objectives:
- Update on current evidence on the beneficial effects of exercise in rheumatic diseases
- Knowledge of indications of what is an optimal dosage of exercise
- Knowledge benefits and harms

Chairperson(s):
Rikke H. Moe (Norway)
Michaela Stoffer (Austria)

Hanne Dagfinrud (Norway) 15:50
Abstract N° SP0185
Intensity levels of exercise and physical activity in rheumatic diseases, and how to measure them

Emalie Hurkmans (Netherlands) 16:08
Abstract N° SP0186
Barriers and facilitators for applying optimal exercise intensity in rheumatic and musculoskeletal diseases

Helene Alexanderson (Sweden) 16:26
Abstract N° SP0187
Does the diagnosis matter for exercise dosage?

Maura D. Iversen (United States) 16:44
Abstract N° SP0188
Adverse effects of exercise in rheumatic and musculoskeletal diseases

A. Ericsson (Sweden) 17:02
Abstract N° OP0286-HPR
Resistance exercise improves multidimensional fatigue in women with fibromyalgia. A randomized controlled trial

15:45 - 17:15 Room 10 H

EULAR projects in epidemiology and health services
Patient reported outcomes and the EULAR outcome measure toolkit

Learning objectives:
- To learn about the EULAR outcome measure toolkit
- To hear the results of EULAR funded projects on patient reported outcome measures

Chairperson(s):
Deborah Symmons (United Kingdom)
Axel Finckh (Switzerland)
Laure Gossec (France)

Loreto Carmona (Spain) 15:50
Abstract N° SP0189
The EULAR outcome measures toolkit - concept and content

Mike C. Horton (United Kingdom) 16:00
Abstract N° SP0189
The EULAR outcome measures toolkit - concept and content

Ayse A. Kucukdeveci (Turkey) 16:10
Cross cultural validation of a disease specific quality of life measure for rheumatoid arthritis

Wilfred F. Peter (Netherlands) 16:20
Development of a cross-cultural validation of a patient reported computer animation questionnaire for measuring functional limitations in patients with arthritis
SCIENTIFIC PROGRAMME / FRIDAY 12 JUNE 2015 / 119

Suzanne Verstappen (United Kingdom) 16:30
Towards a patient global measure to assess at work limitations/productivity loss in patients with inflammatory arthritis and osteoarthritis

Laure Gossec (France) 16:40
Cross-cultural validation of patient reported outcome measures poses specific problems: BRAF and RAID study

Lillian van Tuyl (Netherlands) 16:50
The patient perspective on remission in rheumatoid arthritis

15:45 - 17:15  SC2 - Room A

PARE session
Youth in action

Learning objectives:
• To present the PARE strategy for young people with RMDs
• To learn more about the importance of ‘disclosure’ and the need for raising awareness about the impact of having a RMD when you are young
• To showcase best practice of youth groups campaigning for better services for young people with RMDs

Chairperson(s):
Caroline Ospelt (Switzerland)
Ingrid Põldemaa (Estonia)

Linda van Nieuwkoop (Netherlands) 15:50
Abstract N° SP0190
A milestone in EULAR - the first PARE youth strategy

Lotte Havermann (Netherlands) 16:10
Abstract N° SP0191
Measuring quality of life in young adults with RA in clinical practice

Gudrun Baseler (Germany) 16:30
Abstract N° SP0192
A professional career with a rheumatic disease

L. Hickey (Ireland) 16:50
Abstract N° OP0287-PARE
Incorporating youth into a national organisation

C. Wright (United Kingdom) 17:00
S. R. Stones on behalf of Paediatric Rheumatology CSG Consumers
Abstract N° OP0288-PARE
The top concerns of children and young people living with JIA

Chairperson(s):
Thomas Dörner (Germany)
Gerd R. Burmester (Germany)

Thomas Dörner (Germany) 15:50
APS

Pierre Miossec (France) 16:15
Vasculitis, systemic autoimmunity

Eugen Feist (Germany) 16:40
Inflammatory joint diseases

15:45 - 17:15  Room 9 A

Practical skills session*
MRI I

Learning objectives:
• How to use MRI technique best in the discussed cases and diseases
• What can be read from the MRI - and what not
• How can MRI be used to support the diagnosis and how to control progress of treatment

Chairperson(s):
Kay-Geert Hermann (Germany)
Mikkel Østergaard (Denmark)

Mikkel Østergaard (Denmark) 15:50
Introduction: MRI in arthritis

Kay-Geert Hermann (Germany) 15:55
MRI of sacroiliac joints - basic interpretation skills and pitfalls

Joshua Baker (United States) 16:15
Abstract N° SP0193
Lessons learnt from recent MRI trials in RA

Mikkel Østergaard (Denmark) 16:35
Wholebody MRI, dynamic MRI and diffusion-weighted MRI in inflammatory arthritis. Relevance for clinical practice and research

Iris Eshed (Israel) 16:55
Interactive session: MRI case vignettes - from finding to diagnosis

17:45 - 19:15
Satellite symposia

• UCB  Room 10 B
• Menarini  Room 10 I
• Symposium in German  Room 10 H

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
TRANSLATING SCIENCE INTO PATIENT CARE

Join us for these three symposia
FIERA ROMA | Room F-G

BENEFIT-RISK IN CONTROLLED TRIALS AND REAL WORLD
WHAT DOES IT REALLY MEAN?

AN INTEGRATED APPROACH TO RA MANAGEMENT
HOW TO COMBINE INNOVATION, PATIENT PERSPECTIVES AND COST CONSIDERATIONS

CLINICAL ADVANCEMENTS IN AXIAL SPA
A JOURNEY OF SCIENTIFIC EVOLUTION

WEDNESDAY 10 JUNE 2015
13:00-14:30

THURSDAY 11 JUNE 2015
17:45-19:15

FRIDAY 12 JUNE 2015
08:30-10:00
Guided Poster Tours

Friday 12 June 2015 12:10 - 13:35

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 7, on a "first-come-first-served" basis on the day of the poster tour.

Poster tour F1: RA - predictors of complications and outcomes 2 Hall 6

Chairperson(s): Leslie J. Crofford (United States), Cecilia Chung (United States)


FRI0022 ANEMIA IS AN INDEPENDENT PREDICTOR OF RADIOGRAPHIC DAMAGE PROGRESSION IN ANTI-TNF-TREATED RHEUMATOID ARTHRITIS PATIENTS FROM TWO LARGE PHASE III TRIALS / B. Möller* - S. Florentinus - F. Ganzi - Y. Li - H. Kupper - A. Finckh


FRI0025 PREDICTING RHEUMATOID ARTHRITIS BY MEASURING SURVIVIN IN UNSELECTED SAMPLES - EPIDEMIOLOGICAL STUDY WITHIN TWO UNIVERSITY CITIES OF SWEDEN / M. Turkilda - R. Pullerits - C. Schiller - C. Eriksson - M. Erlandsson - S. Rantapää-Dahlqvist - M. Bokarewa*


Poster tour F2: RA - comorbidities 1 Hall 6

Chairperson(s): Johannes W. J. Bijlsma (Netherlands), Stefan Bruijnen (Netherlands)


* Presenting author
**Poster tour F3: RA - safety and efficacy for treatment after TNF inhibitor**

**Chairperson(s):** Lene Terslev (Denmark), Uffe Møller Døhn (Denmark)

**FRI0145**

**CHOICE AND EFFECTIVENESS OF TOCILIZUMAB AMONG PATIENTS WITH RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS / M. Kihara* - L. Kearsley-Fleet - M. Davies - K. D. Watson - M. Lunt - D. P. Symmons - K. L. Hyrich on behalf of British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

**FRI0146**


**FRI0147**


**FRI0148**


**FRI0149**


**FRI0150**

**MAINTENANCE OF RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AFTER SWITCHING TO TCZ ADMINISTERED ALONE COMPARED TO THE COMBINATION OF TCZ AND MTX / J. Pablos* - F. Navarro - F. Blanco - J. Roman-Ivorra - A. Alonso - E. Martín-Mola - M. Cantalejo

**FRI0151**

**INCIDENCE RATES OF SKIN CANCERS DURING EXPOSURE TO INTRAVENOUS AND SUBCUTANEOUS ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM POOLED CLINICAL TRIAL DATA / T. A. Simon* - C. Poncet - M. Hochberg - M. Boers on behalf of Abatacept Epidemiology and Safety Panel

**FRI0152**

**ON DRUG AND DRUG-FREE REMISSION BY BASELINE DISEASE DURATION IN THE AVERT TRIAL: ABATACEPT VERSUS METHOTREXATE COMPARISON IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / C. Charles-Schoeman* - G. R. Burmester - B. G. Combe - D. E. Furst - T. W. J. Huizinga - D. A. Wong - P. Emery

**FRI0153**

**IMMUNOGENICITY, SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WHO MISSED DOSES / G. R. Burmester* - M. Bao - W. Reiss - T. Wallace - S. Lacey - A. Kivitz

**FRI0154**

**INCIDENCE OF CANCERS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND A HISTORY OF CANCER TREATED WITH RITUXIMAB OR ABATACEPT / J. E. Gottenberg* - J. Morel - P. Ravaud - T. Bardin - P. Cacoub - A. Cantagrel - T. A. Simon* - C. Poncet - M. Hochberg - M. Boers on behalf of Abatacept Epidemiology and Safety Panel

**Poster tour F4: Understanding spondyloarthritis**

**Chairperson(s):** Rik Lories (Belgium), Heleen Cyppers (Belgium)

**FRI0190**


**FRI0191**


* Presenting author


FR10195  ERAp1 ALLOTYPES AND DISEASE SEVERITY IN ANKYLOSING SPONDYLITIS / W. Fong* - E. Reeves - W. Tim - T. Elliot - E. James - C. J. Edwards

FR10196  CCR2 EXPRESSION WAS INCREASED IN PATIENTS WITH ANKYLOSING SPONDYLITIS INDEPENDENT FROM DISEASE ACTIVITY / D. Solmaz* - A. Tekinalp - O. Avci - B. Turgut

FR10197  ROLE OF ARGINASE IN A CELLULAR AND MURINE MODEL OF ENDOCHONDRAL OSSIFICATION / C. Prati* - F. Cailotto - K. Heritage - D. Wendling - R. Lories

Postera tour F5: Vasculitis

Chairperson(s): Carlo Salvarani (Italy), Luca Quartuccio (Italy)


FR10251  CARDIOVASCULAR RISK AND BONE LOSS BASED ON INITIAL DAILY ORAL PREDNISONE DOSE IN BIOPSY-PROVEN GIANT CELL ARTERITIS / M. J. Koster* - C. Labarca - C. Crowson - A. Makol - S. Ytterberg - E. Matteson - K. Warrington


FR10253  PREDICTIVE FACTORS FOR THE RESPONSE TO INFlixIMAB THERAPY IN PATIENTS WITH BEHÇET'S DISEASE / S. D'Angelo* - P. Leccese - A. Padula - M. Nigro - M. Gillo - A. Carriere - C. Palazzi - I. Olivieri

FR10255  PATIENTS TREATED FOR BEHÇET'S SYNDROME IN THE US HAVE HIGHER DISEASE ACTIVITY SCORES AT PRESENTATION IF THEY FULLFILL DIAGNOSTIC CRITERIA AND IF THEY ARE FEMALES / Y. Yazici* - H. Bernstein - C. Swearingen

Poster tour F6: Osteoporosis - new treatment options

Chairperson(s): Willem F. Lems (Netherlands), Marlies van der Goes (Netherlands)

FR10283  LONG-TERM ADHERENCE TO TREATMENT IN A FRACTURE LIAISON SERVICE COORDINATED BY RHEUMATOLOGIST AND NURSE / A. Naranjo* - S. Ojeda-Bruno - A. Bilbao-Cantarero - S. Rodríguez-Moreno - B. V. Díez-González - J. C. Quevedo Abeledo - C. Rodríguez-Lozano on behalf of Fracture Liaison Service Gran Canaria Norte


FR10285  THE EFFECT OF STEROIDS ON FRACTURE, ADJUSTING FOR BONE MINERAL DENSITY / M. Bukhari* - N. Goodman - M. Boers

FR10286  CARDIOVASCULAR RISK AND BONE LOSS IN PATIENTS WITH EROSIve AND NON-EROSIVE HAND OSTEOARTHRITIS / O. Ruzickova* - O. Sleglova

* Presenting author
FRI0287 DAILY TERIPARATIDE TREATMENT FOR TWO YEARS ON OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS - IMPACT OF CONCOMITANT DRUGS (PREDNISOLONE AND BIOLOGICS) ON EFFECTS OF TERIPARATIDE / Y. Hirano* - S. Hirabara - M. Isono - Y. Oishi - T. Kojima - N. Ishiguro

FRI0288 ROLE OF PHYSICAL EXERCISE PROGRAM IN PATIENTS WITH OSTEOPOROSIS / R. I. Marcoa* - S. Patru - A. C. Bighea - R. Traistaru - R. S. Popescu


FRI0290 COMORBIDITIES IN OSTEOPORTIC PATIENTS: A RETROSPECTIVE STUDY / A. M. Ata - F. G. Y. Kutsal* 

FRI0291 DECREASE IN ANTI-OSTEOPOROTIC DRUGS PRESCRIPTIONS: IS THERE AN IMMEDIATE CONSEQUENCE ON HIP FRACTURE INCIDENCE? / K. Briot* - M. Maravic - C. Roux


Poster tour F7: Epidemiology and health services research

Chairperson(s): Ingemar Persson (Sweden), Axel Finchk (Switzerland)


FRI0336 DISEASE ACTIVITY PATTERNS IN RHEUMATOID ARTHRITIS IN THE FIRST 3 YEARS OF FOLLOW-UP IN USUAL CARE: MARKOV MODELING SHOWS RAPID IMPROVEMENT IN DAS28 STATES IN THE 1ST YEAR FOLLOWED BY STABLE STATES IN THE LAST 2 YEARS. RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / M. Tatangelo* - G. Tomlinson - B. Kuriya - C. Bombardier

FRI0337 ASSOCIATION BETWEEN SERUM URIC ACID LEVELS AND CARDIOVASCULAR RISK. A POST HOC ANALYSIS OF THE EUROPEAN CARDIOVASCULAR RISK PATIENTS: DISEASE PREVENTION AND MANAGEMENT IN USUAL DAILY PRACTICE (EURIKA) STUDY / C. Borghi* - J. N. Carman - C. Enger - J. Iles - M. S. Anthony


FRI0340 BIRTH OUTCOMES AMONG INFANTS OF WOMEN WITH CHRONIC INFLAMMATORY ARTHRITIS OR PSORIASIS TREATED AND NOT TREATED WITH ENTERECEPT (ENBREL) DURING PREGNANCY / N. Accortt* - W. J. Carman - C. Enger - J. Iles - M. S. Anthony


FRI0342 MEASURING PAIN INTENSITY IN OLDER ADULTS WITH ‘MULTISITE’ PERIPHERAL JOINT PAIN USING A COMPOSITE SCORE / A. Finney* - K. Dziedzic - M. Lewis - S. Ryan - E. Healey


FRI0344 ECONOMIC BURDEN OF CONTROLLED GOUT, UNCONTROLLED GOUT, AND GOUT EXACERBATED BY COMMON COMORBIDITIES: RESULTS FROM THE 2012-2013 NATIONAL HEALTH AND WELLNESS SURVEY / R. Morlock* - N. M. Flores - K. Annunziata - R. Briot

FRI0345 TAPERING MTX IN PATIENTS WITH RA USING TNFI TREATMENT IS POSSIBLE / S. Manders* - M. van de Laar - R. Morlock* - N. M. Flores - K. Annunziata - J. Chapnick - J. Nuevo

FRI0346 EVALUATION STUDY FOR SELF MANAGEMENT OF PATIENTS WITH ANKYLOSING SPONDYLITIS (AS) THROUGH A PERSONAL HEALTH SYSTEM / M. Gencturk* - O. Eren - M. Yuksel

Poster tour F8: Lupus and APS - etiology, pathogenesis and new treatment approaches

Chairperson(s): Reinerd E. Voll (Germany), Cristiana Pamfil (Romania)


* Presenting author


FRI0378  THE ROLE OF MONOCYTE SUBSETS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATHOGENESIS / E. M. McCarthy* - G. Kearsn - C. Jefferies

FRI0379  METFORMIN SUPPRESSES SYSTEMIC AUTOIMMUNITY IN ROQUINSAN/SAN MICE THROUGH INHIBITION OF B CELL DIFFERENTIATION INTO PLASMA CELLS VIA AMPK/MTOR/STAT3 PATHWAY REGULATION / S.-J. Moon* - J.-K. Min


Poster tour F9: SSc pathogenesis and etiology  

Chairperson(s): Gabriela Riemekasten (Germany), Britta Maurer (Switzerland)


FRI0438  TREATMENT WITH ABATACEPT PREVENTS EXPERIMENTAL DERMAL FIBROSIS AND INDUCES REGRESSION OF ESTABLISHED FIBROSIS IN A PRECLINICAL MODEL OF SYSTEMIC SCLEROSIS / M. Possev - C. Frantz - N. Ruzehaji - M. Elhai - B. Ruiz - A. Cauvet - Y. Allanore - J. Avouac*


FRI0441  MICRORNA-34A UNBALANCE IS ASSOCIATED WITH DIFFUSE SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS / P. Christopoulos* - V. K. Kitsuda - S. Panopoulos - A. Valopoulou - M. Koutsilieris - P. Sutiki

PReS Poster tour F10: Clinical aspects of paediatric rheumatic diseases  

Chairperson(s): Alberto Martini (Italy), Sebastian Vastert (Netherlands)


FRI0495  WHAT MIGHT BE THE FACTORS FOR STAYING IN REMISSION IN JIA? DATA FROM THE GERMAN BIKER REGISTRY / J. Peitz* - I. Becker - G. Horneff

FRI0496  EFFICACY AND SAFETY OF CANAKINUMAB IN CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS WITH AND WITHOUT FEVER / N. Ruperto* - H. Brunner - P. Quartier - T. Constantin - E. Alexseeva - I. Kone-Paut


FRI0498  WHAT MIGHT BE THE FACTORS FOR STAYING IN REMISSION IN JIA? DATA FROM THE GERMAN BIKER REGISTRY / J. Peitz* - I. Becker - G. Horneff


FRI0500  WHAT MIGHT BE THE FACTORS FOR STAYING IN REMISSION IN JIA? DATA FROM THE GERMAN BIKER REGISTRY / J. Peitz* - I. Becker - G. Horneff

* Presenting author


FR10501 ANTINUCLEAR ANTIBODY-POSITIVE PATIENTS - ARE THEY A SEPARATE ENTITY? / M. Glerup* - T. Herlin - M. Twilt


FR1053 Chairperson(s): Esperanza Naredo (Spain), Denis Poddubny (Germany)


**Poster tour F11: Back pain, mechanical musculoskeletal problems, local soft tissue disorders**

**Chairperson:** Elaine Hay (United Kingdom), Christelle Nguyen (France)

**FR10536** INVESTIGATION OF THE EFFECTIVENESS OF MUSCLE INHIBITION AND SPACE CORRECTION TECHNIQUES OF KINESIOTAPING METHOD IN FEMALE PATIENTS WITH MYOFASCIAL PAIN SYNDROME RELATED TO UPPER TRAPEZIUS ACTIVE TRIGGER POINTS / M. F. Akpınar - A. Ketenç - D. Sinder*.


**FR10539** AN INTEGRATED MANUFACTURING METHOD OF CUSTOMIZED MEDICAL KNEE IMPLANTS USING AUTOMATED 3D MODEL RECONSTRUCTION AND PROTOTYPING PROCEDURE / M. Moayedfar - A. M. B. Abdul Rani* - D. Kumar.


**FR10541** TRIGGER POINTS DRY NEEDLING UNDER ULTRASOUND GUIDANCE FOR LOW BACK PAIN THERAPY. COMPARATIVE STUDY / R. V. Rubnov*


**FR10543** DOES ELECTROPHYSIOLOGICALLY SEVERE PATIENTS HAVE ALSO HIGHER NEUROPATHIC COMPLAINTS IN CARPAL TUNNEL SYNDROME? / M. Karadeniz* - T. Dundinyolu.

**FR10544** NON-STRUCTURAL FACTORS ASSOCIATED WITH CURRENT AND NEW FOOT PAIN: DATA FROM THE TASMANIAN OLDER ADULT COHORT STUDY / L. L. Laslett - H. Menz - E. Ciccittini - G. Jones*.

**FR10545** SAFER SLEEPING WITH SOAP? QUININE, CRAMPS AND WEIGHING UP ANECDOTAL EVIDENCE / E. A. Clarke* - S. Bawa.

**FR1056 Chairperson(s): Esperanza Naredo (Spain), Denis Poddubny (Germany)**


* Presenting author
GUIDED POSTER TOURS / FRIDAY 12 JUNE 2015 / 127

HPR Poster tour F13: Multidisciplinary teams

House 5

FR0612-HPR FEAR OF FALLING AND FOOT PAIN, IMPAIRMENT AND DISABILITY IN PEOPLE WITH RHEUMATOID ARTHRITIS: AN EXPLORATORY STUDY / K. Rome* - T. Morpeth - M. Fecklington
FR0613-HPR ASSESSING REPORTING BIAS IN TRIALS OF EXERCISE INTERVENTIONS FOR PAIN MANAGEMENT IN RHEUMATIC DISEASES: AN APPLICATION OF THE TEST FOR EXCESS SIGNIFICANCE / B. D. Thombs* - A. Levis - G. Kelley
FR0615-HPR EVALUATION OF COPING STYLES IN ESTABLISHED RHEUMATOID ARTHRITIS PATIENTS IN AN ASIAN COHORT / E. Chew* - K. Griva - P. Cheung
FR0616-HPR FATIGUE, QUALITY OF SLEEP AND PAIN IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / E. Taracki* - S. N. Arman - K. Barut - O. Kasapcopur
FR0618-HPR MEASURING THE EFFECTIVENESS OF PATIENT EDUCATION FOR PATIENTS RECEIVING INJECTABLE BIOLOGIC MEDICATIONS / V. L. Ruffing* - A. M. Orbai - C. O. Bingham

PARE Poster tour F14: PARE 2

House 5

PARE0012 BUILDING PATIENT LED ORGANISATIONS - AN EXAMPLE OF HUNGARY / J. Ortutay* - E. Rozán
PARE0014 PDTA IN RHEUMATOID INFLAMMATORY AND AUTOIMMUNE DISEASES / U. G. Viora* - R. Giannelli - S. Severoni - G. Voltan on behalf of ANMAR Italia
PARE0015 HOW THE SWEDISH RHEUMATISM ASSOCIATION WORK TO INCREASE RESEARCH ON OSTEOARTHRITIS / K. Blidberg* - A. Carlsson
PARE0016 MULTICHANNELSENITISATION CAMPAIGN WITH PROMINENT AMBASSADORS / E. S. Rösch - M. Siber*
PARE0017 RECOMMENDATIONS FOR RHEUMATOLOGISTS ON PHYSICAL EXERCISE IN SPONDYLOARTHRITIS (EJES 3-D STUDY) / J. Loza* - L. Carmona - P. Zarco - M. T. Florèz
PARE0018 THE DILEMMAS OF DISCLOSURE OF SIDE EFFECTS OF RHEUMATIC BIOLOGICAL DRUGS / S. Moufarrej* - R. Badsheer - K. Thornely
PARE0019 PATIENT PERSPECTIVES ON FOOTWEAR IN RHEUMATOID ARTHRITIS - A PATIENT-LED QUALITATIVE STUDY / S. de Souza* - H. Lempä
PARE0020 TO INFLUENCE BY MEETING THOSE IN POWER - A WEEK OF POLITICAL ACTIVITIES / C. Fjellström - A. Carlsson*
PARE0021 NATIONAL ARTHRITIS ACTIVITY GUIDE (REUMABEWEGWIJZER) DIRECTS PATIENTS TO PHYSICAL ACTIVITIES IN THEIR OWN NEIGHBORHOOD / S. De Jong* - G. Korevaar - Y. Kat

* Presenting author
Scientific Poster Session 2

Friday 12 June 2015  12:00 - 13:45

Adaptative immunity (T cells and B cells) in rheumatic diseases  Hall 6

FRI0001  HUMAN BASOPHILS SUPPORT PLASMA CELL DIFFERENTIATION AND ANTIBODY PRODUCTION / A. Meyer-Bahlburg* - D. Dijkstra
FRI0003  INVOLVEMENT OF ZAP-70, CALCINEURIN AND VOLTAGE-GATED K+ CHANNEL SIGNALING IN RANKL EXPRESSION FROM HUMAN T LYMPHOCYTES FOLLOWING CO-LIGATION OF THE ADHESION MOLECULE CD2 AND THE T CELL RECEPTOR COMPLEX / B. P. Harvey* - Z. Kaymakcalan
FRI0005  COMBINATION BLOCKING OF IL-22 AND IL-17 DURING EXPERIMENTAL ARTHRITIS POTENTLY REDUCES TH17-DRIVEN DISEASE PROGRESSION / D. M. Roeleveld* - R. Rogier - B. Walgreen - M. M. Helsen - L. van den Bersselaar - W. B. van den Berg - P. M. van der Kraan - M. I. Koenders
FRI0007  THE IMPORTANCE OF SOMATIC HYPERMUTATION FOR THE IMMUNOREACTIVITY TOWARDS NEUTROPHIL EXTRACELLULAR TRAPS (NETS)-CITRULLINATED AUTOANTIGENS OF RA SYNOVIAL MONOCLONAL ANTIBODIES / E. Corsiero* - E. Carlotti - C. Pitzalis - M. Bombardieri
FRI0008  LONGITUDINAL ANALYSIS OF THE IGH-VH GENE BY HIGH-THROUGHPUT SEQUENCING IN EARLY RHEUMATOID ARTHRITIS PAIRED BIOPSIES AND ITS ASSOCIATION WITH RESPONSE TO DMARDS / E. Carlotti* - J. Floyd - W. Murray-Brown - M. Barnes - R. Mehr - M. Bombardieri - C. Pitzalis
FRI0010  IDENTIFICATION OF AN ANTIGEN-SPECIFIC REGULATORY B CELL SUBSET IN HUMANS / J.-O. Pers* - L. Le Pottier - C. Goutsmedt
FRI0011  IL-10-PRODUCING REGULATORY B CELLS ARE DECREASED IN SYSTEMIC SCLEROSIS / A. Mavropoulos - T. Simopoulou - A. Varna - C. Liaskos - C. Katsiari - D. Bogdanos - L. Sakkas*
FRI0015  ANTI GP2 ANTIBODY PREVALENCE IN PATIENTS WITH RHEUMATIC DISEASES / M. Volkava* - A. Kundzer - I. Generalov - D. Roggenbuck - D. Petrovich
FRI0016  IGE AS A BIOMARKER OF REGULATORY T CELL ACTIVITY IN AUTOIMMUNE DISEASES / M. F. Moraes-Fontes* - N. Costa - C. Santos - A. Coutinho - C. Fesel

* Presenting author
Rheumatoid arthritis - prognosis, predictors and outcome

FR10019  ANTI-IGG SUBCLASS SPECIFIC RHEUMATOID FACTOR DISCRIMINATES BETWEEN RESTRICTED AND POLYSPECIFIC RF RESPONSES WHICH ARE ASSOCIATED WITH ISOTYPE SWITCHING AND ACPA POSITIVITY / W. Falkenberg* - D. van Schaardenburg - P. Ooijevaar-de Heer - G. Wolbink - T. Rispe


FR10022  ANEMIA IS AN INDEPENDENT PREDICTOR OF RADIOGRAPHIC DAMAGE PROGRESSION IN ANTI-TNF-TREATED RHEUMATOID ARTHRITIS PATIENTS FROM TWO LARGE PHASE III TRIALS / B. Møller* - S. Florentinus - F. Gian - Y. Li - H. Kupper - A. Finckh


FR10025  PREDICTING RHEUMATOID ARTHRITIS BY MEASURING SURVIVIN IN UNSELECTED SAMPLES - EPIDEMIOLOGICAL STUDY WITHIN TWO UNIVERSITY CITIES OF SWEDEN / M. Turkilla - R. Pullerits - C. Schiller - C. Eriksson - M. Erlansson - R. Rantapää-Dahlqvist - M. Bokarewa*


FR10028  GAZING INTO THE CRYSTAL BALL! PROSPECTIVE MRI SCORE TO PREDICT NEGATIVE EULAR-RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) BEFORE THERAPY-ESCALATION TO A BIOMEDICAL THERAPY / P. Sewerin* - R. Brinks - C. Schlech - E. Miese - S. Vordenbäumen - S. Klein - G. Antoeh - M. Schneider - B. Ostendorf

FR10029  RHEUMATOID ARTHRITIS MRI SCORING (RAMRIS) CORRELATES WITH SYNOVIAL CAMPACT ACTIVATION OR FIBER DEPOSIT IN RA PATIENTS / Y.-Q. Mo - Z.-H. Yang - H.-N. He - L.-F. Chen - J.-D. Ma - L. Dai*


FR10033  DESPITE EARLY IMPROVEMENT, PATIENTS WITH RHEUMATOID ARTHRITIS STILL HAVE IMPAIRED GRIP FORCE 5 YEARS AFTER DIAGNOSIS / M. Byholm - C. Book - I. Wikström - L. Jacobsson - C. Turesson*


FR10035  CORRELATIONS BETWEEN CLINICAL, LABORATORY AND ULTRASOUND joint examination in rheumatoid arthritis patients / T. G面目 - I. Contreras-Yañez - L. Llorente


DEVELOPMENT AND VALIDATION OF EULAR ENDORSED NEW PATIENT REPORTED OUTCOME QUESTIONNAIRE TO ESTIMATE VITAMIN D STATUS (D-PRO) AND RELATED DISEASE SEVERITY RISKS IN EUROPEAN RHEUMATOID ARTHRITIS PATIENTS / V. Ricci - J. Tincani - A. Sulli - S. Soldano - M. Cutolo on behalf of D-PRO


RHEUMATOID ARTHRITIS AND MORTALITY FOLLOWING HOSPITALIZED PNEUMONIA: A POPULATION-BASED COHORT STUDY WITH DIAGNOSIS VALIDATION / M. Holland-Fischer* - M. Norgaard - U. Tarp - R. W. Thomsen

SIMPLE CLINICAL AND GENETIC PROGNOSTIC MARKERS OF SECONDARY/RENAL AMYLOIDOSIS IN RHEUMATOID ARTHRITIS PATIENTS / N. Dostanko - V. Yagur - K. Chizh


COMPARISON OF PATIENTS WITH RHEUMATOID ARTHRITIS ON DISEASE REMISSION IN EUROPE AND UNITED STATES / S. Narayanan* - Y. Lu - R. Hutchings - A. Baskett


DEVELOPMENT AND VALIDATION OF EULAR ENDORSED NEW PATIENT REPORTED OUTCOME QUESTIONNAIRE TO ESTIMATE VITAMIN D STATUS (D-PRO) AND RELATED DISEASE SEVERITY RISKS IN EUROPEAN RHEUMATOID ARTHRITIS PATIENTS / J. Tincani - A. Sulli - S. Soldano - M. Cutolo on behalf of D-PRO


* Presenting author
Rheumatoid arthritis - comorbidity and clinical aspects

FR10061 CERVICAL DYSPLASIA AND CERVICAL CANCER IN WOMEN WITH RHEUMATOID ARTHRITIS / H. Wadström* - T. Frisell - J. Askling


FR10064 HOW HAS THE RISK OF SERIOUS INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS CHANGED OVER TIME? / E. Arkema* - J. Askling


FR10067 LACK OF RESPONSE IS ASSOCIATED WITH ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE DURING TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. Akiyama* - K. Kaneko - H. Kondo - K. Yamaoka - T. Takeuchi

FR10068 REMAINING PAIN DESPITE INFLAMMATION CONTROL IN RHEUMATOID ARTHRITIS - LONG-TERM STRONGLY INCREASED RISK FOR WIDESPREAD PAIN AND FATIGUE / M. E. Sandberg* - S. Saevarsdottir - R. Altawl - L. Klareskog - L. Alfredson - J. Lamp on behalf of the EBRA working group


FR10071 CHARACTERIZATION OF PATIENT REPORTED PAIN MEDICATIONS IN RHEUMATOID ARTHRITIS PATIENTS - RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / A. Kelkar - A. Cesta - X. Li - C. Bombardier* - P. Kiel - D. A. Wylie - A. Young

FR10072 IMPLEMENTATION OF TREATING PATIENTS TO TARGET IN A LONG STANDING RHEUMATOID PATIENT POPULATION / C. Wiesenbuthe* - P. J. Askling


FR10075 THE IMPACT OF COMORBIDITY ON FUNCTIONAL STATUS IN RA, 10 YEARS FROM DISEASE-ONSET. RESULTS FROM TWO LARGE UK INCEPTION COHORTS / E. Nikiphorou* - S. Norton - C. Demetriou - J. Dixey - P. Prouse - P. Kiely - D. A. Wylie - A. Young


FR10080 RACIAL DISPARITIES IN TOTAL ANKLE ARTHROPLASTY UTILIZATION AND OUTCOMES / J. A. Singh* - R. Ramachandran


* Presenting author
FRI0102 SERUM LEVEL OF ADIPONECTIN IN RHEUMATOID ARTHRITIS (RA) IS ASSOCIATED WITH CORONARY ARTERY DISEASE / J. R. Eider* - T. P. Utbeim - T. Lyberg - K. Mikkelsen - M. Liang - I. Hollan

FRI0103 PREVALENCE OF ANEMIA IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS - AN INTERIM ANALYSIS / J. Rosner* - B. Mosheimer-Feistritzer - J. Gruber - M. Herold - E. Mur - G. Weiss


FRI0105 COMPARISON OF THE DISEASE ACTIVITY SCORE USING ERYTHROCYTE SEDIMENTATION RATE AND C-REACTIVE PROTEIN IN KOREANS WITH RHEUMATOID ARTHRITIS / K. M. Son* - Y. I. Seo - H. A. Kim

FRI0106 CARDIAC FUNCTION IN PATIENTS OF ACUTE CORONARY SYNDROME COMPPLICATED WITH RHEUMATOID ARTHRITIS / L. Pan* - T. Wang


FRI0108 PREVALENCE AND CHARACTERISTICS OF TRADITIONAL CARDIOVASCULAR RISK FACTORS IN RHEUMATOID ARTHRITIS IN A BLACK AFRICAN POPULATION / M. Doualla* - F. Kema


FRI0110 ATHERSCLEROSIS, HYPERTENSION, ADULT TYPE II DIABETES MELLITUS AND ISOLATED AMYLOIDOSIS LOCALIZED TO THE ISLETS OF LANGERHANS - A POSTMORTEM CLINICOPathOLOGICAL STATISTICAL STUDY OF 234 RHEUMATOID ARTHRITIS PATIENTS / M. Bely* - A. Apathy


FRI0112 QUALITY OR LIFE IN RA PATIENTS: RISK OF FALLS AND FRACTURES (3-YEAR PROSPECTIVE STUDY) / N. Torosovska* - A. Fekistov - O. Nikitinskaya - N. Demin


FRI0114 KIDNEY FUNCTION AND EFFECTIVENESS OF METHOTREXATE TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS / P. Studeinic* - F. Alasti - J. S. Smolen - H. Haslacher - D. Aletaha

FRI0115 SUBCLINICAL HYPOTHYROIDISM IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS / R. Agca* - H. G. Raterman - S. Simsek - A. E. Voskuyl - M. T. Nurmohamed


FRI0117 SEX DIFFERENCES IN THE GAPS BETWEEN THE TENDER JOINT COUNT AND THE SWOLLEN JOINT COUNT IN PATIENTS WITH RHEUMATOID ARTHRITIS / S. Nakazaki* - T. Murayama - S. Kato


FRI0119 DO PATIENTS WITH RHEUMATOID ARTHRITIS WITHOUT EXPOSURE TO BIOLOGICAL THERAPY HAVE AN ADVERSE PROGNOSTIC FACTORS FOR VENOUS THROMBEMBOLIC EVENTS? / M. A. Satybaldyeva* - T. Reshetnyak - N. Seredavkina - S. Glukhova - M. Semenova - D. Karateev - E. Nasonov


FRI0121 OBJECTIVE EVALUATION OF SLEEP AND INFLAMMATION MARKERS IN WOMEN WITH RHEUMATOID ARTHRITIS / T. Dimitroulas* - J. Hodson - A. Sandoo - J. Smith - K. Douglas - G. Kitas


FRI0123 KIDNEY FUNCTION AND EFFECTIVENESS OF METHOTREXATE TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS / P. Studeinic* - F. Alasti - J. S. Smolen - H. Haslacher - D. Aletaha

FRI0124 SUBCLINICAL HYPOTHYROIDISM IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS / R. Agca* - H. G. Raterman - S. Simsek - A. E. Voskuyl - M. T. Nurmohamed


FRI0127 DO PATIENTS WITH RHEUMATOID ARTHRITIS WITHOUT EXPOSURE TO BIOLOGICAL THERAPY HAVE AN ADVERSE PROGNOSTIC FACTORS FOR VENOUS THROMBEMBOLIC EVENTS? / M. A. Satybaldyeva* - T. Reshetnyak - N. Seredavkina - S. Glukhova - M. Semenova - D. Karateev - E. Nasonov


FRI0107  ROMANIAN REGISTRY OF RHEUMATIC DISEASES: EFFICACY AND SAFETY OF BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS / C. Codreanu* - C. Mogosan - L. Enache - D. Stanciu - R. Ionescu - S. Rednic - M. Parvu

FRI0108  CLINICAL AND ECONOMIC OUTCOMES OF DOSE TAPERING AND WITHDRAWAL (DT&W) OF BIOLOGICS COMPARED TO THEIR MAINTENANCE UPON ACHIEVING STABLE DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS (RA) PATIENTS / D. Aletaha* - S. J. Snedecor - V. Ektare - M. Xue - Y. Bao - V. Garg

FRI0109  METHOTREXATE REDUCED TNF BIOACTIVITY BY ANTI-INFLIXIMAB ANTIBODY PREVENTION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB / D. Dénarié* - M. Rinaudo - T. Thomas - S. Paul - H. Marotte

FRI0110  A PHASE I PHARMACOKINETIC STUDY COMPARING SB5, AN ADALIMUMAB BIOSIMILAR, AND ADALIMUMAB REFERENCE PRODUCT (HUMIRA®) IN HEALTHY SUBJECTS / D. Shneyer - Y. Kim - H. S. Kim - R. Fuhr - T. Körnicke


FRI0112  DERMATOLOGIC ADVERSE EVENTS IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS USING BIOLOGICAL THERAPY IN A REAL-LIFE SETTING / F. Salas* - G. Fuquen - J. Castro - G. Saavedra - D. Gomez - J. Bello-Gualtero - P. Santos-Moreno


FRI0114  PATIENTS WITH LOW SERUM ADALIMUMAB CONCENTRATIONS DISPLAY POOR ULTRASONOGRAPHIC RESPONSE TO TREATMENT: RESULTS OF A FOLLOW-UP STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS / H. B. Hammer* - N. Bolstad - D. J. Warren - G. L. Goll


FRI0116  PHARMACOKINETIC RESULTS FROM A PHASE 1, SINGLE-CENTRE, DOUBLE-BLIND, RANDOMISED, SINGLE-DOSE, PARALLEL GROUP STUDY COMPARING 5 MG/KG IV INFUSION OF BOW015 AND REFERENCE INFLIXIMAB IN HEALTHY MALE VOLUNTEERS / J. Lambert* - M. Wyand - C. Lassen - L. Shneyer - E. Thomson - I. Kay

FRI0117  BOW015, A BIOSIMILAR INFLIXIMAB: DISEASE ACTIVITY AND DISABILITY OUTCOMES FROM A PHASE 3 ACTIVE COMPARATOR STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON STABLE METHOTREXATE DOSES / J. Kay* - A. Chopra - C. Lassen - L. Shneyer - M. Wyand


FRI0121  SAFETY OF ADALIMUMAB THERAPY IN HBSAG CARRIERS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE STUDY / L. Fang* - Z. Liao - Z. Lin - O. Jin - Y. Pan - J. Gu

FRI0122  BIOLOGIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON A SPANISH REGISTRY: PREDICTORS OF THERAPY DISCONTINUATION DUE TO REMISSION / M. V. Hernández* - J. A. Gómez-Puerta - J. D. Cañete - J. J. Gómez-Reino - R. Sanmartin on behalf of BIOBADASER 2.0 Study Group


FRI0124  HEPATOTOXICITY OF LATENT ANTI-TUBERCULOSIS TREATMENT PRIOR TO ANTI-TNF THERAPY IN PATIENTS FOR NON-MEDICAL REASONS / M. Parvu

FRI0125  DEVELOPMENT OF NEUROLOGICAL COMPLICATIONS AFTER THERAPY WITH ANTI-TNF DRUGS / N. Errazquin*

FRI0126  CLINICAL AND ECONOMIC OUTCOMES OF DOSE TAPERING AND WITHDRAWAL (DT&W) OF BIOLOGICS IN PATIENTS WITH LOW SERUM ADALIMUMAB CONCENTRATIONS DISPLAY POOR ULTRASONOGRAPHIC RESPONSE TO TREATMENT: RESULTS OF A FOLLOW-UP STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS / H. B. Hammer* - N. Bolstad - D. J. Warren - G. L. Goll

FRI0127  TREATMENT TARGETS WITH FIRST LINE BIOLOGIC DRUGS IN EARLY AND LONGSTANDING RHEUMATOID ARTHRITIS PATIENTS / P. Conigliaro* - P. Triggianese - F. Sunzini - I. Duca - M. Barba - M. S. Chimenti - R. Perricone

FRI0128  A PHASE III RANDOMISED, DOUBLE-BLIND CLINICAL STUDY COMPARING SB4, AN ETANERCEPT BIOSIMILAR, WITH ETANERCEPT REFERENCE PRODUCT (HUMIRA®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY (24-WEEK RESULTS) / J. Vencovský - N. Weisz* - T. Gill - H. Penn - R. Byng-Maddick


* Presenting author
The effect of biological treatment on carbohydrate metabolism disorders and insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis / P. Dąbrowski* - M. Majdan - A. Wadowski - M. Drygelska


Serum levels of TNF antagonists in rheumatoid arthritis: can we establish an optimal cut-off to identify patients in remission or low disease activity? / R. Sanmarti* - J. Inciarte-Mundo - P. Estrada Alarcón - M. García Manrique - J. Narvaez - J. Rodríguez - T. Gómez Centeno - M. Pascal - J. Yagüe


TNF-inhibitors and its effect on disease course and pregnancy outcome in RA and SPA patients / S. van den Brandt* - A. J. Zbinden - D. Baeten - P. M. Villiger - E. Förger


Type I interferon plays a key role in immunogenicity and lupus-like autoimmunity in patients with rheumatoid arthritis treated by infliximab / Y. Ishikawa* - T. Fuji - S. Kondo-Ishikawa

Analysis of the association between cigarette smoking and clinical response to certolizumab pegol treatment in Hungarian patients with rheumatoid arthritis / Z. Szekanecz* - J. Pulai - E. Drescoher - T. Varga - C. Kiss - J. Gál - K. Kerekes - R. Orosz - J. Dunkel - Á. Koncz on behalf of CIMDDORA Study Core Team


Maintenance of response in patients with rheumatoid arthritis after switching to TCZ administered alone compared to the combination of TCZ and MTX / J. P. Vinicki - F. Blanco - J. Roman-Ivorra - A. Alonso - E. Martin-Mola - M. Canto - M. Pascal

Incidence rates of skin cancers during exposure to intravenous and subcutaneous abatacept in patients with rheumatoid arthritis: results from pooled clinical trial data / T. A. Simon* - C. Ponsot - M. Hochberg - M. Boers on behalf of Abatacept Epidemiology and Safety Panel


Rheumatoid arthritis - other biologic treatment

Hall 6


FR10150 Maintenance of response in patients with rheumatoid arthritis (RA) after switching to TCZ administered alone compared to the combination of TCZ and MTX / J. P. Vinicki - F. Blanco - J. Roman-Ivorra - A. Alonso - E. Martin-Mola - M. Canto - M. Pascal

FR10151 Incidence rates of skin cancers during exposure to intravenous and subcutaneous abatacept in patients with rheumatoid arthritis: results from pooled clinical trial data / T. A. Simon* - C. Ponsot - M. Hochberg - M. Boers on behalf of Abatacept Epidemiology and Safety Panel


* Presenting author.


FR10158 SAFETY OF BIOLOGIC AGENTS IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS / A. Murota* - Y. Kaneko - K. Yamaoka - T. Takeuchi


FR10161 A PHASE 1B/2A STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XmAb5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. Jaraczewska-Baumann - M. Korkosz - G. Sulyok - P. Sramek - B. Rojkovich - S. Daniluk - J. Bartalos - D. J. Zack* - P. Foster

FR10162 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY ASSOCIATED WITH BIOLOGIC THERAPY IN RHEUMATIC DISEASES: STRENGTHENING ASSOCIATION WITH RITUXIMAB / E. Molloy* - L. Calabrese


FR10172 COMMONPLACE THOUGH NOT APPROVED - MONOTHERAPY WITH BIOLOGICS. DATA FROM THE AUSTRIAN BIOREG REGISTRY / M. Herold* - G. Eichbauer-Sturm - R. Puchner - B. Rintelen - F. Singer - B. Leeb on behalf of BIOREG


FR10174 THE CLINICAL OUTCOME OF ABATACEPT THERAPY IN SINGLE BIOLOGIC FAILURE AND MULTIPLE BIOLOGIC FAILURE WITH RHEUMATOID ARTHRITIS PATIENTS - RESULTS FROM JAPANESE MULTI CENTER REGISTRY SYSTEM / M. Hanabayashi* - N. Takahashi - H. Miyake - Y. Yokota - T. Kojima - N. Ishiguro on behalf of TBCR study group


* Presenting author
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI0176</td>
<td>ABBT-122, A NOVEL DUAL VARIABLE DOMAIN (DvD)-IG™, TARGETING TNF AND IL-17, INHIBITS PERIPHERAL</td>
<td>M. Ruiz* ** - D. Conlon - H. Mansikka -</td>
</tr>
<tr>
<td></td>
<td>BLOOD MONONUCLEAR CELL PRODUCTION OF GM-CSF AND DECREASES LYMPHOCYTE EXPRESSION OF</td>
<td>R. J. Padley - C. Cuff</td>
</tr>
<tr>
<td>FRI0177</td>
<td>ANALYSIS OF EFFECTIVENESS, SAFETY AND COST OF DIFFERENT DOSES OF RITUXIMAB IN A COHORT OF</td>
<td>M. C. Ordoñez-Calizares - C. Domic -</td>
</tr>
<tr>
<td></td>
<td>PATIENTS WITH RHEUMATOID ARTHRITIS / M. Nena-Vazquez* ** - S. Manrique-Arija - M. C.</td>
<td>L. Ureña-Garnica - C. M. Romero Barco -</td>
</tr>
<tr>
<td></td>
<td>Ordoñez-Calizares - C. Domic - L. Ureña-Garnica - C. M. Romero Barco - F. G. Jiménez-Núñez -</td>
<td>M. Rojas-Giménez - C. Fuego - L. Cano-</td>
</tr>
<tr>
<td>FRI0178</td>
<td>POSITIVITY FOR RHEUMATOID FACTOR IS ASSOCIATED WITH A BETTER SHORT-TERM RESPONSE AND LONG-TERM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TERM DRUG RETENTION OF ABATACEPT: RESULTS FROM CONSECUTIVE 508 PATIENTS WITH RHEUMATOID</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ARTHRITIS IN A JAPANESE MULTICENTER REGISTRY / N. Takahashi* ** - T. Kojima - K. Funahashi -</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N. Ishiguro on behalf of TBCR study group</td>
<td></td>
</tr>
<tr>
<td>FRI0179</td>
<td>REDUCTION IN COMPLEMENT C3 AND C4 LEVELS GREATER WITH TOCILIZUMAB AS COMPARED TO ANTI-TNF</td>
<td></td>
</tr>
<tr>
<td>FRI0180</td>
<td>CORRELATION BETWEEN CLINOMETRIC APPROACH AND GERMAN US7 SCORE IN RHEUMATOID ARTHRITIS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PATIENTS TREATED WITH TOCILIZUMAB: A PILOT STUDY / R. Terenzii* ** - G. Santoboni - E.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bartoloni - A. Alunno - F. Luccioli - R. Gerli</td>
<td></td>
</tr>
<tr>
<td>FRI0181</td>
<td>CHANGE FROM SC TO IV ABATECEPT AND BACK IN PATIENTS WITH RHEUMATOID ARTHRITIS AS SIMULATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gengenbacher - S. Richter - J. Dudler - B. Möller - J. von Kemptis</td>
<td></td>
</tr>
<tr>
<td>FRI0182</td>
<td>COMORRIDITIES INFLUENCE THE CHOICE OF THE BIOLOGIC AGENT: REAL LIFE DATA FROM THE LORHEN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>REGISTRY / S. Monti* ** - R. Gorfa - P. Sarzi-Puttini - F. Atzeni - R. Pellerito - E. Fusoaro-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>G. Paolazzi - P. A. Rocchetta - E. Favalli - A. Marchesoni - R. Caporali</td>
<td></td>
</tr>
<tr>
<td>FRI0183</td>
<td>CHARACTERISTIC CHANGES IN HISTOPATHOLOGY OF SYNOVIAL TISSUES FROM PATIENTS WITH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tomita - H. Yoshikawa</td>
<td></td>
</tr>
<tr>
<td>FRI0184</td>
<td>ENDODERMAL CELLS AS A POTENTIAL OBJECT IN CELLULAR IMMUNOTHERAPY IN RHEUMATOID ARTHRITIS / S.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sennikov</td>
<td></td>
</tr>
<tr>
<td>FRI0185</td>
<td>IMPACT OF TOCILIZUMAB ON NEUTROPHIL SURVIVAL AND FUNCTION / T. Gaber* ** - M. Hahne - C. Strehl-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>P. Hoff - Y. Dörfel - E. Feist - G. Burmester - F. Buttgerit</td>
<td></td>
</tr>
<tr>
<td>FRI0186</td>
<td>IMPACT OF CONCONMITANT METOTREXATE DOSE ON THE EFFICACY AND SAFETY OF SARILUMAB FOR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TREATMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: THE MOBILITY STUDY / T. W. I. Huizinga*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Y. Yazici - D. Thompson - D. L. Decktor - C. Fan - R. Fleischmann</td>
<td></td>
</tr>
<tr>
<td>FRI0187</td>
<td>RITUXIMAB DONE! WHAT’S NEXT IN RHEUMATOID ARTHRITIS? - A EUROPEAN OBSERVATIONAL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LONGITUDINAL STUDY ASSESSING THE EFFECTIVENESS OF BIOLOGICS AFTER RITUXIMAB TREATMENT IN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>E.-M. Hauge</td>
<td></td>
</tr>
<tr>
<td>FRI0188</td>
<td>PATIENTS’ CONCERNS ABOUT BIOLOGIC AGENTS IN RHEUMATOLOGY / Y. Pehlivan* ** - S. Pehlivan - N.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Orucoglu - E. Dalkilic</td>
<td></td>
</tr>
<tr>
<td>FRI0189</td>
<td>COMPARISON OF GENE-EXPRESSION MODIFICATION PROFILES BETWEEN TARGETING IL-6 AND TARGETING JAK</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TREATMENT: EFFECTING COMMON BIOLOGICAL PROCESSES OR DISPARATE? / Y. Koyama* ** - K. Numata -</td>
<td></td>
</tr>
<tr>
<td></td>
<td>S. Nakamura - S. Nagano - T. Ota - T. Higure</td>
<td></td>
</tr>
</tbody>
</table>

**Spondyloarthritis - etiology, pathogenesis and animal models**

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI0190</td>
<td>ROLE OF LEUKOCYTE SUBSETS IN THE INFLAMMATORY, OXIDATIVE STRESS AND BONE TURNOVER IN ANKYLOSING</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Perez-Sanchez - N. Barbarroja - M. D. C. Castro-Villegas - J. Calvo - M. D. C. Abalos-Aguilera -</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Escudero-Contreras - E. Collantes-Estevez</td>
<td></td>
</tr>
<tr>
<td>FRI0191</td>
<td>IL17 PRODUCING NON-T CELL IN PATIENTS WITH ENTEROPATHIC SPONDYLOARTHROPATHY: THE ASSOCIATION</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WITH DISEASE ACTIVITY / P. Triggianese* ** - P. Conigliaro - M. S. Chimenti - E. Ballanti - R.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Perricone - L. Biancone - F. Pallone - G. Monteleone - I. Monteleone</td>
<td></td>
</tr>
<tr>
<td>FRI0192</td>
<td>EFFECT OF TNF BLOCKING THERAPY ON OSTEOCLASTS FROM ANKYLOSING SPONDYLITIS PATIENTS / I. P.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ponte - H. Canhão - M. Ainoa - J. E. Fonseca</td>
<td></td>
</tr>
<tr>
<td>FRI0193</td>
<td>OSTEOSTALS PROMOTE NEW BONE FORMATION AT SITES OF CARTILAGE AND BONE EROSIONS WHILE FAT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MARROW IS FOUND WITHIN THE SUBCHONDRAL BONE MARROW IN ANKYLOSING SPONDYLITIS / J. Blel - R.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maier - A. Hempfing - J. Sieper - H. Appel - U. Sybre*</td>
<td></td>
</tr>
<tr>
<td>FRI0194</td>
<td>IS THERE AN ASSOCIATION BETWEEN Spondyloarthritis And Antibodies Towards Borellia, Ehrlichia</td>
<td></td>
</tr>
<tr>
<td>FRI0195</td>
<td>ERAPI ALLOTYPES AND DISEASE SEVERITY IN ANKYLOSING SPONDYLITIS / W. Fong* ** - E. Reeves - W.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tim - T. Elliot - E. James - C. J. Edwards</td>
<td></td>
</tr>
<tr>
<td>FRI0196</td>
<td>CCR2 EXPRESSION WAS INCREASED IN PATIENTS WITH ANKYLOSING SPONDYLITIS INDEPENDENT FROM</td>
<td></td>
</tr>
<tr>
<td></td>
<td>DISEASE ACTIVITY / D. Sollma** ** - A. Tekinalp - O. Avci - B. Turgut</td>
<td></td>
</tr>
<tr>
<td>FRI0197</td>
<td>ROLE OF ARGINASE IN A CELLULAR AND MURINE MODEL OF ENDOCHONDRAL OSSIFICATION / C. Prati* **</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- F. Cailotto - K. Heritage - D. Wendling - R. Lories</td>
<td></td>
</tr>
</tbody>
</table>

* Presenting author
Spondyloarthritis - clinical aspects (other than treatment)  

Hall 6


FRI0200  ASSOCIATION OF SERUM DKK-1 AND SCEROSTIN LEVELS WITH ACUTE PHASE REACTANTS AND CLINICAL AND RADIOGRAPHIC VARIABLES IN PATIENTS WITH ANKYLosing SPONDYLITIS / G. T. Sakellariou - M. Konsta - C. Berberidis - A. Ilipoulopou*

FRI0201  EFFICACY AND SAFETY OF SIMVASTATIN N UVEITIS ASSOCIATED WITH HLA27 AND/OR RHEUMATIC DISEASES: A RANDOMIZED, OPEN-LABEL STUDY / A. Biryukova* - I. Shirinsky - V. Shirinsky

FRI0202  THE RELATIONSHIP BETWEEN DISEASE ACTIVITY, FUNCTIONAL INDEX, SLEEP QUALITY, ANXIETY, DEPRESSION, FATIGUE AND QUALITY OF LIFE IN PATIENTS WITH ANKYLosing SPONDYLITIS / A. Ates* - F. Dorbats - Y. Karaaslan

FRI0203  IS PATIENT-PHYSICIAN DiscordANCE IN GLOBAL ASSESSMENT IN EARLY Spondyloarthritis Varying Over Time: The DESIR Cohort? / C. Desheux* - A. Molto - A. Sarauz - B. Fautrel - L. Gossec


FRI0206  PREVALENCE OF IRRITABLE BOWEL SYNDROME IN PATIENTS WITH ANKYLosing SPONDYLITIS / D. Solmaz* - O. Avci - O. Yıldırım - R. Mete


FRI0210  A LOWER FREQUENCY OF INFILAMMATORY BACK PAIN IN MALE PATIENTS WITH ANKYLosing SPONDYLITIS COMPARED WITH FEMALE PATIENTS / E. Onen* - D. Solmaz - G. Can - G. Kenar - P. Cetin - M. Birlik - N. Akkoc


FRI0213  TURKISH VERSION OF EASIQOL QUESTIONNAIRE IN PATIENTS WITH ANKYLosing SPONDYLITIS: A VALIDATION AND RELIABILITY STUDY / N. Öncülokur - D. Keskin - Y. Garip Çimen - H. Bodur* - K. Köse


FRI0215  VARIABILITY OVER TIME IN PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH ANKYLosing SPONDYLITIS / I. Essers* - M. Busch - A. Boonen - S. Ramiro - D. van der Heijde - R. Landewé - A. van Tubergen

FRI0216  OBLIQUE VIEW RADIOGRAPHS ARE BETTER IN DIAGNOSING SACROILIITIS / Z. Hu - M. Qiu - J. Qi - Q. Lv - Z. Lin - J. Gu*


FRI0218  STRUCTURAL DAMAGE DISTRIBUTION AT VERTEBRAL LEVEL IN PATIENTS WITH AXIAL SPONDYLARTHITIS / J. L. Garrido-Castro* - J. Calvo-Gutierrez - C. Gonzalez-Navas - P. Font-Ugalde - M. D. C. Castro-Villegas - E. Collantes-Estévez

FRI0219  HIGH DISEASE ACTIVITY IN AXIAL SPONDYLARTHITIS IS ASSOCIATED WITH REDUCED WORK PRODUCTIVITY / L. Van Hoeven* - A. Boonen - J. Hazes - A. Weel


FRI0223  EDUCATION ENHANCES REFERRAL AND RECOGNITION OF SPONDYLARTHITIS BY GENERAL PRACTITIONERS IN DAILY PRACTICE: A STUDY WITH UNANOUNCED STANDARDIZED PATIENTS / M. Van Onna* - S. Gorter - B. Maiburg - G. Waagenaar - A. van Tubergen

* Presenting author


PARADOXICAL ARTIFICIAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASES PATIENTS TREATED BY ANTI-TNF / P. Lasselin* - H. Thiebault - V. Goeb - J. L. Dupas - M. Fumery


SPONDYLODICTICIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A RETROSPECTIVE STUDY OF 16 CASES / R. Kaynar* - H. Sari - M. Uludag - N. Atarod

EVALUATIONS OF STATUS OF BONE MICROARCHITECTURAL STATUS OF THE LUMBAR SPINE IN ANKYLOSING SPONDYLITIS PATIENTS BY TRABECULAR BONE SCORE ASSESSMENT / S. Paolino* - G. Botticella - A. Casabella - D. Fasciolo - A. Sulli - M. Cutolo - B. Seriolo

PERFORMANCE CHARACTERISTICS OF SIMPLIFIED VERSION OF ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE (SASDAS) AND OTHER ACTIVITY INDEX / D. Solmaz - O. Avci - N. Tomas - S. Akar*


FRI0247  THE RELEASE OF NETS FROM MPO-AAV NEUTROPHILS WAS INCREASED BY ANTI-MPO ANTIBODY AND CORRELATED WITH DISEASE ACTIVITY / K. Murakami* - Y. Komagata - C. Mori - K. Fukuoaka - M. Karube - S. Kaname - Y. Arimura

FRI0248  BASELINE DATA ON PATIENTS IN GIACATA (TOCILIZUMAB IN GIANT CELL ARTERITIS) / K. Tuckwell - N. Collinson - M. Klearman - S. Dimonaco - J. H. Stone* on behalf of the GIACATA Investigators

FRI0249  IGAV SCORE - A FEASIBLE PREDICTOR OF IGA VASCULITIS SEVERITY / A. Hocevar* - Z. Rotar - A. Ambrožič - M. Plešivčnik Novljan - B. Lestan - S. Praprotnik - M. Tomšič


FRI0251  GLUCOCORTICOID USE AND ASSOCIATED ADVERSE EVENTS BASED ON INITIAL DAILY ORAL PREDNISONE DOSE IN BIOPSY-PROVEN GIANT CELL ARTERITIS / M. J. Koster* - C. Labarca - C. Crowson - A. Makol - S. Ytterberg - E. Matteson - K. Warrington


FRI0253  CLINICAL EFFICACY OF TOCILIZUMAB IN POLYMALGIA RHEUMATICA: AN OPEN-LABEL STUDY / E. Toussirot* - A. Martin - M. Soubrier - S. Redeker - A. Regent on behalf of Le CRI

FRI0254  PREDICTIVE FACTORS FOR THE RESPONSE TO INFLIIXIMAB THERAPY IN PATIENTS WITH BEHÇET’S DISEASE / S. D’Angelo* - P. Leccese - A. Padula - A. Nigro - M. Gilio - A. Carriero - C. Palazzi - I. Olivieri

FRI0255  PATIENTS TREATED FOR BEHÇET’S SYNDROME IN THE US HAVE HIGHER DISEASE ACTIVITY SCORES AT PRESENTATION IF THEY FULLFILL DIAGNOSTIC CRITERIA AND IF THEY ARE FEMALES / Y. Yazici* - H. Bernstein - C. Swearingen


FRI0257  LONG TERM FOLLOW-UP OF ANCA POSITIVE VASCULITIS PATIENTS. EVALUATION OF OUTCOME AND POTENTIAL CORRELATIONS / E. I. Kampljatka* - L. Pantazi - E. Gravani - K. A. Boki


FRI0261  PRACTICE WHAT YOU PREACH: ADHERENCE TO GUIDELINES IN THE TREATMENT OF BEHÇET’S SYNDROME IN NEW YORK AND THE NETHERLANDS / F. Kerstuk - S. Atalay - R. van Vugt - C. Swearingen - Y. Yazici


FRI0264  CARDIAC MANIFESTATIONS OF GRANULOMATOSIS WITH POLYANGIITIS AT DIAGNOSTIC / G. Pugnet* - X. Puéchal - P. Pillatre - B. Terrier - O. Decaux - L. Guilleuin


* Presenting author
Osteoporosis

FR10273
THE DIAGNOSTIC VALUE OF ULTRASOUND EXAMINATION OF OCULAR AND ORBITAL BLOOD FLOW IN PATIENTS WITH GIANT-CELL ARTERITIS / A. Meshkov - O. Eksarenko - D. Ismailova - P. Novikov* - S. Moisseyev - V. Fomin

FR10274

FR10275

FR10276

FR10277

FR10278
LIFE-THREATENING ONSET OF SYSTEMIC VASculITIS REQUIRING INTENSIVE CARE UNIT ADMISSION: A CASE SERIES / S. Monti* - L. Cavagna - S. Pieropan - C. Montecucco - R. Caporali

FR10279

FR10280

FR10281
PREDICTORS OF QUALITY OF LIFE IN BEHCET’S SYNDROME / S. Bozcan - Y. Ozguler* - C. Saygin - D. Uzunaslan - T. Tasciar - S. Ugurlu - G. Hatemi

FR10282
EXPERIENCE OF BIOLOGICAL AGENTS TREATMENT OF REFRACTORY TAKAYASU ARTERITIS IN CHILDREN / Y. Kostina* - G. Lyskina

Osteoporosis

Hall 6

FR10283
LONG-TERM ADHERENCE TO TREATMENT IN A FRACTURE LIAISON SERVICE COORDINATED BY RHEUMATOLOGIST AND NURSE / A. Naranjo* - S. Ojeda-Bruno - A. Bilbao-Cantarero - S. Rodriguez-Moreno - B. V. Diaz-González - J. C. Quevedo Abeledo - C. Rodriguez-Lozano on behalf of Fracture Liaison Service Gran Canaria Norte

FR10284
INFLUENCE OF VERTEBRAL FRACTURE SEVERITY AND PELVIC PARAMETERS ON GLOBAL SPINAL BALANCE IN OSTEOPOROTIC PATIENTS / J. Fechtenbaum* - K. Briot - A. Etcheto - S. Kolta - A. Feydy - C. Roux

FR10285
THE EFFECT OF STEROIDS ON FRACTURE, ADJUSTING FOR BONE MINERAL DENSITY / M. Bukhari* - N. Goodman - M. Boers

FR10286
CARDIOVASCULAR RISK AND BONE LOSS IN PATIENTS WITH EROSIVE AND NON-EROISIVE HAND OSTEOPAETHRITIS / O. Ruzickova* - O. Sleglova

FR10287

FR10288
ROLE OF PHYSICAL EXERCISE PROGRAM IN PATIENTS WITH OSTEOPOROSIS / R. I. Marcu* - S. Patru - A. C. Bighea - R. Traistaru - R. S. Popescu

FR10289

FR10290
COMORBIDITIES IN OSTEOPOROTIC PATIENTS: A RETROSPECTIVE STUDY / A. M. Ata - F. Y. G. Kutsal*

FR10291
DECREASE IN ANTI-OSTEOPOROTIC DRUGS PRESCRIPTIONS: IS THERE AN IMMEDIATE CONSEQUENCE ON HIP FRACTURE INCIDENCE? / K. Briot* - M. Maravic - C. Roux

FR10292

FR10293

FR10294

FR10295

FR10296

FR10297

FR10298

* Presenting author
Bone diseases other than osteoporosis, metabolic diseases and crystal diseases  

Hall 6


FR1031  ASSESSMENT OF THE EFFECT OF 12 MONTHS ADMINISTRATION OF DENOSUMAB IN PATIENTS WITH RHEUMATIC DISEASES - BONE MINERAL DENSITY INCREASE IN LUMBAR SPINE IS NEGATIVELY CORRELATED WITH BASELINE ORAL PREDNISOLONE DOSE AND PREDICTED BY DECREASING RATE OF SERUM UNDERCARBOXYLATED OSTEOCALCIN AT 6 MONTHS / K. Ebina* - J. Hashimoto - M. Hirao - K. Hagihara - T. Noguchi - H. Yoshikawa

FR1032  ANALYSIS OF THE DEFRA ALGORITHM FOR DEFINITION OF RISK FRACTURE / L. Wolenski* - B. Frediani - A. Marchi

FR1033  THE EFFECT OF SECONDARY AMENORRHOEA ON BONE MINERAL DENSITY / L. Skelly* - A. Oldroyd - A. Blanshard - M. Buhkari


FR1035  PHYSICIAN’S PERSPECTIVE ON THE REASONS FOR NON-TREATMENT OF OSTEOPOORISMS AMONG POSTMENOPAUSAL PATIENTS IN FRANCE - AN OBSERVATIONAL STUDY / K. Olsson - R. Sadasivan* - J. Weaver - S. Sen - A. Modi


FR1037  BONE MINERAL DENSITY, SPINAL MICRO-ARCHITECTURE (TBS DATA) AND BODY COMPOSITION IN THE OLDER UKRAINIAN WOMEN WITH VERTEBRAL FRACTILITY FRACTURES / V. Povoroznyuk* - N. Dzerovych - R. Povoroznyuk

FR1038  GENDER FEATURES OF VERTEBRAL PAIN SYNDROME DEPENDING ON BONE MINERAL DENSITY / V. Povoroznyuk* - T. Orlyk
FRI0322  CANONINIMUMAB IN PATIENTS WITH CHRONIC TOPHACEOUS GOUT: RESISTANT TO CURRENT TREATMENT OPTIONS / M. S. Eliseev* - O. V. Zhelyabina - M. V. Mukagova - E. Nasonov

FRI0323  CRONIC NON-BACTERIAL OSTEOMYELITIS (CNO) IN A COHORT OF PEDIASTRIC PATIENTS: CLINICAL, BIOLOGICAL AND RADIOLOGICAL RESPONSE TO TREATMENT WITH ANAKINRA / M. Pardeo* - D. P. Marafon - V. Messia - R. Nicolai - C. Bracaglia - F. De Benedetti - A. Insalaco

FRI0324  DOES HIGH SERUM URIC ACID INCREASE THE RISK OF RENAL DISEASE IN PATIENTS WITH GOUT? RESULTS FROM A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORD DATA / M. N. Essex* - M. Hoppes - M. Udall - C. Fu - E. J. Bienen - J. Mardekin - G. Makinson

FRI0325  SILENT DEPOSIT OF MSU CRYSTALS ASSOCIATES WITH A MORE SEVERE CORONARY CALCIFICATION IN ASYMPTOMATIC HYPERURICEMIC PATIENTS WITH ACUTE CORONARY SYNDROME / M. Andres* - M. A. Quintanilla - F. Sivera - P. Vela - J. M. A. Ruiz-Nodar

FRI0326  10 YEAR RISK OF CVD EVENT IN GOUTY PATIENTS: THE CORRELATION WITH HEALTH RELATED QUALITY OF LIFE / M. M. Radak Perovic* - M. M. Todorovic

FRI0327  FEBUXOSTAT APPEARS EFFECTIVE AND SAFE IN GOUT PATIENTS WITH SEVERE CHRONIC KIDNEY DISEASE / N. Quilis* - S. Gil - M. Andres - P. Vela - E. Pascual

FRI0328  A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY TO EVALUATE THE EFFECT OF FEBUXOSTAT VERSUS PLACEBO ON JOINT DAMAGE IN HYPERURICEMIC SUBJECTS WITH EARLY GOUT / N. Dalbeth* - K. Saag - W. Palmer - H. Choi - C. Li - P. MacDonald - U. Thienel - L. Gunawardhana

FRI0329  A STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ARHALOFENATE IN COMBINATION WITH FEBUXOSTAT WHEN TREATING HYPERURICEMIA ASSOCIATED WITH GOUT / A. Steinberg - B. Vince - Y. J. Choi - R. Martin - C. McWerther - P. Boudes*

FRI0330  SAFETY AND EFFICACY OF CANONINUMAB IN PATIENTS AT RISK OF FLARING GOUTY ARTHRITIS PATIENTS WHO ARE CONTRAINDICATED, INTOLERANT OR UNRESPONSIVE TO NON-Steroidal ANTI-INFLAMMATORY DRUGS AND/OR COLCHICINE: RESULTS FROM 3 YEARS FOLLOW-UP / R. Alten* - T. Bardin - M. Bloch - K. Lheritier - U. Machein - G. Junge - A. So - N. Schlesinger


FRI0332  NORMALIZATION OF SERUM URIC ACID LEVELS AFTER ALLOGENEIC HEMATOLOGIC STEM CELL TRANSPLANTATION / S. H. Joo* - Y. W. Song - S.-S. Yoon - J. K. Park

FRI0333  LESINURAD, A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN COMBINATION WITH ALLOPURINOL: RESULTS FROM A PHASE III STUDY IN GOUT PATIENTS HAVING AN INADEQUATE RESPONSE TO STANDARD OF CARE (CLEAR 2) / T. Bardin* - R. Keenan - P. Khanna - J. Kopicko - M. Fung - N. Bhakta - S. Adler - C. Storgard - S. Baumgartner - A. So

FRI0334  THE EFFECT OF URATE-LOWERING THERAPY ON THE RADIOGRAPHIC CHANGES IN PATIENTS WITH GOUT / Y. H. Eun* - S. Lee - E.-J. Park - J. Hwang - J. Lee - H.-S. Cha - E.-M. Koh

Epidemiology, health services and outcome research

Hall 6


FRI0336  DISEASE ACTIVITY PATTERNS IN RHEUMATOID ARTHRITIS IN THE FIRST 3-YEARS OF FOLLOW-UP IN USUAL CARE: MARKOV MODELING SHOWS RAPID IMPROVEMENT IN DAS28 STATES IN THE 1ST YEAR FOLLOWED BY STABLE STATES IN THE LAST 2 YEARS. RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / M. Tatangelo* - G. Tomlinson - B. Kuriya - C. Bombardier

FRI0337  ASSOCIATION BETWEEN SERUM URIC ACID LEVELS AND CARDIOVASCULAR RISK. A POST HOC ANALYSIS OF THE EUROPEAN CARDIOVASCULAR RISK PATIENTS: DISEASE PREVENTION AND MANAGEMENT IN USUAL CARE: MARKOV MODELING SHOWS RAPID IMPROVEMENT IN DAS28 STATES IN THE 1ST YEAR FOLLOWED BY STABLE STATES IN THE LAST 2 YEARS. RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / M. Tatangelo* - G. Tomlinson - B. Kuriya - C. Bombardier

FRI0338  DISEASE ACTIVITY PATTERNS IN RHEUMATOID ARTHRITIS IN THE FIRST 3-YEARS OF FOLLOW-UP IN USUAL CARE: MARKOV MODELING SHOWS RAPID IMPROVEMENT IN DAS28 STATES IN THE 1ST YEAR FOLLOWED BY STABLE STATES IN THE LAST 2 YEARS. RESULTS FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI) / M. Tatangelo* - G. Tomlinson - B. Kuriya - C. Bombardier


FRI0340  COMPARING THREE ADHERENCE MEASURES IN EARLY ARTHRITIS PATIENTS / A. Pasma* - E. den Boer - C. Enger - J. Iles - M. S. Anthony


FRI0342  MEASURING PAIN INTENSITY IN OLDER ADULTS WITH MULTISITE PERIPHERAL JOINT PAIN USING A COMPOSITE SCORE / A. Finney* - K. Driedzic - M. Lewis - S. Ryan - E. Healey


* Presenting author

FRI0346 EVALUATION STUDY FOR SELF MANAGEMENT OF PATIENTS WITH ANKYLOSING Spondylitis (AS) THROUGH A PERSONAL HEALTH SYSTEM / M. Gencturk* - O. Eren - M. Yuksel

FRI0347 RISK OF CARDIO- AND CEREBRO-VASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TREATMENT WITH TOCILIZUMAB OR ETANERCEPT: RETROSPECTIVE COHORT STUDY ON HEALTH ADMINISTRATIVE DATABASES OF THE ITALIAN SOCIETY FOR RHEUMATOLOGY (SIR) / G. Carrara* - E. Generali - C. Selmi - C. A. Scirè on behalf of RECORD

FRI0348 COST COMPARISON OF ABATACEPT AND ADALIMUMAB BASED ON AMPLEx A 2-YEAR HEAD-TO-HEAD OUTCOMES STUDY IN RHEUMATOID ARTHRITIS / J. Gaulney* - D. Budd - C. Nappi - M. Benucci - S. Iannazzo - E. Alemão - J. Sabater

FRI0349 ASSOCIATIONS BETWEEN SERUM BIOMARKERS OF AND LIFESTYLE RISK FACTORS FOR INFLAMMATORY ARTHRITIS IN FIRST DEGREE RELATIVES OF PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THE PRE-CLINICAL EVALUATION OF NOVEL TARGETS IN RA (PREVENT RA) STUDY / J. C. Sergeant* on behalf of RA-MAP Consortium


FRI0351 OCCUPATION AND RISK OF SICK LEAVE AND DISABILITY PENSION DUE TO KNEE AND HIP OSTEARTHritIS in Men and Women / J. Hubertsson* - A. Turkiewicz - I. Petersson - M. Englund


FRI0354 THE PATIENT TRAJECTORY FROM SYMPTOM ONSET UNTIL REFERRAL TO A RHEUMATOLOGIST* / D. Peerboom - K. van der Elst* - D. De Cock - V. Stouten - S. Meyfroidt - J. Joly - R. Westhovens - P. Verschueren on behalf of the CareRA study group


FRI0357 PATIENTS WITH OSTEARTHritIS REPORT SYMMETRICAL PAINFUL JOINTS IN SIMILAR NUMBERS AND DISTRIBUTION AS PATIENTS WITH RHEUMATOID ARTHRITIS / M. J. Bergman* - I. Castrejon - K. A. Gibson - C. El-Haddad - A. Huang - T. Pincus


FRI0359 TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION AMONG PATIENTS WITH PSORIATIC DISEASE IN A LARGE NATIONAL CLAIMS DATABASE / M.-A. Hur* - J. Harnett - B. Emir - L. Mallbris - W. Ports - C. Mamolo


FRI0362 RAPID ACQUISITION OF DATA ON THE PATIENT PERSPECTIVE IN RHEUMATOID ARTHRITIS THROUGH A PERSONAL HEALTH SYSTEM / M. Gencturk* - O. Eren - M. Yuksel


FRI0364 REAL-WORLD INCIDENCE OF BIOLOGIC DOSE ESCALATION AND IMPACT ON BIOLOGIC COSTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH INTRAVENOUS AGENTS ABATACEPT, INFLIXIMAB OR TOCILIZUMAB / R. Fowler* - D. McMorrow - D. Smith - A. Nadkarni


FRI0366 FROM SYMPTOM ONSET TO EFFECTIVE EARLY RHEUMATOID ARTHRITIS CARE: THE GENERAL PRACTITIONERS’ PERSPECTIVE / S. Meyfroidt* - J. Stevens - J. De Lepeleire - R. Westhovens - D. De Cock - K. van der Elst - K. Vanhaecht - P. Verschueren

* Presenting author
<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI0370</td>
<td>Development of two novel patient reported outcome (PRO) measures: The systemic lupus erythematosus (SLE) symptom severity diary (SSD) and SLE impact questionnaire (SIQ)</td>
<td>S. D. Mathias* - P. Berry - J. dez - G. A. Askanase - K. Pascoe - H. Colwell - D. Chang</td>
<td></td>
</tr>
</tbody>
</table>

### SLE, Sjögren's and APS - etiology, pathogenesis and animal models

**Hall 5**

<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI0373</td>
<td>Characterization of the microparticles in the plasma and urine of patients affected by SLE: Clinical and laboratory relationships</td>
<td>F. Miranda* - C. Barbati - C. Alessandro - F. R. Spinelli - F. Ceccarelli - S. Truglia - E. Marocchi - F. Conti</td>
<td></td>
</tr>
<tr>
<td>FRI0378</td>
<td>The role of monocyte subsets in systemic lupus erythematosus pathogenesis</td>
<td>E. M. McCarthy* - G. Kearns - C. Jefferies</td>
<td></td>
</tr>
<tr>
<td>FRI0380</td>
<td>Characterization of the microparticles in the plasma and urine of patients affected by SLE: Clinical and laboratory relationships</td>
<td>F. Miranda* - C. Barbati - C. Alessandro - F. R. Spinelli - F. Ceccarelli - S. Truglia - E. Marocchi - F. Conti</td>
<td></td>
</tr>
<tr>
<td>FRI0384</td>
<td>The role of monocyte subsets in systemic lupus erythematosus pathogenesis</td>
<td>E. M. McCarthy* - G. Kearns - C. Jefferies</td>
<td></td>
</tr>
<tr>
<td>FRI0386</td>
<td>Characterization of the microparticles in the plasma and urine of patients affected by SLE: Clinical and laboratory relationships</td>
<td>F. Miranda - C. Barbati - C. Alessandro - F. R. Spinelli - F. Ceccarelli - S. Truglia - E. Marocchi - F. Conti</td>
<td></td>
</tr>
</tbody>
</table>

### SLE, Sjögren’s and APS - clinical aspects (other than treatment)

**Hall 5**

<table>
<thead>
<tr>
<th>Presentation ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRI0384</td>
<td>Usefulness of brain MRI in early lupus: How the morphological imaging changes at onset of the disease and after follow-up</td>
<td>E. Silvagni* - A. Bortoluzzi - M. Padovan - F. Furini - M. Borrelli - M. Gavoni</td>
<td></td>
</tr>
<tr>
<td>FRI0385</td>
<td>UCTD and progression to SLE. Analysis of a wide monocentric cohort with a long follow-up</td>
<td>A. Bortoluzzi* - F. Furini - F. Campanaro - M. Padovan - M. Gavoni</td>
<td></td>
</tr>
<tr>
<td>FRI0387</td>
<td>Association of pre-pregnancy body mass index with preterm birth and birthweight percentiles in systemic lupus erythematosus</td>
<td>A. Eudy* - A. M. Siega-Riz - S. Engel - N. Franceschini - A. G. Howard - M. Colwell - D. Chang</td>
<td></td>
</tr>
<tr>
<td>FRI0388</td>
<td>Monitoring local therapy in sjögren’s syndrome with virtual touch tissue quantification</td>
<td>H. Hofauer* - M. Bas - C. Heiser - J. Schukraft - N. Mansour - A. Knopf</td>
<td></td>
</tr>
</tbody>
</table>

* Presenting author


FR10392 IS PREGNANCY A RISK FACTOR FOR THE ONSET OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN WOMEN OF THE REPRODUCTIVE AGES: A POPULATION BASED CASE-CONTROL STUDY? / C. C. Mok* - S. M. Tse - L. Y. Ho

FR10393 STANDARDIZED INCIDENCE RATIO (SIR), TIME TREND AND RISK FACTORS OF AVASCULAR BONE NECROSIS (AVN) IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) / S. M. Tse - C. C. Mok* - L. Y. Ho

FR10394 DIAGNOSTIC ACCURACY OF SALIVARY GLAND ULTRASONOGRAPHY IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ASSOCIATED SJÖGREN'S SYNDROME / C. Baldini* - N. Luciano - F. Ferro - F. Sernissi - D. Martini - M. Cagnoni - M. Mosca - S. Bombardieri

FR10395 ANTI-N-METHYL-D-ASPARTATE RECEPTOR ANTIBODY IS ASSOCIATED WITH FIBROMYALGIA IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / D. J. Park* - J.-W. Lee - K.-E. Lee - S.-S. Lee


FR10397 OBSTRUCTIVE AIRWAY SYMPTOMS (OAS) PRECEDE THE ONSET AND DIAGNOSIS OF PRIMARY SJÖGREN'S SYNDROME (PSS) BY MANY YEARS / E. Theander* - T. Mandl - C. Turesson - P. Olsson


FR10405 PREDNISONE INCREASES BOTH ARTERIAL AND VENOUS THROMBOSIS IN SLE / K. Hickman* - L. Magder - M. Petri

FR10406 SMALL LDL-P INCREASES WITH INCREASED DISEASE ACTIVITY IN SLE / L. J. Durcan* - D. Winegar - M. A. Connelly - J. Otvos - L. Magder - M. Petri

FR10407 ANTIPHOSPHOLIPID ANTIBODIES AS INDEPENDENT PREDICTORS OF ACCELERATE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / L. Stojanovich* - A. Djokovic - B. Todic - S. Radovanovic


FR10412 SYMPTOMS OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / Y. Gao - Y. Lo - M. Y. Mok*


* Presenting author
Scleroderma, myositis and related syndromes - clinical aspects and treatment

Hall 5

**FR10435**

**FR10436**

**FR10437**

**FR10438**
TREATMENT WITH ABATACEPT PREVENTS EXPERIMENTAL DERMAL FIBROSIS AND INDUCES RERESSION OF ESTABLISHED FIBROSIS IN A PRECLINICAL MODEL OF SYSTEMIC SCLEROSIS / M. Ponsoye - C. Frantz - N. Ruzehaji - M. Elhai - B. Ruiz - A. Cauvet - Y. Allanore - J. Avouac*

**FR10439**

**FR10440**

**FR10441**
MICRORNA-34A UNBALANCE IS ASSOCIATED TO IL-6/IL-6R PATHWAY IN CD14 CELLS AND SKIN COMPARTMENT OF SYSTEMIC SCLEROSIS PATIENTS / S. Alivernini* - S. L. Bosello - M. Kurowska-Stolarska - S. Canestri - L. Bui - M. M. Fabrizi - B. Toluso - I. B. Mclnnes - G. Ferraccioli

**FR10442**
PROGNOSTIC ROLE OF EXHALED BREATH CONDENSATE IN PATIENTS WITH PULMONARY INVOLVEMENT ASSOCIATED TO SYSTEMIC SCLEROSIS / A. Guillet-Del Castillo* - S. Sánchez-Vidaurre - C. P. Simeon-Aznar - M. J. Cruz - V. Fonollosa-Pla - F. Morell - X. Muñoz

* Presenting author


NORMAL PATTERNS OF NAILFOLD VIDEOCAPILLAROSCOPY IN HEALTHY CHILDREN AND ADOLESCENTS BASED ON DIFFERENT AGE RANGES / D. G. P. Piotti* - J. Sekiyama - C. Kayser - M. Yamada - C. Len - M. T. Terreri


ANIMAL (PET)-ASSISTED THERAPY HELPS IN REDUCING PAIN AND PROMOTES SOCIAL-AFFECTIVE REGULATION IN SYSTEMIC SCLEROSIS (SSC) / G. Fiori* - F. Bartoli - T. Marzi - M. Galimberti - M. Palomba - E. Corsi - M. Zolférito - C. Ciceroni - M. Matucci Cerinic


WORK DISABILITY IN EARLY SYSTEMIC SCLEROSIS: A LONGITUDINAL POPULATION-BASED COHORT STUDY / G. Sandqvist* - R. Hesselstrand - I. F. Petersson - L. E. Kristensen


AN OBSERVATIONAL STUDY OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN THE TREATMENT OF GASTROINTESTINAL INVOLVEMENT IN SYSTEMIC SCLEROSIS / J. Raja* - S. I. Nihtyanova - V. P. Denton - C. C. Derrett-Smith - C. P. Denton


* Presenting author

FR10478 SOLUBLE VASCULAR CELL ADHESION MOLECULE-1 IS OVEREXPRESSED AS A DISEASE MARKER IN PATIENTS WITH FIRST-TIME DIAGNOSED ANTINUCLEAR ANTIBODIES AND SIGNIFICANTLY DECREASES AFTER IMMUNOSUPPRESSION IN PATIENTS WITH SYSTEMIC SCLEROSIS / M. Oleszowsky* - M. F. Seidel


FR10481 INCREASED CASPASE-3 ACTIVITY IN THE STOMACH TISSUE CORRELATES WITH DISEASE ACTIVITY AND SEVERITY IN SYSTEMIC SCLEROSIS PATIENTS - A PILOT STUDY / M. Radić* - K. Borić - S. Mardešić - I. Tadin - D. Martinovic Kaliterna


FR10485 PRELIMINARY ANALYSIS OF A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH RITUXIMAB AND MYOCYPHENOLET MOFETIL / P. Fratticelli* - C. Fischetti - L. Manfredi - L. Alban - M. Mattioli - A. Gabrielli


FR10489 IMPROVEMENT OF LOWER ESOPHAGEAL SPhINcTER FUNCTION IN SYSTEMIC SCLEROSIS AFTER LONG TERM ADMINISTRATION OF BUSPIRONE, AN ORALLY AVAILABLE 5-HT1A RECEPTOR AGONIST: A 4-WEEK PILOT STUDY / S. Panopoulos* - G. Karamanolis - K. Denaxas - A. Zorbala - P. P. Sfikakis


FR10494 STEROID-SPARING EFFECT OF ANAKINRA (KINERET®) IN THE TREATMENT OF PATIENTS WITH SEVERE CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES / T. Kullenberg* - B. Hallén - H. Olivecrona - M. Leinonen


FR10496 EFFICACY AND SAFETY OF CANAKINUMAB IN CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS WITH AND WITHOUT FEVER / N. Ruperto* - H. Brunner - P. Quartier - T. Constantin - E. Alexeeva - I. Kone-Paut - M. A. Gonzalez-Gay on behalf of PRINTO/PRCSG


FR10506 CLINICAL PRESENTATIONS, OUTCOMES OF JUVENILE DERMATOMYOSITIS PATIENTS ADMITTED IN THE PAEDIATRIC INTENSIVE CARE UNIT / A. Besançon - C. Gitiaux - K. Brochard - L. Dupic - P. Quartier - C. Bodemer - B. Bader-Meunier


FR10508 CLINICAL PRESENTATIONS, OUTCOMES OF JUVENILE DERMATOMYOSITIS PATIENTS ADMITTED IN THE PAEDIATRIC INTENSIVE CARE UNIT / A. Besançon - C. Gitiaux - K. Brochard - L. Dupic - P. Quartier - C. Bodemer - B. Bader-Meunier


FR10511 CARBOXIVASCULAR RISK FACTORS IN JUVENILE IDIOPATHIC ARTHRITIS / E. Jednacz* - L. Ruzkowska-Sak


FR10513 THE SUCCESSFUL USE OF RITUXIMAB IN THREE PATIENTS WITH JUVENILE SYSTEMIC SCLEROSIS / D. Aleksiev* - I. Nikishina - L. Ananjeva - N. Kuzmina

FR10514 CARDIOVASCULAR RISK FACTORS IN JUVENILE IDIOPATHIC ARTHRITIS / E. Jednacz* - L. Ruzkowska-Sak


FR10521 SERUM AMYLOID A IN FAMILIAL MEDITERRANEAN FEVER: HOW MUCH IMPORTANT? / K. Ozturk* - Z. Ekinci

* Presenting author
FR10522  EARLY SLICC/ACR DAMAGE INDEX IN ADOLESCENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS / L. F. Bogmat*
- N. S. Shchonchenko - E. V. Matvienko
FR10523  CLINICAL VALUE OF SERUM ANTI-C1Q ANTIBODIES AS A MARKER FOR NEPHRISIS ACTIVITY IN PAEDIATRIC PATIENTS WITH SLE IN COMPARISON TO ANTI-DSDNA / M. Helal* - N. A. E. M. Hussein - M. M. E. D. El Kersh - D. M. F. Mohaseb - M. M. El Bardawil - M. M. El Sawy
FR10524  JUVENILE DERMATOMYOSITIS (DM) WITH NORMAL CREATINE KINASE / L. Timpone - C. Forni - F. Fontana - F. Orlando - C. Brin - M. Alessio*
FR10525  EARLY SACROILIITIS AND PROGRESSION TO ANKYLosing SPONDYLITIS IS ASSOCIATED TO POSITIVE HLA-B27 IN JUVENILE SPONDYLOARTHITIS / M. O. Perez* - N. E. Aikawa - S. Carrasco - C. G. Saad - P. D. Sampaio-Barros - C. R. Gonçalves - J. C. B. Moraes - C. Goldenstein-Schaimberg
FR10528  DIAGNOSTIC ACCURACY OF MRI FOR EVALUATING EARLY SACROILIAC ABNORMALITIES IN JUVENILE SPONDYLOARTHRITIS / M. Bou Antoun* - L. Rossi-Semerano - S. Guillaume-Czitrom - L. Kone Paut - C. Adamsbaum
FR10529  ARE BICIPITAL SYNOVIAL CYSTS IN CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS STILL A SIGNIFICANT CLINICAL CHALLENGE? / N. Kyvsgaard* - T. Herlin
FR10534  PHYSICAL ACTIVITY, OVERWEIGHT, AND LEISURE TIME ACTIVITY IN A COHORT OF JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / G. Sherman - V. Moshe - R. Haviv - Y. Reis - A. Consolaro - N. Ruperto - Y. Uziel*

Back pain, mechanical musculoskeletal problems, local soft tissue disorders

Hall 5

FR10536  INVESTIGATION OF THE EFFECTIVENESS OF MUSCLE INHIBITION AND SPACE CORRECTION TECHNIQUES OF KINESIOTAPING METHOD IN FEMALE PATIENTS WITH MYOFAScULAR PAIN SYNDROME RELATED TO UPPER TRAPEZIUS ACTIVe TRIGGER POINTS / M. F. Aklpinar - A. Ketenci - D. Sindel*
FR10538  DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE FOR THE IDENTIFICATION OF DIFFERENT BEHAVIORAL STRATEGIES IN PATIENTS WITH CHRONIC LOW BACK PAIN / F. Baillly* - V. Foltz - S. Rozenberg - L. Gossec - B. Fautrel on behalf of Spine Group of the French Society of Rheumatology
FR10539  AN INTEGRATED MANUFACTURING METHOD OF CUSTOMIZED MEDICAL KNEe IMPLANTS USING AUTOMATED 3D MODEL RECONSTRUCTION AND PROTOTYPING PROCEDURE / M. Moayedfar - A. M. B. Abdul Rani* - D. Kumar
FR10541  TRIGGER POINTS DRY NEEDLING UNDER ULTRASOUND GUIDANCE FOR LOW BACK PAIN THERAPY. COMPARATIVE STUDY / R. V. Bubnov*
FR10542  COMPARISON OF TWO METHODS OF NEUROPATHIC PAIN ASSESSMENT IN CARPAL TUNNEL SYNDROME AND THEIR CORRELATION WITH HAND FUNCTIONS / E. Ceceli* - S. Gümrük - M. Okumuş - S. Kocaoğlu - H. Göksu - C. Orellana - C. Galisteo - J. Gratacós - M. Larrosa
FR10543  DOES ELECTROPHYSIOLOGICALLY SEVERE PATIENTS HAVE ALSO HIGHER NEUROPATHIC COMPLAINTS IN CARPAL TUNNEL SYNDROME? / M. Karadeniz* - T. Dandingo
FR10544  NON-STRUCTURAL FACTORS ASSOCIATED WITH CURRENT AND NEW FOOT PAIN: DATA FROM THE TASMANIAN OLDER ADULT COHORT STUDY / L. L. Laslett - H. Menz - F. Cecchi - G. Jones*
FR10545  SAFER SLEEPING WITH SOAP? QUININE, CRAMPS AND WEIGHING UP ANECDOTAL EVIDENCE / E. A. Clarke* - S. Bawa
FR10546  MULTIPLE VERSUS SINGLE ULTRASOUND GUIDED SUPRASCAPULAR NERVE BLOCK IN TREATMENT OF FROZEN SHOULDER IN DIABETIC PATIENTS / M. Mortada* - M. M. Ashour - S. F. Abbas - H. A. Ammar - N. Ezzeldin - N. A. Salama

* Presenting author
DIAGNOSTICS AND IMAGING PROCEDURES

FR10548 THERAPEUTIC ADHERENCE IN PATIENTS WITH DE QUERVAIN’S DISEASE / C. A. Guillen Astete* - J. Bachiller Corral - L. Villalobos - A. L. Boteanu
FR10553 PRONOSTIC TEST IN CHRONIC LOW BACK PAIN PATIENTS: STABILISATION TEST / M. Norberg* - L. Belgrand - M. Norberg
FR10557 ASSESSMENT OF THE APPROPRIATENESS OF LUMBAR SPINE MAGNETIC RESONANCE IMAGING IN A RHEUMATOLOGY UNIT / S. Gill - N. Quilis - P. Vela*
FR10558 FROM PERSPECTIVE OF DN4 AND LANSS SCALES, DOES SINGLE STEROID INJECTION REALLY RELIEVES NEUROPATHIC PAIN IN CARPAL TUNNEL SYNDROME? / T. Dandinoglu* - M. Karadeniz - V. Yilmaz
FR10559 BURDEN OF SOFT TISSUE RHEUMATISM IN A RURAL COMMUNITY: A WHO-ILAR-COPCORD STUDY FROM KERALA, INDIA / C. Jamaluddeen - V. Ravindran*

** Diagnostics and imaging procedures **

FR10562 ULTRASOUND ENTESITIS IN PRIMARY CARE PSORIASIS PATIENTS WITH MUSCULOSKELETAL COMPLAINTS / M. van der Heijde - M. van der Heijde
FR10563 DETECTION OF IGG ANTI-DOMAIN I BETA2 GLYCOPROTEIN I ANTIBODIES BY CHEMILUMINESCENCE IMMUNOASSAY IN PRIMARY ANTIPHOSPHOLIPID SYNDROME / L. Meneghel* - A. Ruffatti - S. Gavasso - M. Tonello
FR10564 ASSESSMENT OF THE APPROPRIATENESS OF LUMBAR SPINE MAGNETIC RESONANCE IMAGING IN A RHEUMATOLOGY UNIT / S. Gil - N. Quilis - P. Vela*
FR10565 ULTRASOUND ENTHESITIS IN PRIMARY CARE PSORIASIS PATIENTS WITH MUSCULOSKELETAL COMPLAINTS / M. van der Heijde - M. van der Heijde
FR10566 ULTRASOUND DEMONSTRATES TENOSYNOVITIS TO BE FREQUENT IN RA PATIENTS AS WELL AS BEING RESPONSIVE TO BIOLOGIC TREATMENT / H. B. Hammer* - L. Terslev - T. K. Kvien
FR10568 ULTRASOUND ENTHESITIS IN PRIMARY CARE PSORIASIS PATIENTS WITH MUSCULOSKELETAL COMPLAINTS / M. van der Heijde - M. van der Heijde
FR10569 ULTRASOUND ENTHESITIS IN PRIMARY CARE PSORIASIS PATIENTS WITH MUSCULOSKELETAL COMPLAINTS / M. van der Heijde - M. van der Heijde

* Presenting author

FR10572 ULTRASOUND FEATURES OF HAND OSTEOARTHRITIS (OA) CAN BE RELIABLY SCORED BY USE OF REFERENCE ATLASES / A. Mathiessen* - P. S. Robinson - I. K. Haugen - H. B. Hammer


FR10575 THE PRESENCE AND INTENSITY OF ULTRASOUND SYNOVITIS IN PATIENTS WITH RHEUMATOID ARTHRITIS IS HIGHER IN THE DOMINANT HAND, EVEN IN THOSE PATIENTS IN CLINICAL REMISSION / A. M. Bertoli* - G. E. Py - M. J. Audisio

FR10576 CROSS-SECTIONAL EVALUATION OF HIGH-RESOLUTION CT IMAGING COMPARED TO MRI AND CONVENTIONAL RADIOGRAPHY FOR THE DETECTION OF EROSIONS IN RHEUMATOID ARTHRITIS / A. Scharnag* - M. Peters - J. van den Bergh - D. Loefen - B. van Rietbergen - A. van Tubergen - R. Weijers - P. Geusens


FR10585 DOPPLER ULTRASOUND BETTER PREDICTS X-RAY PROGRESSION IN RHEUMATOID ARTHRITIS THAN ANY DEFINITION OF CLINICAL REMISSION / E. de Miguel* - E. de Vicente - F. Diaz Alcazar - J. L. de la Iglesia - A. Scharmga* - M. Peters - J. van den Bergh - D. Loefen - B. van Rietbergen - A. van Tubergen - R. Weijers - P. Geusens


FR10591 LINEAR EXTRAPOLATION OF MISSING RADIOGRAPHIC PROGRESSION SCORES DOES NOT SPURIOUSLY OVERESTIMATE OVERALL RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS / I. Markusse* - R. Landewé - M. Ho - M. Jenkins - D. van der Heijde


FR10595 IS LIPHYCOTIC SIALADENITIS IGG4-RELATED? AN OBSERVATIONAL STUDY / N. Chavarot - M. Hourseu - T. Papo - K. Sacre*
FRI0598 3D ULTRASOUND DOPPLER FINDINGS IN WRIST TENDON SHEATHS OF HEALTHY CONTROLS / M. Ammitzbøll-Danielsen* - I. Janta - S. T. Torp-Pedersen - E. Naredo - M. Østergaard - L. Terslev

FRI0599 EVALUATION OF BRAIN CHANGES IN SYSTEMIC SCLEROSIS PATIENTS USING TWO DIFFERENT TECHNIQUES OF MRI / R. M Gamal - A. M Ghandour - M. A. Galal* - M. Zidan

FRI0600 QUANTIFICATION OF CORTICAL BREAKS USING HIGH-RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY IMAGING; A CASE CONTROL STUDY / M. Peters* - A. Scharmga - J. Van den Bergh - S. Soldano - C. Arts - P. Geusens

FRI0601 A DUAL-CENTER, DOUBLE BLIND RANDOMIZED STUDY FOR A NEW SCIENTIFIC APPROACH IN ASSESSMENT OF TENDER JOINTS IN INFLAMMATORY ARTHRITIS USING THE SMART JOINT ASSESSOR GLOVE DEVICE (SMART JAG DEVICE) / M. F. Khan*


FRI0603 SYNOVIAL FLUID ANALYSIS AND CRYSTAL DETECTION: RESULTS FROM A COHORT OF POSSIBLE ARTROPATHIC CONSECUTIVE PATIENTS WITH EFFUSION / P. Montagna* - R. Brizzolara - A. C. Trombetta - S. Soldano - C. Ferrone - M. Cutolo - M. A. Cimmino


FRI0606 IN VIVO IMAGING OF PHAGOCYTE MIGRATION IN INFLAMMATORY PROCESSES BY FLUORESCENT CELL TRACKING / S. Gran* - M. Schäfers - J. Roth - T. Vogl


Scientific Programme

08:00 - 15:00  Hall 7
Registration

08:30 - 10:00  Hall 8
Clinical Science session
Comorbidities

Learning objectives:
• To understand the impact of comorbidities on disease and treatment in inflammatory rheumatic diseases
• To understand the prevalence of cancer in patients with RA and the impact on choices of treatment

Chairperson(s):
Loreto Carmona (Spain)
Angela Zink (Germany)

Deborah Symmons (United Kingdom) 08:35
Abstract N° SP0196
Impact of comorbidities on disease severity and treatment strategy in inflammatory arthritis

Johan Asklings (Sweden) 09:15
Cancer and RA: prevalence and impact on management

Zoltán Szekanecz (Hungary) 09:35
Uncommon comorbidities in rheumatic diseases

E. Lie (Sweden) 09:45
Abstract N° OP0289
Comorbidity with depression and anxiety is associated with discontinuation of tumour necrosis factor inhibitor (TNFI) therapy in ankylosing spondylitis (AS)

08:00 - 15:00  Hall 3
Challenges in Clinical Practice session

What is New (WIN)
WIN session 8

Connny van der Laken (Netherlands) 08:35
Abstract N° SP0194
Imaging as a predictive tool - prognosis, response and relapse

Mikael Boesen (Denmark) 09:15
Abstract N° SP0195
New imaging modalities for RA remission

08:30 - 10:00  Hall 9

What is New (WIN)

WIN session 8

Conny van der Laken (Netherlands) 08:35
Abstract N° SP0194
Imaging as a predictive tool - prognosis, response and relapse

Mikael Boesen (Denmark) 09:15
Abstract N° SP0195
New imaging modalities for RA remission

08:30 - 10:00  Hall 3
Challenges in Clinical Practice session

Diagnosis in back pain - suspicion of SpA

Learning objectives:
• To understand differential diagnosis of young patients with chronic back pain and the role of imaging in diagnosis making
• To understand the differential diagnosis in patients with new bone formation in the spine

Chairperson(s):
Anna Moltó (Spain)
Helena Marzo-Ortega (United Kingdom)
Salvatore D’Angelo (Italy) 08:35
Abstract N° SP0198
Case 1 presentation: Spinal bone formation: which diagnosis?

Ignazio Benedetto Olivieri (Italy) 08:45
Case 1 discussion: Aberrant spinal bone formation - AS?

Gaelle Varkas (Belgium) 09:15
Case 2 presentation: MRI in young adults with "axial skeleton problems": friend or foe

Filip van den Bosch (Belgium) 09:25
Case 2 discussion: back pain: SpA or non-SpA?

08:30 - 10:00 Room 10 F-G

How to Treat / Manage (HOT)

HOT session 9

Matthias Schneider (Germany) 08:35
SLE

Peter Lamprecht (Germany) 09:15
Abstract N° SP0199
Vasculitis

08:30 - 10:00 Hall 2

Clinical Science session

Coagulation and rheumatology

Learning objectives:
New mechanisms, new therapy, lessons learned from EHEC

Chairperson(s):
Munther Khamashtha (United Kingdom)
Roger A. Levy (Brazil)

Hannah Cohen (United Kingdom) 08:35
Abstract N° SP0200
NOACs: Novel Oral AntiCoagulants - new opportunities in rheumatology?

David D’Cruz (United Kingdom) 08:55
Abstract N° SP0201
New developments in APS

Christof Iking-Konert (Germany) 09:15
HUS and EHEC, lessons learned

Eveline P. Mauser-Bunschoten (Netherlands) 09:35
Abstract N° SP0202
Hemophilia and joint diseases

08:30 - 10:00 Hall 1

Outcome Science session

New challenges in clinical trials

Learning objectives:
• To understand the current issues surrounding the choice of comparator group in clinical trials
• To understand the principles of network meta-analysis and its contribution to evidence synthesis
• To understand the strengths and weaknesses of non-inferiority trial design
• To understand the role of the clinical.trials.gov database in ensuring the integrity of clinical trial research

Chairperson(s):
Maria Suarez-Almazor (United States)
Ernest Choy (United Kingdom)

A. W. Christensen (Denmark) 08:35
S. Tarp, D. Furst, A. Dossing, K. Amris, H. Bliddal, P. Taylor, R. Christensen on behalf of the Parker Institute, Department of Rheumatology, Copenhagen University Hospitals Bispebjerg and Frederiksberg, Denmark
Abstract N° OP0291
How medication history and average disease duration modify treatment effect in randomised trials using targeted therapies for rheumatoid arthritis: a meta-epidemiological study

Maria Suarez-Almazor (United States) 08:45
Placebo vs. no intervention as the comparator in clinical trials - the challenge for the management of musculoskeletal pain

Peter Jüni (Switzerland) 09:10
Network meta-analysis? Combining direct and indirect comparison of treatments from different clinical trials

Emmanuel Lesaffre (Netherlands) 09:35
Abstract N° SP0203
Non-inferiority: non-sense or sense?

08:30 - 10:00 Room 10 B

PReS session

Juvenile localized scleroderma

Learning objectives:
• To recognize the clinical and immunological characteristics of children with different forms of localized scleroderma
• To learn about recent efforts to standardize the assessment and the treatment options of localized scleroderma
• To recognize diseases that can mimic localized scleroderma
Chairperson(s):
Alberto Martini (Italy)
Jelena Vojinovic (Serbia)
Ronald Laxer (Canada) 08:35
Abstract N° SP0205
Clinical aspects and differential diagnosis

Francesco Zulian (Italy) 08:55
Abstract N° SP0206
Assessing disease activity and treatment

Alan Tyndall (Switzerland) 09:15
Abstract N° SP0207
Scleroderma-like fibrosing diseases

M. Osminina (Russian Federation) 09:35
N. Geppe, O. Spitonkova, J. Kostina, E. Afonina, G. Tougarinova
Abstract N° OP0292
Therapeutic strategies for juvenile localized scleroderma

S. O. Hetlevik (Norway) 09:45
B. Flato, E. Nordal, M. Rygg, V. Lilleby
Abstract N° OP0293
Long-term outcome and clinical characteristics in childhood-onset mixed connective tissue disease - a Norwegian nationwide study

08:30 - 10:00  Room 10 I

Basic and Translational Science session
Autoimmune B cells in human disease

Learning objectives:
• To understand how autoimmune B cells do arise in human autoimmune diseases such as RA and SLE
• To understand that autoimmune B cell contribute to autoimmune pathology not only by differentiation to autoantibody-producing plasma cells but also by other mechanisms
• To understand the value and methodology of characterizing autoimmune B cells (rather than autoantibodies)

Chairperson(s):
Guy Serre (France)
Diane van der Woude (Netherlands)

Eric Meffre (United States) 08:35
Abstract N° SP0208
Control of B cell autoimmunity

Frits Koning (Netherlands) 08:55
Abstract N° SP0209
Lessons from coeliac’s disease

Hans-Ulrich Scherer (Netherlands) 09:15
Abstract N° SP0210
Functional characterisation of human citrullinated protein-specific B cells

D. Scheel-Toellner (United Kingdom) 09:35
Abstract N° OP0294
Pro-inflammatory FcRL4+ memory B cells in joints of RA patients; immunoglobulin gene characteristics and antigen specificity

M. Levels (Netherlands) 09:45
M. Van Tok, T. Cantaert, D. Baeten, N. Yeremenko
Abstract N° OP0295
Mice lacking BOB1 exclusively in B cells are resistant to type II collagen-induced arthritis

08:30 - 10:00  Room 10 D-E

Basic and Translational Science session
Bone phenotypes of osteoarthritis: towards personalised treatment

Learning objectives:
• Different phenotypes of osteoarthritis are now-a-days considered
• These phenotypes provide opportunities for more targeted treatment
• In this session you will learn about the role of different bone mediators in the process of osteoarthritis
• Moreover, we learn whether bone directed treatment may be a future strategy in treatment of this specific phenotype of osteoarthritis

Chairperson(s):
Natalia Kuchuk (Netherlands)
Francis Berenbaum (France)

Patrick Orth (Germany) 08:35
Abstract N° SP0211
PTH: good for bone, bad for cartilage

Xu Cao (United States) 08:55
Abstract N° SP0212
TGF-beta: an ambivalent role in bone and cartilage

Graeme Jones (Australia) 09:15
Abstract N° SP0213
Bone directed treatment in OA: what has it brought us

X. Jin (Australia) 09:35
F. Cicuttini, A. Wluka, Z. Zhu, W. Han, B. Antony, X. Wang, T. Winzenberg, L. Blizzard, G. Jones, C. Ding
Abstract N° OP0296
Vitamin D supplementation for the management of knee osteoarthritis: a two year double blind randomized controlled trial

A. Barr (United Kingdom) 09:45
Abstract N° OP0297
Three-dimensional magnetic resonance imaging knee bone shape predicts total knee replacement: data from the osteoarthritis initiative
**The Young Rheumatologist**  
**Strategic decisions in a career**

**Learning objectives:**  
How to use opportunities to further develop a career

**Chairperson(s):**  
Elena Nikiphorou (United Kingdom)  
Britta Maurer (Switzerland)

**Pedro Machado (Portugal)**  
08:35  
Successfully transitioning from trainee to professional

**Simona Rednic (Romania)**  
08:55  
Abstract N° SP0214  
The consultant’s role in strategic career decisions for rheumatology trainees

**Dimitrios Boumpas (Greece)**  
09:15  
Secrets of success

**Gemma Lepri (Italy)**  
09:35  
Abstract N° SP0215  
Prospective correlation of angiogenetic factors, microvascular abnormalities, organ involvement in systemic sclerosis

**Maria Ruiz (Spain)**  
09:45  
Prediction of adverse pregnancy outcome in systemic lupus erythematosus and antiphospholipid antibodies positive patients using a risk score model

**Health Professionals session**  
**Unlocking the mystery of health economics**

**Learning objectives:**  
- Learn about the language, key principles and methods of health economic evaluations  
- Know how to interpret the results of health economic evaluations  
- Gain insight into the perspective of decision makers  
- Understand how this evidence is being used to inform national clinical guidelines and practices

**Chairperson(s):**  
Yeliz Prior (United Kingdom)  
Thea Vliet Vlieland (Netherlands)  
Joshua Pink (United Kingdom)

**Joshua Pink (United Kingdom)**  
08:35  
Abstract N° SP0216  
The principles of health economics

**Melina Dritsaki (United Kingdom)**  
08:53  
Abstract N° SP0217  
From theory to practice: case study from the SARAH trial

**Jan Sorensen (Denmark)**  
09:11  
Abstract N° SP0218  
The challenges in health economics evaluation

---

**Joint Clinical/HPR/PARE session**  
**Family business**

**Learning objectives:**  
How modern families balance their life when one member is affected by an RMD

**Chairperson(s):**  
Maurizio Cutolo (Italy)  
Nele Caeyers (Belgium)  
Giovanni Lamura (Italy)

**Giovanni Lamura (Italy)**  
08:35  
Abstract N° SP0220  
Don’t forget the carers!

**Spyroula David (Cyprus)**  
08:55  
Abstract N° SP0221  
Family dynamics

**Monika Østensen (Norway)**  
09:15  
Abstract N° SP0222  
Top tips for a successful pregnancy for couples affected by an RMD

**M. Khamashta (United Kingdom)**  
09:35  
Abstract N° OP0299-PARE  
Attitudes of patients and physicians in the treatment of rheumatological disease during pregnancy

**D. Pushparajah, E. Chakravarty**  
09:45  
Abstract N° OP0300-PARE  
Centre for psychological and social support in Slovakia

**Practical skills session**

**Ultrasound basic II**

**Learning objectives:**  
Use and interpretation of US techniques to support diagnosis of the bespoken disease manifestations

**Chairperson(s):**  
Sandrine Jousse-Joulin (France)  
Wolfgang A. Schmidt (Germany)

**Maarten de Wit (Netherlands)**  
09:29  
Abstract N° SP0219  
The heart of the matter. A critical evaluation of health economics from a patient perspective

**V. M. Vervoort (Netherlands)**  
09:47  
Abstract N° OP0298-HPR  
Illness perceptions and costs in patients with fibromyalgia

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
Emilio Filippucci (Italy) 08:35
Basic skills for diagnosing crystal deposits in gout + demo

Frédérique Gandjbakhch (France) 08:55
Basic skills for diagnosing enthesitis in SpA + demo

George W. Bruyn (Netherlands) 09:15
Basic skills for diagnosing tenosynovitis in RA + demo

Ingrid Möller (Spain) 09:35
Basic skills for diagnosing lateral hip pain + demo

08:30 - 10:00  Room 9 A

Practical skills session*

MRI II

Learning objectives:
• How to use MRI technique best in the discussed cases and diseases
• What can be read from the MRI - and what not
• How can MRI be used to support the diagnosis and how to control progress of treatment

Chairperson(s):
Mikkel Østergaard (Denmark)
Iris Eshed (Israel)

Mikkel Østergaard (Denmark) 08:35
Introduction: MRI in arthritis

Susanne Juhl Pedersen (Denmark) 08:40
MRI of sacroiliac joints - basic interpretation skills and pitfalls

Joshua Baker (United States) 09:00
Abstract N° SP0223
Lessons learnt from recent MRI trials in RA

Mikkel Østergaard (Denmark) 09:20
Wholebody MRI, dynamic MRI and diffusion-weighted MRI in inflammatory arthritis. Relevance for clinical practice and research

Iris Eshed (Israel) 09:40
Interactive session: MRI case vignettes - from finding to diagnosis

10:00 - 12:00 Halls 5&6

Poster viewing, coffee break & light lunch

Guided Poster tours 10:10 - 11:50 Hall 6

Poster tour

S1: Cytokines and inflammatory mediators

Chairperson(s):
Frank Buttgereit (Germany)
Ulf Müller-Ladner (Germany)
A. Bertoni (Italy)

Abstract N° SAT0001
Cryopyrin associated periodic syndromes (CAPS): investigations on knock-in mouse model to exploit novel approaches for the modulation of the NLRP3 inflammasome

K. W. Frommer (Germany)

Abstract N° SAT0002
Free fatty acids promote an inflammatory profile in osteoblasts

T. W. Kragstrup (Denmark)

Abstract N° SAT0003
The IL-20 receptor axis in early rheumatoid arthritis: novel inflammation-independent links between rheumatoid arthritis-associated autoantibodies and radiographic progression

Z. Zhu (Australia)
X. Jin, B. Wang, A. Wluka, B. Antony, L. Laslett, T. Winzenberg, F. Cicuttini, G. Jones, C. Ding

Abstract N° SAT0004
Cross-sectional and longitudinal associations between serum levels of HS-CRP, resistin and knee bone marrow lesions in patients with knee osteoarthritis

S. Nayar (United Kingdom)
J. Campos, T. Cloake, S. Bowman, M. Bombardieri, C. Pitzalis, S. Luther, C. Buckley, F. Barone

Abstract N° SAT0005
IL22 regulates autoantibody production by inducing lymphoid chemokine expression in tertiary lymphoid organs

W. De Munter (Netherlands)
M. H. van den Bosch, S. W. Annet, K. Croce, N. Hogg, T. Vogl, J. Roth, W. B. van den Berg, P. M. van der Kraan, P. L. van Lent

Abstract N° SAT0006
High systemic LDL cholesterol levels lead to synovial activation and strongly accelerate development of ectopic bone formation during experimental osteoarthritis

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
H. Sato (Japan)  
S. Muraoka, N. Kusunoki, M. Kawazoe, S. Masuoka,  
E. Shindo, N. Fujio, K. Shikano, M. Kaburaki, N. Tanaka,  
K. Kaneko, T. Yamamoto, T. Hasunuma, S. Kawai  
Abstract N° SAT0007  
Resistin directly stimulates chemokine gene expressions in  
rheumatoid synovial fibroblasts: DNA microarray analysis  

A. Syngle (India)  
I. Verma  
Abstract N° SAT0008  
Spironolactone abrogates production of proinflammatory  
cytokines in rheumatoid arthritis via inactivation of nuclear  
factor- kappa B  

Poster tour  
S2: Cartilage - bone - synovium:  
life in the joint  

Chairperson(s):  
Rik Lories (Belgium)  
Barbara Neerinckx (Belgium)  

A. I. Catrina (Sweden)  
M. Sun, A. Haj Hensvold, V. Malmsröm, K. Amara,  
H. Wåhämää  
Abstract N° SAT0033  
Anti-citrullinated proteins antibodies promote synovial  
fibroblast migration in rheumatoid arthritis  

M. van den Bosch (Netherlands)  
A. Blom, A. Maeda, T. Kilts, W. van den Berg, F. Lafeber,  
P. van Lent, M. Young, P. van der Kraan  
Abstract N° SAT0034  
WISP1 aggravates osteoarthritis by modulation of TGF-β  
signaling and positive regulation of canonical WNT signaling  

A. Latourte (France)  
C. Cherifi, H. K. Ea, W. Bouaziz, T. Funck-Brentano,  
M. Cohen Solal, E. Hay, P. Richette  
Abstract N° SAT0035  
Chondroprotective effects of IL-6 inhibition through  
blockade of the STAT3 pathway  

J.-J. Liang (China)  
Abstract N° SAT0036  
Down-regulated PGCG-1β could inhibit RA-FLS induced  
osteoostrogenesis and bone resorption by suppression of  
NF-kB activation  

U. Arad (Israel)  
S. Svetitsky, S. Journo, O. Danino, B. Fischer  
Abstract N° SAT0037  
An ENPP1-specific inhibitor attenuates extracellular ecto-  
pyrophosphatase activity in human osteoarthritic cartilage  

C. Cherifi (France)  
Abstract N° SAT0038  
Osteoclasts activate chondrocyte catabolism through S1P  
production  

B. Carames (Spain)  
M. Ribeiro, P. Lopez de Figueroa, A. F. Mendes,  
F. J. Blanco  
Abstract N° SAT0039  
Insulin-induced cartilage degradation in osteoarthritis is  
associated to defective autophagy  

C. Orr (Ireland)  
T. McGarry, E. Young, E. Linehan, U. Fearon, D. J. Veale  
Abstract N° SAT0040  
Macroscopic scores of synovitis at knee arthroscopy  
correlate well with CRP, inflammatory histology findings,  
and can predict later erosive disease on hands and feet  
plain film radiographs  

W. P. Nieuwenhuis (Netherlands)  
H. W. van Steenbergen, W. Stomp, T. Stijnen,  
T. W. Huizinga, J. L. Bloem, D. van der Heijde,  
M. Reijnierse, A. H. van der Helm-van Mil  
Abstract N° SAT0041  
The course of bone marrow edema in early  
undifferentiated and rheumatoid arthritis; a longitudinal  
MRI study on bone level  

Poster tour  
S3: RA - outcome  

Chairperson(s):  
Deborah Symmons (United Kingdom)  
Helga Radner (Austria)  
J. Weijers (Netherlands)  
S. Rongen-van Dartel, H. Repping-Wuts, J. van Kuijk,  
T. Galesloot, A. Verbeek, P. van Riel, J. Fransen  
Abstract N° SAT0052  
Comparison of physical activity and level of fatigue among  
patients with rheumatoid arthritis and the general Dutch  
population  

S. Miladi (Tunisia)  
K. Ben Abdelghani, S. Kassab, S. Chekili, A. Laatar,  
L. Zakraoui  
Abstract N° SAT0053  
The added value of ultrasound to evaluate remission in  
rheumatoid arthritis  

A. Radix-Bloemen (Netherlands)  
J. van Nies, S. Arends, F. Maas, A. van der Helm-van Mil,  
A. Spoorenberg, E. Brouwer  
Abstract N° SAT0054  
Reliability of self-evaluation of swollen joint count: data  
obtained from two early arthritis recognition clinics  

G. H. Brinkmann (Norway)  
E. S. Norli, T. K. Kvien, A. J. Haugen, L. Grøvle,  
H. Nyaarda, O. Bjørnbeoe, C. Thunem,  
M. D. Mjaavatten, E. Lie  
Abstract N° SAT0055  
Two-year outcome in 495 patients with undifferentiated  
arthritis of very short duration
J. Haschka (Germany)  
Abstract N° SAT0056  
Retro-study of reduction of therapy in patients with rheumatoid arthritis in ongoing remission

G. Cuomo (Italy)  
V. D'Abrosca, B. Russo, G. Valentin  
Abstract N° SAT0057  
The conversion rate of tubercolosis screening tests during biological therapies in patients with rheumatoid arthritis

S. Ajeganova (Sweden)  
H. van Steenbergen, J. van Nies, L. Burgers, T. Huizinga, A. van der Helm-van Mil  
Abstract N° SAT0058  
DMARD-free sustained remission in rheumatoid arthritis: an outcome associated with subsidence of symptoms that is increasingly achieved with improved treatment strategies

T. Tokoroyama (Japan)  
K. Setoguchi, A. Ohta, M. Ando  
Abstract N° SAT0059  
Chronic kidney disease in patients with rheumatoid arthritis: clinical findings from a longitudinal study over 5 years in a single tertiary hospital

L. W. Koh (Singapore)  
E. T. Koh, J. W. L. Tan, T. Lian, W. Q. See, L. Liu, K. P. Leong on behalf of TTSH Rheumatoid Arthritis Study Group  
Abstract N° SAT0060  
Orthopaedic surgery in an Asian rheumatoid arthritis cohort: predictors and impact on quality of life

J. Dale (United Kingdom)  
A. Stirling, C. Grigor, S. Saunders, D. Porter  
Abstract N° SAT0061  
Comparison of outcomes between studies of intensive treatment strategies in early RA from a single centre over 20 years

10:10 - 11:50  Hall 6

Poster tour

S4: RA - comorbidities: the heart at heart

Chairperson(s):  
Johannes W. J. Bijlisma (Netherlands)  
Sjoerd Heslinga (Netherlands)

S. Norton (United Kingdom)  
A. Young, E. Nikiphorou, P. Kiely, D. A. Walsh, J. Dixey  
Abstract N° SAT0096  
The obesity paradox in rheumatoid arthritis: results from UK based multi-centre observational study

R. Agca (Netherlands)  
A. M. van Sijl, A. E. Voskuyl, M. T. Nurmohamed  
Abstract N° SAT0097  
Predicting cardiovascular risk in patients with rheumatoid arthritis

A. Tournadre (France)  
Abstract N° SAT0098  
Changes in metabolic profile during treatment with Tocilizumab in patients with rheumatoid arthritis

M. E. Tsoi (Hong Kong)  
T. T. Cheung, B. M. Y. Cheung  
Abstract N° SAT0099  
Effect of TNF inhibitors on subclinical atherosclerosis in patients with rheumatoid arthritis: a meta-analysis

R. Agca (Netherlands)  
A. M. van Sijl, Y. M. Smulders, A. E. Voskuyl, C. J. van der Laken, R. Boellaard, K.-J. D. Lenzen, M. T. Nurmohamed  
Abstract N° SAT100  
Increased vascular wall inflammation in patients with early rheumatoid arthritis as measured by 18F-FDG-PET/CT

I. G. Fostad (Norway)  
J. R. Eidet, T. Lyberg, O.K. Olstad, T. P. Utheim, K. Mikkelsen, A. Wiik, I. Hollan  
Abstract N° SAT101  
The increased risk of cardiovascular disease in rheumatoid arthritis may be related to NUPR1 activation

A. Syngle (India)  
N. Garg, P. Krishan  
Abstract N° SAT102  
Stem cell augmentation for cardiovascular risk in rheumatoid arthritis with Olmesartan: STAR-O study

G. Ozen (Turkey)  
M. Sunbul, P. Atagunduz, H. Direskeneli, K. Tigen, N. Inanc  
Abstract N° SAT103  
The 2013 ACC/AHA 10-year atherosclerotic cardiovascular disease (ASCVD) risk index is better than score and QRISK II in rheumatoid arthritis: is it enough?

H. Kobayashi (Japan)  
Abstract N° SAT104  
Subclinical myocardial inflammation and fibrosis are common in active rheumatoid arthritis, assessed by cardiac magnetic resonance imaging

G. D. Kitas (United Kingdom)  
P. Nightingale, J. Armitage, N. Satir, TRACE RA Consortium, J. Belch, D. Symmons  
Abstract N° SAT105  
Trial of Atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA)
**Poster tour**

**S5: RA - small molecules 2**

**Chairperson(s):**
João E. Fonseca (Portugal)
Vasco C. Romao (Portugal)
V. Dhir (India)
A. Sandhu, J. Kaur, B. Pinto, P. Kumar, N. Gupta,
A. Sood, S. Sharma, A. Sharma, P. Kaur

Abstract N° SAT0215
Effect of two doses of folic acid on Methotrexate toxicity and
efficacy - a randomized controlled trial

H.-H. Chen (Taiwan)
D.-Y. Chen, C.-C. Lin

Abstract N° SAT0216
Acarbose decreases the risk of rheumatoid arthritis in
diabetic patients and attenuates the incidence and severity of
collagen-induced arthritis in mice: population-based case-control study and animal study

M. C. van der Goes (Netherlands)
J. W. Jacobs, M. Boers, J. R. Kirwan, I. Hafström,
B. Svensson, J. W. J. Bijlsma

Abstract N° SAT0217
Long-term effects of glucocorticoid therapy on radiological progression of joint damage in rheumatoid arthritis: an individual patient meta-analysis

A. S. Avdeeva (Russian Federation)
E. N. Aleksandrova, D. E. Karateev, E. L. Luchikhina,
A. V. Smirnov, A. A. Novikov, M. V. Cherkasova,
E. L. Nasonov

Abstract N° SAT0218
Association of matrix metalloproteinase-3 level with clinical efficacy of subcutaneous Methotrexate in DMARD-naive patients with early rheumatoid arthritis

K. Perdan-Pirkmajer (Slovenia)
S. Pirkmajer, M. Thevis, A. Thomas, S. Praprotnik,
A. Hočevar, Ž. Rotar, N. Gašperšič, S. Sodin-Šemrl,
J. Žibert, J. Omersel, A. Chibalín, M. Tomišič, A. Ambrožič

Abstract N° SAT0219
Methotrexate-induced reduction in concentration of HbA1c in rheumatoid and psoriatic arthritis is not correlated with sustained increase in erythrocyte ZMP or urinary aicar concentration

D. van der Heijde (Netherlands)
C. Connell, J. Bradley, D. Gruben, S. Strengolt,
R. B. Landewé

Abstract N° SAT0220
Radiographic progression in modern RA trials is still a robust outcome: results of comprehensive sensitivity analysis in two phase 3 trials with Tofacitinib

F. Buttgerait (Germany)
V. Strand, E. B. Lee, D. McCabe, S. Kolluri, B. Tammara,
R. Rojo, J. Hey-Hadavi

Abstract N° SAT0221
Efficacy and safety of PF-04171327, a novel dissociated agonist of the glucocorticoid receptor (DAGR): results of a phase 2, randomized, double-blind study

P. G. Conaghan (United Kingdom)
M. Østergaard, M. A. Bowes, C. Wu, T. Fuerst,
D. van der Heijde, P. Hrycaj, Z. Xie, R. Zhang,
B. T. Wyman, J. Bradley, K. Soma, B. Wilkinson

Abstract N° SAT0222
Effects of Tofacitinib on MRI endpoints in Methotrexate-naive early rheumatoid arthritis: a phase 2 MRI study with semi-quantitative and quantitative endpoints

**Poster tour**

**S6: SpA clinical abstracts**

**Chairperson(s):**
Désirée van der Heijde (Netherlands)
Uta Kiltz (Germany)
J. Gu (China)
Z. Hu, Q. Ly, J. Qi, Z. Lin, M. Yang, Z. Liao

Abstract N° SAT0270
Backfill is a specific sign of axial spondyloarthritis seen on MRI

J. Chan (Canada)
I. Sari, D. Salonen, N. Haroon, R. D. Inman

Abstract N° SAT0271
Development of a novel SI joint CT score for diagnosis of axial spondylitis

N. Nigil Haroon (Canada)
M. J. Paterson, P. Li, R. D. Inman, N. Haroon

Abstract N° SAT0272
Increased risk of vascular mortality in axial spondyloarthritis

C. Prati (France)
X. Guillot, D. Wendling

Abstract N° SAT0273
Deaths associated with ankylosing spondylitis in France from 1969 to 2009

M. Dougados (France)
C. Demattei, R. van den Berg, V. Hoang, F. Thevenin,
M. Reijnierse, D. Loeuille, A. Feydy, P. Claudepierre,
D. van der Heijde

Abstract N° SAT0274
Genetic (HLA-B27), environmental (smoking) and inflammatory (MRI positivity) factors are independent predictors of radiographic progression of the sacroiliac joints in early axial non-radiographic spondyloarthritis
L. van Hoeven (Netherlands)
Y. Vergouwe, P. de Buck, K. Han, J. Luime, J. Hazes, A. Weel
Abstract N° SAT0275
Assessing the best referral strategy for axial spondyloarthritis; several referral strategies evaluated in primary care patients with chronic low back

E. J. Nam (Republic of Korea)
S. H. Kwon, J. S. Eun, N. R. Kim, Y. M. Kang
Abstract N° SAT0276
Change of ASDAS over 3 months is a good predictive factor for improvement of metrology index after long-term treatment with TNF-blockers in ankylosing spondylitis

F. Wink (Netherlands)
F. Maas, G. Bruyn, E. Van der Veer, H. Bootsma, E. Brouwer, A. Spoorenberg
Abstract N° SAT0277
Clinical, ultrasound and radiographic evaluation of the hip joints in ankylosing spondylitis patients with active disease

J. J. De Winter (Netherlands)
M. C. Turina, J. E. Paramarta, M. Gamala, N. Yeremenko, R. Landewé, D. L. Baeten
Abstract N° SAT0278
Clinical and imaging signs of spondyloarthritis in first degree relatives of HLA-B27 positive ankylosing spondylitis patients: the pre-spondyloarthritis (pre-SpA) cohort

E. Klingberg (Sweden)
G. Oleröd, O. Hammarsten, H. Forsblad-d’Elia
Abstract N° SAT0279
The vitamin D status in ankylosing spondylitis in relation to intestinal inflammation, disease activity, osteoproliferation, bone mineral density and vertebral fractures

A.-K. Tausche (Germany)
Abstract N° SAT0307
Lesinurad monotherapy in gout patients intolerant to xanthine oxidase inhibitors (light): a randomized, double-blind, placebo-controlled, 6-month phase III clinical trial

J. Rech (Germany)
Abstract N° SAT0308
Tophus resolution with pegloticase - a prospective dual energy computed tomography study

S7: Bone diseases other than metabolic and crystals

Chairperson(s):
Eliseo Pascual (Spain)
Abhishek Abhishek (United Kingdom)

J. W. Lee (Republic of Korea)
S. G. Lee, G. T. Kim, E. K. Park, H. O. Kim
Abstract N° SAT0305
Determinants of erectile dysfunction in patients with gout

A. M. Wennenmers (Netherlands)
I. Meek, R. Bakker, T. Janssen
Abstract N° SAT0306
Real life gout efficacy data: over 80% of crystal-proven patients in an academic setting are cured by SUA level targeted treatment including step-up two modes of action combination therapy

10:10 - 11:50 Hall 6

Poster tour

M. J. Gonçalves (Portugal)
V. C. Romao
Abstract N° SAT0310
Diffuse idiopathic skeletal hyperostosis (DISH) in the renaissance Italian aristocracy: bringing evidence from the past

P. Vela (Spain)
V. Jovani, M. Andrés, E. Pascual
Abstract N° SAT0311
The shape of calcium pyrophosphate crystals determines their intensity of birefringence

A. Adinolfi (Italy)
Abstract N° SAT0312
Ultrasound reliability in the diagnosis of calcium pyrophosphate deposition disease: agreement between observers and main causes of discordance

R. Terkeltaub (United States)
F. Perez-Ruiz, C. Storgard, M. Fung, J. Kopicko, N. Dalbeth
Abstract N° SAT0313
Relationship between sustained lowering of serum urate levels and improvements in gout flares and tophus area: pooled exploratory analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitor combination therapy

J.-S. Song (Republic of Korea)
S. T. Choi, E.-H. Park
Abstract N° SAT0309
The utility of spot urine uric acid to creatinine ratio for predictor of 24-hour urine acid excretion in gouty patients

M. J. Gonçalves (Portugal)
V. C. Romao
Abstract N° SAT0310
Diffuse idiopathic skeletal hyperostosis (DISH) in the renaissance Italian aristocracy: bringing evidence from the past

A. Adinolfi (Italy)
Abstract N° SAT0312
Ultrasound reliability in the diagnosis of calcium pyrophosphate deposition disease: agreement between observers and main causes of discordance

R. Terkeltaub (United States)
F. Perez-Ruiz, C. Storgard, M. Fung, J. Kopicko, N. Dalbeth
Abstract N° SAT0313
Relationship between sustained lowering of serum urate levels and improvements in gout flares and tophus area: pooled exploratory analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitor combination therapy

F. Perez-Ruiz (Spain)
S. P. Chinchilla, I. Urionagüena
Abstract N° SAT0314
Impact of urate-lowering therapy in the risk of acute inflammation episodes during hospital admissions in patients with gout
Poster tour

S8: Sjögren's - pathogenesis and treatment targets

Chairperson(s):
Reinhard E. Voll (Germany)
Antigoni Triantafyllopoulou (Germany)
S. Nayar (United Kingdom)
J. Campos, C. Buckley, R. A. Allen, W. A. Fahy, A. Payne, F. Barone

Abstract N° SAT0370
PI3Kδ pathway a novel therapeutic target for Sjögren's syndrome
J. A. Ice (United States)
I. Adrianto, H. Li, A. Rasmussen, G. B. Wiley,
D. U. Stone, B. M. Segal, N. L. Rhodus, L. Radfar,
J. A. James, C. G. Montgomery, R. H. Scofield,
P. M. Gaffney, L. F. Thompson, A. D. Farris, S. Kovats,
J. D. Wren, K. L. Sivils, C. J. Lessard

Abstract N° SAT0371
Characterization of a Sjögren's syndrome-associated long non-coding RNA at 2p25.1
S. Aguilera (Chile)
M.-J. Barrera, E. Veerman, J. Cortés, S. González,
D. Díaz-Jiménez, I. Castro, C. Molina, V. Bahamondes,
C. Leyton, M. Hermoso, M.-J. González

Abstract N° SAT0372
Ectopically secreted mucins might perpetuate the inflammation in salivary glands of Sjögren's syndrome patients
G. Guggino (Italy)
F. Ciccia, S. Raimondo, R. Alessandro, F. Dieli, G. Triolo,
G. Sireci

Abstract N° SAT0373
Role of iNKT cells in patients with primary Sjögren's syndrome
F. Ciccia (Italy)
R. Alessandro, C. Alessandri, R. Priori, G. Guggino,
S. Raimondo, R. Giacomelli, G. Valesini, A. Rizzo, G. Triolo

Abstract N° SAT0374
IL-36A axis is modulated in patients with primary Sjögren's syndrome and implicated in the regulation of gamma-delta T cells immune functions
J. Campos (United Kingdom)
S. Nayar, M.-M. Chung, D. R. Withers, G. Carlesso,
R. Herbst, C. D. Buckley, F. Barone

Abstract N° SAT0375
ICos-ICosL modulates tertiary lymphoid organ formation, regulating the lymphotxin pathway in an animal model of Sjögren's syndrome
K.-E. Lee (Republic of Korea)
J.-W. Lee, D.-J. Park, S.-S. Lee

Abstract N° SAT0376
Predictive significance of CCL21 and CXCL13 levels in the minor salivary glands of patients with Sjögren's syndrome
A. Alunno (Italy)
V. Caneparo, F. Carubbi, O. Bistoni, S. Caterbi,
E. Bartolini, R. Giacomelli, M. Gariglio, S. Landolfo,
R. Gerli

Abstract N° SAT0377
Interferon gamma-inducible protein 16 (IFI16) in primary Sjögren's syndrome: a novel player in disease pathogenesis?
C. Alessandri (Italy)
F. Ciccia, R. Priori, E. Astorri, G. Guggino, R. Alessandro,
A. Rizzo, F. Conti, A. Minniti, C. Barbati, M. Vomero,
P. M. Pendolino, E. Ortona, T. Colasanti, M. Pierdominici,
W. Malorni, G. Triolo, G. Valesini

Abstract N° SAT0378
Autophagy is up-regulated in the salivary glands of primary Sjögren's syndrome patients and correlates with the focus score and disease activity
J. E. Gottenberg (France)
R. Seror, J. Benessiano, V. Devauchelle-Pensec,
P. Dieude, J. J. Dubost, A. L. Fauchais, V. Goeb,
E. Hachulla, P. Y. Hatron, C. Larroche, V. Le Guern,
C. Micelli-Richard, J. Morel, A. Perdriger, X. Puéchal,
S. Rist, A. Saura, D. Sene, J. Sibilia, O. Vittecoq,
G. Nocturne, P. Ravaud, X. Mariette

Abstract N° SAT0381
Is fatigue immune-mediated in primary Sjögren's syndrome? Data from the prospective ASSESS cohort
S. Aguilera (Chile)
D. Sepúlveda, M.-J. Barrera, V. Bahamondes, I. Castro,
C. Molina, J. Cortés, S. González, C. Leyton,
M.-J. González

Abstract N° SAT0382
Impaired IRE1ΑLPHA/XBP-1 pathway is associated with glandular dysfunction in Sjögren's syndrome
S. Bosello (Italy)
G. Peluso, F. Iavarone, T. Cabras, I. Messana,
M. Castagnola, G. Ferraccioli

Abstract N° SAT0383
Different S100 protein salivary patterns characterized Sjögren's syndrome patients and patients with connective tissue diseases and sicca syndrome

Poster tour

S9: SLE, Sjögren's, APS - clinical aspects

Chairperson(s):
Dimitrios Vassilopoulos (Greece)
Christina Tsalapaki (Greece)
D. Corne (France)
S. Costa, S. Schutz, A. Uguen, I. Quintin-Roué,
A. Lesourd, J.-O. Pers, P. Marcourelles, A. Saraux,
V. Devauchelle-Pensec

Abstract N° SAT0384
B and T cells count in minor salivary glands of primary Sjögren's syndrome: development and validation of a digital procedure
A. C. Vikerfors (Sweden)
F. Mobarrez, J. Gustafsson, I. Gunnarsson, A. Zickert, H. Wallen, E. Svenungsson
Abstract N° SAT0383
Microparticles in 290 SLE patients and matched controls and their relationship to vascular disease

S. Jousse (France)
Abstract N° SAT0384
Multireader reliability using US in salivary glands: an international web exercice to evaluate a new US scoring (NUSC) in primary Sjögren’s syndrome

N. Györi (Sweden)
A. Chatzidionysiou, L. Magder, R. van Vollenhoven, M. Petri
Abstract N° SAT0385
Disease activity patterns over time in patients with SLE - a retrospective descriptive analysis of the Hopkins lupus cohort

Z. Touma (Canada)
Abstract N° SAT0386
What is the best screening test to identify lupus patients with cognitive impairment in an ambulatory setting?

H. Devilliers (France)
Abstract N° SAT0387
Validation of lupus impact tracker (LIT) in five European clinical practice settings

J. G. Hanly (Canada)
on behalf of the Systemic Lupus International Collaborating Clinics (SLICC)
Abstract N° SAT0388
Mood disorders in systemic lupus erythematosus (SLE): results from an international, inception cohort study

P. Henrot (France)
Abstract N° SAT0389
Assessment of subclinical atherosclerosis in systemic lupus erythematosus: a systematic review and meta-analysis

A. Jönsen (Sweden)
R. E. Ingvarsson, A. J. Landgren, A. A. Bengtsson
Abstract N° SAT0390
Increased mortality in systemic lupus erythematosus over 30 years of follow-up

I. Rúa-Figueroa (Spain)
Abstract N° SAT0391
Cumulative incidence and clinical meaning of severe infection in a large Spanish cohort of systemic lupus erythematosus

Poster tour
S10: Scleroderma - clinical aspects and treatment

Chairperson(s):
Nemanja Damjanov (Serbia)
Mislav Radic (Serbia)
K. Stefanantoni (Italy)
N. Iannace, I. Sciarra, M. Vasile, M. Caucci,
M. C. Saturno, G. Valesini, V. Ricciere
Abstract N° SAT0432
Performance of the new EULAR/ACR 2013 classification criteria for systemic sclerosis in the clinical practice: a single center experience

D. Khanna (United States)
Abstract N° SAT0433
Safety and tolerability of Pirfenidone in patients with systemic sclerosis-associated interstitial lung disease - the LOTUSS study

M. Radić (Croatia)
M. O. Becker, O. Distler, D. Huscher, G. Riemekasten
Abstract N° SAT0434
Does Angiotensin and Endothelin receptor blockade have an impact on lung function? An analysis from the EUSTAR data base

V. Codullo (Italy)
L. Cavagna, S. Ghio, C. A. Scirè, E. Guzzafame, L. Scelsi, S. Rossi, C. Montecucco, R. Caporali
Abstract N° SAT0435
Undiagnosed connective tissue diseases in pulmonary arterial hypertension patients: baseline and follow-up results from a PAH referral centre

A. Tjärnlund (Sweden)
Abstract N° SAT0436
Abatacept in the treatment of adult dermatomyositis and polymyositis: ARTEMIS, a randomized, treatment delayed-start trial
W. van den Hombergh (Netherlands)
J. Fransen, H. K. Knaapen-Hans, F. H. van den Hoogen, M. C. Vonk
Abstract N° SAT0437
Occurrence of organ involvement in early systemic sclerosis

Y. Allanore (France)
C. P. Denton, T. Krieg, P. Cornelisse, D. Rosenberg, B. Schwierin, M. Matsuć-Cerinic
Abstract N° SAT0438
Clinical characteristics of systemic sclerosis patients with digital ulcer disease who developed gangrene: data from the DUO registry

R. Dobrota (Switzerland)
B. Maurer, N. Graf, C. Milhaj, O. Kowal-Bielecka, Y. Allanore, O. Distler
Abstract N° SAT0439
Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis - a EUSTAR analysis

P. Moinzadeh (Germany)
Abstract N° SAT0440
New data on renal crisis and predictive markers from more than 3000 patients

M. S. Stoenoiu (Belgium)
C. Galant, M. Vanthuyne, A. Nzeusseu-Toukap, O. Cornu, O. Barbier, F. Lecouvet, F. A. Houssiau
Abstract N° SAT0441
Specific imaging and histological features of systemic sclerosis-related synovitis - a comparison with other arthritides

L. A. Saketkoo (United States)
M. R. Lammi, A. Fischer, J. Molitor, V. D. Steen on behalf of the PHAROS Investigators
Abstract N° SAT0442
Mycophenolate mofetil (MMF) use in scleroderma patients with pulmonary hypertension: FVC, outcomes and survival - observations from the pulmonary hypertension recognition and outcomes in scleroderma (PHAROS) cohort

J. Meijs (Netherlands)
A. Schouffoer, N. Ajmone Marsan, T. Stijnen, M. Ninaber, T. Huizinga, J. de Vries-Bouwstra
Abstract N° SAT0443
A prediction model for progressive disease in systemic sclerosis

10:10 - 11:50  Hall 5

PReS Poster tour

S11: Clinical aspects of paediatric rheumatic diseases 2

Chairperson(s):
Francesco Zulian (Italy)
Juan C. Nieto-Gonzalez (Italy)
F. De Benedetti (Italy)
N. Ruperto, H. Brunner, A. Grom, N. Wulffraat, M. Henrickson, R. Jerath, Y. Kimura, A. K. Kadva, C. Keane, J. Wang, S. Wimalasundera, P. Gokani, A. Martini, D. Lovell on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG)

Abstract N° SAT0483
Tapering and withdrawal of Tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study

R. Caorsi (Italy)
A. Grossi, A. Insalaco, M. Alessio, S. Martino, E. Cortis, A. Morracele, F. Caroli, A. Martini, I. Ceccherini, M. Gattorno
Abstract N° SAT0484
Prevalence of CECR1 mutations in paediatric patients with polyarteritis nodosa, livedo reticularis and/or stroke

M. M. Katsicas (Argentina)
R. A. Russo
Abstract N° SAT0485
Patients with early-onset juvenile spondyloarthropaties: a distinct population

A. Horne (Sweden)
Abstract N° SAT0486
Macrophage activation syndrome and familial hemophagocytic lymphohistiocytosis: is their clinical phenotype really similar?

M. Tsukanaka (Norway)
V. Halvorsen, I. Ø. Engesæter, L. B. Engesæter, L. Nordsetten, S. M. Röhrl
Abstract N° SAT0487
Long time outcome of total hip replacement in teenage patients with systemic inflammatory diseases

S. Lanni (Italy)
A. Ravelli, F. Bovis, S. Viola, F. Magnaguagno, G. M. Magnano, C. Gandolfo, A. Martini, C. Malattia
Abstract N° SAT0488
Therapy-induced changes in US-detected synovial abnormalities in juvenile idiopathic arthritis
M. Romano (Italy)
A. Salmaso, S. Lodi-Rizzini, M. Gattinara, I. Pontikaki, P. L. Meroni, V. Gerlone
Abstract N° SAT0489
Disease activity and health status in a cohort of young adults with JIA

L. McCann (United Kingdom)
L. R. Wedderburn, C. Pilkington, A. M. Huber, A. Ravelli, P. Williamson, J. Kirkham, M. W. Beresford
Abstract N° SAT0490
Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use

G. Horneff (Germany)
K. Minden, H. I. Huppertz, K. Tenbrock, J.-P. Haas
Abstract N° SAT0491
Gender specific comorbidities in juvenile idiopathic arthritis patients

B. Abujam (India)
A. Gupta, D. Suri, A. Rawat, S. Singh
Abstract N° SAT0492
Trends and predictors of mortality in childhood onset lupus over twenty four years: a north Indian single centre experience

10:10 - 11:50 Hall 5

Poster tour
S12: Clinical features and treatment aspects of orphan diseases

Chairperson(s):
Ingrid Lundberg (Sweden)
Ivica Jeremc (Serbia)

G. J. Jaffe, MD (United States)
Abstract N° SAT0523
Adalimumab in patients with active, non-infectious uveitis requiring high-dose corticosteroids: the VISUAL-1 trial

J. Kuemmerle-Deschner (Germany)
Abstract N° SAT0524
Evaluation of long-term safety and effectiveness of Canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from BETA-CONFIDENT registry

N. Palmou (Spain)
Abstract N° SAT0525
Tocilizumab compared with Anakinra in refractory adult onset Still’s disease. Multicenter study of 75 patients

K. Yamada (Japan)
Abstract N° SAT0526
Clinical and laboratory features of IgG4-related disease: retrospective Japanese multicenter study of 328 cases

J. Stone (United States)
Z. Wallace, H. Mattoo, V. Mahajan, M. Kulikova, L. Lu, V. Deshpande, H. Choi, S. Pillai
Abstract N° SAT0527
Predictors of disease relapse in IgG4-related disease

J. Stone (United States)
Z. Wallace, V. Deshpande, H. Mattoo, V. Mahajan, M. Kulikova, S. Pillai
Abstract N° SAT0528
IgG4-related disease: baseline clinical and laboratory features in 125 patients

I. Mizushima (Japan)
Abstract N° SAT0529
Impact of pre-treatment renal insufficiency on renal cortical atrophy after corticosteroid therapy in IgG4-related kidney disease: a retrospective multicenter study

E. Della Torre (Italy)
C. Campochiaro, G. Ramírez, A. Berti, M. Lanzillo, E. Bozzolo, L. Dagna, M. G. Sabbadini
Abstract N° SAT0530
Methotrexate for maintenance of remission in IgG4-related disease

G. N. Goulielmos (Greece)
Abstract N° SAT0531
Altered expression levels of MIR-4520A associated with familial Mediterranean fever (FMF)

H. Lachmann (United Kingdom)
M. Cattalini, L. Obici, R. Barcellona, A. Speziale, Y. Joubert, G. Junge, M. Gattorno
Abstract N° SAT0532
Efficacy and safety of Canakinumab in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS)

T. Origuchi (Japan)
Abstract N° SAT0533
Early diagnosis is associated with the less flair in patients with remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome
M. Rodríguez Carballeira (Spain)

Abstract N° SAT0534
Thrombosis and re-thrombosis manifestations in patients with Behçet disease. Descriptive analysis from REGEB cohort

10:10 - 11:50 Hall 5
Poster tour

S13: PsA - outcomes and treatment 2

Chairperson(s):
Douglas Veale (Ireland)
Christopher Edwards (United Kingdom)
L. C. Coates (United Kingdom)
P. S. Helliwell
Abstract N° SAT0556
Methotrexate efficacy in early psoriatic arthritis - open label data from the TICOPA study

D. Sholter (Canada)
Abstract N° SAT0557
Predictors of response in patients with psoriatic arthritis treated with anti-TNF in a real-world setting

E. Vogelzang (Netherlands)
C. L. Krieckaert, M. T. Nurmohamed, E. L. Kneepkens, T. Rispen, A. W. Van Kuijk, G. Wolbink
Abstract N° SAT0558
Association between Etanercept concentrations and disease activity in psoriatic arthritis during 52 weeks of follow-up

D. Fiorentino (United States)
M. Lebwohl, V. Ho, R. Langley, K. Goyal, S. Fakharzadeh, S. Calabro, W. Langhoff
Abstract N° SAT0559
Malignancies in the psoriasis longitudinal assessment and registry (PSOLAR) study: current status of observations

R. Kalb (United States)
Abstract N° SAT0560
Serious infection events in the psoriasis longitudinal assessment and registry study: current status of observations

A. Menter (United States)
Abstract N° SAT0561
Persistence of biologic therapy in psoriatic disease: results from the psoriasis longitudinal assessment and registry (PSOLAR)

A. Wells (United States)
Abstract N° SAT0562
Long-term (104-week) efficacy and safety of Apremilast monotherapy in DMARD-naïve patients with psoriatic arthritis: a phase 3, randomized, controlled trial and open-label extension (PALACE 4)

10:10 - 11:50 Hall 5
Poster tour

S14: Imaging rheumatic diseases: what is new?

Chairperson(s):
Esperanza Naredo (Spain)
Iustina Janta (Romania)
M. A. Bowes (United Kingdom)
Abstract N° SAT0585
Can we stop using contrast in RA MRI clinical trials? Quantitative MRI demonstrates similar responsiveness for contrast and contrast-free synovitis assessment

M. van der Ven (Netherlands)
Abstract N° SAT0586
Ultrasonographic signs of inflammation of metatarsophalangeal joints in rheumatoid arthritis patients who are treated to target

D. F. Ten Cate (Netherlands)
Abstract N° SAT0587
Additional value of baseline ultrasonography in early RA to predict failure to reach DAS28 remission after 1 year of tight-control treatment

A. Mak (Singapore)
R. C. Ho, H. Y. Tng, H. L. Koh, J. S. Chong, J. H. Zhou
Abstract N° SAT0588
Early cerebral volume reduction and regional improvement of prefrontal gray matter volume with reduced lupus disease activity in patients with newly-diagnosed non-neuropsychiatric systemic lupus erythematosus (SLE)

P. Bakker (Netherlands)
Abstract N° SAT0589
Replacing radiographic sacroiliitis by structural lesions on MRI of the sacroiliac joints: impact on the classification of patients according to the asas axial SpA criteria
I. Cohen (Israel)  
C. Putterman, N. Jordan, K. Jakobi, R. Sorek, Y. Blumenstein, S. Batty  
Abstract N° SAT0590  
SLE-key™ rule-out serlogic test for SLE using the immunarray iChip™

A. Atal (India)  
K. Shanmuganandan, D. Bhakuni, K. Sivasami, A. Hegde  
Abstract N° SAT0591  
Fluorodeoxyglucose positron emission tomography/computed tomography in quantification of disease burden in patients of spondyloarthritis on anti tumour necrosis factor biological disease modifying antirheumatic drugs

L. Semerano (France)  
M. Gutierrez, S. Challal, A. Ariani, E. Minichiello, M.-C. Boissier, W. Grassi  
Abstract N° SAT0592  
Diurnal variation of power Doppler signal in metacarpophalangeal joints of patients with rheumatoid arthritis

T. Okano (Japan)  
Abstract N° SAT0593  
Ultrasonographic evaluation of joint damage in knee osteoarthritis: a comparison with conventional radiography

S. Nakabo (Japan)  
Abstract N° SAT0594  
Will anti-cyclic citrullinated peptide antibody-positive connective tissue disease patients develop rheumatoid arthritis? Association with HLA-DRB1 shared epitope

10:10 - 11:50 Hall 5

HPR Poster tour

S15: Evidence based practice

Chairperson(s):  
Annette de Thurah (Denmark)  
Maura D. Iversen (United States)  
K. K. Viktil (Norway)  
L. Damlien, E. Rossum-Iversen, C. L. Olsen, L. Bergmann, T. Borgen  
Abstract N° SAT0638-HPR  
Close the gap - medication discrepancies revealed by medication reconciliation

M. Safridova (Czech Republic)  
M. Vranova, L. Linkova, S. Sebkova, J. Belacek, S. Fingerhutova, M. Bohm, D. Nemcova, P. Dolezalova  
Abstract N° SAT0639-HPR  
Strengthening the role of multidisciplinary team: can we further improve quality of life of patients with JIA?

S. Otter (New Zealand)  
S. Kumar, P. Gow, N. Dalbeth, M. Corkill, K. A. Davies, S. Panthakalam, K. Rome  
Abstract N° SAT0640-HPR  
Foot problems in patients with systemic lupus erythematosus; under-recognised and under-treated?

C. H. van den Ende (Netherlands)  
L. Willems, L. Kwakkenbos, M. C. Vonk, F. H. van den Hoogen, T. P. Vliet Vlieland  
Abstract N° SAT0641-HPR  
Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study

J. Poole (United States)  
Abstract N° SAT0642-HPR  
Mothers with scleroderma and systemic lupus erythematosus: challenges, limitations, and adaptation

E. Cramp (United Kingdom)  
J. Withall, A. Haase, N. Walsh, A. Young, S. Hewlett  
Abstract N° SAT0643-HPR  
Development of a physical activity programme for people with recently diagnosed rheumatoid arthritis

E. De Cuyper (Belgium)  
V. De Gucht, S. Maes, Y. Van Camp, M. M. Elseviers, L. S. De Clerck  
Abstract N° SAT0644-HPR  
Determinants of Methotrexate adherence in rheumatoid arthritis patients

J. Meesters (Netherlands)  
R. Koele, M. van Gestel, R. Smeets, T. Vliet Vlieland  
Abstract N° SAT0645-HPR  
Which problems in functioning are identified before and improve after a multidisciplinary rehabilitation program for chronic musculoskeletal pain?

12:00 - 13:30 Hall 9

What is New (WIN)

WIN session 9

Anisur Rahman (United Kingdom) 12:05  
Abstract N° SP0224  
SLE-APS

Raashid Luqmani (United Kingdom) 12:45  
Abstract N° SP0225  
Vasculitis

12:00 - 13:30 Hall 8

Clinical Science session

Viral infections and biologics

Learning objectives:  
Understand how we can tackle viral infections in the context of biologics
Chairperson(s):
Mauro Keiserman (Brazil)
Jose Vaz Patto (Portugal)
Rui Marinho (Portugal) 12:05
HBV - how should we manage anti-HBC positive patients?

Kevin Winthrop (United States) 12:25
How to tackle zoster, immunisation and other viruses with background immunosuppression

Maria Jose Santos (Portugal) 12:45
Abstract N° SP0226
Biologic-induced immunodeficiency - is it an issue?

R. Costello (United Kingdom) 13:05
K. Winthrop, S. R. Pye, W. Dixon
Abstract N° OP0301
Vaccination uptake in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drug therapy: a retrospective cohort study using UK primary care electronic medical records

M. Krutikov (United Kingdom) 13:15
J. Lambourne, J. Manson
Abstract N° OP0302
The current Chikungunya epidemic - useful information for rheumatologists

12:00 - 13:30  Hall 3
Challenges in Clinical Practice session
Poly-autoimmune diseases

Learning objectives:
To inform about the coexistence of different diseases in a single patient in terms of pathophysiology, genetics, epidemiology and clinical aspects

Chairperson(s):
Juan M. Anaya (Colombia)
Eugen Feist (Germany)

Carolina Duarte-Rey (Colombia) 12:05
Abstract N° SP0227
Case 1 presentation: Arthritis, lupus and more. Rhupus or polyautoimmunity?

Juan Manuel Anaya (Colombia) 12:15
Abstract N° SP0228
Case 1 discussion: The coexistence of two or more autoimmune diseases in a single patient: diagnosis and significance

Muriel Elhai (France) 12:45
Abstract N° SP0229
Case 2 presentation: Primary biliary cirrhosis associated with systemic sclerosis: a milder disease?

Yannick Allanore (France) 12:55
Abstract N° SP0230
Case 2 discussion: The co-occurrence of other autoimmune diseases within patients with systemic sclerosis

12:00 - 13:30  Room 10 F-G
How to Treat / Manage (HOT)

HOT session 10

Oliver Fitzgerald (Ireland) 12:05
Abstract N° SP0231
Psoriatic arthritis

Martin Rudwaleit (Germany) 12:45
Abstract N° SP0232
Ankylosing spondylitis

12:00 - 13:30  Hall 2
Clinical Science session
Treatment and prognosis for OA beyond the knee

Learning objectives:
To mention hallmarks of hand, hip and patellofemoral osteoarthritis, their differences in comparison to tibiofemoral osteoarthritis and apply specific treatment options

Chairperson(s):
Dennis McGonagle (United Kingdom)
Els van den Ende (Netherlands)

Leonardo Punzi (Italy) 12:05
Abstract N° SP0233
Hand OA

George M. Peat (United Kingdom) 12:25
Patellofemoral OA as cause of knee pain

Sita Bierma-Zeinstra (Netherlands) 12:45
Abstract N° SP0234
Hip OA: does it require specific treatments

J. K. Park (Republic of Korea) 13:05
Abstract N° OP0303
Efficacy and safety of GCSB-5 for hand osteoarthritis treatment: a placebo-controlled, double-blind, randomized trial

N. Basoski (Netherlands) 13:15
W. Lee, L. Ruijgrok, M. Kloppenburg, B. Boxma, M. R. Kok, A. E. Weel
Abstract N° OP0304
Efficacy of hydroxychloroquine in primary hand osteoarthritis: a randomized, double-blind, placebo controlled trial
Joint Outcome/HPR session

Quality indicators - a way to measure the quality of care

Learning objectives:
- To understand how quality indicators are developed
- To learn which quality indicator sets currently exist
- To learn how quality indicators can be used to assess and monitor quality of care

Chairperson(s):
Anthony Redmond (United Kingdom)
Annette de Thurah (Denmark)
Anthony Wolf (United Kingdom)

Abstract N° SP0235
How to develop quality indicators
Estibaliz Loza (Spain)

Abstract N° SP0236
Quality indicator sets for the care of rheumatic diseases
John J. Edwards (United Kingdom)

Abstract N° SP0237
An overview of quality indicators for the management of osteoarthritis in primary care
Linda Li (Canada)

Abstract N° SP0238
How can quality indicators be used to assess or monitor quality of care?

W. F. Peter (Netherlands)

E. J. Hurkmans, P. J. van der Wees, E. J. Hendriks, L. van Bodegom-Vos, T. P. Vliet Vlieland

Abstract N° OP0305-HPR
Quality indicators for physiotherapy management in hip and knee osteoarthritis and rheumatoid arthritis; development and measurability

Basic and Translational Science session

Microvesicles and intracellular transport

Learning objectives:
- In the microvesicle session the audience will gather information on:
  - Various forms of microparticles including microvesicles involved in biological processes
  - Role of microvesicles in the pathogens is of rheumatic diseases and possibilities of targeting
  - Role of platelet-derived microparticles in inflammatory mechanisms

Chairperson(s):
Gyorgy Nagy (Hungary)
Serena Guiducci (Italy)

Abstract N° SP0240
Extracellular vesicles - state of the art of a new paradigm in biology
Gyorgy Nagy (Hungary)

Abstract N° SP0241
Extracellular vesicles in rheumatic diseases
Eric Boilard (Canada)

Abstract N° SP0242
The role of platelets and platelet derived extracellular vesicles in rheumatology

P. Carpintero-Fernández (Spain)

P. Fernández-Puente, R. Raquel Gago-Fuentes, F. J. Blanco, P. R. Brink, M. D. Mayán

Abstract N° OP0308
Cell-to-cell communication via gap junctions between cartilage, synovial membrane and subchondral bone: implications for joint homeostasis
**12:00 - 13:30 Room 10 D-E**

### Basic and Translational Science session

#### Why psoriasis in arthritis

**Learning objectives:**
- Participants will gain insight into genetic and environmental mechanisms that explain why psoriasis may develop in arthritis patients and also why psoriatic patients may develop arthritis

**Chairperson(s):**
- George Goulielmos (Greece)
- Pascal Richette (France)

**Jose U. Scher (United States)**

Abstract N° SP0243

Microbiome in PsA

**Dominique Baeten (Netherlands)**

Abstract N° SP0244

An update on the role of cytokines in PsA

**Anne Barton (United Kingdom)**

Abstract N° SP0244

Genetics of PsA: what is special?

---

**12:00 - 13:30 Room 10 C**

### The Young Rheumatologist

#### The art of teaching rheumatology

**Learning objectives:**
- To assess the current status of rheumatology teaching programs in Europe and the US
- To define the educational needs of young trainees in rheumatology
- To find ways to enrich the teaching environment in rheumatology

**Chairperson(s):**
- Dimitrios Vassilopoulos (Greece)
- Christian Beyer (Germany)

**Francisca Sivera (Spain)**

Abstract N° SP0245

The European status quo and the educational needs of young rheumatologists

**Bernadette Siaton (United States)**

Abstract N° SP0246

The US experience

**Janet Hafler (United States)**

Abstract N° SP0247

How to create a rich learning environment

**Y. El Miedany (Egypt)**

Abstract N° OP0312

Simulated teaching in rheumatology: assessment of an interactive e-learning postgraduate rheumatology teaching module

**E. Nikiphorou (United Kingdom)**

Abstract N° OP0313

The use and impact of social media in modern rheumatology practice based on a survey by the emerging EULAR network (EMEUNET)

---

**12:00 - 13:30 Room 10 A**

### Breaking down barriers - implementing non pharmacological guidelines in clinical practice

**Learning objectives:**
- To define implementation science in health care
- To identify and recognize barriers and facilitators for implementation of guidelines in clinical practice
- To exchange experiences about barriers for implementations and strategies to overcome these barriers

**Chairperson(s):**
- Nina Østerås (Norway)
- Yvette Neijland (Netherlands)
Yvonne van Eijk-Hustings (Netherlands) 12:05
Abstract N° SP0248
Introduction: search and you will find. How EULAR recommendations are developed and implemented on national level

Ingrid Põldemaa (Estonia) 12:23
Abstract N° SP0249
The need for lay versions of guidelines to better educate patients and to improve compliance and get better health outcomes

Philip van der Wees (Netherlands) 12:41
Abstract N° SP0250
Implementing non-pharmacological guidelines in clinical practice

Krysia Dziedzic (United Kingdom) 12:59
Abstract N° SP0251
Barriers and facilitators in the MOSAICS project

M. Heslinga (Netherlands) 13:17
I. Oever, van den, M. J. L. Peters, W. Lems, A. E. Voskuyl, D. Schaardenburg, van, Y. M. Smulders, M. Boers, M. T. Nurmohamed
Abstract N° OP0314
Is cardiovascular risk management in patients with rheumatoid arthritis effective? Two year follow up reveals unexpected rise in cardiovascular risk!

12:00 - 13:30  SC2 - Room A

PARE session
Taking control: success through empowerment and self-management

Learning objectives:
• How to empower hard-to-reach people with rheumatic and musculoskeletal diseases
• Top tips for self-management
• How to reach my personal goals

Chairperson(s):
Jacob A. Holch (Denmark)
Kate Betteridge (United Kingdom)
Gráinne O’Leary (Ireland)

Gráinne O’Leary (Ireland) 12:05
Abstract N° SP0252
The case for self-management - 9 years of positive patient outcomes

Codruţa Zabalan (Romania) 12:25
Abstract N° SP0253
Introducing the concept of self-management in Southern Europe. Challenges of the Agora partner in treatment initiative

Kate Gadsby (United Kingdom) 12:45
Abstract N° SP0254
How does shared decision-making affect outcomes

Charlotte Secher Jensen (Denmark) 13:05
Stene Prize winner 2015: Taking control of my life - working together with health professionals to achieving my personal goals

J. Rickmann (Denmark) 13:15
B. Schiøttz-Christensen, A. Dam
Abstract N° OP0315-PARE
Rheumabuddy, a smartphone App, used to empower patients with rheumatoid arthritis

12:00 - 13:30  Room 8 A

Practical skills session*
Ultrasound advanced II

Learning objectives:
• When and how to best apply contrast in US
• How to use US in evaluation and diagnosis of the bespoken disease manifestations

Chairperson(s):
Annamaria Iagnocco (Italy)
Marcin Szkudlarek (Denmark)

Louise Diederichsen (Denmark) 12:05
How useful are contrast agents in US for myositis? Demo

Joelle Decamps (France) 12:25
How to evaluate subclinical atherosclerosis with US of the carotid artery + demo

Georgios Filippou (Italy) 12:45
How to evaluate CPPD using ultrasound + demo

Hilde Berner Hammer (Norway) 13:05
How to enhance synovitis detection: impact of joint position and scanning technique + demo

12:00 - 13:30  Room 9 A

Practical skills session*
ABC of biopsies: when to perform and how to interpret II

Learning objectives:
Learn when to perform and how to interpret biopsies

Chairperson(s):
Pedro Machado (Portugal)
Karen Salomon-Escoto (United States)
Costantino Pitzalis (United Kingdom)

Aike Kruize (Netherlands) 12:05
Diagnostic & prognostic value of synovial histopathology in RA

Costantino Pitzalis (United Kingdom) 12:05
Novel insights in Sjögren’s syndrome salivary gland histopathology

Jérôme Avouac (France) 12:45
Histopathology of systemic sclerosis: the skin and beyond

Ingrid Lundberg (Sweden) 13:05
Histopathology of inflammatory myositis

* In order to participate in this session, please register at the poster tours & workshops desk, located in the registration area in Hall 7
13:45 - 14:45  Hall 8

**Highlight session**

**Clinical/Basic/Translational**

**Chairperson(s):**
Maya Buch (United Kingdom)
Dirk Elewaut (Belgium)

Maxime Breban (France) 13:50
Basic and translational science highlights

João E. Fonseca (Portugal) 14:15
Clinical science highlights

13:45 - 14:45  Room 10 A

**Highlight session**

**Health Professionals**

**Chairperson(s):**
Emalie Hurkmans (Netherlands)
Agnes Kocher (Switzerland)
Désirée van der Heijde (Netherlands) 13:50
Highlights from the Scientific programme

Mathilda Bjork (Sweden) 14:08
Highlights from the Health Professional programme

Souzi Makri (Cyprus) 14:26
Highlights from the PARE programme

13:45 - 14:45  SC2 - Room A

**Highlight session**

**PARE**

**Chairperson(s):**
Diana Skingle (United Kingdom)
Marios Kouloumas (Cyprus)
Nina Brodin (Sweden) 13:50
Highlights from the Health Professional programme

Jürgen Braun (Germany) 14:15
Highlights from the Scientific programme
Guided Poster Tours

Saturday 13 June 2015

Please note that you need to register in order to participate in a guided poster tour. The number of participants per poster tour is limited to 20. Registrations can be made at the poster tours & workshop desk, located in the registration area in Hall 7, on a "first-come-first-served" basis on the day of the poster tour.

Poster tour S1: Cytokines and inflammatory mediators

Chairperson(s): Frank Buttgereit (Germany), Ulf Müller-Ladner (Germany)


SAT0005 IL22 REGULATES AUTOANTIBODY PRODUCTION BY INDUCING LYMPHOID CHEMOKINE EXPRESSION IN TERTIARY LYMPHOID ORGANS / S. Nayar* - J. Campos - T. Cloake - S. Bowman - M. Bombardieri - C. Pitzalis - S. Luther - C. Buckley - F. Barone


SAT0008 SPIRONOLACTONE ABROGATES PRODUCTION OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ARTHRITIS VIA INACTIVATION OF NUCLEAR FACTOR-KAPPA B / A. Syngle* - I. Verma

Poster tour S2: Cartilage - bone - synovium: life in the joint

Chairperson(s): Rik Lories (Belgium), Barbara Neerinckx (Belgium)


* Presenting author
SAT0037  AN ENPPI-SPECIFIC INHIBITOR ATTENUATES EXTRACELLULAR ECTO-PYROPHOSPHATASE ACTIVITY IN HUMAN OSTEOARTHRITIC CARTILAGE / U. Arad* - S. Svetitsky - S. Journo - O. Danino - B. Fischer


SAT0039  INSULIN-INDUCED CARTILAGE DEGRADATION IN OSTEOARTHRITIS IS ASSOCIATED TO DEFECTIVE AUTOPHAGY / B. Carames* - M. Ribeiro - P. Lopez de Figueroa - A. F. Mendes - F. J. Blanco

SAT0040  MACROSCOPIC SCORES OF SYNOVITIS AT KNEE ARTHROSCOPY CORRELATE WELL WITH CRP, INFLAMMATORY HISTOLOGY FINDINGS, AND CAN PREDICT LATER ERODIVE DISEASE ON HANDS AND FEET / C. Orr* - T. McGarry - F. Young - E. Linehan - U. Fearon - D. J. Veale


Poster tour S3: RA - outcome

Chairperson(s): Deborah Symmons (United Kingdom), Helga Radner (Austria)


SAT0057  THE CONVERSION RATE OF TUBERCULOSIS SCREENING TESTS DURING BIOLOGICAL THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS / G. Cuomo* - V. D’Ambrosca - B. Russo - G. Valentini

SAT0058  DMARD-FREE SUSTAINED REMISSION IN RHEUMATOID ARTHRITIS: AN OUTCOME ASSOCIATED WITH SUBSIDENCE OF SYMPTOMS THAT IS INCREASINGLY ACHIEVED WITH IMPROVED TREATMENT STRATEGIES / S. Ajeganova* - H. van Steenbergen - J. van Nies - L. Burgers - T. Huizinga - A. van der Helm-van Mil

SAT0059  CHRONIC KIDNEY DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS: CLINICAL FINDINGS FROM A LONGITUDINAL STUDY OVER 5 YEARS IN A SINGLE TERTIARY HOSPITAL / T. Tokoroyama* - K. Setoguchi - A. Ohita - M. Ando


SAT0061  COMPARISON OF INTENSIVE TREATMENT STRATEGIES IN EARLY RA FROM A SINGLE CENTRE OVER 20 YEARS / J. Dale* - A. Stirling - C. Grigor - S. Saunders - D. Porter

Poster tour S4: RA - comorbidities: the heart at heart

Chairperson(s): Johannes W. J. Bijlsma (Netherlands), Sjoerd Heslinga (Netherlands)


SAT0097  PREDICTING CARDIOVASCULAR RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS / R. Agca* - A. M. van Sijl - A. E. Voskuyl - M. T. Nurmohamed

SAT0098  CHANGES IN METABOLIC PROFILE DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH A. E. Voskuyl - M. T. Nurmohamed

SAT0099  EFFECT OF TNF INHIBITORS ON SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A META-ANALYSIS / T. T. Cheung - M. F. Tsoi* - B. M. Y. Cheung

SAT0100  INCREASED VASCULAR WALL INFLAMMATION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: A META-ANALYSIS / T. T. Cheung - M. F. Tsoi* - B. M. Y. Cheung


* Presenting author


SAT0105  TRIAL OF ATORVASTATIN FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS (TRACE RA) / G. D. Kitas* - P. Nightingale - J. Armitage - N. Sattar - TRACE RA Consortium - J. Belch - D. Symmons

Poster tour S5: RA - small molecules 2  Hall 6

Chairperson(s): João E. Fonseca (Portugal), Vasco C. Romao (Portugal)


SAT0216  ACARBOSE DECREASES THE RISK OF RHEUMATOID ARTHRITIS IN DIABETIC PATIENTS AND ATTENUATES THE INCIDENCE AND SEVERITY OF COLLAGEN-INDUCED ARTHRITIS IN MICE: POPULATION-BASED CASE-CONTROL STUDY AND ANIMAL STUDY / H.-H. Chen* - D.-Y. Chen - C.-C. Lin

SAT0217  LONG TERM EFFECTS OF GLUCOCORTICOID THERAPY ON RADIOLOGICAL PROGRESSION OF JOINT DAMAGE IN RHEUMATOID ARTHRITIS: AN INDIVIDUAL PATIENT META-ANALYSIS / M. C. van der Goes* - J. W. Jacobs - M. Boers - J. R. Kirwan - I. Hafström - B. Svensson - J. W. Bijlsma


SAT0220  RADIOGRAPHIC PROGRESSION IN MODERN RA TRIALS IS STILL A ROBUST OUTCOME: RESULTS OF COMPREHENSIVE SENSITIVITY ANALYSIS IN TWO PHASE 3 TRIALS WITH TOFACITINIB / D. van der Heijde* - C. Connell - J. Bradley - D. Gruben - S. Strømholt - R. B. Landewé


Poster tour S6: SpA clinical abstracts  Hall 6

Chairperson(s): Désirée van der Heijde (Netherlands), Uta Kiltz (Germany)

SAT0270  BACKFILL IS A SPECIFIC SIGN OF AXIAL SPONDYLOARTHITIS SEEN ON MRI / Z. Hu - Q. Lv - J. Qi - Z. Lin - M. Yang - Z. Liao - J. Gu*

SAT0271  DEVELOPMENT OF A NOVEL SI JOINT CT SCORE FOR DIAGNOSIS OF AXIAL SPONDYLITIS / J. Chan* - I. Sari - D. Salonen - N. Haroon - R. D. Inman

SAT0272  INCREASED RISK OF VASCULAR MORTALITY IN AXIAL SPONDYLOARTHRITIS / N. Nigil Haroon* - M. J. Paterson - P. Li - R. D. Inman - N. Haroon

SAT0273  DEATHS ASSOCIATED WITH ANKYLOSING SPONDYLITIS IN FRANCE FROM 1969 TO 2009 / C. Prati* - X. Guillot - D. Wendling

SAT0274  GENETIC (HLA B27), ENVIRONMENTAL (SMOKING) AND INFLAMMATORY (MRI POSITIVITY) FACTORS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC PROGRESSION OF THE SACROILIAC JOINTS IN EARLY AXIAL NON-RADIOGRAPHIC SPONDYLOARTHITIS / M. Dougados* - C. Demattei - R. van den Berg - V. V. Hoang - F. Thevenin - M. Reijnierse - D. Loeuille - A. Feydy - P. Claudepierre - D. van der Heijde

SAT0275  ASSESSING THE BEST REFERRAL STRATEGY FOR AXIAL SPONDYLOARTHITIS: SEVERAL REFERRAL STRATEGIES EVALUATED IN PRIMARY CARE PATIENTS WITH CHRONIC LOW BACK / L. Van Hoeven* - X. Prati - J. Prati - X. Guillot - D. Wendling

SAT0276  CHANGE OF ASDAS OVER 3 MONTHS IS A GOOD PREDICTIVE FACTOR FOR IMPROVEMENT OF METROLOGY INDEX AFTER LONG-TERM TREATMENT WITH TNF-BLOCKERS IN ANKYLOSING SPONDYLITIS / E. J. Nam* - S. H. Kwon - J. S. Eun - N. R. Kim - Y. M. Kang


* Presenting author
**Poster tour S7: Bone diseases other than metabolic and crystals**

**Chairperson(s):** Eliseo Pascual (Spain), Abhishek Abhishek (United Kingdom)

**SAT0305**

**SAT0306**
**REAL LIFE GOUT EFFICACY DATA: OVER 80% OF CRYSTAL-PROVEN PATIENTS IN AN ACADEMIC SETTING ARE CURED BY SUA LEVEL TARGETED TREATMENT INCLUDING STEP-UP TWO MODES OF ACTION COMBINATION THERAPY** / A. M. Wennekem* - I. Meek - R. Bakker - T. Janssen

**SAT0307**

**SAT0308**

**SAT0309**
**THE UTILIZATION OF SPOT URINE URIC ACID TO CREATININE RATIO FOR PREDICTOR OF 24-OUR URINE URIC ACID EXCRETION IN GOUTY PATIENTS** / J.-S. Song* - S. T. Choi - E.-H. Park

**SAT0310**
**DIFFUSE IDIOPATHIC SKELLETAL HYPEROSTOSIS (DISH) IN THE RENAISSANCE ITALIAN ARISTOCRACY: BRINGING EVIDENCE FROM THE PAST** / M. J. Gonçalves* - V. C. Romao

**SAT0311**
**THE SHAPE OF CALCIUM PYROPHOSPHATE CRYSTALS DETERMINES THEIR INTENSITY OF BIREFRINGENCE** / P. Vela* - V. Iovani - M. André - E. Pascual

**SAT0312**

**SAT0313**

**SAT0314**
**IMPACT OF URATE-LOWERING THERAPY IN THE RISK OF ACUTE INFLAMMATION EPISODES DURING HOSPITAL ADMISSIONS IN PATIENTS WITH GOUT** / F. Perez-Ruiz* - S. Chinchilla - I. Urionagüena

---

**Poster tour S8: Sjögren’s - pathogenesis and treatment targets**

**Chairperson(s):** Reinhard E. Voll (Germany), Antigoni Triantafyllopoulou (Germany)

**SAT0370**

**SAT0371**

**SAT0372**

**SAT0373**
**ROLE OF INKT CELLS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME** / G. Guggino* - F. Ciccia - S. Raimondo - R. Alessandro - F. Dieli - G. Triolo - G. Sireci

**SAT0374**

**SAT0375**

**SAT0376**
**PREDICTIVE SIGNIFICANCE OF CCL21 AND CXCL13 LEVELS IN THE MINOR SALIVARY GLANDS OF PATIENTS WITH SJÖGREN’S SYNDROME** / K.-E. Lee* - J.-W. Lee - D.-J. Park - S.-S. Lee

**SAT0377**

**SAT0378**

* Presenting author
SAT0379
IS FATIGUE IMMUNE-MEDIATED IN PRIMARY SJÖGREN'S SYNDROME? DATA FROM THE PROSPECTIVE ASSESS

SAT0380
IMPAIRED IRE1ALPHA/XBP-1 PATHWAY IS ASSOCIATED WITH GLANDULAR DYSFUNCTION IN SJÖGREN'S SYNDROME / D. Sepúlveda - S. Aguilera* - M.-J. Barrera - V. Bahamondes - I. Castro - C. Molina - J. Cortés - S. González - C. Leyton - M.-J. González

SAT0381
DIFFERENT S100 PROTEIN SALIVARY PATTERNS CHARACTERIZED SJÖGREN'S SYNDROME PATIENTS AND PATIENTS WITH CONNECTIVE TISSUE DISEASES AND SICCA SYNDROME / S. Bosello* - G. Peluso - F. Iavarone - T. Cabras - I. Messana - M. Castagnola - G. Ferraccioli

Poster tour S9: SLE, Sjögren's, APS - clinical aspects

Chairperson(s): Dimitrios Vassilopoulos (Greece), Christina Tsalapaki (Greece)

Hall 5

SAT0382

SAT0383
MICROPARTICLES IN 290 SLE PATIENTS AND MATCHED CONTROLS AND THEIR RELATIONSHIP TO VASCULAR DISEASE / A. C. Vikerfors* - M. Mobarrez - J. Gustafsson - I. Gunnarssson - A. Zickert - H. Wällen - E. Svenungsson

SAT0384

SAT0385

SAT0386
WHAT IS THE BEST SCREENING TEST TO IDENTIFY LUPUS PATIENTS WITH COGNITIVE IMPAIRMENT IN AN AMBULATORY SETTING? / S. Nantes - M. Urowitz - D. Gladman - J. Su - A. Dhaliwal - Z. Touma*

SAT0387

SAT0388
MOOD DISORDERS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY / J. G. Hanly* on behalf of the Systemic Lupus International Collaborating Clinics (SLICC)

SAT0389

SAT0390

SAT0391

Poster tour S10: Scleroderma - clinical aspects and treatment

Hall 5

Chairperson(s): Nemanja Damjanov (Serbia), Mislav Radic (Serbia)

SAT0432

SAT0343

SAT0344
DOES ANGIOTENS AND ENDOTHELIN RECEPTOR BLOCKADE HAVE AN IMPACT ON LUNG FUNCTION? - N. Khalidi - L. Chung - E. Schiopu - D. Chen - E. Gorina

SAT0345
INTERSTITIAL LUNG DISEASE - THE LOTUSS STUDY / D. Khanna* - C. Albera - A. Fischer - J. R. Seibold - G. Raghu

SAT0346

SAT0347

SAT0348
WHAT IS THE BEST SCREENING TEST TO IDENTIFY LUPUS PATIENTS WITH COGNITIVE IMPAIRMENT IN AN AMBULATORY SETTING? / S. Nantes - M. Urowitz - D. Gladman - J. Su - A. Dhaliwal - Z. Touma*

* Presenting author


SAT0442 MYCOPHENOLATE MOFETIL (MMP) USE IN SCLERODERMA PATIENTS WITH PULMONARY HYPERTENSION: FVC OUTCOMES AND RESULTS FROM THE PULMONARY HYPERTENSION RECOGNITION AND OUTCOMES IN SCLERODERMA (PHAROS) COHORT / L. A. Saketko* - M. R. Lammi - A. Fischer - J. Mollitor - V. D. Steen on behalf of the PHAROS Investigators


PReS Poster tour S11: Clinical aspects of paediatric rheumatic diseases 2

Chairperson(s): Francesco Zulian (Italy), Juan C. Nieto-Gonzalez (Italy)


SAT0485 PATIENS WITH EARLY-ONSET JUVENILE Spondyloarthopathies: A DISTINCT POPULATION / M. Katsicas* - R. A. Russo


SAT0487 LONG TIME OUTCOME OF TOTAL HIP REPLACEMENT IN TEENAGE PATIENTS WITH SYSTEMIC INFFLAMMATORY DISEASES / M. Tsukanaka* - V. Halvorsen - I. Ø. Engesæter - L. B. Engesæter - L. Nordsletten - S. M. Röhr


SAT0489 DISEASE ACTIVITY AND HEALTH STATUS IN A COHORT OF YOUNG ADULTS WITH JIA / M. Romano* - A. Salmaso - S. Lodi-Rizzini - M. Gattinara - I. Pontikaki - P. L. Meroni - V. Gerloni

SAT0490 DEVELOPMENT OF AN INTERNATIONALLY AGREED MINIMAL DATASET FOR JUVENILE DERMATOMYOSITIS (JDM) FOR CLINICAL AND RESEARCH USE / L. McCann* - L. R. Wedderburn - C. Pilkington - A. M. Huber - A. Ravelli - P. Williamson - J. Kirkham - M. W. Beresford


SAT0492 TRENDS AND PREDICTORS OF MORTALITY IN CHILDHOOD ONSET LUPUS OVER TWENTY FOUR YEARS: A NORTH INDIAN SINGLE CENTRE EXPERIENCE / B. Abujam* - A. Gupta - D. Suri - A. Rawat - S. Singh

Poster tour S12: Clinical features and treatment aspects of orphan diseases

Chairperson(s): Ingrid Lundberg (Sweden), Ivica Jeremic (Serbia)


* Presenting author

SAT0528  IGG4-RELATED DISEASE: BASELINE CLINICAL AND LABORATORY FEATURES IN 125 PATIENTS / Z. Wallace - J. Stone* - V. Deshpande - H. Mattoo - V. Mahajan - M. Kulikova - S. Pillai


SAT0530  METHOTREXATE FOR MAINTENANCE OF REMISSION IN IGG4-RELATED DISEASE / E. Della Torre* - C. Campochiaro - G. Ramirez - A. Berti - M. Lanzillotta - E. Bozzo - L. Dagna - M. G. Sabbadini


**Poster tour S13: PsA - outcomes and treatment 2** Hall 5

Chairperson(s): Douglas Veale (United Kingdom)

SAT0556  METHOTREXATE EFFICACY IN EARLY PSORIATIC ARTHRITIS - OPEN LABEL DATA FROM THE TICOPA STUDY / L. C. Coates* - P. S. Hellwell


**Poster tour S14: Imaging rheumatic diseases: what is new?** Hall 5

Chairperson(s): Esperanza Naredo (Spain), Justina Janta (Romania)


SAT0586  ULTRASONOGRAPHIC SIGNS OF INFLAMMATION OF METATARSOPHALANGEAL JOINTS IN RHEUMATOID ARTHRITIS PATIENTS WHO ARE TREATED TO TARGET / M. van der Ven* - D. Ten Cate - A. Gerards - H. Jacobs - N. Swen - M. de Jager - N. Basoski - C. Haagsma - J. Luime - A. H. Gerards


* Presenting author

SAT0591  FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY IN QUANTIFICATION OF DISEASE BURDEN IN PATIENTS OF SPONDYLOARTHRITIS ON ANTI-TUMOUR NECROSIS FACTOR BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS / A. Atal* - K. Shannuganandan - D. Bhakuni - K. Sivasami - A. Hegde

SAT0592  DIURNAL VARIATION OF POWER DOPPLER SIGNAL IN METACARPOPHALANGEAL JOINTS OF PATIENTS WITH RHEUMATOID ARTHRITIS / M. Gutierrez - S. Challal - A. Ariani - E. Minichiello - M.-C. Boissier - W. Grassi - L. Semerano*


HPR Poster tour S15: Evidence based practice

Chairperson(s): Annette de Thurah (Denmark), Maura D. Iversen (United States)


SAT0642-HPR  MOTHERS WITH SCLERODERMA AND SYSTEMIC LUPUS ERYTHEMATOSUS: CHALLENGES, LIMITATIONS, AND ADAPTATION / J. Poole*

SAT0643-HPR  DEVELOPMENT OF A PHYSICAL ACTIVITY PROGRAMME FOR PEOPLE WITH RECENTLY DIAGNOSED RHEUMATOID ARTHRITIS / F. Cramp* - J. Withall - A. Haase - N. Walsh - A. Young - S. Hewlett

SAT0644-HPR  DETERMINANTS OF METHOTREXATE ADHERENCE IN RHEUMATOID ARTHRITIS PATIENTS / E. De Cuypier* - V. De Gucht - S. Maes - Y. Van Camp - M. M. Elseviers - L. S. De Clerck


* Presenting author
Scientific Poster Session 3

Saturday 13 June 2015

10:00 - 12:00

Cytokines and inflammatory mediators

Hall 6


SAT0005 IL22 REGULATES AUTOANTIBODY PRODUCTION BY INDUCING LYMPHOID CHEMOKINE EXPRESSION IN TERTIARY LYMPHOID ORGANS / S. Nayar* - J. Campos - T. Cloake - S. Bowman - M. Bombardieri - C. Pitzalis - S. Luther - C. Buckley - F. Barone

SAT0006 HIGH SYSTEMIC LDL CHOLESTEROL LEVELS LEAD TO SYNOVIAL ACTIVATION AND STRONGLY ACCELERATE DEVELOPMENT OF ECTOPIA BONE FORMATION DURING EXPERIMENTAL OSTEOARTHRITIS / W. De Munter* - M. H. van den Bosch - S. W. Annet - K. Croce - N. Hogg - T. Vogl - J. Roth - W. B. van den Berg - P. M. van der Kraan


SAT0008 SPIRONOLACTONE ABROGATES PRODUCTION OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ARTHRITIS VIA INACTIVATION OF NUCLEAR FACTOR-KAPPA B / A. Syngle* - I. Verma


SAT0011 AN IL-32 PROMOTER SNP ASSOCIATED WITH LOWER HDL AND ANTI-CCP PROMOTING ATHEROSCLEROSIS IN RA / R. Heinhuis* - M. Damen - S. Holewijn - J. de Graaf - J. Fransen - C. Popa - L. Joosten


SAT0013 MOLECULAR AND CELLULAR REPONSES TO INHIBITION OF JAK-STAT SIGNALLING IN RA SYNOVIAL FIBROBLASTS AND WHOLE TISSUE EXPLANTS / A. Scantu* - E. Linehan - W. Gao - K. Creevey - T. McCarr - C. Marot - D. J. Veale

SAT0014 A NOVEL 3D MODEL OF RHEUMATOID ARTHRITIS SYNOVIAL ANGIOGENESIS TO SCREEN NEW THERAPEUTIC COMPOUNDS / C. X. Maracle* - B. Holder - J. Noort - S. W. Noort


* Presenting author


CENTROSOMAL PROTEIN 70KDA IS DOWN-REGULATED BY DECOY RECEPTOR 3 IN SPECIFICALLY RHEUMATOID SYNOVIAL FIBROBLASTS / K. Fukuda* - Y. Miura - T. Maeda - S. Hayashi - M. Kurosaka

LEPTIN AS PROGNOSTIC MARKER IN OSTEOARTHRITIS PATIENTS / L. Seewordova* - B. Zavadovsky - J. Polyakova - Y. A. Akhverdyan - V. Kravtsov - E. Simakov


EVALUATION OF ENDOMETRIAL NATURAL KILLER CELL DENSITY IN CASES OF UNEXPLAINED INFERTILITY HAVING RHEUMATOID ARTHRITIS / M. H. Nasreldin* - E. S. El Mahgoob - M. H. Nasr El Dein - A. M. Awad Allah

SHIFT IN GENETIC COMPOSITION OF AN IL-32 PROMOTER POLYMORPHISM RESULTS IN A HIGHER CYTOKINE PRODUCTION IN RA PATIENTS / M. Damen* - B. Heimhuis - L. Tweehuysen - A. den Broeder - M. Netea - C. Popa - L. Joosten


SERUM AMYLOID A IS ASSOCIATED WITH CHRONIC INFLAMMATION AND MARKERS OF DISEASE SEVERITY IN ADULT PATIENTS WITH PULMONARY HYPERTENSION / B. Salobir - M. Tercelj - P. Miklar - J. T. Toplišek - L. Joosten

ATTENUATION OF HYALURONAN FRAGMENT INDUCED INFLAMMATORY RESPONSE IN MACROPHAGES BY CHONDROITIN SULPHATE / T. Stabler - J. M. Young - P. van der Kraan

RELEASE OF SECONDARY MEDIATORS OF INFLAMMATION BY HUMAN SECRETORY PHOSPHOLIPASES A2 (SPLA2’S) / W. Pruzanski* - A. Kuksis

TOFACITINIB REGULATES SYNOVIAL INFLAMMATION IN PSORIATIC ARTHRITIS, INHIBITING STAT ACTIVATION AND INDUCTION OF NEGATIVE FEEDBACK INHIBITORS / W. Gao* - T. McGarry - C. Orr - D. J. Veale - U. Fearon

A NOVEL OSTEOGENIC ACTIVITY ASSOCIATED WITH SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) IS SYNERGIZED WITH BMP-2 / Z. H. Lee*

Cartilage, synovium and osteoimmunology


WISP1 AGGRAVATES OSTEOARTHRITIS BY MODULATION OF TGF-B SIGNALING AND POSITIVE REGULATION OF Canonical WNT SIGNALING / M. van den Bosch* - A. Blom - A. Maeda - T. Kilts - W. van den Berg - F. Lafeber - P. van Lent - M. Young - P. van der Kraan


AN ENPP1-SPECIFIC INHIBITOR ATTENUATES EXTRACELLULAR ECTO-PYROPHOSPHATASE ACTIVITY IN HUMAN OSTEOARTHRITIC CARTILAGE / U. Arad* - S. Svetitsky - S. Journo - O. Danino - B. Fischer


INSULIN-INDUCED CARTILAGE DEGRADATION IN OSTEOARTHRITIS IS ASSOCIATED TO DEFECTIVE AUTO PHAGY / B. Carames* - M. Ribeiro - P. Lopez de Figueroa - A. F. Mendes - F. J. Blanco

MACROSCOPIC SCORES OF SYNOVITIS AT KNEE ARTHROSCOPY CORRELATE WELL WITH CRP, INFLAMMATORY HISTOLOGY FINDINGS, AND CAN PREDICT LATER EROSIVE DISEASE ON HANDS AND FEET / C. Orr* - T. McGarry - F. Young - E. Linehan - U. Fearon - D. J. Veale

* Presenting author
Rheumatoid arthritis - prognosis, predictors and outcome

**Hall 6**

SAT0041

SAT0042
CHARACTERIZATION OF LEVELS OF COL3DEL (MMP13 ISOFORM) PROTEIN PRODUCTION AND COLLAGENOLODY ACTIVITY IN HUMAN OSTEOARTHRITIC (OA) SAMPLES / A. Farran* - L. Tio - J. Martel-Pelletier - P. Benito - J. Monfort

SAT0043

SAT0044
CCN4/WISP-1 INDUCES REACTIVE OXYGEN SPECIES PRODUCTION IN OSTEOARTHRITIC SYNOVIAL FIBROBLASTS / C. Premat* - C. Chereau - M. Corvol - C. Chauvet - F. Rannou - D. Borderie

SAT0045

SAT0046

SAT0047

SAT0048
IDENTIFICATION OF GENES REGULATING TRAIL-INDUCED APOPTOSIS IN RHEUMATOID ARTHRITIS FIBROBLASTS-LIKE SYNOVIOCYTES (RA FLS) / J. Morel* - M. Hahne - B. Combe - R. Audo

SAT0049

SAT0050
IL-10 SYNEXERINE INDUCES DIRECT AND INDIRECT STRUCTURAL CARTILAGE REPAIR IN OA / M. F. Pustjens* - C. Steen-Louws - J. A. Van Roon - C. E. Hack - S. C. Mastbergen - F. P. Lafeber

SAT0051

**Rheumatoid arthritis - prognosis, predictors and outcome**

SAT0052

SAT0053

SAT0054

SAT0055

SAT0056

SAT0057
THE CONVERSION RATE OF TUBERCULOCOSS SCREENING TESTS DURING BIOLOGICAL THERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS / G. Cuomo* - V. D’Abrasca - B. Russo - G. Valentini

SAT0058
DMARD-FREE SUSTAINED REMISSION IN RHEUMATOID ARTHRITIS: AN OUTCOME ASSOCIATED WITH SUBSIDENCE OF SYMPTOMS THAT IS INCREASINGLY ACHIEVED WITH IMPROVED TREATMENT STRATEGIES / S. Ajeganova* - H. W. van Steenbergen - J. van Nies - L. Burgers - T. Huizinga - A. van der Helm-van Mil

SAT0059
CHRONIC KIDNEY DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS: CLINICAL FINDINGS FROM A LONGITUDINAL STUDY OVER 5 YEARS IN A SINGLE TERTIARY HOSPITAL / T. Tokoroyama - V. Malmström - H. Wåhåmaa - A. I. Catrina*

SAT0060

SAT0061
COMPARISON OF OUTCOMES BETWEEN STUDIES OF INTENSIVE TREATMENT STRATEGIES IN EARLY RA FROM A SINGLE CENTRE OVER 20 YEARS / J. Dale* - A. Stirling - C. Grigor - S. Saunders - D. Porter

SAT0062

SAT0063
ASSOCIATION OF THE PROGRAMMED DEATH 1 GENE POLYMORPHISM WITH THE DEVELOPMENT OF RHEUMATOID ARTHRITIS IN THE POPULATION OF SOUTH-EASTERN POLAND / A. Swiec - M. Majdan* - M. Ciesieka - R. Mlak - T. Krajka

* Presenting author


SAT0066 VALUE OF ANTINUCLEAR ANTIBODIES IN THE THERAPEUTIC EFFICACY OF BIOLOGICS IN RHEUMATOID ARTHRITIS / C. Mogosan* - C. Codreanu - L. Enache - D. Stanciu - R. Ionescu - D. Opris - S. Rednic - M. Parvu


SAT0080 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN SELF-REPORT QUESTIONNAIRES AND COMPOSITE CLINICAL DISEASE INDEX FOR ASSESSING RHEUMATOID ARTHRITIS. IDENTIFICATION OF CUT-OFF POINTS FOR ROUTINE CARE / F. Safa - M. Carotti - M. Di Carlo* - R. De Angelis - M. Gutierrez


SAT0086 RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND (RANKL) AND SCLOEROSTIN ARE RELATED TO JOINT DESTRUCTION IN EARLY RHEUMATOID ARTHRITIS / S. Rantapää-Dahlqvist* - A. Boman - H. Kokkonen - E. Berglin

* Presenting author
**Rheumatoid arthritis - comorbidity and clinical aspects**

**Hall 6**

**SAT0096**

**SAT0097**

**SAT0098**

**SAT0099**
Effect of TNF inhibitors on subclinical atherosclerosis in patients with rheumatoid arthritis: a meta-analysis / T. T. Cheung - M. F. Tsot* - B. M. Y. Cheung

**SAT1000**

**SAT1001**

**SAT1002**
STEM cell augmentation for cardiovascular risk in patients with rheumatoid arthritis with Olmesartan: STAR-O study / A. Sgle* - N. Garg - P. Krishan

**SAT1003**
The 2013 ACC/AHA 10-year atherosclerotic cardiovascular disease (ASCVD) risk index is better than score and QRisk II in rheumatoid arthritis: is it enough? / G. Ozen* - M. Sunbul - P. A. Cooper - T. Kaczyński - M. T. Nurmohamed

**SAT1004**

**SAT1005**
Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA) / G. D. Kitas* - P. Nightingale - J. Armitage - N. Sattar - TRACE RA consortium - J. Belch - D. Symmons

**SAT1006**
Progression of mild and severe amyloidosis in a deposition in rheumatoid arthritis - a postmortem clinicopathologic study of 161 rheumatoid arthritis patients / Á. Apáthy* - M. Bély

**SAT1007**

**SAT1008**

**SAT1009**
The number of different autoantibodies is associated with phenotypic characteristics at presentation in patients with rheumatoid arthritis / V. Derksen - A. van der Helm- van Mil - T. Huizinga - T. Kaczyński - R. Toes - D. van der Woude*


SAT0113  BETA2-ADRENERGIC RECEPTORS POLYMORPHISMS INCREASE THE RISK OF ARTERIOSCLEROSIS: CLINICAL-ULTRASOUND-GENETIC STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS / O. Malyshева - H. Barghan* - K. Muchilberg - C. Baerwald


SAT0115  RHEUMATOID ARTHRITIS ALSO DISADVANTAGES FEMALE AND YOUNGER PATIENTS FOR CARDIOVASCULAR DISEASE: RESULTS OF A SYSTEMATIC REVIEW WITH META-ANALYSIS / J. Fransen* - S. M. Kazemi-Bajestani - S. J. Brede - C. D. Popa


SAT0117  TREND IN AND PREDICTORS FOR CARDIOVASCULAR MORTALITY IN PATIENTS WITH RHEUMATOID ARTHRITIS OVER A PERIOD OF 15 YEARS: A PROSPECTIVE COHORT STUDY / J. van den Hoek* - L. D. Roorda - H. C. Boshuijn - G. J. Tijhuis - J. Dekker - G. A. van den Bos - M. T. Nurmohamed

SAT0118  CALPROTECTIN STRATIFIES DISEASE ACTIVITY BETTER THAN ACUTE PHASE REACTANTS IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TNF INHIBITORS / J. Inciarte-Mendoza* - M. Fernández-Valdés - M. Hernández - V. Ruiz-Esquide

SAT0119  PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS ASSOCIATIONS WITH DISEASE SEVERITY IN RHEUMATOID ARTHRITIS PATIENTS - DATA FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBR) / K. Cui* - B. Jacob - J. Widdifield - J. Pope - B. Kuriya - P. Akhavan - C. Bombardier


SAT0121  SERUM B-D-GLUCAN-POSITIVE PNEUMOCYSTIS IROVECI-POLYMERASE CHAIN REACTION-NEGATIVE ACUTE BILATERAL LUNG INJURY IS A CLINICAL CONDITION SPECIFIC TO RHEUMATOID ARTHRITIS AMONG SYSTEMIC AUTOIMMUNE DISEASES / K. Yokosuka* - K. Shimada - T. Kunokawa - S. Sugi


SAT0123  INHERITANCE IN RHEUMATIC DISEASES (RHEUMATOID ARTHRITIS) AND IN VITRO FERTILIZATION / M. Panchovska - F. Martinova - N. Nikolov* - D. Stoychev


SAT0126  SPECTRUM OF AMYLOID DEPOSITS (AMYLOIDOSIS) IN RA - A POSTMORTEM CLINICOPATHOLOGIC STUDY OF 161 PATIENTS / J. Bély* - Á. Apáthy


SAT0128  ASSESSMENT OF FATIGUE, SLEEP QUALITY AND MOOD DISTURBANCES IN RHEUMATOID ARTHRITIS AND THEIR RELATION TO DISEASE ACTIVITY AND ANEMIA / N. Hammam* - R. M. Gamal - A. M. Rashed - E. Mohamed - M. Khedr


SAT0131  URIC ACID IS ASSOCIATED WITH METABOLIC SYNDROME IN LONGSTANDING RHEUMATOID ARTHRITIS / R. Agca* - A. M. van Sijl - A. E. Voskuyl - M. T. Nurmohamed

* Presenting author
**Rheumatoid arthritis - anti-TNF therapy**

**Hall 6**

**SAT0139**
ANALYSIS OF OUTCOMES AFTER NON-MEDICAL SWITCHING OF ANTI-TUMOR NECROSIS FACTOR AGENTS / A. Gibofsky* - M. Skup - S. Johnson - J. Chao - D. Rubin

**SAT0140**

**SAT0141**
SAFETY OF ANTI-TNFs IN RA PATIENTS IN REAL LIFE: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSES FROM BIOLOGIC REGISTERS / M. de la Forest - J. Brugneaux - G. Utard - C. Salliot*

**SAT0142**

**SAT0143**

**SAT0144**

**SAT0145**

**SAT0146**

**SAT0147**

**SAT0148**

**SAT0149**

**SAT0150**
OPTIMISING TREATMENT WITH TNF INHIBITORS IN RHEUMATOID ARTHRITIS WITH DIFFERENT DOSE TAPERING STRATEGIES: THE OPTITIRA TRIAL / J. B. Galloway* - G. Kingsley - M. Ma - B. Lorente-Canovas - A. Cope - F. Ibrahim - D. L. Scott

**SAT0151**
SAFETY PROFILE OF BOW015, A BIOSIMILAR INFLIXIMAB, IN HEALTHY SUBJECTS AND PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS / J. Kay* - C. Lassen - L. Trokan - M. Wyand

**SAT0152**

**SAT0153**

* Presenting author
A 6-MONTH INDUCTION TREATMENT WITH INFliximAB ADDED ON INTENSIVE COMBINATION THERAPY WITH CONVENTIONAL DMARDS AND LOW-DOSE PREDNISOLONE SAVES WORK PRODUCTIVITY LOSS DURING THE FIRST TREATMENT YEAR IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS / K. Puolakkas* - H. Kautianen - V. Rantalalho - J. Martikainen - M. Leirisalo-Repo on behalf of NEO-RACo Trial Group


SAT0156 THE EFFECT OF METHOTREXATE IN TREATMENT WITH ADALIMMAB AND ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. Anm* - E. Kneepkens - C. Krieckaert - A. Marsman - J. Ruwaard - G. Wobink - M. T. Nurmohamed


SAT0161 MAJORITY OF PATIENTS DO NOT STORE THEIR BIOLOGICAL DISEASE MODIFYING ANTI-RHEUMATIC DRUGS WITHIN RECOMMENDED TEMPERATURE RANGE / N. D. Vliegend* - H. Gardardssottt - M. L. Bouvy - A. C. Egberts - B. J. van den Bent

SAT0162 TREATMENT TARGET STATUS AT 6 MONTHS AND LONG-TERM OUTCOMES AT 5 YEARS: ANALYSIS OF METHOTREXATE-NAIVE PATIENTS WITH RHEUMATOID ARTHRITIS IN THE GO-BEFORE TRIAL / P. Emery* - R. Fleischmann - S. Xu - E. C. Hia

SAT0163 RISK OF MALIGNANCY AND SEVERE INFECTION IN A POPULATION OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH BIOLOGICS OR DMARDS / Q. Gillaux - M. Stoenoiu - L. Meric de Bellfon - G. Depresseux - A. Nzeusseu Toupak - B. Lauwerys - F. Houssai - P. Durez


SAT0169 HIGH RISK OF FLARES DURING PREGNANCY IN WOMEN WITH RHEUMATOID ARTHRITIS WHO DISCONTINUE TREATMENT WITH TNF-INHIBITORS AT CONCEPTION / R. Fischer-Betz* - O. Sander - C. Specker - R. Brinks - M. Schneider

SAT0170 RISK OF SKIN CANCER FOLLOWING ANTI-TUMOUR NECROSIS FACTOR TREATMENT IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW / R. Chatterjea* - M. Mc Laughlin - I. L. Kuhn - A. Ostór

SAT0171 Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid or Psoriatic Arthritis: Results from the First Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study / S. Wassenberg* - R. Rau - T. F. Cordtz - R. Lippe - U. Lendl - P. A. Loechmann

SAT0172 ESTABLISHING MARGINS TO DEMONSTRATE EQUIVALENTY IN EFFICACY FOR BIOSIMILAR CLINICAL TRIALS IN RHEUMATOID ARTHRITIS PATIENTS: A META-ANALYSIS APPROACH / S. Y. Hua* - K. B. Barker - P. Qu - M. I. Rehman - R. Schaum - S. Visvalingam - J. E. McClellan - S. Salts - A. Al-Sabbagh


* Presenting author
**Rheumatoid arthritis - other biologic treatment**

**Hall 6**

**SAT0174**
CLINICAL EXPERIENCE WITH INFliximAB BIOSIMILAR - SWITCH FROM REMICADE / T. Sokka* - H. Kautiainen

**SAT0175**

**SAT0176**

**SAT0177**

**SAT0178**
READY TO USE CE-IVD SMART ELISA KITS FROM SANQUIN FOR INFliximAB AND ADALIMUMAB LEVELS CORRELATE WITH THE GOLDEN STANDARD AND CAN BE USED FOR OPTIMISATION OF PERSONALISED TREATMENT IN RA PATIENTS / Y. van Hensbergen* - H. te Velthuis
Rheumatoid arthritis - non biologic treatment and small molecules

Hall 6

SAT0215

SAT0216

SAT0217
LONG TERM EFFECTS OF GLUCOCORTICOID THERAPY ON RADIOLOGICAL PROGRESSION OF JOINT DAMAGE IN RHEUMATOID ARTHRITIS: AN INDIVIDUAL PATIENT META-ANALYSIS / M. C. van der Goes* - J. W. Jacobs - W. I. White

SAT0218

* Presenting author
ALREADY AFFECTED BY INFLAMMATION IN THE PAST / D. Poddubnyy* - J. Sieper

NEW INFLAMMATORY LESIONS IN AXIAL SPONDYLOARTHRITIS ARE MORE LIKELY TO OCCUR IN THE AREAS
J. P. Daures - S. Ferkal - P. Le Corvoisier - A. Rahmouni - D. Loeuille - P. Claudepierre

INFLAMMATORY BACK PAIN, RESULTS FROM THE DESIR COHORT / C. Poulain* - M. A. D' Agostino - S. Thibault -

ENTHESES EVALUATION BY POWER DOPPLER ULTRASONOGRAPHY IN PATIENTS WITH RECENT
C. Stolwijk - R. Landewé - D. van der Heijde - F. van den Bosch - M. Dougados - A. van Tubergen

FROM THE OUTCOME IN ANKYLOSING SPONDYLITIS INTERNATIONAL STUDY / C. Webers* - I. Essers - S. Ramiro -
M. Østergaard - M. A. Bowes - C. Wu - T. Fuerst - D. van der Heijde - P. Hrycay - Z. Xie - R. Zhang - B. T. Wyman -
I. Bradley - K. Soma - B. Wilkinson

ACTUAL NEED IN NON-STERoidal ANTI-INFLAMMATory DRUGS (NSAIDS) IN RA PATIENTS TREATED WITH SUBCUTANEOUS METHOTREXATE WITHIN “TREAT TO TARGET” STRATEGY / A. Karateev* - D. Karateev - E. Luchikhina - E. Nasonov


SYSTEMATIC REVIEW AND META-ANALYSIS ON THE EFFICACY OF LEFLUNOMIDE VS. METHOTREXATE AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) / F. Espinosa* - C. A. Arce-Salinas - R. Alfaro-Lara


THE EFFECT OF DEUTERATION OF VX-509 (DECERNOTINIB) ON DRUG-DRUG INTERACTIONS (DDI) WITH MIDAZOLAM / J. Huang* - F. Yang - J. Yogaratnam - J. Shen


HERPES ZOSTER AND TOFACITINIB: THE RISK OF CONCOMITANT NONBIOLOGIC THERAPY / K. Winthrop* -


PHASE 1A PHASE 1 CLINICAL TRIAL OF PRN1008, AN ORAL, REVERSIBLE, COVALENT BTK INHIBITOR DEMONSTRATES CLINICAL SAFETY AND THERAPEUTIC LEVELS OF BTK OCCUPANCY WITHOUT SUSTAINED SYSTEMIC EXPOSURE / F. F. Smith - J. Krishnarajah - P. A. Nunn - R. J. Hill - D. Karr - D. Tam - M. Masjedizadeh - S. G. Gourlay*


NEW INFLAMMATORY LESIONS IN AXIAL SPONDYLOARTHRITIS ARE MORE LIKELY TO OCCUR IN THE AREAS ALREADY AFFECTED BY INFLAMMATION IN THE PAST / D. Poddubnyy* - J. Sieper

Spondyloarthritis - clinical aspects (other than treatment) Hall 6


THE EFFECT OF DEUTERATION OF VX-509 (DECERNOTINIB) ON DRUG-DRUG INTERACTIONS (DDI) WITH MIDAZOLAM / J. Huang* - F. Yang - J. Yogaratnam - J. Shen


PHASE 1A PHASE 1 CLINICAL TRIAL OF PRN1008, AN ORAL, REVERSIBLE, COVALENT BTK INHIBITOR DEMONSTRATES CLINICAL SAFETY AND THERAPEUTIC LEVELS OF BTK OCCUPANCY WITHOUT SUSTAINED SYSTEMIC EXPOSURE / F. F. Smith - J. Krishnarajah - P. A. Nunn - R. J. Hill - D. Karr - D. Tam - M. Masjedizadeh - S. G. Gourlay*


NEW INFLAMMATORY LESIONS IN AXIAL SPONDYLOARTHRITIS ARE MORE LIKELY TO OCCUR IN THE AREAS ALREADY AFFECTED BY INFLAMMATION IN THE PAST / D. Poddubnyy* - J. Sieper

* Presenting author


SAT0245 IN VIVO EVIDENCE OF IL-17/IL-23 AXIS ACTIIVATION IN ANKYLOSING SPONDYLOITIS PATIENTS WITH LONG-TERM TNF BLOCKADE: THE MISSING THERAPY TARGET? / F. M. Milanez - C. G. Saad - V. T. Viana - J. C. Moraes - G. V. Perico - C. A. Silva - C. R. Goncalves - E. Bonfa


SAT0250 A TAILORED APPROACH TO REDUCE DOSE OF ANTI-TNF DRUGS IS EQUALLY EFFECTIVE AND LESS COSTLY THAN STANDARD DOING IN PATIENTS WITH ANKYLOSING SPONDYLITIS OVER TWO YEARS: A PROPENSITY SCORE-MATCHED COHORT STUDY / J. Zavada* - M. Uhier - K. Sislo - S. Forejtova - K. Jarosova - B. Man - J. Vencovsky - K. Pavelka


SAT0253 REAL WORLD COMPARISON OF ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHITIS PATIENTS - INVESTIGATING PATIENT PROFILES AND TREATMENT STRATEGIES / L. Chanroux* - J. Casellas


SAT0255 NSAID USE IN RELATION TO DISEASE ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH AND WITHOUT TNF-A BLOCKING THERAPY IN DAILY CLINICAL PRACTICE / M. J. Carbo* - S. Arends - E. Brouwer - F. Wink - M. Ede - H. Bootsma - E. van der Veer - F. Maas - A. Spoorenb erg


SAT0258 REAL WORLD COMPARISON OF ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS PATIENTS: INVESTIGATING PATIENT PROFILES AND TREATMENT STRATEGIES / L. Chanroux* - J. Casellas


SAT0262 THE PREVALENCE OF VERTEBRAL FRACTURES IN SPONDYLOARTHROPATHIES: RELATION TO DISEASE CHARACTERISTICS, BONE MINERAL DENSITY, SYNDROMES, AND HISTORY OF BACK PAIN AND TRAUMA / P. Peusens* - L. De Winter - D. Quaden - J. Vanhoof - D. Vosse - V. Somers

SAT0263 SECONDARY SJÖGREN'S SYNDROME IN PATIENTS WITH SPONDYLOARTHRITIS / S. Bello* - C. Rotondo - C. Bonali - L. Serafini - G. Lapadula

* Presenting author
SAT0266

SAT0267

SAT0268
GENDER DIFFERENCES IN THE RESPONSE TO ANTI-TNF TREATMENT IN AXIAL SPA / V. Hammelin* - F. Faustini - F. Ometto - S. Sandström - R. E. van Vollenhoven

SAT0269

SAT0270
BACKFILL IS A SPECIFIC SIGN OF AXIAL SPONDYLOARTHRITIS SEEN ON MRI / Z. Hu - Q. Lv - J. Qi - Z. Lin - M. Yang - Z. Liao - J. Gu*

SAT0271
DEVELOPMENT OF A NOVEL SI JOINT CT SCORE FOR DIAGNOSIS OF AXIAL SPONDYLITIS / J. Chan* - I. Sari - D. Salonen - N. Haroon - R. D. Inman

SAT0272
INCREASED RISK OF VASCULAR MORTALITY IN AXIAL SPONDYLOARTHRITIS / N. Nigil Haroon* - M. J. Paterson - P. Li - R. D. Inman - N. Haroon

SAT0273
DEATHS ASSOCIATED WITH ANKYLOSING SPONDYLITIS IN FRANCE FROM 1969 TO 2009 / C. Prati* - X. Guillo - D. Wendumling

SAT0274
GENETIC (HLA B27), ENVIRONMENTAL (SMOKING) AND INFLAMMATORY (MRI POSITIVITY) FACTORS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC PROGRESSION OF THE SACROILIAC JOINTS IN EARLY AXIAL NON-ANCA SPONDYLOARTHRITIS / M. Dougdas* - C. Dematté - R. van den Berg - V. V. Hoang - F. Thevenin - M. Reijnierse - D. Loeuille - A. Feydy - P. Claudepierre - D. van der Heijde

SAT0275
ASSESSING THE BEST REFERRAL STRATEGY FOR AXIAL SPONDYLOARTHRITIS; SEVERAL REFERRAL STRATEGIES EVALUATED IN PRIMARY CARE PATIENTS WITH CHRONIC LOW BACK / L. Van Hooven* - Y. Vergouwe - P. de Buck - K. Han - J. Luime - J. Hazes - A. Weel

SAT0276
CHANGE OF ASDAS OVER 3 MONTHS IS A GOOD PREDICTIVE FACTOR FOR IMPROVEMENT OF METROLOGY INDEX AFTER LONG-TERM TREATMENT WITH TNF-BLOCKERS IN ANKYLOSING SPONDYLITIS / E. J. Nam* - S. H. Kwon - J. S. Eun - N. R. Kim - Y. M. Kang

SAT0277

SAT0278

SAT0279
THE VITAMIN D STATUS IN ANKYLOSING SPONDYLITIS IN RELATION TO INTESTINAL INFLAMMATION, DISEASE ACTIVITY, OSTEOPROLIFERATION, BONE MINERAL DENSITY AND VERTEBRAL FRACTURES / E. Klingberg* - G. Oleröd - O. Hammarsten - H. Forsblad-d’Elia

## Osteoporosis

**Hall 6**

**Osteoporosis**

SAT0280

SAT0281

SAT0282
VITAMIN D DEFICIENCY IN PATIENTS WITH PSORIATIC ARTHRITIS AND ITS ROLE IN DISEASE ACTIVITY, OSTEOPROLIFERATION, BONE MINERAL DENSITY AND VERTEBRAL FRACTURES / E. Casado* - M. Arévalo - L. Lluís - M. García-Manrique - J. Calvet - J. Gratacos - M. Larrosa

SAT0283
SHORT-TERM RADIOGRAPHIC PROGRESSION IN PATIENTS WITH NON-TRAUMATIC CLINICAL VERTEBRAL FRACTURE / E. Klingberg* - G. Oleröd - O. Hammarsten - H. Forsblad-d’Elia

SAT0284

SAT0285

SAT0286

SAT0287
FACTORS ASSOCIATED WITH SPINE STRENGTH ASSESSED BY FINITE ELEMENT ANALYSIS OF CLINICAL COMPUTED TOMOGRAPHY INCREASE IN RESPONSE TO DAILY TERIPARATIDE TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS / K. Ono* - S. Ohashi - H. Oka - Y. Kadono - T. Yasui - Y. Omata - N. Shoda - S. Tanaka

* Presenting author
Bone diseases other than osteoporosis, metabolic diseases and crystal diseases


SAT0289 PREDICTORS OF FRACTILITY HUMERAL FRACTURES: AN OBSERVATIONAL STUDY / M. H. Dobrzynska* - A. Oldroyd - M. Bukhari

SAT0290 PROSPECTIVE OBSERVATIONAL STUDY OF 5-YEAR FOLLOW-UP OF DISTAL RADIUS FRACTURES IN A TRAUMA CENTER / M. Lisbona* - C. Aguiler - P. Leon - M. Anaya - E. Rubio - J. Povedano - M. Muñoz


SAT0293 HIP FRACTURES IN PATIENTS WITH DIALYSIS: THE IMPACT OF DEMENTIA / M. Maravic* - A. Oestergaard - P. Urena - M. Cohen-Solal

SAT0294 FRACTURE RISK ASSESSMENT OF PATIENTS WITH INFLAMMATORY JOINT DISEASE RECEIVING BIOLOGICAL AGENTS ATTENDING A RHEUMATOLOGY SERVICE IN A UNIVERSITY AFFILIATED TEACHING HOSPITAL / O. McDonnell - M. B. O'Connor* - U. Bond - M. J. Philan


SAT0296 BONE MINERAL DENSITY CHANGES AFTER KIDNEY TRANSPLANTATION / N. Segaud* - I. Legoux - M. Hazzan - C. Noel - B. Cortet


SAT0298 PATIENTS' PERSPECTIVE ON THE REASONS FOR NON-TREATMENT OF OSTEOPOOROSIS AMONG POSTMENOPAUSAL PATIENTS IN FRANCE - AN OBSERVATIONAL STUDY / R. Sadasivan* - K. Olsson - J. Weaver - S. Sen - A. Modi


SAT0300 TERIPARATIDE INHIBITS BONE LOSS AND IMPROVES HYPERALGESIA IN OVARIECTOMIZED MICE / S. Kato* - H. Wakabayashi - T. Nakagawa - Y. Naito - A. Sudo


SAT0302 INFLUENCE OF VERTEBRAL DEFORMATION ON THE VERTEBRAL PAIN SYNDROME / V. Povoroznyuk* - T. Orlyk

SAT0303 TRABECULAR BONE SCORE AND BONE MINERAL DENSITY IN UKRAINIAN MEN WITH VERTEBRAL FRACTURES / V. Povoroznyuk* - A. Musienko

SAT0304 ATORVASTATIN INHIBITS OSTEOCLAST DIFFERENTIATION AND BONE RESORBING ACTIVITY BY SUPPRESSING NF-ΚB AND MAPK SIGNALING DURING IL-1Β-INDUCED OSTEOPOOROSIS / W. S. Lee* - Y. J. Choi - M.-J. Hong - C.-H. Lee - M. S. Lee - S.-I. Lee - W.-H. Yoo

Bone diseases other than osteoporosis, metabolic diseases and crystal diseases


SAT0306 REAL LIFE GOUT EFFICACY DATA: OVER 80% OF CRYSTAL-PROVEN PATIENTS IN AN ACADEMIC SETTING ARE CURED BY SUA LEVEL TARGETED TREATMENT INCLUDING STEP-UP TWO MODES OF ACTION COMBINATION THERAPY / A. M. Wennemers* - I. Meek - R. Bakker - T. Janssen


SAT0309 THE UTILITY OF SPOT URINE URIC ACID TO CREATININE RATIO FOR PREDICTOR OF 24-HOUR URINE URIC ACID EXCRETION IN GOUTY PATIENTS / J.-S. Song* - S. T. Choi - E.-H. Park


SAT0311 THE SHAPE OF CALCIUM PYROPHOSPHATE CRYSTALS DETERMINES THEIR INTENSITY OF BIREFRINGENCE / V. Pela* - V. Jovani - M. Andrés - E. Pascual


* Presenting author
Epidemiology, health services and outcome research

Hall 6

SAT0330

SAT0331
CLINICAL AND ULTRASOUND PARAMETERS INFLUENCE THE VARIABILITY OF PATIENTS' AND PHYSICIANS' GLOBAL ASSESSMENT IN PSORIATIC ARTHRITIS / A. Novikov - E. N. Aleksandrova - E. L. Nasonov

SAT0332
RELATIONSHIP OF SERUM URIC ACID LEVELS WITH CARDIOVASCULAR DISEASE IN PATIENTS WITH GOUT: A BASIC AND TRANSLATIONAL RESEARCH STUDY / M. Andres* - R. Francesc - E. Pascual

SAT0333

SAT0334

SAT0335
IMPACT OF URATE-LOWERING THERAPY IN THE RISK OF ACUTE INFLAMMATION EPISODES DURING HOSPITAL ADMISSIONS IN PATIENTS WITH GOUT / F. Perez-Ruiz* - S. P. Chinchilla - I. Urionagüena

SAT0315

SAT0316

SAT0317

SAT0318
LEMON JUICE REDUCES SERUM URIC ACID LEVEL VIA ALKALIZATION OF URINE IN GOUTY AND HYPERUREMIC PATIENTS: A PILOT STUDY / E. K. Biernatkaluzka* - N. Schlesinger

SAT0319
DIASTOLIC ASYMMETRIC VOLUME OF ULSURUS IN CALCIUM PYROPHOSPHATE DEPOSITION DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS / E. Gamon* - G. Mouterde - T. Barnetche - B. Combe

SAT0320
CLINICAL FEATURES OF WOMEN WITH GOUT ARTHRITIS IN CAMEROON, CENTRAL AFRICA / F. Kema Lekpa* - M. S. Doualla

SAT0321

SAT0322

SAT0323
TWO-YEAR FOLLOW-UP STUDY OF THE RELATIONSHIP BETWEEN SERUM HOMOCYSTEINE, URIC ACID AND RENAL FUNCTION IN GOUTY PATIENTS / J.-S. Song* - S. T. Choi - E. H. Park

SAT0324

SAT0325

SAT0326

SAT0327

SAT0328
LEMON JUICE REDUCES SERUM URIC ACID LEVEL VIA ALKALIZATION OF URINE IN GOUTY AND HYPERUREMIC PATIENTS: A PILOT STUDY / E. K. Biernatkaluzka* - N. Schlesinger

SAT0329
RELATIONSHIP OF SERUM URIC ACID LEVELS WITH CARDIOVASCULAR DISEASE IN PATIENTS WITH GOUT: A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORD DATA / M. N. Essex* - M. Hopps - M. Udall - C. Fu - E. J. Bienen - J. Mardekian - G. Makinson

SAT0330

SAT0331

SAT0332

SAT0333

SAT0334

SAT0335

SAT0336
BREASTFEEDING IS ASSOCIATED WITH A DECREASED RISK OF ACPA-POSITIVE RHEUMATOID ARTHRITIS: RESULTS FROM THE SWEDISH EIRA STUDY / C. Orellana* - L. Klareskog - L. Alfredsson - C. Bengtsson

SAT0337

* Presenting author

SAT0339 COMPARATIVE EFFECTIVENESS OF FIRST-LINE BIOLOGICS USED FOR RHEUMATOID ARTHRITIS IN A MANAGED CARE POPULATION / T. Gu - N. Shah - G. Deshpande - D. H. Tang* - D. F. Eisenberg - B. S. Stolshok - D. J. Harrison

SAT0340 EVALUATION OF RESOURCE UTILIZATION IN RA PATIENTS WITH AND WITHOUT INFECTIONS IN A CLINICAL PRACTICE SETTING / E. Alemao* - S. Joo - M. Frits - C. Iannaccone - N. Shadick - M. Weinblatt

SAT0341 POLYMYALGIA RHEUMATICA AND ITS ASSOCIATION WITH CANCER / E. Pfeifer* - C. Crowson - B. Major - E. Matteson


SAT0343 HOW MUCH DOES FATIGUE CONTRIBUTE TO THE PHYSICIAN AND PATIENT GLOBAL ESTIMATES IN DIFFERENT RHEUMATIC DISEASES? ANALYSIS FROM ROUTINE CARE ON A MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE (MDHAQ) / I. Castronjon* - E. Nikiphorou - R. Jain - A. Huang - J. A. Block - T. Pincus


SAT0349 PATIENT-REPORTED OUTCOMES FROM A PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS / J. S. Smolen* - J. Kremer - C. Gaich - A. M. Delozier - D. Schlichting - L. Xie - M. C. Genovese


SAT0351 IS ILLNESS PERCEPTION AND COPING ASSOCIATED WITH THE PATIENT-RELATED TREATMENT DELAY IN EARLY RHEUMATOID ARTHRITIS? AN EXPLORATIVE STUDY WITHIN THE CARERA TRIAL / K. van der Elst* - D. De Cock - E. Vecoven - S. Arat - S. Meyfroidt - J. Joly - P. Moons - P. Verschueren - B. Westhovens on behalf of the CareRa study group


SAT0353 THE RELATIONSHIP BETWEEN PATIENT SATISFACTION WITH MEDICAL CARE AND DISEASE ACTIVITY IN DMARD NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS / L. B. Nordberg* - E. Lie - A.-B. Aga - M. Maehlen - M. C. Genovese

SAT0354 VALIDITY OF GOUT DIAGNOSIS IN SWEDISH PRIMARY AND SECONDARY CARE / M. I. Dehlin* - K. Stasinopoulou - L. Jacobsson

SAT0355 RISK AND CHARACTERISTICS OF DRUG INDUCED VASCULITIS IN PATIENTS EXPOSED TO TUMOUR NECROSIS FACTOR INHIBITORS / E. R. Curtis* - L. Klareskog - R. Zhang - S. Krishnaswami - A. Anisfeld - Y. Chen - J. Geier

SAT0356 TUBERCULOSIS AND BIOLOGICS: REAL WORLD EXPERIENCE FROM HIGH TUBERCULOSIS PREVALENCE AREA / K. M. Cebanu* - V. Sadovici - M. Cebanu

SAT0357 PREDICTIVE UTILITY OF ANTI-CITRULLINATED PEPTIDE ANTIBODIES AND RHEUMATOID FACTOR - A RETROSPECTIVE DATA ANALYSIS / M. Gärtner* - M. Schneeweiss - J. Smolen - K. Machold

SAT0358 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN REPUBLIC OF MOLDOVA / M. Cebanu* - V. Sadovici - M. Cebanu

SAT0359 THE RELATIONSHIP BETWEEN PATIENT SATISFACTION WITH MEDICAL CARE AND DISEASE ACTIVITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN REPUBLIC OF MOLDOVA / M. Cebanu* - V. Sadovici - M. Cebanu


* Presenting author
SLE, Sjögren's and APS – clinical aspects (other than treatment)  

**Hall 5**

**SAT0380**  
IMPARED IRE1αLPHA/XBP-1 PATHWAY IS ASSOCIATED WITH GLANDULAR DYSFUNCTION IN SJÖGREN'S SYNDROME / D. Sepúlveda - S. Aguilera* - M.-J. Barrera - V. Bahamonde - I. Castro - C. Molina - J. Cortés - S. González - C. Leyton - M.-J. González

**SAT0381**  

**SAT0382**  

**SAT0383**  
MICROPARTICLES IN 290 SLE PATIENTS AND MATCHED CONTROLS AND THEIR RELATIONSHIP TO VASCULAR DISEASE / A. C. Vikerkors* - E. Mobarrez - J. Gustafsson - I. Gunnarsson - A. Zickert - H. Wallen - E. Svenungsson

**SAT0384**  

**SAT0385**  

**SAT0386**  
WHAT IS THE BEST SCREENING TEST TO IDENTIFY LUPUS PATIENTS WITH COGNITIVE IMPAIRMENT IN AN AMBULATORY SETTING? / S. Nantes - M. Urowitz - D. Gladman - J. Su - A. Dhaliwal - Z. Touma*

**SAT0387**  

**SAT0388**  
MOOD DISORDERS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM AN INTERNATIONAL, INCHEPON COHORT STUDY / J. G. Hanly* on behalf of the Systemic Lupus International Collaborating Clinics (SLICC)

**SAT0389**  

**SAT0390**  
INCREASED MORTALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS OVER 30 YEARS OF FOLLOW-UP / A. Jönsen* - R. F. Ingvason - A. J. Landgren - A. A. Bengtsson

**SAT0391**  

**SAT0392**  

**SAT0393**  
HEALTH RELATED QUALITY OF LIFE IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS IN SWITZERLAND: NOT THE SAME IMPACT! / B. Chaigne* - A. Finckh - D. Neto - D. Alpizar Rodriguez - C. Ribi - C. Chizzolini on behalf of Swiss Clinical Quality Management Program For Rheumatoid Arthritis and the Swiss Systemic Lupus Erythematosus Cohort Study Group

**SAT0394**  
CAN IMMUNOSUPPRESSIVE DRUG TREATMENT REDUCE MORTALITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A PROPENSITY SCORE ANALYSIS OF A LONGITUDINAL COHORT OF 803 PATIENTS? / C. Ribi - C. Chizzolini on behalf of Swiss Clinical Quality Management Program For Rheumatoid Arthritis and the Swiss Systemic Lupus Erythematosus Cohort Study Group

**SAT0395**  

**SAT0396**  

**SAT0397**  
MICROPARTICLES IN 290 SLE PATIENTS AND MATCHED CONTROLS AND THEIR RELATIONSHIP TO VASCULAR DISEASE / A. C. Vikerkors* - E. Mobarrez - J. Gustafsson - I. Gunnarsson - A. Zickert - H. Wallen - E. Svenungsson

**SAT0398**  

**SAT0399**  
MICROPARTICLES IN 290 SLE PATIENTS AND MATCHED CONTROLS AND THEIR RELATIONSHIP TO VASCULAR DISEASE / A. C. Vikerkors* - E. Mobarrez - J. Gustafsson - I. Gunnarsson - A. Zickert - H. Wallen - E. Svenungsson

**SAT0400**  

**SAT0401**  

* Presenting author


SAT0404 SPOT URINE PROTEIN/CREATININE RATIO IS USEFUL IN SCREENING FOR PROTEINURIA BUT SHOULD NOT SUBSTITUTE 24 HOURS URINE COLLECTION SAMPLE TO QUANTIFY PROTEINURIA IN LUPUS / J. E. Medina* - D. O. Gladman - M. B. Urowitz - J. Su - A. Sabapathy - Z. Touma


SAT0407 MUSCULOSKELETAL COMPLICATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS: RISK FACTORS FOR AND PREVALENCE OF AVASCULAR NECROSIS AND OSTEOPOROSIS / M. Gamble* - J. E. Pope


SAT0411 COGNITIVE AND EMOTIONAL PROCESSING IN SYSTEMIC LUPUS ERYTHEMATOSUS: AN FMRI STUDY / M. Barracough* - R. Elliott - S. McKie - B. Parker - I. Bruce


SAT0413 URINARY LIPOCALIN-2 AS A BIOMARKER OF RENAL DISEASE ACTIVITY IN PATIENTS WITH LUPUS NEPHRITIS: A PROSPECTIVE STUDY / N. M. Gamal* - N. M. Mustafa - E. A. M. Abda - O. Afifi - N. Fathi

SAT0414 ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH VASCULAR EVENTS / N. M. Gamal* - N. M. Mustafa - E. A. M. Abda - O. Afifi - N. Fathi


SAT0417 CANCER AND PRIMARY SJÖGREN’S SYNDROME IN 1216 PATIENTS (GEAS-SS REGISTRY): SYSTEMIC ACTIVITY MEASURED BY THE ESSDAI IS RELATED TO HEMATOLOGICAL, BUT NOT SOLID NEOPLASIA / P. Brito Zeron* - M. Barraclough* - R. Elliott - S. McKie - B. Parker - I. Bruce


SAT0419 PROTEIN/CREATININE RATIO IS USEFUL IN SCREENING FOR PROTEINURIA BUT SHOULD NOT SUBSTITUTE 24 HOURS URINE COLLECTION SAMPLE TO QUANTIFY PROTEINURIA IN LUPUS / J. E. Medina* - D. O. Gladman - M. B. Urowitz - J. Su - A. Sabapathy - Z. Touma


SAT0424 SEUM TWEAK AS A BIOMARKER FOR DISEASE ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS / S.-K. Kim* - J.-Y. Choe

SAT0425 PREGNANCY IN WOMAN WITH SYSTEMIC LUPUS ERYTHEMATOSUS / S. Monov* - D. Monova - S. Basheva - R. Shumnalieva - A. Nikolov

* Presenting author


SAT0428  Application of New EULAR Definitions of Remission in SLE: Durable One-Year Remission is Rare / T. R. Fischer - M. Petri - L. S. Magder


SAT0431  A Meta-analysis of the Diagnostic Value of Minor Salivary Gland Biopsy for Primary Sjögren’s Syndrome / Y. H. Lee* - G. G. Song

Scleroderma, myositis and related syndromes - clinical aspects and treatment

Hall 5


SAT0434  Does Angiotensin and Endothelin Receptor Blockade Have an Impact on Lung Function? - An Analysis from the EUSTAR Database / M. Radić* - M. O. Becker - O. Distler - D. Huscher - G. Riemekasten

SAT0435  Undiagnosed Connective Tissue Diseases in Pulmonary Arterial Hypertension Patients: Baseline and Follow-Up Results from a PAH Referral Centre / V. Codullo* - L. Cavagna - S. Ghio - C. A. Sciré - E. Guzzafame - L. Scelsi - S. Rossi - C. Montecucco - R. Caporal

SAT0436  Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: ARTEMIS, a Randomized, Treatment Delayed-Start Trial / A. Tjärnlund* - M. Dastmalchi - H. Mann - J. Tomasová


SAT0438  Clinical Characteristics of Systemic Sclerosis Patients with Digital Ulcer Disease Who Developed Gangrene: Data from the Duo Registry / Y. Allane - C. P. Denton - T. Krieg - P. Cornelisse - D. Rosenberg - B. Schwein - M. Mautucci-Cerin


SAT0442  Myocophenolate Mofetil (MMP) Use in Scleroderma Patients with Pulmonary Hypertension: FVC, Outcomes and Survival - Observations from the Pulmonary Hypertension Recognition and Outcomes in Scleroderma (PHAROS) Cohort / L. A. Saketkou* - M. R. Lammi - O. Distler - V. D. Steen on behalf of the PHAROS Investigators


SAT0445  Sjögren’s Syndrome / Y. H. Lee* - G. G. Song


SAT0447  Correlations Between Blood Perfusion and Dermal Thickness in Different Skin Areas of Systemic Sclerosis Patients / B. Ruoaro* - A. Sulli - V. Smith - A. C. Trombetta - E. Bernero - M. Cutolo


* Presenting author
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT0473</td>
<td>ALTERATIONS IN CEREBRAL PERFUSION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND COGNITIVE IMPAIRMENT / O. Veralasta* - J. Moreno-Gutierrez - M. D. P. Cruz Dominguez</td>
</tr>
<tr>
<td>SAT0475</td>
<td>CANCER RISKS IN KOREAN PATIENTS WITH MYOSITIS: COMPARISON BETWEEN CANCERS RELATED AND UNRELATED TO MYOSITIS ACTIVITY / S. J. Lee* - E. H. Kang - S. W. Chung - Y. J. Ha - Y. J. Lee - E. Y. Lee - Y. W. Song</td>
</tr>
<tr>
<td>SAT0478</td>
<td>INCIDENCE AND PREDICTORS OF INTERSTITIAL LUNG DISEASE (ILD) IN EARLY SYSTEMIC SCLEROSIS PATIENTS: INCEPTION COHORT STUDY / S. Wangkaew* - J. Euathlithit - P. Watanawittawas - N. Kasitanon - S. Puntana - W. Louthrenoo</td>
</tr>
<tr>
<td>SAT0481</td>
<td>EARLY DETECTION AND TREATMENT FOR BORDERLINE PULMONARY ARTERIAL HYPERTENSION IN PATIENTS WITH SYSTEMIC SCLEROSIS IN JAPAN / Y. Kawaguchi* - K. Takagi - A. Tochimoto - T. Higuchi - H. Yamanaka</td>
</tr>
<tr>
<td>SAT0482</td>
<td>CLINICAL AND SEROLOGICAL FEATURES OF PATIENTS WITH DERMATOMYOSITIS COMPLICATED BY SPONTANEOUS PNEUMOMEDIASTINUM / Z. Chen* - Y. Wang - M. Kuwana - L. Sun</td>
</tr>
</tbody>
</table>

**Paediatric rheumatology** Hall 5

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT0485</td>
<td>PATIENTS WITH EARLY-ONSET JUVENILE SPONDYLOARTHROPATIES: A DISTINCT POPULATION / M. M. Katsicas* - R. A. Russo</td>
</tr>
<tr>
<td>SAT0487</td>
<td>LONG TIME OUTCOME OF TOTAL HIP REPLACEMENT IN TEENAGE PATIENTS WITH SYSTEMIC INFLAMMATORY DISEASES / M. Tsukanaka* - V. Halvorsen - I. Ø. Engesæter - L. B. Engesæter - L. Nordsletten - S. Puntana - W. Louthrenoo</td>
</tr>
<tr>
<td>SAT0489</td>
<td>DISEASE ACTIVITY AND HEALTH STATUS IN A COHORT OF YOUNG ADULTS WITH JIA / M. Romano* - C. Malattia</td>
</tr>
<tr>
<td>SAT0490</td>
<td>DEVELOPMENT OF AN INTERNATIONALLY AGREED MINIMAL DATASET FOR JUVENILE DERMATOMYOSITIS (PRCSG) FOR CLINICAL AND RESEARCH USE / L. McCann* - L. R. Wedderburn - C. Pilkington - A. M. Huber - A. Ravelli</td>
</tr>
<tr>
<td>SAT0491</td>
<td>DEVELOPMENT OF AN INTERNATIONALLY AGREED MINIMAL DATASET FOR JUVENILE DERMATOMYOSITIS (PRCSG) FOR CLINICAL AND RESEARCH USE / L. McCann* - L. R. Wedderburn - C. Pilkington - A. M. Huber - A. Ravelli</td>
</tr>
<tr>
<td>SAT0494</td>
<td>ALARMS IN CEREBRAL PERFUSION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND COGNITIVE IMPAIRMENT / O. Veralasta* - J. Moreno-Gutierrez - M. D. P. Cruz Dominguez</td>
</tr>
</tbody>
</table>

* Presenting author

SAT0496  COUNTERMEASURES AGAINST METHOTREXATE INTOLERANCE IN JUVENILE IDIOPATHIC ARTHRITIS INSTITUTED BY PARENTS SHOW NO EFFECT / A. Scheuern - N. Fischer - J.-P. Haas - B. Hugle*


SAT0499  TUBERCULIN SKIN TEST RESPONSE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS / M. Patricia - A. O. Baranik - N. E. Aikawa - S. Bombarda - M. Seiscento - C. A. A. Silva - C. Goldenstein-Schainerg

SAT0500  THE IMMUNE RESPONSE TO HEPATITIS A VACCINE IN CHILDREN WITH PFAPA SYNDROME / D. Marritt* - G. Vartzelis - N. Spyridis - A. Garoufi - S. Diamantopoulos

SAT0501  INFLUENCE OF MEFV GENE MUTATIONS AND R202Q POLYMORPHISM ON INFLAMMATORY CLINICAL MANIFESTATIONS AND OXIDATIVE STRESS / D. S. Lazarevic* - J. Radovic - M. Delbeljak - N. Toplak - T. Avcin - I. Vojinovic

SAT0502  HIGH PARTIPATION IN SCHOOL AND PHYSICAL EDUCATION IN CHILDREN IN A NORDIC JUVENILE IDIOPATHIC ARTHRITIS COHORT / E. B. Nordal* - L. M. A. Carneiro - A. Fasth - T. Herlin - S. Nielsen - S. Petloniemi - M. Zak - M. Rygg on behalf of the Nordic Study Group of Paediatric Rheumatology (NoSPeR)

SAT0503  A PROSPECTIVE SINGLE-CENTRE STUDY ON INDICATORS OF INFECTIOUS RISK AFTER RITUXIMAB THERAPY IN CHILDREN AND ADOLESCENTS WITH RHEUMATIC DISEASES / F. Speth* - C. Hinze - J.-P. Haas


SAT0505  SEVERE VITAMIN D DEFICIENCY IN PATIENTS WITH KAWASAKI DISEASE: ITS POSSIBLE ROLE IN THE RISK TO DEVELOP CORONARY ARTERY DAMAGE / F. Falcin* - S. Stagi - G. Lepri - E. Casalini - D. Rigante - M. Maturi-Cerinic

SAT0506  TOWARDS THE DEVELOPMENT OF AN ULTRASOUND COMPOSITE DISEASE ACTIVITY SCORE FOR JUVENILE IDIOPATHIC ARTHRITIS / L. Borzani* - G. Di Landro - A. Raveli - F. Corona - G. Filocomo


SAT0510  ABATACEPT IN THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED WITH UVEITIS / L. Galstian - E. Zholobova

SAT0511  PULMONARY ABNORMALITIES IN CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS / L. Galstian* - E. Zholobova

SAT0512  COMPARISON OF ASDAS ESR/ASDAS CRP WITH BASDAI AND CLINICAL DISEASE ACTIVITY IN ENTHESITIS RELATED ARTHRITIS / M. Agarwal* - S. Sawhney

SAT0513  BRAINSTEM AUDITORY EVOKED POTENTIALS AND VISUAL POTENTIALS IN KAWASAKI DISEASE: EXPRESSION OF CNS VASCULITIS? / M. C. Hinojosa - L. Galstian* - E. Zholobova


SAT0515  ULTRASOUND STRUCTURE PARAMETERS OF THE KNEE JOINT IN TEENAGERS / N. S. Shevchenko*


SAT0517  VALIDATION OF A MODIFIED OMERACT SCORE FOR WRIST ARTHRITIS IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS / P. Van Dijkhuizen* - F. Vanoni - A. Martini - C. Malattia

SAT0518  TREATMENT PATHWAY OF PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA)-ASSOCIATED UVEITIS REQUIRING SYSTEMIC IMMUNOSUPPRESSION / S. P. Li* - S. Compeyrot-Lacassagne - C. Edelsten


SAT0521  JUVENILE ONSET CONNECTIVE TISSUE DISEASES IN NORWAY - A HOSPITAL BASED REGISTRY / T. M. Ingebriksen* - T. Garen - B. Flate - H. Sanner

* Presenting author
SAT0522

Other orphan diseases

SAT0523

SAT0524

SAT0525

SAT0526

SAT0527

SAT0528
IGG4-RELATED DISEASE: BASELINE CLINICAL AND LABORATORY FEATURES IN 125 PATIENTS / Z. Wallace - J. Stone* - V. Deshpande - H. Mattoo - V. Mahajan - M. Kulikova - S. Pillai

SAT0529

SAT0530
METHOTREXATE FOR MAINTENANCE OF REMISSION IN IGG4-RELATED DISEASE / E. Della Torre* - C. Campochiaro - G. Ramirez - A. Berti - M. Lanzillotta - E. Bozzolo - L. Dagna - M. G. Sabbadini

SAT0531

SAT0532

SAT0533

SAT0534

SAT0535

SAT0536
THE PATHOLOGICAL FINDINGS OF SKIN, LYMPH NODE, LIVER AND BONE MARROW IN PATIENTS WITH ADULT ONSET STILL'S DISEASE: A COMPREHENSIVE ANALYSIS OF 40 CASES / H. Horuchi* - J. H. Han - C. H. Sun - J. Y. Jung

SAT0537
SERUM INTERLEUKIN-18 AND S100A8/A9 AS PREDICTION MARKERS FOR DISEASE ACTIVITY IN PATIENTS WITH INACTIVE ADULT-ONSET STILL'S DISEASE / I. Kim* - J. H. Han - C. H. Sun - J. Y. Jung

SAT0538

SAT0539

SAT0540
METHOTREXATE FOR MAINTENANCE OF REMISSION IN IGG4-RELATED DISEASE / E. Della Torre* - C. Campochiaro - G. Ramirez - A. Berti - M. Lanzillotta - E. Bozzolo - L. Dagna - M. G. Sabbadini

SAT0541

SAT0542

SAT0543
THE PATHOLOGICAL FINDINGS OF SKIN, LYMPH NODE, LIVER AND BONE MARROW IN PATIENTS WITH ADULT ONSET STILL'S DISEASE: A COMPREHENSIVE ANALYSIS OF 40 CASES / H. Horuchi* - J. H. Han - C. H. Sun - J. Y. Jung

* Presenting author
Psoriatic arthritis Hall 5


SAT0546 CLINICAL MANIFESTATIONS AND FEATURES OF CRYOFIBRINOGENEMIA: RUSSIAN EXPERIENCE / T. Shevtsova - I. Smittenko - S. Moiseev - P. Novikov*


SAT0550 FAMILIAL MEDITERRANEAN FEVER IN THE GREEK CYPRIOT POPULATION. EXPERIENCE FROM TWO CENTRES / S. Psarelis* - E. Mina - E. Nikifherou


SAT0552 RESPONSE TO ANAKINRA IS EFFECTIVE FOR THE DIAGNOSIS AND TREATMENT OF SYSTEMIC AUTOINFLAMMATORY DISORDER OF UNKNOWN GENETIC CAUSE / S. R. Harrison* - D. G. McGonagle - M. F. McDermott - S. Savic


SAT0555 ERYTHEMA NODOSUM IN RHEUMATOLOGY CLINIC: A STUDY OF 130 CASES / Y. Karpova* - B. Belov - O. Egorova

**Psoriatic arthritis**

SAT0556 METHOTREXATE EFFICACY IN EARLY PSORIATIC ARTHRITIS - OPEN LABEL DATA FROM THE TICOPA STUDY / L. C. Coates* - P. S. Hellwell


SAT0562 LONG-TERM IMPROVEMENTS IN PHYSICAL FUNCTION ARE ASSOCIATED WITH IMPROVEMENTS IN DACTYLISTIS, ENTHESITIS, TENDER AND SWOLLEN JOINT COUNTS, AND PSORIASIS SKIN INVOLVEMENT: RESULTS FROM A PHASE 3 STUDY OF USTEKINUMAB IN PSORIATIC ARTHRITIS PATIENTS / A. Kavanaugh* - L. Puig - A. B. Gottlieb - C. Ritchlin - S. Li - Y. You - A. M. Mendelsohn - P. Rahman - I. McInnes

SAT0563 CLINICAL RESPONSES IN JOINT AND SKIN OUTCOMES AND PATIENT-REPORTED OUTCOMES ARE ASSOCIATED WITH INCREASED PRODUCTIVITY IN THE WORKPLACE AND AT HOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL / A. Kavanaugh* - D. Gladman - D. van der Heijde - O. Pucuraru - P. J. Mease


SAT0566 HIGH PREVALENCE OF METABOLIC SYNDROME AND SUBCLINICAL CAROTID ATHEROSCLEROSIS AND THEIR RELATIONSHIP WITH BODY MASS INDEX, DISEASE ACTIVITY AND DURATION IN PSORIATIC ARTHRITIS PATIENTS / E. Markelova* - T. Koroteava - D. Novikova - L. Denisov - E. Loginova - E. Nasonov

* Presenting author
SAT0568  LONG-TERM WORK PRODUCTIVITY IMPROVEMENT ASSOCIATED WITH APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF 3 PHASE 3 STUDIES / F. Zhang* - Z. Clancy - S. Li

SAT0569  UTILITY OF A SELF ADMINISTERED QUESTIONNAIRE AS A TOOL FOR SCREENING JOINT INVOLVEMENT UNDERWAY PSORIASIS / G. Sandri* - V. Cestelli - M. T. Mascia - C. Lasagni - G. Pellacani

SAT0570  JOINT DAMAGE IS NOT ASSOCIATED WITH SMOKING STATUS IN PATIENTS WITH PSORIATIC ARTHRITIS / H. Maldonado-Fico* - D. Gladman

SAT0571  PERSISTENCE WITH ANTI-TUMOR NECROSIS FACTOR THERAPIES IN PATIENTS WITH PSORIATIC ARTHRITIS IN ROUTINE PRACTICE / J. Morel* - B. Combe - C. Däien - C. Lukas

SAT0572  SCREENING FOR PSA IN PRIMARY CARE PSORIASIS PATIENTS WITH MUSCULOSKELETAL COMPLAINTS WITH PEST, PASE & EAR / M. Karreman* - A. Week - M. van der Ven - M. Vis - I. Tchetverikov - M. Wakkee - T. Nijsten - J. Haze - J. Laime


SAT0576  SCORE UNDERSTIMATES THE REAL CARDIOVASCULAR RISK IN PSORIATIC ARTHRITIS / M. Martinez-Vidal* - F. Sivera - C. Fernández-Carballido - R. Martin-Doménech - A. San Martin-Álvarez


SAT0579  SECURINUMAB SAFETY AND TOLERABILITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED SAFETY ANALYSIS OF TWO PHASE 3, RANDOMIZED, CONTROLLED TRIALS (FUTURE 1 AND FUTURE 2) / P. Mease* - I. B. McInnes - H. Richards - L. Pricop - A. Widmer - S. Mpofo


SAT0581  PREDICTORS OF MINIMAL DISEASE ACTIVITY IN PATIENTS TREATED WITH ADALIMUMAB FOR 52 WEEKS IN CLINICAL PRACTICE / S. Tujii* - M. Higashiyama - T. Tomita - M. Matsui - H. Tsuboi - J. Hashimoto


**Presenting author**

---

**Diagnoses and imaging procedures**

**Hall 5**


**SAT0586**  ULTRASONOGRAPHIC SIGNS OF INFLAMMATION OF METATARSOPHALANGEAL JOINTS IN RHEUMATOID ARTHRITIS PATIENTS WHO ARE TREATED TO TARGET / M. van der Ven* - D. Ten Cate - A. Gerards - H. Jacobs - N. Swen - M. de Jager - J. Luime


SAT0591  FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY IN QUANTIFICATION OF DISEASE BURDEN IN PATIENTS OF SPONDYLOARTHROPATHY ON ANTI-TUMOUR NECROSIS FACTOR BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS / A. Ata* - K. Shanmuganandan - D. Bhakuni - K. Sivasami - A. Hegde

SAT0592  DIURNAL VARIATION OF POWER DOPPLER IN METACARPOPHALANGEAL JOINTS OF PATIENTS WITH RHEUMATOID ARTHRITIS / M. Gutierrez - S. Challal - A. Ariani - E. Minichelli - M.-C. Boissier - W. Grassi - L. Sermano*


SAT0596  ULTRASONOGRAPHIC EVALUATION OF SUBCLINICAL ENTHESITIS IN PATIENTS AFFECTED BY PAEDIATRIC INFAMMATORY BOWEL DISEASE / A. Batticciotto* - D. Dilillo - M. Antivalle - M. Nugnes - V. Varisco - M. Ferrari - S. Santandrea - A. Mutti - F. Atzeni - G. V. Zuccotti - P. Parri-Puttini


SAT0598  DYNAMIC MAGNETIC RESONANCE AS A USEFUL TOOL TO ESTIMATE THE RESPONSE TO DMARDS AND ANTITNF IN PATIENTS WITH PSORIATIC ARTHRITIS / A. Garcia Sanchez* - M. Lopez-Sidro Ibanez - F. Ruiz Santiago

SAT0599  RESULTS AND INDICATIONS OF ULTRASOUND GUIDED SYNODIAL BIOPSY IN "REAL LIFE": RETROSPECTIVE ANALYSIS OF 75 SYNOVIAL BIOPSY / A. Najm* - M. F. Heymann - Y. Maugars - B. Le Goff

SAT0600  PATHOLOGICAL CHANGE CAUSED BY BIOLOGICAL DRUGS IN RHEUMATOID ARTHRITIS SYNOVIAL TISSUE / A. Kubota* - M. Sekiguchi - T. Namakumura - S. Ikata - T. Suguro


SAT0602  ULTRASOUND ASSESSMENT OF THE MEDIAN NERVE IN CARPAL TUNNEL SYNDROME BEFORE AND AFTER CORTICOSTEROID INJECTION / C. McDonagh* - M. Alexander - D. Kane


SAT0606  IMPACT OF MUSCULOSKELETAL ULTRASOUND IN TREATMENT DECISION IN ROUTINE DAILY CARE OF RHEUMATOID ARTHRITIS / A. Batticciotto* - D. Dilillo - M. Antivalle - M. Nugnes - V. Varisco - M. Ferrari - S. Santandrea - A. Mutti - F. Atzeni - G. V. Zuccotti - P. Parri-Puttini

SAT0607  GREY SCALE OR DOPPLER ULTRASOUND, JOINT COUNTS OR SUMMATIVE SCORES. WHICH ONE IS A BETTER PREDICTOR OF X-RAY PROGRESSION? / E. de Miguel* - E. de Vicente - F. Diaz Alcazar - J. L. de la Iglesia


SAT0610  MAGNETIC RESONANCE IMAGING OUTCOMES IN PATIENTS WITH CHRONIC OR RECURRENT GONARTHITIS TREATED WITH INTRA-ARTICULAR INFLIXIMAB OR CORTICOSTEROID INJECTIONS / G. Akdemir* - E. Mattia* - A. Peall - A. Filer

* Presenting author


SAT0616  CURRENT SMOKING AND HYPERTENSION ARE ASSOCIATED WITH PERSISTENT POWER DOPPLER ULTRASOUND (PDUS) SIGNALS AT 12 MONTHS IN PATIENTS WITH INFLAMMATORY ARTHRITIS / J. Callhoff* - K. Albrecht - A. Zink - M. Backhaus

SAT0617  PELVIC PLAIN RADIOGRAPH AND THORACO-ABDOMINAL AND PELVIC CT SCAN COMPARED TO CT OF THE SACROILIAC JOINTS TAKEN AS GOLD STANDARD IN THE DIAGNOSIS OF STRUCTURAL SACROILIITIS / J. Melchior* - Y. Azaq - I. Chary-Valckenaere - A.-C. RAT - P. A. Gondim Texeira - A. Blum - D. Loeuille

SAT0618  AGE AND PRE-TREATMENT WITH GLUCOCORTICOIDS INFLUENCE THE B-MODE AND POWER DOPPLER ULTRASOUND (PDUS) SYNOVITIS SCORES AT THE ONSET OF INFLAMMATORY ARTHRITIS / K. Albrecht* - J. Callhoff - A. Zink - M. Backhaus


SAT0620  WRIST PD SIGNAL DETECTED BY ULTRASONOGRAPHY RELATES TO JOINT DESTRUCTION IN RHEUMATOID ARTHRITIS UNDER BIOLOGICS THERAPY IN REAL WORLD / M. Hamu* - Y. Kirino - Y. Toyota - K. Minegishi - R. Yoshimi - M. Takeno - A. Ueda - Y. Ishigatsubo

SAT0621  VALIDATION STUDY OF PREDICTIVE VALUE OF CAPILLAROSCOPY SKIN ULCER RISK INDEX (CSURI) IN SCLERODERMA PATIENTS TREATED WITH BOSENTAN / M. Sebastiani* - V. Cestelli - A. Manfredi - E. Praino - F. Cannarile - A. Spinella - M. Colaci - D. Giuggioli - C. Ferri

SAT0622  THE CLINICAL USE OF DIGITAL JOINT SPACE WIDTH AND X-RAY RADIOGRAMMETRY AS MARKERS FOR EARLY RADIOGRAPHIC PROGRESSION IN RA / M. Platt* - Y. Kisten - J. Kälvesten - K. Forslid - R. van Vollenhoven

SAT0623  DO WE ALWAYS NEED SPECIFIC TEST FOR ANTI-RO/SSA ANTIBODIES IN ADDITION TO IMMUNOFLUORESCENCE METHOD FOR ANTINUCLEAR ANTIBODY ANALYSIS / M. Sefik Bukilica* - L. Kovacevic - N. Roganovic - D. Petrovic - A. Kadic

SAT0624  PREDICTORS OF PERSISTENT POWER DOPPLER ULTRASOUND SYNOVITIS IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION / N. Filippi* - C. Lukas - J. Morel - B. Combe - G. Mouton


SAT0628  HIGH PREVALENCE OF ULTRASOUND VERIFIED ENTHESITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE WITH OR WITHOUT SPONDYLARTHITIS / R. Husic* - A. Lackner - A. Ficjan - P. Kump - C. Hoegenauer - W. Graninger - C. Dejaco

SAT0629  DIAGNOSTIC PERFORMANCE OF HIGH RESOLUTION TRANS-THOTACIC LUNG ULTRASONOGRAPHY IN PULMONARY INVOLVEMENT OF CONNECTIVE LUNG DISEASE IN TREATMENT WITH CYCLOPHOSPHAMIDE / S. Tropea* - M. Bentivegna - I. De Andres - A. Russo - P. Santonocito - E. Battaglia


* Presenting author
PReS Programme
Paediatric Rheumatology European Society Programme

WEDNESDAY, 10 JUNE 2015

15:00 - 16:30  Room 10 B

PReS session
Autoinflammatory diseases

Learning objectives:
• To understand the last advances in the exciting field of autoinflammatory diseases
• To understand how to diagnose and manage these disorders

Chairperson(s):
Michael Hofer (Switzerland)
Carine Wouters (Belgium)

Orsetta Zuffardi (Italy) 15:05
Rare-disease genetics in the era of next-generation sequencing

Seza Ozen (Turkey) 15:25
New autoinflammatory diseases

Marco Gattorno (Italy) 15:45
Impact on NGS in daily practice in autoinflammatory diseases

E. Santori (Switzerland) 16:05
S. Volpi, P. Picco, G. Rice, R. Caorsi, A. Martini, Y. Crow, M. Gattorno, F. Candotti
Abstract N° OP0007
Blood interferon signature as a screening for type I interferonopathies in children with early-onset SLE and vasculopathy

16:30 - 17:00  Halls 5&6
Coffee break

17:00 - 18:30  Room 10 B

PReS session
From children to adults

Learning objectives:
• To understand how to manage transition from paediatric to adult care
• To know the fate of childhood rheumatic diseases in adult age

Chairperson(s):
Pierre Quartier (France)
Marco Gattorno (Italy)

Nico Wulffraat (Netherlands) 17:05
Abstract N° SP0039
The SHARE recommendations

Helen E. Foster (United Kingdom) 17:25
Abstract N° SP0040
Transition

Marite Rygg (Norway) 17:45
Abstract N° SP0041
Adult outcome of paediatric diseases

P. Van Pelt (Netherlands) 18:05
A. Kruize, R. Dolhain, J. W. J. Bijlsma, N. Wulffraat
Abstract N° OP0021
Young persons with JIA in transition of care show higher drop-out rates; results from a longitudinal observational study

F. Oliveira Ramos (Portugal) 18:15
Abstract N° OP0022
Juvenile idiopathic arthritis in adulthood: clinical pattern and long-term outcomes of 512 patients

18:45 - 20:00  Hall 9
EULAR 2015 Opening Plenary Session

20:00 - 22:00  EULAR Garden
Networking platform
**THURSDAY, 11 JUNE 2015**

**10:30 - 12:00 Room 10 B**

**PreS Abstract session**

**Clinical aspects of paediatric rheumatology**

**Chairperson(s):**
Isabelle Koné-Paut (France)
Jordi Anton (Spain)
J. Swart (Netherlands)

**10:35**


**Abstract N° OP0062**

The addition of one or more biologics to Methotrexate in children with juvenile idiopathic arthritis increases the incidence of infections and serious adverse events. The 5882 PHARMACHILD cohort

**L. S. H. Lim (Canada)**

**10:45**

E. Pullenayegum, L. Lim, D. D. Gladman, B. M. Feldman, E. D. Silverman

**Abstract N° OP0063**

From childhood to adulthood: longitudinal trajectory of damage in patients with childhood-onset systemic lupus erythematosus (CSLE)

**G. Horneff (Germany)**

**10:55**

H. I. Huppertz, P. Haas, K. Tenbrock, K. Minden on behalf of BIKER Registry Collaborative Group

**Abstract N° OP0064**

Drug survival and reasons for discontinuation of biological therapy in 1679 polyarticular juvenile idiopathic arthritis patients

**N. Ruperto (Italy)**

**11:05**


**Abstract N° OP0065**

Long-term safety and effectiveness of Adalimumab in children with moderately to severely active polyarticular or polyarticular-course juvenile idiopathic arthritis

**M. E. Zannin (Italy)**

**11:15**


**Abstract N° OP0066**

Safety of anti-TNFΑ agents for the treatment of juvenile idiopathic arthritis-related uveitis: data from the ORCHIDEA registry

**G. Alayli (Turkey)**

**11:25**

O. Kuru, Y. Durmaz, S. Canbaz, A. Bilgici, D. Durmus, Y. Zahioglu, I. Ilhanli

**Abstract N° OP0067**

Chronic widespread pain in childhood and adolescence

**P. Hissink Muller (Netherlands)**

**11:35**

D. M. Brinkman, D. Schonenberg, Y. Koopman-Keemink, J. M. van den Berg, P. Bekkering, M. van Rossum, L. W. van Suijlekom-Smit, C. F. Allaart, R. ten Cate

**Abstract N° OP0068**

Three treatment strategies in recent onset DMARD naïve juvenile idiopathic arthritis: initial results of the Best for Kids-study

**E. Speth (Germany)**

**11:45**

C. Hinzke, S. Loeb, J.-P. Haas

**Abstract N° OP0069**

Varicella vaccination in patients with paediatric rheumatic diseases receiving immunosuppression: proposal of a pre-vaccination check list to ensure safety

**12:00 - 13:45 Halls 5&6**

**Poster viewing & lunch**

**13:45 - 15:15 Room 10 B**

**PreS session**

**Dermatomyositis 1**

**Learning objectives:**
- To have a comprehensive view on the pathogenesis of chronic myositis
- To have understand the role of autoantibodies and imaging in diagnosis and management of juvenile dermatomyositis

**Chairperson(s):**
Lucy Wedderburn (United Kingdom)
Angelo Ravelli (Italy)
Kanneboyina Nagaraju (United States)

**Neil McHugh (United Kingdom)**

**14:10**

**Abstract N° SP0079**

Pathogenesis

**Kanneboyina Nagaraju (United States)**

**13:50**

**Abstract N° SP0078**

Autoantibodies

**Neil McHugh (United Kingdom)**

**14:10**

**Abstract N° SP0080**

Autoantibodies

**Clara Malattia (Italy)**

**14:30**

**Abstract N° SP0081**

Imaging

**G. M. Moneta (Italy)**

**14:50**

A. D’Amico, M. Verardo, D. Pires Marafon, L. Bracci-Laudiero, F. De Benedetti, R. Nicolai

**Abstract N° OP0134**

Increased muscle interferon-γ expression levels in juvenile dermatomyositis
A. Meyer (France) 15:00
Abstract N° OP0135
Interferon-beta induced reactive oxygen species participate in muscle inflammation and mitochondrial oxidative phosphorylation defects contributing to dermatomyositis muscle impairment

15:15 - 15:45  Halls 5&6
Coffee break

15:45 - 17:15  Room 10 B

**PreS session**
**Dermatomyositis II**

**Learning objectives:**
- To understand the differences between childhood and adult dermatomyositis
- To know the last advances in treatment

**Chairperson(s):**
Pavla Dolezalova (Czech Republic)
Nico Wulffraat (Netherlands)

**Brian Feldman (Canada) 15:50**
Abstract N° SP0111
Calcinosis, lipodystrophy and other paediatric features

**Nicola Ruperto (Italy) 16:10**
Abstract N° SP0112
Treatment

**Angelo Ravelli (Italy) 16:30**
Course and outcome

**A. Consolaro (Italy) 16:50**
Abstract N° OP0150
Development and preliminary validation of a new composite disease activity measure for juvenile dermatomyositis

**K. S. Bernsten (Norway) 17:00**
Abstract N° OP0192
S100 proteins in dendritic cells regulate inflammatory processes

**S. K. Fassl (Germany) 10:45**
Abstract N° OP0193
Pyrin and PSTPIP1, mutated in FMF, PAPA-, and PAMI syndrome, are involved in the hypersecretion of alarmins MRP8/14

**C. Kessel (Germany) 10:55**
S. Fühner, S. Brockmeyer, H. Wittkowski, D. Füll
Abstract N° OP0194
Hexameric S100A12 is required for pro-inflammatory TLR4-signalling

**A. Omenetti (Italy) 11:05**
Abstract N° OP0195
Enhanced NLRP3-dependent interleukin-1B secretion correlates with disease activity in pyogenic sterile arthritis pyoderma gangrenosum and severe acne (PAPA) syndrome

**N. Ter Haar (Netherlands) 11:15**
T. Tak, B. Vastert, S. de Roock
Abstract N° OP0196
The role of neutrophils in the inflammatory cascade of systemic onset juvenile idiopathic arthritis

**L. E. Ling (United States) 11:25**
Abstract N° OP0197
High-resolution, integrated molecular profiling reveals persistent inflammation in Kawasaki disease patients with coronary artery aneurysms

**J. Ong (United Kingdom) 11:35**
A. Midgley, M. Beresford
Abstract N° OP0198
Expression of low density granulocytes and histone citrullination in juvenile-onset systemic lupus erythematosus and juvenile idiopathic arthritis
L. Lamot (Croatia) 11:45
M. Vidović, M. Perica, L. Tambić Bukovac, K. Gotovac, F. Borovečki, M. Harjaček
Abstract N° OP0199
TRP channels overexpression contributes to inflammasome activation in clavicular cortical hyperostosis?

12:00 - 13:45 Halls 5&6
Poster viewing & lunch

12:10 - 13:35 Hall 5
PreS Poster tour
F10: Clinical aspects of paediatric rheumatic diseases 1
Chairperson(s):
Alberto Martini (Italy)
Sebastian Vastert (Netherlands)
T. Kullenberg (Sweden)
B. Hallén, H. Olivecrona, M. Leinonen
Abstract N° FRI0494
Steroid-sparing effect of Anakinra (Kineret®) in the treatment of patients with severe cryopyrin-associated periodic syndromes
J. Peitz (Germany)
I. Becker, G. Horneff
Abstract N° FRI0495
What might be the factors for staying in remission in JIA? Data from the German BIKER registry
N. Ruperto (Italy)
Abstract N° FRI0496
Efficacy and safety of Canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
E. G. Favalli (Italy)
I. Pontikaki, A. Becciolini, M. Biggioggero, N. Ughi, A. Marchesoni, V. Gerloni, P. I. Meroni
Abstract N° FRI0497
Drug retention and pattern of discontinuation of the first-line anti-TNF drug in a large cohort of patients with adult or juvenile-onset inflammatory arthritides
K. Minden (Germany)
J. Klotsche, M. Niewerth, A. Zink, E. Seipelt, J.-P. Haas, G. Ganser, G. Horneff
Abstract N° FRI0498
How tolerable is Methotrexate in the long-term use in juvenile idiopathic arthritis (JIA)?
J. Guzman (Canada)
T. Loughin, A. Henrey, R. Berard, N. Shiff, R. Jurencak, S. Benseler, L. Tucker on behalf of ReACCh-Out Investigators
Abstract N° FRI0499
Using patient-relevant variables to describe the disease course in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort
D. Ekdawy (United Kingdom)
E. Smith, L. Oni, A. Midgley, R. Corkhill, C. Jones, S. Marks, P. Newland, C. Pilkington, K. Tullus, M. Beresford
Abstract N° FRI0500
Exploring the relationship of urinary vascular cell adhesion molecule-1 with lupus nephritis disease activity over time
M. Glerup (Denmark)
T. Herlin, M. Twilt
Abstract N° FRI0501
Antinuclear antibody-positive patients - are they a separate entity?
N. Ruperto (Italy)
Abstract N° FRI0502
Long-term safety of Adalimumab treatment in paediatric patients with polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis
A. N. Colebatch-Bourn (United Kingdom)
Abstract N° FRI0503
EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice
13:45 - 15:15 Room 10 B
PReS session
Other myopathies
Learning objectives:
• To know the various forms of inflammatory myopathies
• To understand those diseases that can mimic inflammatory myopathies
Chairperson(s):
Rolando Cimaz (Italy)
Seza Ozen (Turkey)
Ingrid Lundberg (Sweden) 13:50
Idiopathic inflammatory myopathies other than JDM
Carlo Minetti (Italy) 14:10
Primary myopathies mimicking inflammatory myositis
12-13 June 2015
PRES PROGRAMME / FRIDAY 12 JUNE AND SATURDAY 13 JUNE 2015 / 215

Andy Mammen (United States) 14:30
Abstract N° SP0146
Drugs causing muscle disease

G. C. Varnier (Italy) 14:50
Abstract N° OP0270
Further validation of the hybrid MMT/CMAS (HMC), a new measure of muscle disease activity in juvenile dermatomyositis

A. Notarnicola (Sweden) 15:00
Abstract N° OP0271
Analysis of the autoantibody repertoire in idiopathic inflammatory myopathies using antigen bead array

15:15 - 15:45  Halls 5&6
Coffee break

15:45 - 17:15  Room 10 B
PRES session
From basic science: JIA pathogenesis

Learning objectives:
• To understand the role of innate immunity in the pathogenesis of juvenile idiopathic arthritis
• To understand the interplay between T regulatory cells and effector cell in the pathogenesis of chronic synovitis

Chairperson(s):
Fabrizio de Benedetti (Italy)
Berent J. Prakken (Netherlands)

Berent J. Prakken (Netherlands) 15:50
Regulatory T cells and the pathogenesis of JIA

Lucy Wedderburn (United Kingdom) 16:10
Abstract N° SP0176
The TH-1/TH-17 balance in JIA

Johannes Roth (Germany) 16:30
Innate immunity and JIA

J. A. Ellis (Australia) 16:50
Abstract N° OP0282
The association of PTPN22 RS2476601 with juvenile idiopathic arthritis is specific to females

G. Schulert (United States) 17:00
N. Fall, N. Shen, S. Thornton, A. Grom
Abstract N° OP0283
MicroRNA 125A-5P has increased expression in active systemic juvenile idiopathic arthritis and is an essential modulator of regulatory macrophage phenotypes in vitro

SUNDAY, 13 JUNE 2015

08:30 - 10:00  Room 10 B
PRES session
Juvenile localized scleroderma

Learning objectives:
• To recognize the clinical and immunological characteristics of children with different forms of localized scleroderma
• To learn about recent efforts to standardize the assessment and the treatment options of localized scleroderma
• To recognize diseases that can mimic localized scleroderma

Chairperson(s):
Alberto Martini (Italy)
Jelena Vojinovic (Serbia)

Ronald Laxer (Canada) 08:35
Abstract N° SP0205
Clinical aspects and differential diagnosis

Francesco Zulian (Italy) 08:55
Abstract N° SP0206
Assessing disease activity and treatment

Alan Tyndall (Switzerland) 09:15
Abstract N° SP0207
Scleroderma-like fibrosing diseases

M. Osminina (Russian Federation) 09:35
N. Geppe, O. Spitonkova, J. Kostina, E. Afonina, G. Tougarinova
Abstract N° OP0292
Therapeutic strategies for juvenile localized scleroderma

S. O. Hetlevik (Norway) 09:45
B. Flato, E. Nordal, M. Rygg, V. Lilleby
Abstract N° OP0293
Long-term outcome and clinical characteristics in childhood-onset mixed connective tissue disease - a Norwegian nationwide study

10:00 - 12:00  Halls 5&6
Poster viewing, coffee break & light lunch

10:10 - 11:50  Hall 5
PRES Poster tour
S11: Clinical aspects of paediatric rheumatic diseases 2

Chairperson(s):
Francesco Zulian (Italy)
Juan C. Nieto-Gonzalez (Italy)
F. De Benedetti (Italy)
N. Ruperto, H. Brunner, A. Grom, N. Wulffraat, M. Henrickson, R. Jerath, Y. Kimura, A. Kadva, C. Keane, J. Wang, S. Wimalasundera, P. Gokani, A. Martini, D. Lovell on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG)

Abstract N° SAT0483
Tapering and withdrawal of Tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study

R. Caorsi (Italy)
A. Grossi, A. Insalaco, M. Alessio, S. Martino, E. Cortis, A. Morreale, F. Caroli, A. Martini, I. Ceccherini, M. Gattorno

Abstract N° SAT0484
Prevalence of CECR1 mutations in paediatric patients with polyarteritis nodosa, livedo reticularis and/or stroke

M. M. Katsicas (Argentina)
R. A. Russo

Abstract N° SAT0485
Patients with early-onset juvenile spondyloarthropathies: a distinct population

A. Horne (Sweden)

Abstract N° SAT0486
Macrophage activation syndrome and familial hemophagocytic lymphohistiocytosis: is their clinical phenotype really similar?

M. Tsukanaka (Norway)
V. Halvorsen, I. Ø. Engesæter, L. B. Engesæter, L. Nordsletten, S. M. Röhrl

Abstract N° SAT0487
Long time outcome of total hip replacement in teenage patients with systemic inflammatory diseases

S. Lanni (Italy)
A. Ravelli, F. Bovis, S. Viola, F. Magnaguagno, G. M. Magnano, C. Gandolfo, A. Martini, C. Malattia

Abstract N° SAT0488
Therapy-induced changes in US-detected synovial abnormalities in juvenile idiopathic arthritis

M. Romano (Italy)
A. Salmaso, S. Lodi-Rizzini, M. Gattinara, I. Pontikaki, P. L. Meroni, V. Gerloni

Abstract N° SAT0489
Disease activity and health status in a cohort of young adults with JIA

L. McCann (United Kingdom)
L. R. Wedderburn, C. Pilkington, A. M. Huber, A. Ravelli, P. Williamson, J. Kirkham, M. W. Beresford

Abstract N° SAT0490
Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use

G. Horneff (Germany)
K. Minden, H. I. Huppertz, K. Tenbrock, J. P. Haas

Abstract N° SAT0491
Gender specific comorbidities in juvenile idiopathic arthritis patients

B. Abujam (India)
A. Gupta, D. Suri, A. Rawat, S. Singh

Abstract N° SAT0492
Trends and predictors of mortality in childhood onset lupus over twenty four years: a north Indian single centre experience

12:00 - 13:30  Room 10 B

PReS session
Systemic sclerosis

Learning objectives:
- To understand the difference between adult and juvenile systemic sclerosis
- To be updated on the last advances in treatment options of juvenile systemic sclerosis

Chairperson(s):
Gerd Horneff (Germany)
Francesco Zulian (Italy)

Gabriela Riemekasten (Germany) 12:05
Systemic sclerosis in adults

Ivan Foeldvari (Germany) 12:25
Abstract N° SP0239
Juvenile systemic sclerosis

Jacob M. van Laar (Netherlands) 12:45
Treatment options including HSCT

I. Foeldvari (Germany) 13:05
Is there a difference in the presentation of diffuse and limited subtype of juvenile systemic sclerosis in childhood? Results from the juvenile scleroderma inception cohort (www.juvenilescleroderma.com)

M. Cappella (Italy) 13:15
Abstract N° OP0307
Infrared thermography after cold challenge: validation in diagnosis of Raynaud’s phenomenon in paediatric age
HEALTH PROFESSIONALS / WEDNESDAY 10 JUNE 2015 / 217

Health Professionals in Rheumatology Programme

Health Professionals session
Health Professionals Welcome Session

Learning objectives:
• To gain an insight into the HPR programme during congress and the perspective of the incoming President of EULAR and chair elect of HPR Standing Committee
• To be informed about the HPR newsletter and value of access to the HP stand whilst attending the congress
• To network with other attendees

Chairperson(s):
Susan Oliver (United Kingdom)
Devid Biscontini (Italy)
Kate Betteridge (United Kingdom) 13:35

Health Professionals in Rheumatology Programme

Anthony Redmond (United Kingdom) 14:11
Abstract N° SP0002
EULAR Congress 2015: vision from the Chair Elect for HPR and the insights into the programme; key points

14:30 - 15:00  Halls 5&6
Coffee break

15:00 - 16:30  Room 10 A

Health Professionals session
Get on the move with rheumatic and musculoskeletal disease

Learning objectives:
• Present existing evidence about physical activity, physical inactivity and sedentary time in patients with inflammatory arthritis
• Investigate the level of activity and presence of symptoms
• Describe challenges in long-term physical activity promotion

Chairperson(s):
Thijs Swinnen (Belgium)
Carine Savel (France)
Katrine Loeppenthin (Denmark) 15:05

Bente Appel Esbensen (Denmark) 15:23
Abstract N° SP0022
Reduction of sedentary behavior in patients with rheumatoid arthritis - experiences from an intervention study

Louise Larkin (Ireland) 15:41
Abstract N° SP0023
How to measure physical activity in people with rheumatoid arthritis - focus on objective measurements

Birgitta Nordgren (Sweden) 15:59
Abstract N° SP0024
Challenges in supporting behaviour change in a two-year real-life physical activity program

N. Konijn (Netherlands) 16:17
Abstract N° OP0013
Effective treatment rapidly improves both disease activity and physical activity in early rheumatoid arthritis
Health Professionals session

Ethnicity - a blind spot within rheumatology?

Learning objectives:
• Awareness of existing barriers to health care in ethnic minority patients
• Awareness of the different cultural health beliefs about disease and treatments
• Knowledge on reasons for variations in priority treatment outcomes for different cultural groups
• Knowledge on interventions to overcome health literacy barriers in minority patients

Chairperson(s):
Marios Kouloumas (Cyprus)
Rinie Geenen (Netherlands)
Heidi A. Zangi (Norway)

Abstract N° SP0046
Barriers to health care in ethnic minority patients with rheumatic and musculoskeletal diseases
Kanta Kumar (Kenya)

Abstract N° SP0047
The minority patient’s journey - delay in seeking medical help, beliefs about medicines and consequences for adherence to treatment
Homaira Sofia Khan (United Kingdom)

Are patients' ethnic, religious and cultural backgrounds important to consider for rheumatological treatment? A patient perspective

Ade Adebajo (United Kingdom)

Overcoming barriers to health literacy in ethnic populations using a multi-lingual interactive mind-map

Y. Prior (United Kingdom)
I. Ahlstrand, M. Bjork

Participation in valued life activities in people with rheumatoid arthritis: a comparison between the UK and Sweden

Abstract N° SP0048
Overcoming barriers to health literacy in ethnic populations using a multi-lingual interactive mind-map

I. Cordeiro, A. Cordeiro, M. J. Santos, J. C. da Silva

Men living with rheumatoid arthritis - a qualitative study

L. Barbosa (Portugal)

Abstract N° OP0095-HPR
Medication adherence in rheumatoid arthritis and psoriatic arthritis patients
R. Arends (Netherlands)

Abstract N° OP0096-HPR
The longitudinal relation between patterns of goal management and adaptation to arthritis
E. M. H. Selten (Netherlands)
R. Geenen, W. H. van der Laan,
R. G. van der Meulen-Dilling, H. J. Schers,
M. W. Nijhof, C. H. van den Ende, J. E. Vriezekolk

Abstract N° OP0097-HPR
Structure and importance of patients' reasons for treatment choices in hip and knee osteoarthritis: a concept mapping study
H. Alexanderson (Sweden)
å. Björklund, C. Ottosson, M. Dastmalchi, I. E. Lundberg

Abstract N° OP0098-HPR
Fatigue in adult idiopathic inflammatory myopathies
O. S. Wilson (United Kingdom)

Abstract N° OP0100-HPR
Does self-report of foot problems agree with clinical examination in people with rheumatoid arthritis?
S. Hilberdink (Netherlands)

Abstract N° OP0101-HPR
Action planning’s parameters for effectiveness in increasing exercise adherence behaviour

EULAR 2015 Opening Plenary Session

20:00 - 22:00  EULAR Garden
Networking platform

THURSDAY, 11 JUNE 2015

10:30 - 12:00  Room 10 A

HPR Abstract session

Evidence based practice

Chairperson(s):
Christina H. Opava (Sweden)
Yvonne van Eijk-Hustings (Netherlands)
I. Larsson (Sweden)
S. Bergman, A. Bremander

Abstract N° OP0094-HPR
Person-centred care (PCC) may improve health care consumer skills more than regular care - a RCT in patients with CIA undergoing biological therapy
B. A. Esbensen (Denmark)
K. V. Jensen, C. B. Jacobsen

Abstract N° OP0095-HPR
Men living with rheumatoid arthritis - a qualitative study
L. Barbosa (Portugal)
I. Cordeiro, A. Cordeiro, M. J. Santos, J. C. da Silva

Abstract N° OP0096-HPR
Medication adherence in rheumatoid arthritis and psoriatic arthritis patients
C. Bode, E. Taal, M. van de Laar

Abstract N° OP0097-HPR
The longitudinal relation between patterns of goal management and adaptation to arthritis
E. M. H. Selten (Netherlands)
R. Geenen, W. H. van der Laan,
R. G. van der Meulen-Dilling, H. J. Schers,
M. W. Nijhof, C. H. van den Ende, J. E. Vriezekolk

Abstract N° OP0098-HPR
Structure and importance of patients' reasons for treatment choices in hip and knee osteoarthritis: a concept mapping study
H. Alexanderson (Sweden)
Å. Björklund, C. Ottosson, M. Dastmalchi, I. E. Lundberg

Abstract N° OP0099-HPR
Fatigue in adult idiopathic inflammatory myopathies
O. S. Wilson (United Kingdom)

Abstract N° OP0100-HPR
Does self-report of foot problems agree with clinical examination in people with rheumatoid arthritis?
S. Hilberdink (Netherlands)

Abstract N° OP0101-HPR
Action planning’s parameters for effectiveness in increasing exercise adherence behaviour
Cross-cultural validity of the animated activity questionnaire (AAQ) that assesses activity limitations in patients with hip or knee osteoarthritis

Abstract N° OP0102-HPR

12:10 - 13:35 Hall 5

HPR Poster tour

T13: Getting to grips with the evidence

Chairperson(s):
Annette de Thurah (Denmark)
Reuben Escorpizo (Switzerland)

S. Pettersson (Sweden)
S. Möller, J. Gustafsson, E. Sveungsson, I. Gunnarsson, E. Welin Henriksson
Abstract N° THU0603-HPR
Patients' versus physicians' assessment of disease activity in systemic lupus erythematosus

C. A. Flurey (United Kingdom)
S. Hewlett, K. Rodham, A. White, R. Noddings, J. Kirwan
“Men don’t cry”: the experiences and coping styles of men with RA: a Q-methodology study

T. Swinnen (Belgium)
M. Milosevic, T. Scheers, J. Lefevre, S. van Huffel, W. Dankaeuts, R. Westhovens, K. de Vlam
Abstract N° THU0605-HPR
Patterns of physical activity matter: bout analysis reveals differences between patients with axial spondyloarthritis and healthy controls

S. McKenna (Ireland)
N. Kennedy
Abstract N° THU0606-HPR
The effects of physical activity interventions on body functions & structures, activity and participation outcomes, in people who have rheumatoid arthritis: a systematic review

C. Brumini (Brazil)
J. Natour, L. Y. Miura, A. Jones
Abstract N° THU0607-HPR
Effectiveness of bracing in elderly with knee osteoarthritis: a randomized controlled trial

L. M. Edelaar (Netherlands)
J. H. van Dieën, M. van der Esch, L. D. Roorda, J. Dekker, W. F. Lems, M. van der Leeden
Abstract N° THU0608-HPR
Nonlinearity and relevant thresholds in the relationship between muscle strength and activity limitations in patients with knee osteoarthritis: results of the AMS-OA cohort

B. Hammes (Norway)
J. Primdahl, Y. van Eijk-Hustings
Abstract N° THU0609-HPR
Readability of patient information and consent documents in rheumatologic studies compared to participants educational level

B.-M. Gilljam (Sweden)
J. Nygren, S. Arvidsson, P. Svedberg on behalf of Health innovations for children's mental health
Abstract N° THU0610-HPR
Involving children with juvenile idiopathic arthritis in health-related research - why and how?
Danielle Moens (Netherlands) 14:30
Abstract N° SP0093
Common issues between diabetes and rheumatoid arthritis regarding cardiovascular risk assessment and management

T. Harrison (Canada) 14:50
L. Martin
Abstract N° OP0141-HPR
Modifiable lifestyle factors negatively impact treating to target and haq scores in early rheumatoid arthritis patients

E. Sivera (Spain) 15:00
N. Martinez Alberola, M. Andres, C. Fernández-Carballido, R. Martín-Domenech, M. P. Martínez-Vidal, A. San Martin-Alvarez
Abstract N° OP0140-HPR
The role of a nurse-clinic in the assessment and prevention of cardio-vascular risk

13:45 - 15:15 Room 10 H
EULAR Projects in Health Professionals
Health Professionals' mentoring and networking

Chairperson(s):
Christina H. Opava (Sweden)
Jo Adams (United Kingdom)

Faculty
13:50
Interactive session on future options for HPR mentoring and networking activities

15:15 - 15:45 Halls 5&6
Coffee break

15:45 - 17:15 Room 10 A
Health Professionals session
Innovations in healthcare - can you Google it?

Learning objectives:
• Explore factors that facilitate innovation
• Identify new approaches to encourage innovation in the workplace
• Discuss models of innovation in healthcare for 2020

Chairperson(s):
Susan Oliver (United Kingdom)
Staffan Lindblad (Sweden)

Samuel Dickinson (United Kingdom) 15:50
Unlocking healthcare's great innovation potential - the Google way

Maura D. Iversen (United States) 16:15
Abstract N° SP0117
Doing it differently - new approaches to student education and improving health outcomes

Caroline Brand (Australia) 16:40
Abstract N° SP0118
People movers - how you can influence and effectively implement change?

P. Tapping (United Kingdom) 17:05
A. Rashid, W. Thomson, D. Ghio, L. Cordingley, R. Calam, P. Jimmieson, A. Chieng on behalf of The Childhood Arthritis Prospective Study (CAPS)
Abstract N° OP0157-HPR
“This feeling!” Can a new iPad app help children with juvenile idiopathic arthritis communicate their pain experiences? Feasibility, usability and acceptability
K. Hackett (United Kingdom) 11:15
K. Deane, T. Rapley, V. Deary, N. Kolehmainen, S. Bowman, E. Price, J. Newton, W.-F. Ng
Abstract N° OP0228-HPR
Identifying targets for a non-pharmacological therapy intervention package to improve participation in primary Sjögren’s syndrome patients: a group concept mapping study

M. Klokkerud (Norway) 11:25
Abstract N° OP0229-HPR
Developing a national core set of outcome measures for rehabilitation in rheumatic and musculoskeletal diseases

I. Thyberg (Sweden) 11:35
P. Arvidsson, M. Thyberg, M. Björk, Ö. Dahlström
Abstract N° OP0230-HPR
Increased health related quality of life in early RA today compared to patients diagnosed during the 1990’s. The Swedish TIRA project

N. Cuperus (Netherlands) 11:45
Abstract N° OP0231-HPR
How do we perceive activity pacing in rheumatology care? An international DELPHI survey

12:00 - 13:45 Halls 5&6
Poster viewing & lunch

12:10 - 13:35 Hall 5
HPR Poster tour

F13: Multidisciplinary teams

Chairperson(s):
Susan Oliver (United Kingdom)
Yvonne van Eijk-Hustings (Netherlands)

F. M. Lourenzi (Brazil)
Abstract N° FR0611-HPR
Global progressive resistance training improved functional capacity in patients with rheumatoid arthritis

K. Rome (New Zealand)
T. Morpeth, M. Frecklington
Abstract N° FR0612-HPR
Fear of falling and foot pain, impairment and disability in people with rheumatoid arthritis: an exploratory study

B. D. Thombs (Canada)
A. Levis, G. Kelley
Abstract N° FR0613-HPR
Assessing reporting bias in trials of exercise interventions for pain management in rheumatic diseases: an application of the test for excess significance

Y. Prior (United Kingdom)
A. Hammond, S. Tyson, A. Tennant
Abstract N° FR0614-HPR
Development and psychometric testing of the British English measure of activity performance of the hand (MAP-Hand) questionnaire in rheumatoid arthritis

E. Chew (Singapore)
K. Griva, P. Cheung
Abstract N° FR0615-HPR
Evaluation of coping styles in established rheumatoid arthritis patients in an Asian cohort

E. Tarakci (Turkey)
S. N. Arman, K. Barut, O. Kasapcopur
Abstract N° FR0616-HPR
Fatigue, quality of sleep and pain in children with juvenile idiopathic arthritis

N. Smith (United Kingdom)
H. Foster, R. Wylie, C. English, B. Davies, T. Rapley
Abstract N° FR0617-HPR
What are the educational needs of nurses involved in the care of children and young people with rheumatic disease?

V. L. Ruffing (United States)
A.-M. Orbai, C. O. Bingham
Abstract N° FR0618-HPR
Measuring the effectiveness of patient education for patients receiving injectable biologic medications

13:45 - 15:15 Room 10 A
Health Professionals session
Social and work participation - research into practice

Learning objectives:
- To describe the different restrictions in social participation in adults with musculoskeletal conditions and their impact on health and well-being
- To discuss different ways to assess social and work participation in clinical practice
- To learn and spark ideas through a workshop, through discussion and formation of collaboration across different disciplines and countries, for different ways to manage social and work participation in adults with musculoskeletal conditions
- To develop strategies and intervention plans for people with arthritis, to improve social and work participation

Chairperson(s):
Hana Smucrová (Czech Republic)
Begonya Alcacer-Pitarch (United Kingdom)
Ross Wilkie (United Kingdom) 13:50
Abstract N° SP0153
Social and work participation in clinical practice

Mathilda Björk (Sweden) 14:08
Abstract N° SP0154
“Social participation is important to me”; the experience of adults with rheumatoid arthritis
Abstract N° SP0155
Jenny Hubertsson (Sweden) 14:26
Arthritis and work: an inventory of European studies

Abstract N° SP0156
Hendrik J. Bieleman (Netherlands) 14:44
Work disability management in musculoskeletal disorders

Abstract N° OP0277-HPR
B. Hamnes (Norway) 15:02
A. Rønningen, Å. Skarbø
‘I am so much more than my work’: A qualitative study of experiences after participating in return to work programs for people with rheumatic diseases

Abstract N° SP0185
Emalie Hurkmans (Netherlands) 16:08
Intensity levels of exercise and physical activity in rheumatic diseases, and how to measure them

Abstract N° SP0186
Helene Alexanderson (Sweden) 16:26
Does the diagnosis matter for exercise dosage?

Abstract N° SP0187
Maura D. Iversen (United States) 16:44
Adverse effects of exercise in rheumatic and musculoskeletal diseases

Abstract N° OP0286-HPR
A. Ericsson (Sweden) 17:02
Resistance exercise improves multidimensional fatigue in women with fibromyalgia. A randomized controlled trial

15:15 - 15:45
Halls 5&6
Coffee break

15:45 - 17:15
Room 10 A

Health Professionals session
Fit to fight rheumatic and musculoskeletal diseases - how much exercise is beneficial and safe?

Learning objectives:
• Update on current evidence on the beneficial effects of exercise in rheumatic diseases
• Knowledge of indications of what is an optimal dosage of exercise
• Knowledge benefits and harms

Chairperson(s):
Rikke Helene Moe (Norway)
Michaela Stoffer (Austria)

Hanne Dagfinrud (Norway) 15:50
Abstract N° SP0185
Intensity levels of exercise and physical activity in rheumatic diseases, and how to measure them

Melina Dritsaki (United Kingdom) 08:53
Abstract N° SP0217
From theory to practice: case study from the SARAH trial

Jan Sorensen (Denmark) 09:11
Abstract N° SP0218
The challenges in health economics evaluation

Maarten de Wit (Netherlands) 09:29
Abstract N° SP0219
The heart of the matter. A critical evaluation of health economics from a patient perspective

V. M. Vervoort (Netherlands) 09:47
Abstract N° OP0298-HPR
Illness perceptions and costs in patients with fibromyalgia

Joshua Pink (United Kingdom) 08:35
Abstract N° SP0216
The principles of health economics

Unlocking the mystery of health economics

Learning objectives:
• Learn about the language, key principles and methods of health economic evaluations
• Know how to interpret the results of health economic evaluations
• Gain insight into the perspective of decision makers
• Understand how this evidence is being used to inform national clinical guidelines and practices

Chairperson(s):
Yeliz Prior (United Kingdom)
Thea Vliet Vlieland (Netherlands)
Joshua Pink (United Kingdom) 09:11
Abstract N° SP0218
The challenges in health economics evaluation
**Joint Clinical/HPR/PARE session**

**Family business**

**Learning objectives:**
How modern families balance their life when one member is affected by an RMD

**Chairperson(s):**
Maurizio Cutolo (Italy)
Nele Caeyers (Belgium)

**Giovanni Lamura (Italy)**
Abstract N° SP0220
Don't forget the carers!

**Spyroula David (Cyprus)**
Abstract N° SP0221
Family dynamics

**Monika Østensen (Norway)**
Abstract N° SP0222
Top tips for a successful pregnancy for couples affected by an RMD

**M. Khamashta (United Kingdom)**
D. Pushparajah, E. Chakravarty
Abstract N° OP0299-PARE
Attitudes of patients and physicians in the treatment of rheumatological disease during pregnancy

**P. Bednarova (Slovakia)**
J. Dobsovicova Cernakova
Abstract N° OP0300-PARE
Centre for psychological and social support in Slovakia

---

**HPR Poster tour**

**S15: Evidence based practice**

**Chairperson(s):**
Annette de Thurah (Denmark)
Maura D. Iversen (United States)

**K. K. Viktil (Norway)**
L. Damlien, E. Rossum-Iversen, C. L. Olsen, L. Bergmann, T. Borgen
Abstract N° SAT0638-HPR
Close the gap - medication discrepancies revealed by medication reconciliation

**M. Safridova (Czech Republic)**
M. Vranova, L. Linkova, S. Sebkova, J. Belacek, S. Fingerhutova, M. Bohm, D. Nemcova, P. Dolezalova
Abstract N° SAT0639-HPR
Strengthening the role of multidisciplinary team: can we further improve quality of life of patients with JIA?

**S. Otter (New Zealand)**
S. Kumar, P. Gow, N. Dalbeth, M. Corkill, K. A. Davies, S. Panthakalam, K. Rome
Abstract N° SAT0640-HPR
Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study

**C. H. van den Ende (Netherlands)**
I. Willems, L. Kwakkenbos, M. C. Vonk, F. H. van den Hoogen, T. P. Vliet Vlieland
Abstract N° SAT0641-HPR
Mothers with scleroderma and systemic lupus erythematosus: challenges, limitations, and adaptation

**F. Cramp (United Kingdom)**
J. Withall, A. Haase, N. Walsh, A. Young, S. Hewlett
Abstract N° SAT0643-HPR
Development of a physical activity programme for people with recently diagnosed rheumatoid arthritis

**E. De Cuyper (Belgium)**
V. De Gucht, S. Maes, Y. Van Camp, M. M. Elseviers, L. S. De Clerck
Abstract N° SAT0644-HPR
Determinants of Methotrexate adherence in rheumatoid arthritis patients

**J. Meesters (Netherlands)**
R. Koele, M. van Gestel, R. Smeets, T. Vliet Vlieland
Abstract N° SAT0645-HPR
Which problems in functioning are identified before and improve after a multidisciplinary rehabilitation program for chronic musculoskeletal pain?
Joint Outcome/HPR session

Quality indicators - a way to measure the quality of care

**Learning objectives:**
- To understand how quality indicators are developed
- To learn which quality indicator sets currently exist
- To learn how quality indicators can be used to assess and monitor quality of care

**Chairperson(s):**
Anthony Redmond (United Kingdom)
Annette de Thurah (Denmark)

**Abstract N° SP0235**
How to develop quality indicators
Estibaliz Loza (Spain)

**Abstract N° SP0236**
Quality indicator sets for the care of rheumatic diseases
John J. Edwards (United Kingdom)

**Abstract N° SP0237**
An overview of quality indicators for the management of osteoarthritis in primary care
Linda Li (Canada)

**Abstract N° SP0238**
How can quality indicators be used to assess or monitor quality of care?

W. F. Peter (Netherlands)

**Abstract N° OP0305-HPR**
Quality indicators for physiotherapy management in hip and knee osteoarthritis and rheumatoid arthritis; development and measurability
E. J. Hurkmans, P. J. van der Wees, E. J. Hendriks, L. van Bodegom-Vos, T. P. Vliet Vlieland

Highlight session

**Health Professionals**

Chairperson(s):
Emalie Hurkmans (Netherlands)
Agnes Kocher (Switzerland)

**Highlights from the Scientific programme**
Mathilda Bjork (Sweden)

**Highlights from the Health Professional programme**
Souzi Makri (Cyprus)

**Highlights from the PARE programme**

---

Health Professionals session

Breaking down barriers - implementing non pharmacological guidelines in clinical practice

**Learning objectives:**
- To define implementation science in health care
- To identify and recognize barriers and facilitators for implementation of guidelines in clinical practice
- To exchange experiences about barriers for implementations and strategies to overcome these barriers

**Chairperson(s):**
Nina Østerås (Norway)
Yvette Neijland (Netherlands)
Health Professionals in Rheumatology Posters

Thursday 11 June 2015

12:00 - 13:45

Physiotherapy

Hall 5

THU0603-HPR PATIENTS’ VERSUS PHYSICIANS’ ASSESSMENT OF DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS / S. Pettersson* - S. Möller - J. Gustafsson - E. Sveungsson - I. Gunnarsson - E. Welin Henriksson


THU0606-HPR THE EFFECTS OF PHYSICAL ACTIVITY INTERVENTIONS ON BODY FUNCTIONS & STRUCTURES, ACTIVITY AND PARTICIPATION OUTCOMES, IN PEOPLE WHO HAVE RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW / S. McKenna* - N. Kennedy


THU0609-HPR READABILITY OF PATIENT INFORMATION AND CONSENT DOCUMENTS IN RHEUMATOLOGIC STUDIES COMPARED TO PARTICIPANTS EDUCATIONAL LEVEL / B. Hamnes* - J. Primdahl - Y. van Eijk-Hustings


THU0612-HPR HEALTH ENHANCING PHYSICAL ACTIVITY IN PATIENTS WITH HIP OR KNEE OSTEOARTHRITIS / A. Ernstgård* - M. PirouziFard - C. Thorstensson

THU0613-HPR CHALLENGES IN CO-DESIGNING A WEB SERVICE TO SUPPORT SELF-MANAGEMENT OF PHYSICAL ACTIVITY IN INDIVIDUALS WITH RHEUMATOID ARTHRITIS / A. Revenäs* - C. Martin - C. H. Opava - C. Keller - P. Åsenlöf

THU0614-HPR THE CHARACTERISTICS, FUNCTIONAL IMPACT, PHYSICAL ACTIVITY LEVELS AND HEALTH RELATED QUALITY OF LIFE IN WOMEN WITH CHRONIC MUSCULOSKELETAL DISEASE AND CHRONIC DISEASES ATTENDING COMMUNITY HEALTH CENTERS IN SOUTH AFRICA / C. Hendricks* - J. Jelsma - R. Parker

THU0615-HPR CONCEPTIONS AFTER TOTAL HIP REPLACEMENT IN PATIENTS WHO ARE NOT SATISFIED WITH THE OUTCOME OF SURGERY. A QUALITATIVE CONTENT ANALYSIS / C. Veenhof* - C. Kloek - J. Dekker - D. de Bakker

THU0616-HPR A 10 YEAR FOLLOW-UP OF TAILORED BEHAVIOURAL TREATMENT AND EXERCISE BASED PHYSIOTHERAPY IN PERSISTENT MUSCULOSKELETAL PAIN / C. Emilson* - J. Demmelmaier - S. Bergman - P. Lindberg - E. Denison - P. Åsenlöf

THU0617-HPR THE ITERATIVE DEVELOPMENT OF E-EXERCISE, A BLENDED EXERCISE INTERVENTION FOR PATIENTS WITH OSTEOARTHRITIS OF HIP AND/OR KNEE / C. Veenhof* - C. Kloek - D. Bossen - J. Dekker - D. de Bakker

THU0618-HPR IMMEDIATE EFFECTS OF MULLIGAN’S CONCEPT MOBILIZATION WITH MOVEMENT ON KNEE PAIN AND FUNCTIONS IN PATIENTS WITH KNEE OSTEOARTHRITIS / D. Oskay* - H. Altıns - I. Düzgün - B. Elbasan

THU0619-HPR RESISTANCE TRAINING IN PATIENTS WITH PSORIATIC ARTHRITIS IMPROVES FUNCTION, DISEASE ACTIVITY AND QUALITY OF LIFE / D. R. Silva* - E. Jennings - E. Moreira - J. Natour


* Presenting author
Friday 12 June 2015

**12:00 - 13:45**

**Miscellaneous forms of clinical care**

**Hall 5**

**FR1061-HPR**

**FR1062-HPR**
FEAR OF FALLING AND FOOT PAIN, IMPAIRMENT AND DISABILITY IN PEOPLE WITH RHEUMATOID ARTHRITIS: AN EXPLORATORY STUDY / K. Rome* - T. Morpeth - M. Frecklington

**FR1063-HPR**
ASSESSING REPORTING BIAS IN TRIALS OF EXERCISE INTERVENTIONS FOR PAIN MANAGEMENT IN RHEUMATOID DISEASES: AN APPLICATION OF THE TEST FOR EXCESS SIGNIFICANCE / B. D. Thombs* - A. Levis - R. Meroni - M. Testa*

**FR1064-HPR**
THE EFFECTIVENESS OF SCAPULAR STABILIZATION EXERCISES IN PATIENTS WITH SCAPULAR IMPINGEMENT SYMPTOMS AND SCAPULAR DYSKINESIS / E. Yaksel* - S. S. Yesilyaprak

**FR1065-HPR**

**FR1066-HPR**
EVALUATION OF COPING STYLES IN ESTABLISHED RHEUMATOID ARTHRITIS PATIENTS IN AN ASIAN COHORT / E. Chew* - K. Griva - P. Cheung

**FR1067-HPR**
FATIGUE, QUALITY OF SLEEP AND PAIN IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS / E. Tarakci* - S. N. Arman - K. Barut - O. Kasapcopur

* Presenting author

FRI0618-HPR  MEASURING THE EFFECTIVENESS OF PATIENT EDUCATION FOR PATIENTS RECEIVING INJECTABLE BIOLOGIC MEDICATIONS / V. L. Rufing* - A.-M. Orbai - C. O. Bingham


FRI0623-HPR  BODY AWARENESS IN PERSONS DIAGNOSED WITH RHEUMATOID ARTHRITIS / H. Lööf* - U.-B. Johansson - E. Welin Henriksen - S. Lindblad - J. Bullington


FRI0625-HPR  THE PATIENTS‘ PERSPECTIVE ON NURSE-LED SCREENING FOR CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS: A QUALITATIVE FOCUS GROUP INTERVIEW STUDY / J. C. Froelund* - J. Primdahl

FRI0626-HPR  HIGHER LEVEL OF PSYCHOLOGICAL DISTRESS, PAIN AND TENDINOLAINEN HAVE A NEGATIVE INFLUENCE ON ARTHRITIS PATIENTS’ WELL-BEING / K. Grønning* - O. Bratås


FRI0628-HPR  SURVEY ON AWARENESS OF RHEUMATOLOGY NURSES FOR EULAR RECOMMENDATIONS / M. Kaneko* - S. Honjo

FRI0629-HPR  LONG-TERM QOL EVALUATION WITH AMS2 IN PATIENTS WITH RHEUMATOID ARTHRITIS - 4-YEAR EVALUATION IN PATIENTS RECEIVING TREATMENT WITH BIOLOGICALS - / M. Kaneko* - S. Honjo

FRI0630-HPR  ASSESSMENT OF DISEASE ACTIVITY IN RHEUMATIC PATIENTS BY RHEUMATOLOGY NURSES - FEASIBILITY STUDY OF VALIDITY AND PRACTICABILITY / M. Salomon* - I. Litinsky - R. Almog - O. Elkayam


FRI0632-HPR  SURVEY ON ATTITUDES REGARDING THE ROLE OF NURSES INVOLVED IN MEDICAL CARE OF PATIENTS WITH RHEUMATOID ARTHRITIS / M. Fusama* - H. Nakahara - T. Takeuchi


FRI0635-HPR  EFFECTS OF A COMMUNITY-BASED MULTIFACETED INTERVENTION FOR KOREAN PEOPLE WITH OSTEOARTHRITIS / Y.-H. Ahn* 

Psychology/Social sciences

FRI0636-HPR  DOES NEW PHARMACOLOGICAL TREATMENT CHANGE FUNCTIONING AND PSYCHOSOCIAL ADJUSTMENT IN PERSONS WITH JUVENILE IDIOPATHIC ARTHRITIS (JIA). FOLLOW-UP OF TWO PATIENT POPULATIONS BEFORE AND AFTER NEW MEDICATION STRATEGY / C. Bengtsson* - A. O'hegden

FRI0637-HPR  MEASUREMENT OF FATIGUE IN RA: THE CONSTRUCT VALIDITY OF A MULTIDIMENSIONAL COMPUTERIZED ADAPTIVE TEST / S. Nikolaus - C. Bode* - E. Taal - H. Vonkeman - C. Glas - M. van de Laar


* Presenting author
Occupational therapy


SAT0634-HPR DEVELOPMENT AND RELIABILITY OF TURKISH VERSION OF THE SHORT FORM-JOINT PROTECTION BEHAVIOR ASSESSMENT (JPBA-S) / E. Tonga* - S. A. Uysal - S. Karayazgan - M. Hayran

SAT0635-HPR LINGUISTIC VALIDATION AND CULTURAL ADAPTATION OF THE VALUED LIFE ACTIVITIES SCALE IN TURKEY IN PEOPLE WITH RHEUMATOID ARTHRITIS / E. Tonga* - A. Hammond - Y. Prior

SAT0636-HPR DEVELOPMENT OF MEASURING DEVICES FOR EVALUATING HAND FORCE IN RHEUMATOID ARTHRITIS / M. Björk - I. Thyberg - J. Lindstrand - N. Bodin - J. Rosengreen - U. Nordenskiöld - S. Brorsson*


Miscellaneous forms of clinical care


SAT0642-HPR MOTHERS WITH SCLERODERMA AND SYSTEMIC LUPUS ERYTHEMATOSUS: CHALLENGES, LIMITATIONS, AND ADAPTATION / J. Poole*

SAT0643-HPR DEVELOPMENT OF A PHYSICAL ACTIVITY PROGRAMME FOR PEOPLE WITH RECENTLY DIAGNOSED RHEUMATOID ARTHRITIS / F. Cramp* - J. Withall - A. Haase - N. Walsh - A. Young - S. Hewlett

SAT0644-HPR DETERMINANTS OF METHOTREXATE ADHERENCE IN RHEUMATOID ARTHRITIS PATIENTS / E. De Cuyper* - V. De Gucht - S. Maes - Y. Van Camp - M. M. Elseviers - L. S. De Clerck


SAT0646-HPR REHABILITATION COORDINATION FOR RETURN TO WORK, AS EXTENDED ROLE FOR HEALTH PROFESSIONALS - RESULTS FROM A RANDOMIZED CONTROLLED TRIAL / A.-M. Norén* - J. Bengtner - S. Landström - E. Sjöberg

SAT0647-HPR A SURVEY OF RHEUMATOID ARTHRITIS PATIENTS’ AWARENESS OF PRESCRIPTION DRUGS / N. Iwata* - M. Sato - S. Sasahara - A. Takeuchi

SAT0648-HPR DEVELOPMENT OF A PATIENT EDUCATION PROGRAM FOR NEW MOTHERS WITH RHEUMATIC DISEASE / T. Moksnes* - I. R. Nilsen

* Presenting author
PARE Programme
People with Arthritis/Rheumatism in Europe Programme

15:00 - 16:30  SC2 - Room A

PARE session
Building sustainable relationships between patients and researchers

Learning objectives:
• To gain insights into the facilitators and barriers of sustainable involvement of patients in rheumatology research and the benefits of the network model
• To learn more about the limitations and opportunities of patient involvement in clinical research, in particular in clinical trials

Chairperson(s):
Maarten de Wit (Netherlands)
Ingvild Kjeken (Norway)

15:05
Lena Andersen (Denmark)
Abstract N° SP0025
Participatory research - my role as a collaborative partner in scientific initiatives

15:23
Jette Primdahl (Denmark)
Abstract N° SP0026
A fairy tale from the land of Andersen - enabling patients to contribute to arthritis research

15:41
Ilse De Keyser (Belgium)
Abstract N° SP0027
One for all - patient research partners involved in disseminating EULAR recommendations among Belgium patients

15:59
Ulrika Bergsten (Sweden)
Abstract N° SP0028
A happy ending after all - patient initiated research in rheumatic diseases in Sweden

16:17
A. Higginbottom (United Kingdom)
C. Jinks, J. Bird, C. Rhodes, S. Blackburn, K. Dziedzic
Abstract N° OP0014-PARE
From design to implementation - patient and public involvement in an NIHR research programme in osteoarthritis in primary care

16:30 - 17:00  Halls 5&6
Coffee break
PARE session
Measuring success - how to evaluate the impact of your campaign

Learning objectives:
• How to measure the impact of projects and campaigns
• How campaigns lead to policy changes

Chairperson(s):
Kirsten Lerstroem (United Kingdom)
Elsa Mateus (Portugal)

Jurgen Clausen (Germany) 17:05
Abstract N° SP0049
Evaluating the work of a patient organisation: results of a member and non-member survey of Deutsche Rheuma-Liga

Jacob Andreas Holch (Denmark) 17:25
Abstract N° SP0050
Successfully measuring impact in practice - changing national policy in Denmark

Jaan Aps (Estonia) 17:45
Abstract N° SP0051
Redefining success in campaigning: from activities to collective impact

M. Ekroth (Finland) 18:05
J. Hirvonen, R. Katko, L. Salminen, M. Kukkurainen, L. Pirila, H. Makinen on behalf of the Finnish Rheumatism Association, the Finnish Rheumatology Nurses, the Finnish Society for Rheumatology, Abbvie, Astra Zeneca, Pfizer, BMS and MSD
Abstract N° OP0025-PARE
Campaign against the shortage of rheumatology professionals

A. Stara (Greece) 18:15
K. Koutsogianni, J. Papadakis, M. Skoulataki, M. Chatzioannou, T. Kalantzii
Abstract N° OP0026-PARE
Campaign for early and accurate diagnosis and early intervention in RMDs

PARE session
Championing work

Learning objectives:
• To provide best practices in promoting interventions to support people with RMDs to find a job or to stay at work
• To present the role of patients, patient organisations, health professionals and employers to find opportunities to overcome barriers

Chairperson(s):
Souzi Makri (Cyprus)
Jolanta Grygielska (Poland)

Robbert Janssen (Netherlands) 10:35
Abstract N° SP0064
EU awarded best practice: professional peer support in staying at work

Debbie Cohen (United Kingdom) 10:55
Abstract N° SP0065
What really works: Engaging health care professionals in supporting patients into work

Suzanne Verstappen (United Kingdom) 11:15
Abstract N° SP0066
Challenges to make work productivity a meaningful outcome for clinical trials and for health care interventions

A. Bosworth (United Kingdom) 11:35
C. Jacklin, L. Wetherly
Abstract N° OP0111-PARE
National rheumatoid arthritis society - rheumatoid arthritis and chronic fatigue

F. Moscogiuri (United Kingdom) 11:45
Abstract N° OP0112-PARE
Improving patient outcomes through clinical networks

EULAR 2015 Opening Plenary Session

20:00 - 22:00  EULAR Garden Networking platform

12:00 - 13:45  Halls 5&6
Poster viewing & lunch

PARE Poster tour
T14: PARE 1

Chairperson(s):
Dieter Wiek (Germany)
Elsa Mateus (Portugal)
C. B. Jacklin (United Kingdom)
A. Bosworth, S. Collins
Abstract N° PARE0001
Development of a training module for health professionals called “rheum2talk”
K. Blidberg (Sweden)
A. Carlsson
Abstract N° PARE0002
Swedish national guidelines for musculoskeletal diseases

J.-N. Dachicourt (France)
D. Poivret, C. Bonnet, G. Chales, F. Alliot-Launois, L. Carton, L. Grange on behalf of Association Francaise de lutte anti-rhumatismale
Abstract N° PARE0003
Mobile apps "the bone thief ", first electronic application on osteoporosis

I. A. Bulgakova (Russian Federation)
Abstract N° PARE0004
Important TUVA children school at the world arthritis day

I. Cederlund (Sweden)
Abstract N° PARE0005
Patient education - a joint venture. National health care working together with the Swedish rheumatism association

J. Loza (Spain)
L. Carmona, P. Zarco, M. T. Flórez
Abstract N° PARE0006
Facilitators and barriers of patients with SpA to physical exercise

K. Fligelstone (United Kingdom)
Abstract N° PARE0007
Systemic sclerosis medical student lecture - the benefits of patient participation

K. Gilbert (United Kingdom)
Abstract N° PARE0008
Using online self-publishing to publish and market a book for patient education (polymyalgia rheumatica and giant cell arteritis: a survival guide): a description and analysis of the process and an evaluation of the result

A. Claassen (Netherlands)
Abstract N° PARE0009
Factors influencing the use of a self-management care booklet for patients with rheumatoid arthritis

S. Sestini (Italy)
L. Millucci, D. Braconi, G. Bernardini, A. Santucci
Abstract N° PARE0010
Alkaptonuria: an old disorder with a late diagnosis

C. A. Rhodes (United Kingdom)
H. Hayes
Abstract N° PARE0011
An insight into membership of involve from the patient and organisational perspective

13:45 - 15:15  SC2 - Room A
PARE session
Lost in the system - how to use innovative care to bring health services back to the patient

Learning objectives:
- Introduction to the chronic care model
- How a multi-disciplinary team improves patient outcomes
- How national organisations can support patients in their journey through the healthcare system

Chairperson(s):
Ailsa Bosworth (United Kingdom)
Jean-Noël Dachicourt (France)
Rafael Bengoa (Spain)

Abstract N° SP0094
Introduction to the chronic care model

Thea Vliet Vlieland (Netherlands)
Abstract N° SP0095
Multi disciplinary team

Ursula Faubel (Germany)
Abstract N° SP0096
Deutsche Rheuma-Liga supporting people to find their way through the health system

S. Blackburn (United Kingdom)
K. Stevenson, S. Somerville, H. Duffy, R. Hughes, K. Dziedzic
Abstract N° OP0142-PARE
Improving the routine care of patients with back pain: the role of public involvement in taking successful research into clinical practice

G. Korevaar (Netherlands)
Abstract N° OP0143-PARE
Patient advocacy: patient choice in Dutch healthcare

15:15 - 15:45  Halls 5&6
Coffee break

15:45 - 17:15  SC2 - Room A
Joint Primare care/PARE session
Who cares? Primary care focus

Learning objectives:
- How to improve the dialogue between patients, primary and secondary care
- How to optimise the care provided by primary care

Chairperson(s):
Stefan Bergman (Sweden)
Codruţa Zabalan (Romania)
Jurgen Damen (Netherlands)

Abstract N° OP0142-PARE
Bridging the gap: the GP as spider in the web
Zoe Paskins (United Kingdom) 16:08
Abstract N° SP0119
Bridging the gap with education: what can rheumatologists learn from primary care?

Stala Kioupi (Cyprus) 16:26
Abstract N° SP0120
National patient organisation training GPs

Connie Ziegler (Denmark) 16:44
Abstract N° SP0121
Me and my GP

L. Ball (United Kingdom) 17:02
J. Kirk, T. Mirando, E. Edwards, B. Colaco
Abstract N° OP0158-PARE
Lack of patient public engagement at introduction of a new model of community DMARD monitoring

FRIDAY, 12 JUNE 2015

10:30 - 12:00 SC2 - Room A

PARE Abstract session
PARE

Chairperson(s):
Ursula Faubel (Germany)
Boriana Boteva (Bulgaria)

A. Carlsson (Sweden) 10:35
E. Sundin, K. Blidberg
Abstract N° OP0240-PARE
Empowerment and support for a healthier life style

H. Thorseng (Denmark) 10:45
Abstract N° OP0241-PARE
How to live a better life with osteoarthritis - a socially imbalanced disease

K. Lerstrom (United Kingdom) 10:55
B. Rubio
Abstract N° OP0242-PARE
Capabilities of European lupus groups: members of lupus Europe

S. R. Stones (United Kingdom) 11:05
V. Swallow, R. Majeed-Aris, A. Hall on behalf of MobAPP Steering Group
Abstract N° OP0243-PARE
Involvement of children and young people with long-term conditions in the development of mobile App technology to promote disease self-management

D. Chichikj (Macedonia) 11:15
I. Hadji Mitova, N. Bogdanovska, V. Ognenovski
Abstract N° OP0244-PARE
Determining the barriers for medicine application in patients with RA in Macedonia

M. de Wit (Netherlands) 11:25
Abstract N° OP0245-PARE
Helping patients to make informed decisions. The pare guide to disseminate EULAR recommendations among patients.

R. Guastalli (France) 11:35
Abstract N° OP0246-PARE
Health democracy in rheumatoid arthritis and spondyloarthritis - a practical application to management recommendations in France

C. Jacklin (United Kingdom) 11:45
R. Grosart, A. Bosworth
Abstract N° OP0247-PARE
The remission mission: understanding remission in rheumatoid arthritis from the patient's perspective

12:00 - 13:45 Halls 5&6
Poster viewing & lunch

12:10 - 13:35 Hall 5

PARE Poster tour
F14: PARE 2

Chairperson(s):
Diana Skingle (United Kingdom)
Jean-Noël Dachicourt (France)

J. Ortutay (Hungary) 11:05
E. Rozán
Abstract N° PARE0012
Building patient led organisations - an example of Hungary

R. Taylor (United Kingdom) 11:15
S. Blackburn, A. Higginbottom, C. Rhodes, K. Dziedzic
Abstract N° PARE0013
Demystifying research jargon: a volunteer led glossary

U. G. Viora (Italy) 11:25
R. Giannelli, S. Severoni, G. Voltan on behalf of ANMAR Italia
Abstract N° PARE0014
PDTA in rheumatic inflammatory and autoimmune diseases

K. Blidberg (Sweden) 11:35
A. Carlsson
Abstract N° PARE0015
How the Swedish rheumatism association work to increase research on osteoarthritis
M. Siber (Switzerland)
E. S. Rösch
Abstract N° PARE0016
Multichannel sensitisation campaign with prominent ambassadors

J. Loza (Spain)
L. Carmona, P. Zarco, M. T. Flórez
Abstract N° PARE0017
Recommendations for rheumatologists on physical exercise in spondyloarthritis (EJES 3-D study)

S. Moufarrej (United Arab Emirates)
R. Basheer, K. Thornely
Abstract N° PARE0018
The dilemmas of disclosure of side effects of rheumatic biological drugs

S. de Souza (United Kingdom)
H. Lempp
Abstract N° PARE0019
Patient perspectives on footwear in rheumatoid arthritis - a patient-led qualitative study

A. Carlsson (Sweden)
C. Fjellström
Abstract N° PARE0020
To influence by meeting those in power - a week of political activities

S. De Jong (Netherlands)
G. Korevaar, Y. Kat
Abstract N° PARE0021
National arthritis activity guide (reumabeweegwijzer) directs patients to physical activities in their own neighborhood

13:45 - 15:15 SC2 - Room A

PARE session
What is new? Latest advances in treatment and management

Learning objectives:
An overview of the latest advances in glucocorticoids and lupus

Chairperson(s):
Johannes W. J. Bijlsma (Netherlands)
Neil Betteridge (United Kingdom)

Frank Buttgereit (Germany) 13:50
Abstract N° SP0157
Glucocorticoids: How to achieve a good benefit: risk balance using this double-edged sword

Donald E. Thomas (United States) 14:20
Abstract N° SP0158
“The lupus secrets”: latest treatment recommendations

Richard Vesely (United Kingdom) 14:50
Abstract N° SP0159
What EMA is doing for patients with rheumatic diseases

15:15 - 15:45 Halls 5&6
Coffee break

15:45 - 17:15 SC2 - Room A

PARE session
Youth in action

Learning objectives:
• To present the PARE strategy for young people with RMDs
• To learn more about the importance of ‘disclosure’ and the need for raising awareness about the impact of having a RMD when you are young
• To showcase best practice of youth groups campaigning for better services for young people with RMDs

Chairperson(s):
Caroline Ospelt (Switzerland)
Ingrid Põldemaa (Estonia)

Linda van Nieuwkoop (Netherlands) 15:50
Abstract N° SP0190
A milestone in EULAR - the first PARE youth strategy

Lotte Havermann (Netherlands) 16:10
Abstract N° SP0191
Measuring quality of life in young adults with RA in clinical practice

Gudrun Baseler (Germany) 16:30
Abstract N° SP0192
A professional career with a rheumatic disease

L. Hickey (Ireland) 16:50
Abstract N° OP0287-PARE
Incorporating youth into a national organisation

C. Wright (United Kingdom) 17:00
S. R. Stones on behalf of Paediatric Rheumatology CSG Consumers
Abstract N° OP0288-PARE
The top concerns of children and young people living with JIA
**Joint Clinical/HPR/PARE session**

**Family business**

**Learning objectives:**
How modern families balance their life when one member is affected by an RMD

**Chairperson(s):**
Maurizio Cutolo (Italy)
Nele Caeyers (Belgium)

**Giovanni Lamura (Italy)** 08:35
Abstract N° SP0220
Don't forget the carers!

**Spyroula David (Cyprus)** 08:55
Abstract N° SP0221
Family dynamics

**Monika Østensen (Norway)** 09:15
Abstract N° SP0222
Top tips for a successful pregnancy for couples affected by an RMD

**M. Khamashta (United Kingdom)** 09:35
D. Pushparajah, E. Chakravarty
Abstract N° OP0299-PARE
Attitudes of patients and physicians in the treatment of rheumatological disease during pregnancy

**P. Bednarova (Slovakia)** 09:45
J. Dobsovicova Cernakova
Abstract N° OP0300-PARE
Centre for psychological and social support in Slovakia

**13:45 - 14:45**

**Highlight session**

**PARE**

**Chairperson(s):**
Diana Skingle (United Kingdom)
Marios Kouloumas (Cyprus)
Nina Brodin (Sweden)

**Jürgen Braun (Germany)** 14:15
Highlights from the Scientific programme

---

**PARE session**

**Taking control: success through empowerment and self-management**

**Learning objectives:**
- How to empower hard-to-reach people with rheumatic and musculoskeletal diseases
- Top tips for self-management
- How to reach my personal goals

**Chairperson(s):**
Jacob Andreas Holch (Denmark)
Kate Betteridge (United Kingdom)

**Gráinne O’Leary (Ireland)** 12:05
Abstract N° SP0252
The case for self-management - 9 years of positive patient outcomes

**Codruța Zabalan (Romania)** 12:25
Abstract N° SP0253
Introducing the concept of self-management in Southern Europe. Challenges of the Agora partner in treatment initiative

**Kate Gadsby (United Kingdom)** 12:45
Abstract N° SP0254
How does shared decision-making affect outcomes

**Charlotte Secher Jensen (Denmark)** 13:05
Stene Prize winner 2015: Taking control of my life - working together with health professionals to achieving my personal goals

**J. Rickmann (Denmark)** 13:15
B. Schiøttz-Christensen, A. Dam
Abstract N° OP0315-PARE
Rheumabuddy, a smartphone App, used to empower patients with rheumatoid arthritis
PARE Posters
People with Arthritis/Rheumatism in Europe Poster Session

PARE Posters Thursday to Saturday

PARE0001 DEVELOPMENT OF A TRAINING MODULE FOR HEALTH PROFESSIONALS CALLED “RHEUM2TALK” / C. B. Jacklin* - A. Bosworth - S. Collins

PARE0002 SWEDISH NATIONAL GUIDELINES FOR MUSCULOSKELETAL DISEASES / K. Bliedberg* - A. Carlsson


PARE0004 IMPORTANT TUVA CHILDREN SCHOOL AT THE WORLD ARTHRITIS DAY / I. A. Bulgakova*

PARE0005 PATIENT EDUCATION - A JOINT VENTURE NATIONAL HEALTH CARE WORKING TOGETHER WITH THE SWEDISH RHEUMATISM ASSOCIATION / I. Cederlund*

PARE0006 FACILITATORS AND BARRIERS OF PATIENTS WITH SPA TO PHYSICAL EXERCISE / J. Loza* - L. Carmona - P. Zarco - M. T. Flórez

PARE0007 SYSTEMIC SCLEROSIS MEDICAL STUDENT LECTURE - THE BENEFITS OF PATIENT PARTICIPATION / K. Fligelstone*

PARE0008 USING ONLINE SELF-PUBLISHING TO PUBLISH AND MARKET A BOOK FOR PATIENT EDUCATION (POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: A SURVIVAL GUIDE): A DESCRIPTION AND ANALYSIS OF THE PROCESS AND AN EVALUATION OF THE RESULT / K. Gilbert*


PARE0010 ALKAPTONURIA: AN OLD DISORDER WITH A LATE DIAGNOSIS / S. Sestini* - L. Millucci - D. Braconi - G. Bernardini - A. Santucci

PARE0011 AN INSIGHT INTO MEMBERSHIP OF INVOLVE FROM THE PATIENT AND ORGANISATIONAL PERSPECTIVE / C. A. Rhodes* - H. Hayes

PARE0012 BUILDING PATIENT LED ORGANISATIONS - AN EXAMPLE OF HUNGARY / J. Ortutay* - E. Rozán


PARE0014 P RTA IN RHEUMATIC INFILAMMATORY AND AUTOIMMUNE DISEASES / U. G. Viora* - R. Giannelli - S. Severoni - G. Voltan on behalf of ANMAR Italia

PARE0015 HOW THE SWEDISH RHEUMATISM ASSOCIATION WORK TO INCREASE RESEARCH ON OSTEOARTHRITIS / K. Bliedberg* - A. Carlsson

PARE0016 MULTICHANNELSENSITISATION CAMPAIGN WITH PROMINENT AMBASSADORS / E. S. Rösch - M. Siber*

PARE0017 RECOMMENDATIONS FOR RHEUMATOLOGISTS ON PHYSICAL EXERCISE IN SPONDYLOARTHRITIS (EJES 3-D STUDY) / J. Loza* - L. Carmona - P. Zarco - M. T. Flórez

PARE0018 THE DILEMMAS OF DISCLOSURE OF SIDE EFFECTS OF RHEUMATIC BIOLOGICAL DRUGS / S. Moufarrej* - R. Basheer - K. Thornely

PARE0019 PATIENT PERSPECTIVES ON FOOTWEAR IN RHEUMATOID ARTHRITIS - A PATIENT-LED QUALITATIVE STUDY / S. de Souza* - H. Lempp

PARE0020 TO INFLUENCE BY MEETING THOSE IN POWER - A WEEK OF POLITICAL ACTIVITIES / C. Fjellström - A. Carlsson*

PARE0021 NATIONAL ARTHRITIS ACTIVITY GUIDE (REUMABEWEGWJIZER) DIRECTS PATIENTS TO PHYSICAL ACTIVITIES IN THEIR OWN NEIGHBORHOOD / S. De Jong* - G. Korevaar - Y. Kat

* Presenting author
IN RHEUMATOID ARTHRITIS (RA),

AS IL-6 ELEVATES, THE EFFECTS GO BEYOND THE JOINTS

ATTENDING EULAR? LEARN MORE ABOUT THE ROLE OF IL-6 IN RA. VISIT REGENERON AND SANOFI AT BOOTH 5.17 IN HALL 5

IL-6=interleukin-6.
SATELLITE SYMPOSIA / WEDNESDAY 10 JUNE 2015 / 237

Satellite Symposia

Status as of 5 April 2015

WEDNESDAY, 10 JUNE 2015

13:00-14:30  Hall 3

AbbVie
The value of inhibiting progression in RA: recent aspects of treat to target

Chairperson(s):
Josef Smolen (Austria)

Josef Smolen (Austria) 13:00
Targeting remission to stop progression of RA

Paul Emery (United Kingdom) 13:15
Targeting early remission - How can we do better?

Arthur Kavanaugh (United States) 13:35
From early remission to long-term disease control

Philip Conaghan (United Kingdom) 13:55
Dose tapering after achieving sustained remission - Can we predict disease progression?

All 14:15
Questions and answers

13:00-14:30  Room 10 F-G

Pfizer
Benefit - risk in controlled trials and real world: what does it really mean?

Chairperson(s):
Gianfranco Ferraccioli (Italy)

Gianfranco Ferraccioli (Italy) 13:00
Welcome and introduction

Ronald van Vollenhoven (Sweden) 13:05
Establishing a foundation for the benefit-risk profile: the role of clinical trials

Xavier Mariette (France) 13:25
From clinical trials to clinical practice: using registry data to further characterise the benefit-risk profile

Stanley B. Cohen (USA) 13:45
Completing the benefit-risk profile: insights from real-world experience

Gianfranco Ferraccioli (Italy) 14:05
The road from clinical trials to the real world: translating clinical and observational data and the benefit-risk profile into treatment decisions for patient care

All 14:15
Panel discussion and wrap-up
**Hospira**  
**What is the place for biosimilars in rheumatology?**

**Chairperson(s):** Peter Taylor (United Kingdom)  
*Welcome and introduction*

**Peter Taylor (United Kingdom)**  
13:00  
*Welcome and introduction*

**Joao Goncalves (Portugal)**  
13:05  
*Biosimilarity: overcoming myths and misconceptions*

**Ulf Mueller-Ladner (Germany)**  
13:30  
*The importance of confirmatory clinical studies for regulatory approval of biosimilars*

**Tore K. Kvien (Norway)**  
13:50  
*The real value of Biosimilars: what is the experience in Norway?*

*All*  
14:10  
*Discussion and meeting close*

---

**Novartis Pharmaceuticals**  
**IL-17 Inhibition in spondyloarthritis: a targeted approach in psoriatic arthritis**

**Chairperson(s):** Philip Mease (United States)  
*Welcome and introduction*

**Philip Mease (United States)**  
13:00  
*Welcome and introduction*

**Erik Lubberts (Netherlands)**  
13:15  
*Understanding the pathophysiology of psoriatic arthritis: the role of IL-17*

**Iain B. McInnes (United Kingdom)**  
13:35  
*IL-17 inhibition in psoriatic arthritis: current evidence and future perspectives*

**Désirée van der Heijde (Netherlands)**  
14:00  
*Recent advances in joint structural damage assessment in psoriatic arthritis*

**Philip Mease (United States)**  
14:20  
*Summary and meeting close*

---

**International Medical Press**  
**Overcoming barriers in SLE management: the patient at the heart of decision-making**

**Chairperson(s):** David Isenberg (United Kingdom)  
*Chairperson’s introduction and welcome*

**David Isenberg (United Kingdom)**  
13:00  
*Chairperson’s introduction and welcome*

**David Isenberg (United Kingdom) and Charlotte Franks (United Kingdom)**  
13:05  
*What matters to people with SLE?*

**Marta Mosca (Italy)**  
13:30  
*Sharing best practice in early and moderate SLE*

**Ian Bruce (United Kingdom)**  
13:55  
*How can we improve care in severe SLE?*

**David Isenberg (United Kingdom)**  
14:20  
*Summary and conclusions*

An application has been made to the EACCME® for CME accreditation of this symposium  
This symposium is supported by an educational grant from UCB Biopharma SPRL

---

**Biogen**  
**What rheumatologists need to know about biosimilars of complex Biologics**

**Chairperson(s):** Thomas Dörner (Germany)  
*Till Uhlig (Germany)  
The promise and the questions*

**Thomas Ryll (United States)**  
13:00  
*The promise and the questions*

**Mourad Rezk (Switzerland)**  
13:15  
*The road from development to approval*

**Thomas Dörner (Germany)**  
13:30  
*The road from development to approval*

**Thomas Dörner (Germany)**  
14:00  
*The emerging role of biosimilars of complex Biologics in rheumatology*
Sanofi and Regeneron Pharmaceuticals
New frontiers and treatment advances in Rheumatoid Arthritis (RA)

**Chairperson(s):**
Mark C. Genovese (United States)

**Mark C. Genovese (United States) 13:00**
The evolving scientific and clinical landscape for rheumatoid arthritis (RA): paradigms for RA: the foundational role of biologic therapy - what do we know? What do we still need to know?

**Roy M. Fleishmann (United States) 13:10**

**Ernest Choy (United Kingdom) 13:30**
The immunobiology of IL-6 signaling systems and their role in the inflammatory cascade and disease progression in RA: the scientific and mechanistic rationale for is IL-6 targeted therapy in RA

**Mark C. Genovese (United States) 13:50**
Evidence - and experience- based therapeutic profiles for IL-6 inhibition - a review of landmark trials, Clinical experience, and improvements in disease activity resulting from targeted inhibition of the IL-6 signaling system in patients with RA

**Eric Ruderman (United States) 14:10**
From science, mechanisms and data to real world clinical approaches: aligning IL-6 and other biologic therapies to optimize RA management in special patient populations with RA - poor responders, elderly, obese and men with RA

**Mark C. Genovese (United States) 14:20**
Chairperson's summary and near future vision statement

**All 14:25**
Interactive Questions & Answers

AstraZeneca
Uric acid: Another side to the story

**Chairperson(s):**
Davide Grassi (Italy)

**Davide Grassi (Italy) 13:00**
Prologue

**Thomas Bardin (France) 13:10**
The protagonist: Hyperuricaemia under the spotlight

**Pascal Richette (France) 13:25**
The plot thickens: Uric acid and disease pathogenesis beyond gout

**Allan Struthers (United Kingdom) 13:45**
An unexpected twist: The potential of urate-lowering therapy

**Panel discussion 14:05**
Evaluating the evidence: When should hyperuricaemia be treated?

**Davide Grassi (Italy) 14:25**
Epilogue

SHARE
SHARE satellite on patient participation in pediatric rheumatic diseases

**Chairperson(s):**
Nico. M. Wulffraat (Netherlands)

**Nico M. Wulffraat (Netherlands) 13:00**
Welcome and introduction

**S. Vastert (Netherlands) 13:15**
Treatment recommendations and best practices in pediatric rheumatology: an update of the SHARE project

**Karen Durrant (United States) 13:30**
Increasing awareness for rare paediatric rheumatic diseases, the experience of the autoinflammatory alliance

**Marijn Sikken (Netherlands) 13:45**
The patients perspective. Implications for building meaningful patient participation

**Vicky Seyfert-Margolis (United States) 14:00**
Digital technology and active patient participation - the way forward
**THURSDAY, 11 JUNE 2015**

**AbbVie**

The complexity of SpA: Is there a simple solution?

**Chairperson(s):**
Iain B. McInnes (United Kingdom)

Iain B. McInnes (United Kingdom) 08:30
The complexity of SpA

Dominique L. P. Baeten (Netherlands) 08:45
Aiming for simple solutions: How to approach features of SpA

Désirée van der Heijde (Netherlands) 09:10
Comorbidities: The additional burden of inflammatory arthritis

Laure Gossec (France) 09:25
Aiming for standardised quality of care in SpA rheumatology clinical practice

All 09:45
Questions & Answers

**Sanofi and Regeneron Pharmaceuticals**

The science of IL-6 pain and its impact on the rheumatoid arthritis patient

**Chairperson(s):**
Gianfranco Ferraccioli (Italy)

Gianfranco Ferraccioli (Italy) 08:30
Opening remarks

Cem Gabay (Switzerland) 08:35
What scientists have discovered about IL-6 and what clinicians need to know

Stephen McMahon (United Kingdom) 09:00
The role of IL-6 in persistent pain in RA

Bernard Combe (France) 09:15
Utilizing patient-reported outcomes (PROs) in the treatment decision-making process

All 09:35
Panel discussion

Gianfranco Ferraccioli (Italy) 09:55
Closing remarks

**GSK**

Current issues in the management of SLE

**Chairperson(s):**
Dimitrios Boumpas (Greece)

Dimitrios Boumpas (Greece) 08:30
Opening Statement

Ian Bruce (United Kingdom) 08:35
and Andrea Doria (Italy)

Understanding the SLE patient: a discussion of patient needs, clinical challenges and treatment goals based on three real world case examples

Key topics include:
- Understanding the SLE patient and the challenges faced in the clinic
- Setting appropriate short-term treatment goals
- The use of Belimumab plus standard of care

All 09:35
Q&A

Dimitrios Boumpas (Greece) 09:50
Closing statement and discussion of long-term outcomes

**UCB**

Why is the timing of treatment initiation important for RA patients?

**Chairperson(s):**
Roberto Caporali (Italy)

Roberto Caporali (Italy) 08:30
Welcome and introduction

Paul Emery (United Kingdom) 08:35
RA in time: pathogenesis and ‘window of opportunity’

Roberto Caporali (Italy) 08:50
Time to RA treatment in Europe and the impact on patients

Vivian Bykerk (United States) 09:05
Optimising time: predictors of treatment success

Josef Smolen (Austria), Paul Emery (United Kingdom) 09:20
+ moderator: Vivian Bykerk (United States)
The debate: when, who and which biologic in RA

Roberto Caporali (Italy) 09:50
Question and answer session
08:30-10:00 Room 10 B

**medac**

**Lifetime management of arthritis - the value of MTX in clinical practice**

Chairperson(s):
- James O’Dell (United States)

**08:30**
- Welcome and introduction

**08:35**
- Ivan Foeldvari (Germany)
  The role of Methotrexate in juvenile idiopathic arthritis

**08:55**
- Gerolamo Bianchi (Italy)
  Management of arthritis with MTX in middle-aged patients

**09:15**
- James O’Dell (United States)
  Methotrexate: the foundation of combination therapy in RA

**09:35**
- Suzanne V erstappen (United Kingdom)
  Adherence to Methotrexate in patients with rheumatoid arthritis

**09:55**
- James O’Dell (United States)
  Summary

08:30-10:00 Room 10 C

**Celgene**

**Targeting PDE4 in psoriatic arthritis: scientific rationale and clinical results**

Chairperson(s):
- Philip J. Mease (United States)

**08:30**
- Filip van den Bosch (Belgium)
  Cytokines associated with the clinical manifestations of PsA

**08:50**
- Georg A. Schett (Germany)
  The role of PDE4 in inflammatory responses

**09:10**
- Philip J. Mease (United States)
  The efficacy and safety of a novel, oral PDE4 inhibitor for the treatment of PsA

**09:30**
- All
  Question and answer

08:30-10:00 Room 10 H

**IBSA**

**Fighting pain in rheumatic diseases: what we know, what to learn**

Chairperson(s):
- Hans Georg Kress (Austria)
- Ignazio Olivieri (Italy)

**08:30**
- Filip van den Bosch (Belgium)
  Cytokines associated with the clinical manifestations of PsA

**08:50**
- Tom Huizinga (Netherlands)
  Exploring real-world methotrexate use and treatment adherence

**09:10**
- Paul Emery (United Kingdom)
  RA: More than just a joint disease

**09:30**
- All
  Question and answer session

**09:50**
- Alison Kent (United Kingdom)
  How patient-nurse interactions drive comprehensive RA management

17:45-19:15 Hall 8

**Roche**

**One disease, many impacts: How do I treat my RA patient?**

Chairperson(s):
- Paul Emery (United Kingdom)
- Marcello Govoni (Italy)

**17:45**
- Marcello Govoni (Italy)
  Welcome and introduction

**17:50**
- Paul Emery (United Kingdom)
  RA: More than just a joint disease

**18:05**
- Tom Huizinga (Netherlands)
  Exploring real-world methotrexate use and treatment adherence

**18:20**
- All
  Question and answer session

**18:30**
- Alison Kent (United Kingdom)
  How patient-nurse interactions drive comprehensive RA management

**18:45**
- Laure Gossec (France)
  Aligning physician goals and patient expectations in RA management

**19:00**
- Paul Emery (United Kingdom)
  Summary

All
  Question and answer session
### AbbVie

**The skin-joint disconnect: Assessing the many faces of psoriatic arthritis**

**Chairperson(s):**  
Philip J. Mease (United States)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45</td>
<td>Philip J. Mease (United States)</td>
<td>The importance of inhibiting progression in PsA</td>
</tr>
<tr>
<td>18:05</td>
<td>Wolf-Henning Boehncke (Switzerland)</td>
<td>Why do dermatologists care about PsA?</td>
</tr>
<tr>
<td>18:20</td>
<td>Dafna Gladman (Canada)</td>
<td>The skin-joint disconnect: Critical driver of disease management decisions</td>
</tr>
<tr>
<td>18:40</td>
<td>Philip Helliwell (United Kingdom)</td>
<td>Quality of care in PsA</td>
</tr>
<tr>
<td>19:00</td>
<td>All</td>
<td>Question and Answer session</td>
</tr>
</tbody>
</table>

### Pfizer

**An integrated approach to RA management: how to combine innovation, patient perspectives and cost considerations**

**Chairperson(s):**  
Pier Luigi Meroni (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45</td>
<td>Pier Luigi Meroni (Italy)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>17:50</td>
<td>Chris Buckley (United Kingdom)</td>
<td>Is it time to start to talk about acure in rheumatoid arthritis?</td>
</tr>
<tr>
<td>18:15</td>
<td>João E. Fonseca (Portugal)</td>
<td>Are we moving towards value-driven treatment decisions?</td>
</tr>
<tr>
<td>18:40</td>
<td>John Isaacs (United Kingdom)</td>
<td>Will Omics deliver more than patient-reported outcomes?</td>
</tr>
<tr>
<td>19:05</td>
<td>All</td>
<td>Panel discussion</td>
</tr>
<tr>
<td>19:15</td>
<td>All</td>
<td>Summary and close</td>
</tr>
</tbody>
</table>

### Bristol-Myers Squibb

**Unlocking the potential to predict treatment outcomes: autoantibodies and other predictors of RA disease progression**

**Chairperson(s):**  
Gianfranco Ferraccioli (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45</td>
<td>Gianfranco Ferraccioli (Italy)</td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>17:50</td>
<td>Michael Schiff (United States)</td>
<td>Recommendations for the treatment of RA: can we predict how patients will respond to treatment?</td>
</tr>
<tr>
<td>18:05</td>
<td>Jacques-Eric Gottenberg (France)</td>
<td>Defining patient types in real-world clinical practice: what prognostic factors have been identified?</td>
</tr>
<tr>
<td>18:20</td>
<td>Georg Schett (Germany)</td>
<td>Joint destruction and autoantibodies: unique mechanisms and opportunities for intervention</td>
</tr>
<tr>
<td>18:40</td>
<td>Tom Huizinga (Netherlands)</td>
<td>Autoantibody maturation as a biomarker for RA development - is there a place for targeted therapies?</td>
</tr>
<tr>
<td>19:00</td>
<td>All</td>
<td>Panel discussion and questions</td>
</tr>
</tbody>
</table>

### MSD

**Answering clinical questions in spondyloarthritis: insights into the management of your SpA patient**

**Chairperson(s):**  
Ignazio Olivieri (Italy)  
Maxime Dougados (France)

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:45</td>
<td>Ignazio Olivieri (Italy)</td>
<td>Welcome and opening remarks?</td>
</tr>
<tr>
<td>17:50</td>
<td>Maxime Dougados (France)</td>
<td>Diagnosis, treatment and disease course of axial SpA</td>
</tr>
<tr>
<td>18:15</td>
<td>Dirk Elewaut (Belgium)</td>
<td>Treatment strategies for the complex manifestations of axial SpA</td>
</tr>
<tr>
<td>18:40</td>
<td>Martin Rudwaleit (Germany)</td>
<td>Keeping the focus on the patient in the management of axial SpA</td>
</tr>
<tr>
<td>19:05</td>
<td>All</td>
<td>Panel discussion / Question and Answer</td>
</tr>
<tr>
<td>Time</td>
<td>Room</td>
<td>Topic</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>17:45-19:15</strong></td>
<td><strong>Room 10 I</strong></td>
<td><strong>Amgen</strong></td>
</tr>
<tr>
<td><strong>Chairperson(s):</strong></td>
<td></td>
<td>Oliver FitzGerald (Ireland)</td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>17:50</td>
<td></td>
<td>Psoriatic arthritis: what still needs to be done to improve the lives of patients?</td>
</tr>
<tr>
<td>18:15</td>
<td></td>
<td>Investigating the IL-17 receptor pathway: a role in psoriatic diseases and other spondyloarthropathies</td>
</tr>
<tr>
<td>18:40</td>
<td></td>
<td>Inhibiting the IL-17 receptor: a new approach to psoriasis and psoriatic arthritis</td>
</tr>
<tr>
<td>All</td>
<td></td>
<td>Panel discussion and concluding remark</td>
</tr>
<tr>
<td><strong>17:45-19:15</strong></td>
<td><strong>Room 10 C</strong></td>
<td><strong>RAISE supported by Janssen</strong></td>
</tr>
<tr>
<td><strong>Chairperson(s):</strong></td>
<td></td>
<td>Josef Smolen (Austria)</td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>17:50</td>
<td></td>
<td>The role of IL-6 in inflammation, B cell activation and T cell differentiation</td>
</tr>
<tr>
<td>18:10</td>
<td></td>
<td>The pros and cons of disease assessment measures in RA</td>
</tr>
<tr>
<td>18:35</td>
<td></td>
<td>Targeting IL-6 in RA: what are the options?</td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td>Questions and closing remarks</td>
</tr>
<tr>
<td><strong>17:45-19:15</strong></td>
<td><strong>Room 10 D-E</strong></td>
<td><strong>AstraZeneca</strong></td>
</tr>
<tr>
<td><strong>Chairperson(s):</strong></td>
<td></td>
<td>Frédéric Lioté (France)</td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td>Welcome and introduction</td>
</tr>
<tr>
<td>17:55</td>
<td></td>
<td>Uric acid transport: Latest scientific insights</td>
</tr>
<tr>
<td>18:10</td>
<td></td>
<td>Advances in imaging: Changing how we see gout</td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>The MOZArT trial: TRAUMEEL/ZEEL T in the management of OA of the knee</td>
</tr>
<tr>
<td>18:50</td>
<td></td>
<td>BioKnee - a future pathway towards OA management with cartilage stimulation, repair, regeneration and replacement</td>
</tr>
<tr>
<td>19:10</td>
<td></td>
<td>Q&amp;A and closure</td>
</tr>
<tr>
<td><strong>17:45-19:15</strong></td>
<td><strong>Room 10 H</strong></td>
<td><strong>Biologische Heilmittel Heel</strong></td>
</tr>
<tr>
<td><strong>Chairperson(s):</strong></td>
<td></td>
<td>Cathy Speed (United Kingdom)</td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td>Welcome and objectives</td>
</tr>
<tr>
<td>17:50</td>
<td></td>
<td>Management of OA: how to do it well</td>
</tr>
<tr>
<td>18:10</td>
<td></td>
<td>The relevance of a rehabilitative intervention based on biomechanics in the management of early osteoarthritis</td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td>The MOZArT trial: TRAUMEEL/ZEEL T in the management of OA of the knee</td>
</tr>
<tr>
<td>18:50</td>
<td></td>
<td>BioKnee - a future pathway towards OA management with cartilage stimulation, repair, regeneration and replacement</td>
</tr>
<tr>
<td>19:10</td>
<td></td>
<td>Q&amp;A and closure</td>
</tr>
</tbody>
</table>
FRIDAY, 12 JUNE 2015

08:30-10:00  Hall 3

AbbVie

Consistency of biologic therapies: how different is similar?

Chairperson(s): Josef Smolen (Austria)

Josef Smolen (Austria)  08:30
Biologics to biosimilars: the journey

Roy Jefferis (United Kingdom)  08:45
Why structural differences matter

Paul W. Tebbey (United States)  09:05
Structural consistency of adalimumab, a glycosylated monoclonal antibody

Paul Emery (United Kingdom)  09:25
Translating structural differences to clinical practice

All  09:45
Questions and answers

08:30-10:00  Room 10 F-G

Pfizer

Clinical advancements in axial SpA: a journey of scientific evolution

Chairperson(s): Maxime Dougados (France)

Maxime Dougados (France)  08:30
Welcome and introduction

Martin Rudwaleit (Germany)  08:35
Understanding AxSpA: a decade of progress

Walter Maksymowych (Canada)  08:55
Imaging modalities in AxSpA: a clearer view?

Valderilio Azevedo (Brazil)  09:25
Designing the blueprints for treatment success?

All  09:45
Questions and closing remarks

08:30-10:00  Hall 2

PEARLS supported by Janssen

The spectrum of spondyloarthopathies: molecules to medicine

Chairperson(s): Iain B. McInnes (United Kingdom)

Iain B. McInnes (United Kingdom)  08:30
Welcome and introduction

Matt Brown (Australia)  08:35
What causes SpA?

Filip van den Bosch (Belgium)  09:00
Can pathogenesis drive the therapeutic strategy in the SpA spectrum?

Iain B. McInnes (United Kingdom)  09:20
PsA: moving towards optimal outcomes?

All  09:45
Questions and closing remarks

08:30-10:00  Hall 1

Novartis Pharmaceuticals

IL-17 inhibition: emerging perspectives in the future management of axial spondyloarthritis

Chairperson(s): Atul Deodhar (United States)

Atul Deodhar (United States)  08:30
Welcome and introduction

Dirk Elewaut (Belgium)  08:45
Why target IL-17 in axial spondyloarthritis?

Dominique Baeten (Netherlands)  09:05
Recent advances in current and emerging treatments

Xenofon Baraliakos (Germany)  09:30
The imaging perspective: bone inflammation and structural damage

Atul Deodhar (United States)  09:50
Summary and meeting close
08:30-10:00 Room 10 B

**Lilly**

**Mapping the impact of chronic inflammation in rheumatoid arthritis (RA): From molecular triggers and disease pathophysiology to patient quality of life**

Chairperson(s):
- Gianfranco Ferraccioli (Italy)

- **Gianfranco Ferraccioli (Italy)** 08:30  Welcome and introduction

- **Peter Taylor (United Kingdom)** 08:35  Biology of signaling pathways in inflammatory arthritis

- **Tom Huizinga (Netherlands)** 08:55  Impact of chronic inflammation on comorbidities

- **Bruno Fautrel (France)** 09:15  Living with chronic inflammatory disease: the patients’ perspective

- **Gianfranco Ferraccioli (Italy)** 09:35  Panel discussion, questions and answers

08:30-10:00 Room 10 C

**GSK**

**Management of PAH - CTD patients in 2015 milestones towards the future**

Chairperson(s):
- Jean-Luc Vachiéry (Belgium)

- **Jean-Luc Vachiéry (Belgium)** 08:30  Welcome and introduction

- **Marco Matucci (Italy)** 08:32  Challenges in treatment of PAH and DDI’s

- **Chris Denton (United Kingdom)** 08:50  VOLT data in CTD-PAH

- **Gerry Coghlan (United Kingdom)** 09:10  Treatment strategies in PAH associated to CTD

- **Jean-Luc Vachiéry (Belgium)** 09:30  Closing

08:30-10:00 Room 10 H

**Bioiberica**

**Latest evidence on osteoarthritis treatment: Can we turn back the clock?**

Chairperson(s):
- Philip Conaghan (United Kingdom)
- Jean-Pierre Pelletier (Canada)

- **Philip Conaghan (United Kingdom)** 08:30  Osteoarthritis, drug use and risk of cardiac ischaemic events: case-control studies

- **Jasvinder Singh (United States)** 08:35  Latest cochrane review on osteoarthritis: what’s the evidence?

- **Pascal Richette (France)** 08:37  MOVES: Multicentre Osteoarthritis interVEntion trial with Sysadoa

- **Johanne Martel-Pelletier (Canada)** 08:40  Long-term effects of treatment on the progression of structural changes in knee osteoarthritis: 6-year follow-up data from the Osteoarthritis Initiative cohort

- **Jean-Pierre Pelletier (Canada)** 08:43  MOSAIC: 24 MOnth Study on structural changes in knee osteoarthritis Assessed by mri with Chondroitin sulphate
UCB
Optimal management of spondyloarthritis is more than just spine and joints: ask the experts!

Chairperson(s):
Filip van den Bosch (Belgium)

Filip Van den Bosch (Belgium)  17:45
Overview and learning objectives

Ignazio Olivieri (Italy)   17:55
Adopting an integrated approach to optimise patient care in SpA

Marina Mesquida (Spain)  18:10
Management of uveitis associated with SpA: ask the ophthalmologist!

Wolf-Henning Boehncke (Switzerland)  18:25
Management of psoriasis manifestations in SpA: ask the dermatologist!

Anne-Grete Semb (Norway)  18:40
Management of cardiovascular comorbidity in SpA: ask the cardiologist!

Filip Van den Bosch (Belgium)  18:55
Wrap-up and conclusion

All  19:00
Ask the experts! (question and answer session)

Menarini
Shaping the actual burden of hyperuricaemia with deposits

Chairperson(s):
Fernando Perez-Ruiz (Spain)
Leonardo Punzi (Italy)

Leonardo Punzi (Italy)  17:45
Introduction

Fernando Perez-Ruiz (Spain)  17:50
Outlining multi-systemic impact of elevated uric acid

Giovambattista Desideri (Italy)  18:10
Tracing pharmaco-economic load of hyperuricaemia with or without deposits

Geraldine McCarthy (Ireland)  18:30
Drawing pharmacological approach of hyperuricaemia with deposition

Discussion  18:50

Symposium in German supported by Chugai and Roche
Highlights of EULAR 2015

German rheumatologists present highlights of EULAR 2015 and their impact on patients care

Frank Behrens (Frankfurt)  17:45
Psoriatic arthritis

Xenofon Baraliakos (Bochum)  18:00
Axial spondylarthritis

Torsten Witte (Hanover)  18:15
Novelties in RA treatment

Christof Iking-Konert (Hamburg)  18:30
Biologica monotherapy

Christof Specker (Essen)  18:45
Collagenoses

Peer M. Aries (Hamburg)  19:00
Vasculitis

Discussion after each presentation by presenters and the panelists:
Frank Buttgereit (Berlin), Jens G. Kuipers (Bremen), Ulf Müller-Ladner (Bad Nauheim), Andrea Rubbert-Roth (Cologne), Matthias Schneider (Dusseldorf)
Company Profiles

Status as of 5 April 2015

Booth N° 5.1

AbbVie

1 North Waukegan Rd
North Chicago, IL 60064
United States
www.abbvie.com

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Booth N° 6.3a

ACTELION PHARMACEUTICALS LTD

Gewebestrasse 16
4123 Allschwil
Switzerland
www.actelion.com

Actelion Ltd is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

Booth N° V14

AGORA SECRETARIAT

P.O BOX 51199
3502, Limassol
Cyprus
www.agora-platform.eu
www.agora-pait.com

Agora is a platform of organizations representing people with Rheumatic and Musculoskeletal Diseases in Southern Europe, which has been active since 2011. Agora aims to bring awareness, create a stronger voice for people with RMDs and motivate them to become more active and conscious through its various projects and initiatives. Furthermore, Agora aims in assisting the foundation and development towards user-led organizations of people with RMDs in Southern Europe, as well as to promote supportive attitudes towards RMDs and enable patients to live independent and participate fully in society.
Alfa Wassermann is a pharmaceutical group with an Italian heart and an international outlook. Founded in 1948, the company has gradually established itself on the market thanks to heavy investments in research and technology that have produced innovative drugs of great success in the two main areas of activity: prescription specialties and OTC products. Alfa Wassermann Group employs over 1370 employees worldwide. In 2014 it had a turnover of 408 million euro, 54% of which came from international sales and with over 60% of the revenue generated by its own products.

ANMAR was born in Rome in 1985 by a group of patients and physicians, who together and by mutual agreement, are seeking over more than 20 years to spread and promote knowledge of "Rheumatic Diseases" at the Society, Health Institutions and National Authorities. Today ANMAR is particularly focused on raising public awareness through information campaigns, targeted primarily to the difficulties of managing all the problems related to the onset and evolution of these diseases. ANMAR is composed of Regional Associations based in 19 regions and therefore is present and active throughout Italy.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
ARD-RHEUMATOLOGY NEWS FROM BMJ

BMA House
Tavistock Square
London, WC1H 9JR
United Kingdom
www.bmj.com

BMJ is a global healthcare knowledge provider and a leader in rheumatology content. Visit stand 5.18a to find out about the official EULAR/BMJ journal, Annals of the Rheumatic Diseases, the #1 ranked original research journal in its field, and its new Open Access companion title, RMD Open. You can also learn more about the new 2nd edition of the EULAR Textbook on Rheumatic Diseases, Lupus Science & Medicine, the first Open Access lupus journal from Lupus Foundation of America, as well find out more about our other evidence based solutions which can be used to improve your patient care.

ASIF - ANKYLOSING SPONDYLITIS INTERNATIONAL FEDERATION

4 Albion Court, Hammersmith
London, W6 0QT
United Kingdom
www.asif.info

ASIF’s Vision is to be the global voice of those living with Ankylosing Spondylitis. Its Mission is to increase awareness of Ankylosing Spondylitis (AS) and disseminate knowledge of the disease around the world to all key stakeholders be they people living with AS, health professionals, researchers, pharmaceutical organisations, policy makers or the general public.

Formed in 1988, ASIF represents 37 AS organizations from 35 countries.

ASTRAZENECA

2 Kingdom Street
London - W2 6BD
United Kingdom
www.astrazeneca.com

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca.com

BAYER

Muellerstrasse 178
13353 Berlin
Germany
www.healthcare-bayer.com

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 20 billion (2014), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 60700 employees (Dec 31, 2014) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com

BE THE CURE

Karolinska Institutet
Leiden University Medical Center
Sweden/Netherlands
www.btcure.eu

BTCure is a research initiative with 25 academic and 14 industrial partners, funded by the IMI (www.imi.europa.eu).

This initiative aims to bring together academic rheumatology research and research in pharmaceutical companies in Europe to further broaden our knowledge of disease causing factors and disease progression in Rheumatoid Arthritis (RA), thereby identifying improved or targeted therapeutic treatments. The focus will be the development of new diagnostic methods to discover early forms of RA as well as tools to separate the different forms of RA.

BIOGEN

Landis & Gyr-strasse 3
6300 Zug
Switzerland
www.biogenidec.com

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders.
Founded in 1978, Biogen is the world’s oldest independent biotechnology company. In 2012, Biogen entered into a joint venture (JV) with Samsung Biologics to form Samsung Bioepis to bring advanced biosimilars to patients. As part of the JV, Biogen will commercialize a number of anti-TNF biosimilars therapies in Europe, Turkey, Russia and Japan. The company will also manufacture these therapies in its large-scale manufacturing facility in Hillerød, Denmark, one of the largest in the world.

**Booth N° 5.16**

**BIOIBERICA, S.A.**

Plaza Francesc Macià, 7 08029, Barcelona Spain www.bioiberica.com

BIOIBERICA is a biotechnology company specialized in osteoarthritis (OA) and chondroprotection. Based on a holistic approach of the disease, it has a full range of chondroprotective drugs such as Condrosan® / Cartexan® (Chondroitin Sulfate) and Cartisorb® (Glucosamine Sulfate) and Droglican®, the first combination of chondroitin and glucosamine approved as an ethical reimbursed drug product. BIOIBERICA is also positioned within the OA Personalized Medicine field, with genetic tests, biomarkers, tissue engineering and cell therapy.

**Booth N° 6.29a**

**Biologisches Heilmittel Heel**

Dr.-Reckeweg-Str. 2-4 76532 Baden-Baden Germany www.heel.com

Heel is a pharmaceutical company that develops, manufactures and distributes homeopathic medicines based on natural substances for a wide range of indications. The company is a pioneer in the field of scientific research in natural healthcare. In cooperation with academic institutions, Heel actively fosters the concept of Integrative Medicine. Traumeel and Zeel are two of the company’s leading products. Both are approved with a therapeutic indication in many countries, e.g. Austria. In Italy both products are notified without approved therapeutic indication. They will both be featured at the Heel booth and during a satellite symposium.

**Booth N° 6.6c**

**BIOMED CENTRAL**

236 Gray’s Inn Road London, WC1X 8HB United Kingdom www.biomedcentral.com

BioMed Central is an online STM publisher of 277 peer-reviewed open access journals. The portfolio spans across areas of biology, biomedicine and medicine, with many journals publishing content related to rheumatology and musculoskeletal disorders. Examples of such journals include: Arthritis Research and Therapy, BMC Musculoskeletal Disorders and Journal of Foot and Ankle Research. Authors publishing retain copyright of their work, licensing it under the Creative Commons Attribution License. BioMed Central is owned by Springer Science+Business Media, and also hosts SpringerOpen.

**Booth N° 6.19**

**BK MEDICALS**

Mileparken 34 2730, Herlev Denmark www.bkultrasound.com

BK Ultrasound is a leading provider premium performance ultrasound for musculoskeletal applications. The bk3000 and the Flex Focus ultrasound systems have excellent image quality and very sensitive color flow with superb spatial resolution and sensitivity. The systems all very mobile with a small footprint so they can fit into tight spaces. There is a broad range of innovative transducers and most have a smart button for ease of use. The high frequency 18 MHz transducer provides extremely high resolution imaging to enable visualisation of details.

**Booth N° 5.4a & 5.4b**

**Bristol-Myers Squibb**

P.O. Box 4000 Princeton, NJ 08543 United States www.bms.com

Bristol-Myers Squibb is a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit www.bms.com, or follow us on Twitter at http://twitter.com/bmsnews
The British Society for Rheumatology and British Health Professionals in Rheumatology promote excellence in the treatment of people with rheumatic and musculoskeletal disorders, and support those delivering care. With members in over 55 countries, we are a global network of consultants, trainees, nurses and allied healthcare professionals who share a common in the field of rheumatology. Visit us at stand V8 and find our website at www.rheumatology.org.uk

Celgene is a global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies. Our growing investment in the development of immunomodulatory agents and cell signaling inhibitors, as well as in the development of cellular and tissue therapeutics, will allow us to provide physicians/clinicians with a more comprehensive and integrated set of solutions for managing complex human disorders such as cancer and other severe, immune, inflammatory conditions.

RheumaKit is the first IVD product developed by the Belgian company DNAlytics. RheumaKit provides an early differential diagnosis for patients with undifferentiated arthritis (UA) and allows to differentiate diagnosis of Rheumatoid Arthritis, Osteoarthritis or other types of arthritis. RheumaKit is based on a transcriptomic signature and three clinical/biological factors, combined into a mathematical model and implemented in a web application. It represents a first step in the introduction of biomarker-based in vitro diagnostic tools in rheumatology.

EMEUNET, the Emerging EUlar NETwork, is a EULAR working group of young clinicians and researchers in rheumatology promoting education, research, widening collaborations and integrating with EULAR activities. The principle objectives of EMEUNET include the development of a European-wide network of young, emerging rheumatologists and rheumatology researchers, enabling continued excellence in research, and promoting and facilitating a comprehensive higher educational platform for all rheumatology trainees.

Esaote is a top-10 diagnostic imaging company offering innovative clinical solutions from prevention to therapy. It focuses exclusively on ultrasound and office-based MRI, boasting an extended range of products specifically tuned to rheumatology applications and able to satisfy any clinical need. The ultrasound MyLab family boasts a complete range of rheuma-dedicated systems, from portable to premium-
end products. Whilst the dedicated MRI line represents an optimal solution for excellent rheuma images with low installation requirements and costs per exam. Come visit Esaote Booth 5.19.

Booth N° 5.14

EULAR

EULAR Executive Secretariat
Seestrasse 240
8802 Kilchberg
Switzerland
www.eular.org

The European League against Rheumatism (EULAR) is the European umbrella organisation in the area of rheumatic and musculoskeletal diseases. EULAR represents scientific societies, health professionals associations and organisations of people with arthritis/rheumatism throughout Europe. The aims of EULAR are to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases. More information at www.eular.org

Booth N° V1 & V2

EULAR HEALTH PROFESSIONALS IN RHEUMATOLOGY

EULAR Executive Secretariat
Seestrasse 240
8802 Kilchberg
Switzerland
www.eular.org

The Health Professional Standing Committee (HPSC) is actively engaged as part of the EULAR Executive Committee to represent Health Professionals (HPs) working within the field of rheumatic and musculoskeletal diseases (RMDs) across Europe. The HPSC aims to improve the standard of care for people with RMDs. HPs work with all members of the EULAR Executive Committee to ensure that people with RMDs have access to optimal health care provision by encouraging high quality research, raising awareness of RMDs, and identifying educational and training needs. The role of the patient as an active and empowered member of the multi-disciplinary team is a key component of our work. The HPSC collaborates across Europe with health professionals to raise standards, encourage research that is effectively disseminated and implemented, together with supportive educational initiatives. The HPSC welcomes the application of new HP Country Members of EULAR.

Booth N° V27 & V28

EULAR PARE

EULAR Executive Secretariat
Seestrasse 240
8802 Kilchberg
Switzerland
www.eular.org

The EULAR Standing Committee of PARE gathers representatives of rheumatic and musculoskeletal user groups around Europe to work together towards improving the quality of life for the more than 120 million people in Europe living with these conditions.

The committee's vision is of people with rheumatic and musculoskeletal diseases (RMDs) in Europe being empowered to lead full and independent lives. To achieve this, the committee organises a range of high-quality activities and programmes. Activities may include lobbying at the national level, e.g., raising awareness of the disease, defending the civil rights of people with RMDs, or having access to the latest and most appropriate treatments.

Booth N° 6.22

EUROPEAN JOURNAL OF RHEUMATOLOGY

İzmir Katip Çelebi University,
Faculty of Medicine
Department of Rheumatology
İzmi,
Turkey
www.eurjrheumatol.org

European Journal of Rheumatology (Eur J Rheumatol) is an international, open access peer reviewed journal committed to promoting the highest standards of scientific exchange and education. The journal is published quarterly on March, June, September and December. The aim of the European Journal of Rheumatology is to cover various aspects of rheumatology for its readers, encompassing the spectrum of diseases with arthritis, musculoskeletal conditions, autoinflammatory diseases, connective tissue disorders, osteoporosis, translational research, the latest therapies and treatment programs. European Journal of Rheumatology publishes original articles, invited reviews, case reports, letters to the editor and images in rheumatology.

The publication language of the journal is English. The journal's target audience includes academicians, practicioners, specialists and students from all disciplines of rheumatology.

European Journal of Rheumatology adheres to the principles outlined by the guidelines of ICMJE, WAME, EASE and COPE.

All published content of the European Journal of Rheumatology is available online at www.eurjrheumatol.org, free of charge.
**Booth N° 5.23**

**EYELED - HELP POINT FOR SMARTPHONES AND MOBILE DEVICES**

Science Park 1  
66123 Saarbrücken  
Germany  
www.eyeled.de

Enterprise Mobility

With our knowledge and experience from more than 200 mobility projects, we offer our customers comprehensive advice, implement mobile solutions and provide long-term support for them.

**Booth N° 5.12**

**EXPANSCIENCE**

Laboratoires Expanscience  
10, avenue de l’Arche  
92419 Courbevoie Cedex  
France  
www.expanscience.com

In 2014, Expanscience - a French independently-owned pharmaceutical and dermo-cosmetics laboratory - generated turnover of €271.8 million, 46.5% of which was through exports, and employed 967 people. Over more than 60 years, the company has built up a solid international reputation as an innovator and as a specialist in skin and the treatment of arthritis. Its products, which include two leading brands - Piasclédine 300 and Mustela - are sold in more than 99 countries (86 distributing countries and 13 subsidiaries). Expanscience develops and also sells natural-origin active ingredients for use in cosmetics, both in France and abroad. The whole value chain is integrated into the company - from research through to production and distribution. Its CSR policy, which was introduced 10 years ago, was recognised as exemplary by the AFAQ 26000 assessment in 2013.

**Booth N° V4**

**FESCA**

Le Versailles  
Avenue des Etats-Unis 20/32  
7500 Tournai  
Belgium

FESCA aisbl., founded in 2007, is an umbrella group of currently 23 national scleroderma patient support and advocacy organizations in 18 European countries. Friends of FESCA aisbl, includes the USA, Canada, and Australia, giving us a global presence and unity of purpose with other groups in the world. FESCA’s objectives include encouraging the active involvement of politicians and pharmaceutical companies, working with doctors to secure earlier diagnosis and better treatments, and creating greater awareness of scleroderma so that those who suffer from it can access proper, equitable care.

**Booth N° 6.18**

**FIDIA FARMACEUTICI S.P.A.**

Via Ponte della Fabbrica 3/A  
35031 Abano Terme PD  
Italy  
www.fidiapharma.com

Fidia Farmaceutici S.p.A. is a fully integrated Italian Healthcare Company, with R&D, manufacturing, marketing and sales capabilities. Fidia operates worldwide to develop and market patented, innovative products, mainly based on hyaluronan (HY) and its derivatives, focusing on Advanced Wound Care and Joint Healthcare, including OA. Among major products: HY-based products for i.a. knee injection (Hyalgan/Hyalart; Hymovis, a new generation hydrogel); fermentation-derived, HY-based viscosupplements for knee and hip (Hyalubrix; Hyalone, single administration); diclofenac-based products for local treatment of pain and inflammation (Itami Plaster, Itamidol foam). The company’s manufacturing operation is FDA-inspected and approved, and complies with multiple international regulation systems and safety standards.

**Booth N° 6.28**

**GE HEALTHCARE**

42665 Solingen  
Germany  
www.gehealthcare.com

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.
Established on 2005 by a group of Italian Rheumatologists, GISEA is a no-profit organization founded to promote the study on early arthritis. GISEA created a web-based Registry to collect and analyze data, in order to encourage scientific exchange throughout Europe. The GISEA Registry stores data of more than 10000 patients, collecting case studies about biologics since 1999. Up today 28 Rheumatology Centers belong to the GISEA organization across Italy. GISEA deals with the scientific organization of congresses, seminars, publications and any other project relevant to its goals.

GLAXOSMITHKLINE

980 Great West Road
Brentford, Middlesex TW8 9GS
United Kingdom
www.gsk.com

GSK - a science-led global healthcare company that researches and manufactures a range of products - is committed to improving the quality of human life by enabling people do more, feel better, live longer. For further information please visit www.gsk.com

HEMICS

Torenallee 20
5617 BC, Eindhoven
Netherlands
www.hemics.com

Hemics is a medical device company active in the field of inflammatory joint diseases. Hemics launches the Hemics® HandScan, a new non-invasive optical imaging device. It supports rheumatologists in objective assessment of inflammatory status in patients with Rheumatoid Arthritis (RA). The technique is time saving, non-invasive, safe and operator independent, and thus very suitable for monitoring RA. Hemics was founded as a spin-off of Royal Philips.

Hologic NV

Leuvensesteenweg 250A
1800 Vilvoorde
Belgium
www.hologic.com

We’re committed to making a difference by helping people everywhere live stronger, healthier lives. And with that, delivering tools to help people maintain stronger, healthier bones. From imaging solutions that can identify osteoporosis and fractures that might otherwise go undetected to state-of-the-art diagnostic tools, Hologic keeps skeletal health a top priority.

HOSPIRA

Horizon building, Honey Lane,
Hurley, SL6 6RJ
United Kingdom
www.hospira.com

Hospira is the world’s leading provider of injectable drugs and infusion technologies, offering one of the broadest portfolios of generic acute-care and oncology injectables, biosimilar medicines, integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Illinois, United States and has more than 16000 employees. The head office for Hospira in Europe, Middle East and Africa is in Royal Leamington Spa, UK. Learn more about Hospira at www.hospira.com

IBSA INSTITUT BIOCHIMIQUE SA

Via del Piano
6915 Pambio Noranco
Switzerland
www.ibsa-international.com

IBSA is an international pharmaceutical company based in Lugano, Switzerland, active in different therapeutic areas. For OA and related syndromes, IBSA’s portfolio includes a wide range of pharmaceutical options such as pharmaceutical-grade chondroitin sulphate for oral intake (Condrosulf®, Chondrosulf®, Condral®), a highly purified intra-articular hyaluronic acid of biofermentative origin (Sinovial®, Yaral®, Intragel®), topical and oral forms of diclofenac epolamine (Flector®) and an innovative subcutaneous injection of diclofenac also available at low dosages and in form of pre-filled syringe (Akis®, Dicloin®).
Booth N° V10

INTERNATIONAL LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (ILAR)

2200 Lake Boulevard, NE
Atlanta, GA 30319
United States
www.ilar.org

The International League of Associations for Rheumatology’s (ILAR) mission is to advance rheumatology in developing countries. The ILAR Executive Committee consists of the Presidents and Presidents-Elect of ACR, EULAR, PANLAR, APLAR and AFLAR. The collaboration of the leaders of these international organizations has resulted in a renewed commitment to support programs that lead to progress in the practice and education of rheumatology in countries where there is an exceptional need.

Booth N° 5.21

IMAGE ANALYSIS LTD

Image Analysis Ltd
QABC Minster House,
Vauxhall Bridge Road 272-274
London, SW1V 1BA
United Kingdom
www.ImageAnalysis.org.uk

Image Analysis is the industry leader in quantitative assessment of MRI scans taken from patients with inflammatory musculoskeletal conditions. Diagnosis and treatment decisions in inflammation-driven arthritis and many other disorders increasingly depend on examination of medical images, particularly Magnetic Resonance Imaging (MRI) data. To ensure the success of a clinical trial and patient well-being, it is critical to have consistent quantitative measurement of the state of the disease at the point of diagnosis and objective assessment of patient response to drug treatment.

Image Analysis team works with pharmaceutical companies and major hospitals providing remote analysis and support for multi-center global clinical trials in therapeutic areas where MRI is a critical differentiator, including in rheumatoid arthritis, psoriatic arthritis, lupus, gout and others.

Our proprietary software platform Dynamika is used by clinical and research investigators to analyse MRI scans and to produce quantitative measures of inflammation through measuring the volume and perfusion as well structural changes. Fully and semi-automated algorithms for image reading and scoring help to reduce human bias in treatment effect assessment and recognise treatment induced changes at the earliest stage.

With the largest global network of clinical and research users, Image Analysis helps our biotech and pharmaceutical clients to identify the most suitable imaging sites, design optimal imaging protocols, standardise multi-site image acquisition and analysis, centralise reading and scoring, delivering reproducible, standardized and accurate image analytics in early phase trials.

Visit our STAND 5.21 to discuss your projects with our technical, clinical and research experts during our educational sessions and sign up for a free version of Dynamika Open Access for research investigators.

Booth N° 5.7 & 5.11

JANSSEN PHARMACEUTICA NV

Turnhoutseweg 30
2340 Beerse
Belgium
www.janssen-emea.com/

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in immunology, oncology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people with serious diseases throughout the world. Beyond its innovative medicines, Janssen is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates and health care professionals have access to the latest treatment information, support services and quality care. Janssen Pharmaceutica NV is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit www.janssen-emea.com for more information.

Booth N° V5

JAPAN COLLEGE OF RHEUMATOLOGY

1-22-16 Toranomon
Minato-ku,
Tokyo 105-0001
Japan
www.eng.ryumachi-jp.com

The Japan College of Rheumatology (JCR) holds the Annual Scientific Meeting every spring and provides a platform for rheumatologists and other specialists to share knowledge on the prevention and treatment of rheumatic diseases. The Meeting welcomes thousands of rheumatologists and researchers from Japan, as well as from the rest of the world.

The JCR publishes its official journal, Modern Rheumatology, which provides information on the latest developments in rheumatic diseases.
Pierre Fabre Laboratories, the second largest French independent pharmaceutical group created by M. Pierre Fabre. Its turnover achieves more than 2 billions Euros in 2013, with international sales accounting for 56%. Pierre Fabre Laboratories have affiliates in 42 countries and their products are distributed in over 130 countries. Their activities cover all aspects of healthcare, from prescription drugs and family health products to dermo-cosmetics. Pierre Fabre Laboratories employ nearly 10000 people worldwide, 1400 of whom are dedicated to R&D. In 2012, Pierre Fabre Laboratories were audited by the French certification group AFNOR at advanced level for its corporate social responsibility (CSR) performance.

LCA Pharmaceutical is expert in osteoarthritis field with sodium hyaluronate joint injections of high molecular weight and high concentration:
- ARTHRUM H 2% 3 weekly intra-articular injections
- ARTHRUM 2.5% single injection for knee osteoarthritis
- COXARTHUM single injection for hip osteoarthritis
- RHIZARTHUM for small joints injection

Two other new innovative products are also available with the first combination of chondroitin sulfate and sodium hyaluronate indicated for treatment of osteoarthritis pain:
- SYNOVIUM SURGICAL for pain relief and joint function recovery after joint trauma and arthroscopy
- ARTHRUM HCS 3 weekly intra-articular injections

Lupus EUROPE was founded in 1989 and today unites 24 members representing national lupus groups of 23 countries in Europe:
It is the vision of LUPUS EUROPE to have a fulfilling life for all people with lupus in Europe until we have reached a world without lupus.

LUPUS EUROPE mission is to be the voice of lupus in Europe and to empower the national organisations for people living with lupus.

Strategic drivers 2013-2017 will be:
1. People with lupus in Europe participate in and benefit from research in lupus
2. Enthusiasm and empowerment to member organisations
3. LUPUS EUROPE is heard & acting

Booth N° 6.30

MDT INT’L S.A.

36, Rue du 31 Decembre
1207 Geneva
Switzerland

MDT Int’l s.a. is a Swiss company specialising in medical devices. We present 2 innovative and patented products, distributed worldwide. SportVisTM / TendoVisTM containing STABHATM (Soft Tissue Adapted Biocompatible Hyaluronic Acid): is used for soft tissue injuries (i.e. sprains and strains). RenehaVisTM / DualVisTM: contains 2 different concentrations of 2 molecular weights of Sodium Hyaluronate. This product is efficacious up to 1 year with just 2 injections.

Booth N° 6.21

MD CONFERENCES EXPRESS

400 West Cummings Park, Suite 4000
Woburn, MA 01801
United States

MD Conference Express, a division of SAGE, fills the gap between live presentation and publication in academic literature by applying the rigorous standard of peer review to the creation of medical conference highlights reports. Influential opinion leaders trust MD Conference Express® to deliver authoritative, balanced, and insightful reports of conference news.

Booth N° 6.9

MEDAC GMBH

Theaterstrasse 6
22880 Wedel
Germany

www.medicus.de
www.metoject.com

Metoject®/Metex® -
50 mg/ml and 10 mg/ml methotrexate pre-filled syringes and 50 mg/ml methotrexate pre-filled pen*
- Indicated for RA, PsA, JIA, Psoriasis and Crohn's Disease
- Concentration: 50 mg/ml (10 mg/ml in some countries)
- Smallest available injection volume
- Ready-to-use syringe with pre-attached s.c. needle
- Efficacious, safe and convenient application of the gold standard
- Available in 10 different doses (7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, 30 mg)
- Colour code for each dose
- Storage at room temperature
- Registered in more than 30 countries

Metoject®/Metex® can combine the advantages of parenteral methotrexate, i.e. higher efficacy due to increased bioavailability and less gastrointestinal side effects compared to oral application.

* Registered products, doses and indications may vary between countries

Booth N° 5.22

MEDI

Medicusstr. 1
95448 Bayreuth
Germany

www.medi.de

Founded in Germany in 1951, medi GmbH & Co. KG has become one of the world’s leading manufacturers of medical aids. Thanks to the dedication of our international distribution partners and 1700 employees, the company exports to over 90 countries worldwide.

Our orthopaedic assortment consists of supports and braces for the treatment of joint conditions and injuries for all parts of the human body such as back, shoulder/spine, hip, knee, ankle, wrist, elbow or foot. Our full range of premium-quality products are the first choice of many renowned healthcare professionals all across the globe especially for indications like osteoarthritis, osteoporosis, cruciate ligament rupture, post-operative shoulder immobilization and much else besides. For further information please visit our website www.medi.de
A. Menarini is the largest Italian pharmaceutical group: it ranks the world’s number 37 and the Europe’s number 17. Menarini is present in more than 100 countries worldwide. Menarini Group is investing 9.1% of its revenues from prescription drugs in R&D, mainly in cardiovascular field, oncology, pain-inflammation and asthma. Febuxostat, a drug for the treatment of chronic hyperuricaemia in gout, is the first non-purine, selective xanthine oxidase inhibitor, and is a highly effective therapy to lower and maintain serum uric acid to the EULAR target of ≤6 mg/dl.

METEOR is an online tool to improve treatment of patients with rheumatoid arthritis (RA) by allowing rheumatologists to regularly measure and follow individual patients while at the same time a database is constructed for benchmarking and research purposes.

METEOR aims to:
- Encourage rheumatologists to undertake regular monitoring of disease activity
- Help rheumatologists setting goals and sharing treatment progress with patients
- Create a central database that can be used for research and benchmarking
- Allows data upload of local databases and download for local databases

Crescendo Bioscience (a subsidiary of Myriad Genetics) focuses on enabling more effective management of autoimmune and inflammatory diseases by providing quantitative, objective molecular tests and disease information services to rheumatologists and patients. Crescendo Bioscience’s current products are: Vectra® DA, the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity, and MyRA, a free mobile app designed to empower people living with RA to regularly track multiple aspects of their RA and easily share the information with their physician.

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland. Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only local company with leading positions in these areas. Novartis products are available in more than 180 countries around the world.
OXFORD UNIVERSITY PRESS

Great Clarendon Street
OX2 6DP, Oxford
United Kingdom
www.oup.com

Oxford University Press is a leading publisher in rheumatology journals, books and online products and our worldwide publishing furthers the University’s objectives of excellence in scholarship, research, and education. Visit us at stand 6.26 today to pick up your FREE copy of Rheumatology, enter our competition and browse our extensive collection of books, available to buy with an exclusive 20% conference discount.

PANLAR

2200 Lake Boulevard North East
Atlanta, GA 30319
United States
www.panlar.org

The Pan American League of Associations for Rheumatology (PANLAR), founded in 1943, brings together the societies, associations, and scientific colleges of rheumatology of all of the member nations comprising the American continent. PANLAR has two main objectives: (1) to stimulate and promote the study and research of rheumatic diseases for its prevention, treatment, and rehabilitation to benefit patients with rheumatic diseases in the American continent and (2) to stimulate the continuing development of rheumatology in the Americas.

PFIZER

Pfizer Italia s.r.l
Via Vialbondlone
00188 Roma
Italy
www.pfizer.eu

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

REGENERON

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
www.regeneron.com

Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.

LATIUM TECHNOLOGICAL BIOSCIENCE DISTRICT - INNOVATION AND HEALTH RESEARCH

RHEUMATOLOGY NEWS

5635 Fishers Lane, Suite 6100
Rockville MD 20852
United States
www.rheumatologynews.com

Rheumatology News is an independent newspaper providing the practicing specialist with timely and relevant news and commentary about clinical developments in the field, plus reports on the impact of health care policy on the specialty and physician's practice. The Rheumatology News website, www.rheumatologynews.com is the online destination and resource for rheumatologists, providing the specialist daily news and multimedia coverage. The Joint, the weekly e-Newsletter of Rheumatology News, delivers headline news in the field to over 10000 rheumatologists worldwide. Rheumatology News is published by Frontline Medical Communications, Inc.
Roche

Grenzacherstrasse 124
4070 Basel
Switzerland
www.roche.com

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com

All trademarks used or mentioned in this release are protected by law.

Sanofi

54, rue La Boétie
75414 Paris Cedex 8
France
www.sanofi.com

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Scandinavian Journal of Rheumatology

Aarhus University Hospital, Norrebrogade 44
8000 Aarhus
Denmark
www.scandjrheumatol.dk

The Scandinavian Journal of Rheumatology publishes international, peer reviewed, high quality, original reports of clinical and basic research, as well as editorials, review articles and informative case reports covering all aspects of rheumatology. Subscriptions include print, online access, and supplements to the Journal. Published since 1955 by the Scandinavian Society for Rheumatology. Detailed information is available on our website www.scandjrheumatol.dk

Swedish Orphan Biovitrum

Tomtebodavägen 23A
112 76 Stockholm
Sweden
www.sobi.com

Sobi is an international specialty healthcare company dedicated to rare diseases. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases.

Kineret® is indicated in adults for the treatment of the signs and symptoms of Rheumatoid Arthritis (RA) in combination with methotrexate, with an inadequate response to methotrexate alone. Kineret® is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).
The Turkish League Against Rheumatism (TLAR) is the organization which represents the health professionals and patients in Turkey. It was founded in 1947. The aims of TLAR are to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases as well as to stimulate and support education and research in the field of rheumatology.

TRB Chemedica International is a Swiss pharmaceutical company, with a focus on research, development and marketing of innovative niche products in rheumatology. Our rheumatology line consists of:

- DIACEREIN, an oral interleukin-1 inhibitor for the treatment of osteoarthritis with beneficial structure-modifying effects
- OSTENIL® Line, i.a. hyaluronic acid-based injections for the symptomatic treatment of osteoarthritis of large and small joints
- OSTENIL® TENDON, hyaluronic acid-based injection for the treatment of pain and restricted mobility in tendon disorders

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8500 people in approximately 40 countries, the company generated revenue of € 3.3 billion in 2014. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Wisepress.com, Europe's leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.
## EULAR Related Meetings

By invitation only

### Wednesday, 10 June 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 10:00</td>
<td>SC1 Room Amalfi</td>
<td>EULAR / ACR Board meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>SC2 Room Quirinale</td>
<td>EULAR Standing Committee Health Professionals Business meeting</td>
</tr>
<tr>
<td>08:00 - 10:00</td>
<td>SC2 Room Viminale</td>
<td>SHARE consensus meeting ethical aspects</td>
</tr>
<tr>
<td>08:15 - 12:15</td>
<td>SC2 Room Esquilino</td>
<td>Serum urate as a biomarker/surrogate for clinically relevant outcomes in gout</td>
</tr>
<tr>
<td>08:15 - 13:00</td>
<td>SC2 Room Palatino</td>
<td>EULAR Sclero-ID</td>
</tr>
<tr>
<td>09:00 - 11:00</td>
<td>SC2 Room Celio</td>
<td>GLORIA project meeting</td>
</tr>
<tr>
<td>09:00 - 11:30</td>
<td>SC2 Room Campidoglio</td>
<td>Development of EULAR classification criteria for arthralgia that is clinically suspect for progression to RA</td>
</tr>
<tr>
<td>10:00 - 12:00</td>
<td>Hall 3 Room Verdi</td>
<td>Steering Committee Meeting EULAR-ACR classification criteria for systemic Lupus erythematosus</td>
</tr>
<tr>
<td>10:00 - 12:00</td>
<td>Room 10 L</td>
<td>Rheumatology Editorial board meeting</td>
</tr>
<tr>
<td>10:00 - 12:00</td>
<td>SC1 Room Amalfi</td>
<td>ACR Executive Committee meeting</td>
</tr>
<tr>
<td>10:15 - 13:00</td>
<td>SC2 Room Quirinale</td>
<td>ATACC-RA group</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>Room 10 O</td>
<td>EULAR Synovitis study group</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>SC2 Room Celio</td>
<td>PReS Council meeting</td>
</tr>
<tr>
<td>11:00 - 13:00</td>
<td>SC2 Room Viminale</td>
<td>Sjögren’s genetic network meeting</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>SC2 Room Campidoglio</td>
<td>ESOS Investigator meeting</td>
</tr>
</tbody>
</table>

### Thursday, 11 June 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 - 09:15</td>
<td>SC2 Room Campidoglio</td>
<td>HPR Psychology study group</td>
</tr>
<tr>
<td>08:15 - 10:00</td>
<td>Room 10 L</td>
<td>Contextual factors OMERACT methods group</td>
</tr>
<tr>
<td>08:15 - 10:00</td>
<td>SC1 Room Amalfi</td>
<td>The World Forum on Rheumatic and Musculoskeletal Diseases (WFRMD) meeting</td>
</tr>
<tr>
<td>08:15 - 10:15</td>
<td>Hall 3 Room Verdi</td>
<td>GRAPPA adjacent to EULAR</td>
</tr>
<tr>
<td>08:15 - 10:15</td>
<td>Hall 4 Room Rossini</td>
<td>EMEUNET Business Meeting</td>
</tr>
<tr>
<td>08:15 - 10:15</td>
<td>SC2 Room Palatino</td>
<td>HPR Standing Committee - Scientific Sub Committee meeting</td>
</tr>
<tr>
<td>08:15 - 10:15</td>
<td>SC2 Room Quirinale</td>
<td>EULAR Standing Committee on Epidemiology and Health Services business meeting</td>
</tr>
<tr>
<td>08:30 - 10:15</td>
<td>Room 10 O</td>
<td>EULAR Standing Committee on Education and Training business meeting</td>
</tr>
<tr>
<td>09:15 - 10:15</td>
<td>SC2 Room Campidoglio</td>
<td>HPR foot &amp; ankle study group</td>
</tr>
<tr>
<td>09:15 - 10:15</td>
<td>SC2 Room Celio</td>
<td>EULAR Young PARE</td>
</tr>
<tr>
<td>09:15 - 10:15</td>
<td>SC2 Room Esquilino</td>
<td>NORD-STAR, Nordic steering committee meeting</td>
</tr>
<tr>
<td>09:15 - 10:15</td>
<td>SC2 Room Viminale</td>
<td>EULAR Standing Committee on paediatric rheumatology business meeting</td>
</tr>
<tr>
<td>13:45 - 14:45</td>
<td>Room 10 M</td>
<td>PReS Education &amp; Training Committee</td>
</tr>
<tr>
<td>13:45 - 15:15</td>
<td>Room 10 L</td>
<td>PReS JDM WP</td>
</tr>
<tr>
<td>14:00 - 16:00</td>
<td>SC1 Room Amalfi</td>
<td>ILAR Executive Committee meeting</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td>Room 10 M</td>
<td>PReS Autoinflammatory WP &amp; Eurofever</td>
</tr>
<tr>
<td>15:45 - 17:15</td>
<td>Room 10 L</td>
<td>PReS SLE WP</td>
</tr>
<tr>
<td>16:15 - 17:15</td>
<td>Room 10 M</td>
<td>PReS Scleroderma WP</td>
</tr>
<tr>
<td>17:15 - 18:15</td>
<td>SC2 Room Palatino</td>
<td>HPR Occupational therapies</td>
</tr>
<tr>
<td>17:15 - 19:00</td>
<td>Hall 3 Room Verdi</td>
<td>ASAS meeting</td>
</tr>
<tr>
<td>17:15 - 19:00</td>
<td>SC2 Room Celio</td>
<td>Kommission der studentischen Ausbildung der DGRh</td>
</tr>
<tr>
<td>17:15 - 19:00</td>
<td>SC1 Room Amalfi</td>
<td>OMERACT MRI in arthritis group</td>
</tr>
</tbody>
</table>
17:15 - 19:00 SC2 Room Esquilino  US-pSS-study group - ultrasonography in primary Sjögren’s
17:15 - 19:15 Hall 2 Room Vivaldi  PRoS AGM and PRINTO meeting
17:15 - 19:15 Hall 4 Room Rossini  EMEUNET Subgroup breakout session
17:15 - 19:15 Room 10 O  Personalized medicine in chronic inflammatory diseases. Opportunities for a Canadian-Dutch collaboration
17:15 - 19:15 SC2 Room Campidoglio  PMR& GCA study group
17:15 - 19:15 SC2 Room Viminale  EULAR Lupus nephritis trials network study group
17:30 - 18:30 Room 10 M  PRoS SHARE Council meeting
17:30 - 19:00 SC2 Room Quirinale  EULAR Standing Committee on Investigative Rheumatology business meeting
17:45 - 19:15 Room 10 L  PRoS Vasculitis WP
18:15 - 19:15 SC2 Room Palatino  HPR NP Nurses study group - Research & strategy group

**Friday, 12 June 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 - 09:15</td>
<td>Room 10 L</td>
<td>PRoS Clinical Affairs Committee</td>
</tr>
<tr>
<td>08:15 - 09:15</td>
<td>Room 10 M</td>
<td>PRoS AHP Committee</td>
</tr>
<tr>
<td>08:15 - 09:45</td>
<td>SC1 Room Amalfi</td>
<td>HPR Standing Committee / ACR / AHRP meeting</td>
</tr>
<tr>
<td>08:15 - 10:00</td>
<td>Hall 4 Room Rossini</td>
<td>eSsential Study group for Sjögren’s syndrome</td>
</tr>
<tr>
<td>08:15 - 10:15</td>
<td>Room 10 O</td>
<td>EUSTAR Business meeting</td>
</tr>
<tr>
<td>08:15 - 10:15</td>
<td>SC2 Room Esquilino</td>
<td>PARE CEO meeting</td>
</tr>
<tr>
<td>08:15 - 10:15</td>
<td>SC2 Room Palatino</td>
<td>UEMS Section of Rheumatology Board meeting</td>
</tr>
<tr>
<td>08:15 - 10:15</td>
<td>SC2 Room Viminale</td>
<td>EULAR Standing Committee in musculoskeletal imaging business meeting</td>
</tr>
<tr>
<td>08:30 - 10:00</td>
<td>SC2 Room Campidoglio</td>
<td>Scandinavian Society of Rheumatology board meeting</td>
</tr>
<tr>
<td>08:30 - 10:00</td>
<td>SC2 Room Quirinale</td>
<td>EULAR Standing Committee on Clinical Affairs business meeting</td>
</tr>
<tr>
<td>09:15 - 10:15</td>
<td>Room 10 L</td>
<td>PRoS MAS WP</td>
</tr>
<tr>
<td>09:15 - 10:15</td>
<td>Room 8 A</td>
<td>Online course authors workshop</td>
</tr>
<tr>
<td>09:15 - 10:15</td>
<td>SC2 Room Celio</td>
<td>EULAR patient research partner network</td>
</tr>
<tr>
<td>09:30 - 10:30</td>
<td>Room 10 M</td>
<td>PRoS Trainee’s group</td>
</tr>
<tr>
<td>13:45 - 14:45</td>
<td>Room 10 L</td>
<td>PRoS imaging WP</td>
</tr>
<tr>
<td>13:45 - 17:15</td>
<td>Room 10 M</td>
<td>PRoS ENCA meeting I</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td>Room 10 L</td>
<td>PRoS Pharmachild open meeting</td>
</tr>
<tr>
<td>16:15 - 17:15</td>
<td>Room 10 L</td>
<td>PRoS UCAN WP</td>
</tr>
<tr>
<td>17:15 - 18:15</td>
<td>Room 10 O</td>
<td>ARD Editorial board meeting</td>
</tr>
<tr>
<td>17:15 - 18:15</td>
<td>SC2 Room Palatino</td>
<td>EMEUNET country liaison meeting</td>
</tr>
<tr>
<td>17:15 - 19:15</td>
<td>Hall 3 Room Verdi</td>
<td>Obesity nutrition and rheumatic diseases</td>
</tr>
<tr>
<td>17:15 - 19:15</td>
<td>SC2 Room Quirinale</td>
<td>ESCIR study group risk factors for RA</td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>Room 10 L</td>
<td>PRoS Uveitis WP</td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>Room 10 M</td>
<td>PRoS SHARE meeting</td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>Room 8 A</td>
<td>Online course authors workshop</td>
</tr>
<tr>
<td>17:45 - 19:15</td>
<td>SC2 Room Viminale</td>
<td>Rheumatology International - Editorial board meeting</td>
</tr>
<tr>
<td>18:15 - 19:15</td>
<td>Room 10 O</td>
<td>RMD open Editorial board meeting</td>
</tr>
<tr>
<td>18:15 - 19:15</td>
<td>SC2 Room Campidoglio</td>
<td>HPR Physio study group</td>
</tr>
</tbody>
</table>

**Saturday, 13 June 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 14:00</td>
<td>Room 10 L</td>
<td>PRoS ENCA meeting II</td>
</tr>
<tr>
<td>10:00 - 12:00</td>
<td>Room 10 O</td>
<td>Standing Committee of PARE business meeting</td>
</tr>
<tr>
<td>15:00 - 16:00</td>
<td>SC2 Room Celio</td>
<td>MATURA CMB</td>
</tr>
</tbody>
</table>
Plan - Overview
Exhibitors' List

Status as of 5 April 2015

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
<th>HALL</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBVIE</td>
<td>5.1</td>
<td>5</td>
</tr>
<tr>
<td>ABBVIE IMMUNOLOGY R&amp;D</td>
<td>6.7</td>
<td>6</td>
</tr>
<tr>
<td>ABIOGEN PHARMA S.P.A.</td>
<td>6.20</td>
<td>6</td>
</tr>
<tr>
<td>ACTELION PHARMACEUTICALS LTD</td>
<td>6.3a</td>
<td>6</td>
</tr>
<tr>
<td>AGORA</td>
<td>V14</td>
<td>5</td>
</tr>
<tr>
<td>ALFA WASSERMANN</td>
<td>5.18b</td>
<td>5</td>
</tr>
<tr>
<td>AMERICAN COLLEGE OF RHEUMATOLOGY (ACR)</td>
<td>V9</td>
<td>5</td>
</tr>
<tr>
<td>AMGEN</td>
<td>6.11</td>
<td>6</td>
</tr>
<tr>
<td>ANKYLosing SPONDYLITIS INTERNATIONAL FEDERATION (ASIF)</td>
<td>V22</td>
<td>5</td>
</tr>
<tr>
<td>ANMAR (ITALIAN ASSOCIATION PEOPLE WITH RHEUMATIC DISEASES)</td>
<td>V17</td>
<td>5</td>
</tr>
<tr>
<td>APLAR 2015</td>
<td>V15</td>
<td>5</td>
</tr>
<tr>
<td>ARD / RHEUMATOLOGY FROM BMJ</td>
<td>5.18a</td>
<td>5</td>
</tr>
<tr>
<td>Astra Zeneca</td>
<td>6.1</td>
<td>6</td>
</tr>
<tr>
<td>BAYER</td>
<td>6.6a</td>
<td>6</td>
</tr>
<tr>
<td>BE THE CURE</td>
<td>V23</td>
<td>5</td>
</tr>
<tr>
<td>BIOGEN</td>
<td>5.3b</td>
<td>5</td>
</tr>
<tr>
<td>BIOIBERICA SA</td>
<td>5.16</td>
<td>5</td>
</tr>
<tr>
<td>BIOLOGISCHE HEILMITTEL HEEL</td>
<td>6.29a</td>
<td>6</td>
</tr>
<tr>
<td>BIOMED CENTRAL</td>
<td>6.6c</td>
<td>6</td>
</tr>
<tr>
<td>BK ULTRASOUND</td>
<td>6.19</td>
<td>6</td>
</tr>
<tr>
<td>BRISTOL-MYS SQUIBB</td>
<td>5.4a &amp; 5.4b</td>
<td>5</td>
</tr>
<tr>
<td>BRITISH SOCIETY FOR RHEUMATOLOGY</td>
<td>V8</td>
<td>5</td>
</tr>
<tr>
<td>CELGENE</td>
<td>6.27</td>
<td>6</td>
</tr>
<tr>
<td>CLINICAL AND EXPERIMENTAL RHEUMATOLOGY</td>
<td>V13</td>
<td>5</td>
</tr>
<tr>
<td>CRESCENDO BIOSCIENCE</td>
<td>6.16</td>
<td>6</td>
</tr>
<tr>
<td>DYNATICS</td>
<td>6.15</td>
<td>6</td>
</tr>
<tr>
<td>EMEUNET</td>
<td>V25</td>
<td>5</td>
</tr>
<tr>
<td>ESAOTE</td>
<td>5.19</td>
<td>5</td>
</tr>
<tr>
<td>EULAR</td>
<td>5.14</td>
<td>5</td>
</tr>
<tr>
<td>EULAR HEALTH PROFESSIONS IN RHEUMATOLOGY</td>
<td>V1 &amp; V2</td>
<td>5</td>
</tr>
<tr>
<td>EULAR HOUSING BUREAU</td>
<td>6.3d</td>
<td>6</td>
</tr>
<tr>
<td>EULAR PARE</td>
<td>V27 &amp; V28</td>
<td>5</td>
</tr>
<tr>
<td>EUROPEAN JOURNAL OF RHEUMATOLOGY</td>
<td>6.22</td>
<td>6</td>
</tr>
<tr>
<td>EYLED - HELP POINT FOR SMARTPHONES AND MOBILE DEVICES</td>
<td>5.23</td>
<td>5</td>
</tr>
<tr>
<td>FESCA</td>
<td>V4</td>
<td>5</td>
</tr>
<tr>
<td>FIDIA FARMACEUTICI S.P.A.</td>
<td>6.18</td>
<td>6</td>
</tr>
<tr>
<td>FUTURE EVENTS</td>
<td>6.3c</td>
<td>6</td>
</tr>
<tr>
<td>GE HEALTHCARE</td>
<td>6.28</td>
<td>6</td>
</tr>
<tr>
<td>GISEA</td>
<td>V19</td>
<td>5</td>
</tr>
<tr>
<td>GLAXOSMITHKLINE</td>
<td>6.4</td>
<td>6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND N°</th>
<th>HALL</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEMICS</td>
<td>6.31</td>
<td>6</td>
</tr>
<tr>
<td>HOLOGIC</td>
<td>6.6e</td>
<td>6</td>
</tr>
<tr>
<td>HOSPIRA</td>
<td>5.13</td>
<td>5</td>
</tr>
<tr>
<td>IBSA INSTITUT BIOCHIMIQUE SA</td>
<td>6.17</td>
<td>6</td>
</tr>
<tr>
<td>IMAGE ANALYSIS</td>
<td>5.21</td>
<td>5</td>
</tr>
<tr>
<td>INTERNATIONAL AKU SOCIETIES</td>
<td>V24</td>
<td>5</td>
</tr>
<tr>
<td>INTERNATIONAL LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (ILAR)</td>
<td>V10</td>
<td>5</td>
</tr>
<tr>
<td>JANSSEN PHARMACEUTICA NV</td>
<td>5.7 &amp; 5.11</td>
<td>5</td>
</tr>
<tr>
<td>JAPAN COLLEGE OF RHEUMATOLOGY</td>
<td>V5</td>
<td>5</td>
</tr>
<tr>
<td>LABORATOIRE PIERRE FABRE SANTE</td>
<td>6.12</td>
<td>6</td>
</tr>
<tr>
<td>LABORATOIRES EXPANSIENCE</td>
<td>5.12</td>
<td>5</td>
</tr>
<tr>
<td>LATIUM TECHNOLOGICAL BIOSCIENCE DISTRICT - INNOVATION AND HEALTH RESEARCH</td>
<td>5.10</td>
<td>5</td>
</tr>
<tr>
<td>LCA PHARMECEUTICAL</td>
<td>6.29b</td>
<td>6</td>
</tr>
<tr>
<td>LETTER TO EDITOR RHEUMATOLOGY (LER)</td>
<td>V11</td>
<td>5</td>
</tr>
<tr>
<td>LILLY</td>
<td>5.9</td>
<td>5</td>
</tr>
<tr>
<td>LUPUS EUROPE</td>
<td>V20</td>
<td>5</td>
</tr>
<tr>
<td>MD CONFERENCES EXPRESS</td>
<td>6.21</td>
<td>6</td>
</tr>
<tr>
<td>MDT INTL</td>
<td>6.30</td>
<td>6</td>
</tr>
<tr>
<td>MEDAC GMBH</td>
<td>6.9</td>
<td>6</td>
</tr>
<tr>
<td>MEDI</td>
<td>5.22</td>
<td>5</td>
</tr>
<tr>
<td>MENARINI</td>
<td>6.3b</td>
<td>6</td>
</tr>
<tr>
<td>METEOR</td>
<td>V21</td>
<td>5</td>
</tr>
<tr>
<td>MSD</td>
<td>5.6</td>
<td>5</td>
</tr>
<tr>
<td>MYRIAD GENETICS</td>
<td>6.16</td>
<td>6</td>
</tr>
<tr>
<td>NOVARTIS PHARMACEUTICAL</td>
<td>6.5 &amp; 6.8</td>
<td>6</td>
</tr>
<tr>
<td>OXFORD UNIVERSITY PRESS</td>
<td>6.26</td>
<td>6</td>
</tr>
<tr>
<td>PANLAR</td>
<td>V16</td>
<td>5</td>
</tr>
<tr>
<td>PFIZER</td>
<td>5.2 &amp; 5.3a</td>
<td>5</td>
</tr>
<tr>
<td>REGENERON</td>
<td>5.17</td>
<td>5</td>
</tr>
<tr>
<td>RHEUMATOLOGY NEWS</td>
<td>V12</td>
<td>5</td>
</tr>
<tr>
<td>ROCHE</td>
<td>5.5</td>
<td>5</td>
</tr>
<tr>
<td>ROMANIAN SOCIETY OF RHEUMATOLOGY</td>
<td>V6</td>
<td>5</td>
</tr>
<tr>
<td>SANOFI</td>
<td>5.15</td>
<td>5</td>
</tr>
<tr>
<td>SCANDINAVIAN JOURNAL OF RHEUMATOLOGY</td>
<td>V18</td>
<td>5</td>
</tr>
<tr>
<td>SWEDISH ORPHAN BIOVITRUM</td>
<td>6.23</td>
<td>6</td>
</tr>
<tr>
<td>TRB CHEMEDICA INTERNATIONAL</td>
<td>6.24</td>
<td>6</td>
</tr>
<tr>
<td>TURKISH LEAGUE AGAINST RHEUMATISM</td>
<td>V7</td>
<td>5</td>
</tr>
<tr>
<td>UCB PHARMA</td>
<td>6.2</td>
<td>6</td>
</tr>
<tr>
<td>WISEPRESS MEDICAL BOOKSHOP</td>
<td>6.6d</td>
<td>6</td>
</tr>
</tbody>
</table>
Exhibition Area, Hall 5

Status as of 5 April 2015

EULAR Village Exhibitor's List

<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGORA</td>
<td>V14</td>
</tr>
<tr>
<td>AMERICAN COLLEGE OF RHEUMATOLOGY (ACR)</td>
<td>V9</td>
</tr>
<tr>
<td>ANMAR (ITALIAN ASSOCIATION PEOPLE WITH RHEUMATIC DISEASES)</td>
<td>V17</td>
</tr>
<tr>
<td>APLAR 2015</td>
<td>V15</td>
</tr>
<tr>
<td>ANKYLOSING SPONDYLITIS INTERNATIONAL FEDERATION (ASIF)</td>
<td>V22</td>
</tr>
<tr>
<td>BE THE CURE</td>
<td>V23</td>
</tr>
<tr>
<td>BRITISH SOCIETY FOR RHEUMATOLOGY</td>
<td>V8</td>
</tr>
<tr>
<td>CLINICAL AND EXPERIMENTAL RHEUMATOLOGY</td>
<td>V13</td>
</tr>
<tr>
<td>EMEUNET</td>
<td>V25</td>
</tr>
<tr>
<td>EULAR HEALTH PROFESSIONALS IN RHEUMATOLOGY</td>
<td>V1 &amp; V2</td>
</tr>
<tr>
<td>EULAR PARE</td>
<td>V27 &amp;V28</td>
</tr>
<tr>
<td>FESCA</td>
<td>V4</td>
</tr>
<tr>
<td>INTERNATIONAL AKU SOCIETIES</td>
<td>V24</td>
</tr>
<tr>
<td>JAPAN COLLEGE OF RHEUMATOLOGY</td>
<td>V5</td>
</tr>
<tr>
<td>FESCA</td>
<td>V4</td>
</tr>
<tr>
<td>INTERNATIONAL LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (ILAR)</td>
<td>V10</td>
</tr>
<tr>
<td>LETTER TO EDITOR RHEUMATOLOGY (LER)</td>
<td>V11</td>
</tr>
<tr>
<td>LUPUS EUROPE</td>
<td>V20</td>
</tr>
<tr>
<td>METEOR</td>
<td>V21</td>
</tr>
<tr>
<td>PANLAR</td>
<td>V16</td>
</tr>
<tr>
<td>RHEUMATOLOGY NEWS</td>
<td>V12</td>
</tr>
<tr>
<td>ROMANIAN SOCIETY OF RHEUMATOLOGY</td>
<td>V12</td>
</tr>
<tr>
<td>SCANDINAVIAN JOURNAL OF RHEUMATOLOGY</td>
<td>V6</td>
</tr>
<tr>
<td>TURKISH LEAGUE AGAINST RHEUMATISM</td>
<td>V7</td>
</tr>
</tbody>
</table>
New Frontiers and Latest Perspectives

A Fresh Outlook on Gout

Thursday 11 June 2015
17:45 – 19:15
Room D/E, Fiera Roma
Rome, Italy

This symposium explores the latest advances in gout in collaboration with experts at the forefront of scientific research.

Join us for a future-focused session examining recent developments in our understanding of gout – with fresh insights from both the bench and clinic.

Take a deeper look at gout at booth 6.1

Scientific Programme
Chairied by Frédéric Lioté, France

Uric Acid Transport
Latest Scientific Insights
Jeff Miner, USA

Advances in Imaging
Changing How We See Gout
Nicola Dalbeth, New Zealand

Lowering Serum Urate
Novel Concepts and Future Possibilities
Fernando Perez-Ruiz, Spain

Treatment Success
What’s the Target and How Do We Get There?
Panel Discussion

CELGENE IS COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE